<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">"" "" "" "the present document is a summary of the European Public Department report (EPAR), which explains how the studies for human medicines will be assessed in order to get recommendations concerning the application of medication." "" "" ""</seg>
<seg id="2">"" "" "" "if you need further information about your illness or treatment, please read the package directions (also part of the EPAR) or apply to your doctor or pharmacist." "" "" ""</seg>
<seg id="3">"" "" "" "if you wish more information regarding the recommendations of CHMP, please read the scientific discussion (also part of the EPAR)." "" "" ""</seg>
<seg id="4">It is available as 5 mg / 10 mg, 15 mg and 30 mg of tablets (tablets that dissolve in the mouth) as a solution for inserting (1 mg / ml) and as a injection solution (7.5 mg / ml).</seg>
<seg id="5">"" "" "" "B. wirres thinking and speaking, hallucinations or interpreting of things that are not present); • Bipolar-I-disorder, a psychic episodes (periods of abnormal high mood) alternately with periods of normal mood." "" "" ""</seg>
<seg id="6">"" "" "" "Abilify is used for the treatment of severe to severe manic episodes and for the prevention of manic episodes in patients who have addressed in the past to the medicine." "" "" ""</seg>
<seg id="7">Injection solution is used for rapid control of increased unrest or behavioural disorders when the oral treatment is not possible.</seg>
<seg id="8">"" "" "" "in both illnesses, the solution can be applied or used to treat melting tablets in patients who trouble the swallowing of tablets difficulties." "" "" ""</seg>
<seg id="9">"" "" "" "in patients who are using other medicines at the same time, the dose should be adjusted from Abilify." "" "" ""</seg>
<seg id="10">"" "" "" "this impairs signal transmission between brain cells by" neurotransmitters, "i.e. chemical substances that allow the communication of nerve cells." "" "" ""</seg>
<seg id="11">Aripiprazole seems to be used mainly as a "partial agonist" for the receptors for the neurotransmitters Dopamine and 5-hydroxytryptamine (also called serotonin).</seg>
<seg id="12">"" "" "" "this means Aripiprazole, such as 5-hydroxytryptamine and dopamine, but in lower dimensions than the neurotransmitters to activate the receptors." "" "" ""</seg>
<seg id="13">"" "" "" "as dopamine and 5-hydroxytryptamine play a role in schizophrenia and bipolar disorder, helps to normalize the activity of the brain and prevent psychotic or manic symptoms." "" "" ""</seg>
<seg id="14">"" "" "" "Abilify, the efficacy of symptoms, was investigated in three trials over one year." "" "" ""</seg>
<seg id="15">"" "" "" "the effectiveness of injection solution was compared with schizophrenia or similar conditions in two studies with schizophrenia, or similar diseases, over a period of two hours with placebo." "" "" ""</seg>
<seg id="16">"" "" "" "in another study Abilify about twelve weeks at 347 patients with Haloperidol, in another study the effectiveness of asbilify and placebo have been stabilized with Abilify, compared with Abilify." "" "" ""</seg>
<seg id="17">The efficacy of asbilify injections was observed in a study on 301 patients with bipolarised disorder used by Lorazepam (another antipsychotic medication) and placebo over a period of two hours.</seg>
<seg id="18">"" "" "" "in all studies, the changes in patients received from a standard scale of bipolar disorder or the number of patients who spoke on treatment." "" "" ""</seg>
<seg id="19">"" "" "" "the company also conducted studies through to examine how the body absorbs the melting tablets and the solution to remove them (absorbs)." "" "" ""</seg>
<seg id="20">"" "" "" "in the two trials with injection solution, patients received asbilify in doses of 5.25 mg, 9.75 mg or 15 mg, a significantly stronger reduction in symptoms of increased unrest than the patients receiving a placebo." "" "" ""</seg>
<seg id="21">In the use of bipolar disorder Abilify in four of five short-term studies of manic symptoms are more effective than placebo.</seg>
<seg id="22">"" "" "" "Abilify also hindered up to 74 weeks, effective as placebo the reappeared Manic Episodes in previously treated patients and if it was administered in addition to an existing treatment." "" "" ""</seg>
<seg id="23">Asbilify injections in 10- or 15-mg doses have also proven effective as placebo the symptoms of germinated unrest and were similar to Lorazepam.</seg>
<seg id="24">The most common side effects of Abilify (observe at 1 to 10 of 100 patients) are extrapolated pyramidal disorders (deficiencies), vomiting (deficiencies), spacial (deficiencies), suction and fatigue, insomnia (insomnia) and anxiety.</seg>
<seg id="25">"" "" "" "the Committee for Human Use (CHMP) came to the conclusion that the advantages of asbilify in treating schizophrenia, and in the prevention of a new manic result in patients suffering from manic eprazors to the treatment with Aripiprazole, compared to the risks." "" "" ""</seg>
<seg id="26">"" "" "" "furthermore, the Committee came to the conclusion that the advantages of injection solution in patients with schizophrenia or patients with manic episodes occur in bipolar-I disorder when oral therapy is not suitable against the risks." "" "" ""</seg>
<seg id="27">"" "" "" "in June 2004, the European Commission approved the company Otsuka Pharmaceutical Europe Ltd. a permit for the transport of asbilify throughout the European Union." "" "" ""</seg>
<seg id="28">ABILIFY is indicated for the treatment of moderate to severe manic episodes of the bipolar disorder and for the prevention of a new manic episode in patients who were mostly manic episodes and their manic episodes on the treatment with Aripiprazole (see Section 5.1).</seg>
<seg id="29">The recommended starting dose for ABILIFY is 10 or 15 mg / day at a maintenance dose of 15 mg / day a day regardless of meals.</seg>
<seg id="30">"" "" "" "an increased effectiveness in dosages about a daily dose of 15 mg has not been proven, although individual patients can benefit from a higher dose." "" "" ""</seg>
<seg id="31">The recommended starting dose for ABILIFY is 15 mg once a day regardless of the meals as monotherapy or combination therapy (see Section 5.1).</seg>
<seg id="32">ABILIFY's efficacy in treating schizophrenia and bipolar disorder in patients ≥ 65 years has not been proven.</seg>
<seg id="33">"" "" "" "with regard to the greater sensitivity of these patients, a lower initial dose should be considered when clinical factors justify this (see Section 4.4)." "" "" ""</seg>
<seg id="34">"" "" "" "if the CYP3A4 induction is removed from combination therapy, it should be reduced to the recommended dose (see section 4.5)." "" "" ""</seg>
<seg id="35">"" "" "" "the occurrence of suicidal behaviour is reported to psychotic disorders and affective disorders, and in some cases prior to the beginning or after change of antipsychotic therapy, also in treatment with Aripiprazole (see section 4.8)." "" "" ""</seg>
<seg id="36">Results of an epidemiological study showed that in patients with bipolar disorder no increased risk of loss with Aripiprazole was compared to other antipsychotics.</seg>
<seg id="37">Aripiprazole should be used with caution in patients with known cardiovascular disease (dehydration disorders), cerebrovascular diseases (dehydration disorders) or hypertonia (including acelogenous and malignant form).</seg>
<seg id="38">"" "" "" "3 late dyskinesien: in clinical trials which lasted one year or less, there were occasional reports during treatment with Aripiprazole." "" "" ""</seg>
<seg id="39">"" "" "" "when treated with ABILIFY patients signs and symptoms of late dyskinesia occur in consideration, the dose should reduce or break the treatment." "" "" ""</seg>
<seg id="40">"" "" "" "if a patient emerge signs and symptoms that has a mns to indicate or unclear fever without an additional clinical manifestation of mns, all Antipsychotics, including ABILIFY, must be removed." "" "" ""</seg>
<seg id="41">"" "" "" "therefore, Aripiprazole should be used in patients with seizures in the Anamnese or at states that are used with cramping cases linked to caution." "" "" ""</seg>
<seg id="42">"" "" "" "56 - 99 years old associated with Aripiprazole in patients with psychosis who were treated with the Alzheimer's disease, an increased risk of death in comparison to placebo." "" "" ""</seg>
<seg id="43">"" "" "" "however, in one of these studies, a study with fixer dosage, a significant relationship between the dosage and the response to unintended cerebrovascular events were treated with Aripiprazole patients." "" "" ""</seg>
<seg id="44">"" "" "" "hyperglycemia, in some cases extremely and associated with etoazide or hyperosmolarem coma or death, was reported in patients who were treated with atypical antipsychotic drugs including ABILIFY." "" "" ""</seg>
<seg id="45">"" "" "" "there are no precise risk assessment for hyperglycemia-related events associated with ABILIFY and other atypical antipsychotic drugs, which allow direct comparisons." "" "" ""</seg>
<seg id="46">Polydipsy (polyurie, polyphagie and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be regularly monitored in relation to deterioration of glucose levels.</seg>
<seg id="47">"" "" "" "in general, a weight gain is generally observed in schizophrens patients and patients with bipolar mandities, the use of anti-psychotics that gain weight gain as a side effect, and could lead to serious complications." "" "" ""</seg>
<seg id="48">"" "" "" "due to the primary effect of Aripiprazole on the central nervous system, caution is advisable when Aripiprazole is used in combination with alcohol or other centrally-effective medicines such as sedation (see section 4.8)." "" "" ""</seg>
<seg id="49">"" "" "" "the H2 antagonist famotidine, a gastric-blockers, reduces the resorption of Aripiprazole, although this effect is regarded as clinically irrelevant." "" "" ""</seg>
<seg id="50">"" "" "" "in a clinical trial with healthy volunteers, a highly effective CYP2D6 inhibitor (Chinidin) increased the AUC from Aripiprazole to 107%, while the Cmax remained unchanged." "" "" ""</seg>
<seg id="51">"" "" "" "it is expected that other highly effective inhibitors of CYP2D6, like Fluoxetine and paroxetine, similar effects have, and therefore should similar dose reductions to be performed." "" "" ""</seg>
<seg id="52">CYP2D6 'bad' (= 'Poor') Metabolisierans can result in the common application using highly effective inhibitors of CYP3A4 into higher plasma concentration of Aripiprazole in comparison to CYP2D6.</seg>
<seg id="53">"" "" "" "if you take the joint gift of Ketoconazole or other highly effective CYP3A4-inhibitors with ABILIFY, the potential benefit should weigh the potential risks for the patient." "" "" ""</seg>
<seg id="54">"" "" "" "other highly effective inhibitors of CYP3A4, like Itraconazole and HIV-protein inhibitors, may have similar effects, and therefore similar doses should be made." "" "" ""</seg>
<seg id="55">"" "" "" "after placing the CYP2D6- or 3A4 Inhibitors, the dose of ABILIFY should be raised to the dose height prior to the companion therapy." "" "" ""</seg>
<seg id="56">Diaztiazem or Escitalopram) or CYP2D6 together with ABILIFY will be given together with an excessive increase in Aripiprazol- concentrations.</seg>
<seg id="57">Clinical trials showed doses of 10-30 mg Aripiprazole per day no significant effect on the metabolism of the substrates of CYP2D6 (Dextromethorphan / 3-methodology), 2C9 (Omeprazole) and 3A4 (Dextromethorphan).</seg>
<seg id="58">"" "" "" "patients should be advised to notify your doctor if they are pregnant or a pregnancy, during treatment with Aripiprazole." "" "" ""</seg>
<seg id="59">"" "" "" "due to insufficient data protection for humans and due to recurring studies, this medicine may not be applied in pregnancy, unless possible benefits does clearly justify the potential risk for the fetus." "" "" ""</seg>
<seg id="60">"" "" "" "however, patients should be warned against other antipsychotics that have been warned to operate dangerous machines, including motor vehicles, until they are certain that Aripiprazole does not have any negative influence." "" "" ""</seg>
<seg id="61">The following adverse events were more common (≥ 1 / 100) than placebo or were classified as possible medically-related side effects (*):</seg>
<seg id="62">"" "" "" "the frequency of the side-related side effects is defined according to the following criteria: frequently (&gt; 1 / 100, &lt; 1 / 10); occasionally (&gt; 1 / 1000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="63">Schizophrenia - In a controlled long-term study of 52 weeks in patients who were treated with Aripiprazole (25.8%) from EPS including parinsonism, acathic and dyskinesia against patients who were treated with Haloperidol (57.3%).</seg>
<seg id="64">"" "" "" "in a placebo-controlled study for over 26 weeks, the incidence of EPS 19% was under Aripiprazole treatment and 13.1% in patients under placebo." "" "" ""</seg>
<seg id="65">"" "" "" "in another controlled long-term study over 26 weeks, the incidence of EPS 14.8% was treated with Aripiprazole, and 15.1% in patients under Olanzapin therapy." "" "" ""</seg>
<seg id="66">Manic Episodes in bipolar-I-disorder - In a controlled trial over 12 weeks the incidence of EPS 23,5% was among patients under Aripiprazol- treatment and 53.3% in patients under Haloperidol treatment.</seg>
<seg id="67">"" "" "" "in another study over 12 weeks, the incidence of EPS 26.6% was diagnosed with Aripiprazole treatment and 17.6% for those under lithium-treatment." "" "" ""</seg>
<seg id="68">"" "" "" "during the long-term phase of over 26 weeks in a placebo-controlled trial, the incidence of EPS 18,2% for patients suffering from Aripiprazol- treatment and 15.7% for placebo treated patients." "" "" ""</seg>
<seg id="69">"" "" "" "a comparison between the patient groups below Aripiprazole and placebo, in which potentially clinically significant changes of routinely controlled laboratory parameters came up, showed no medically significant differences." "" "" ""</seg>
<seg id="70">Enhancements of the Cpk (creatine phosphating kinase) generally observed temporarily and asymptomatically, compared to 2.0% of patients treated with placebo.</seg>
<seg id="71">"" "" "" "the malignant neuroleptic syndrome, hyperglycemia and diabetes mellitus, hyperglycemia and diabetes mellitus, belong to the adverse effects associated with Aripiprazole, and diabetes mellitus (see Section 4.4)." "" "" ""</seg>
<seg id="72">"" "" "" "in clinical trials and since the market launch, unintentionally notices with Aripiprazole alone was observed with an estimated doses of up to 1260 mg and without death." "" "" ""</seg>
<seg id="73">"" "" "" "although there are no information on the effectiveness of a hemostalysis in the treatment of an overdosing with Aripiprazole, however, it is unlikely that hemostalysis has a high plasma rotation." "" "" ""</seg>
<seg id="74">It is presumed that the effectiveness of Aripiprazole in schizophrenia and bipolar-I disorder is mediated on a combination of a partial sensory effect on dopamine D2- and serotonin 5HT1a- receptors and a antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="75">"" "" "" "in vitro, Aripiprazole showed a high affinity to the dopamine D2- and D3 receptor and the serotonin 5HT2c- and 5HT7-, for the serotonin 5HT2c- and 5HT7-, for alpha-1-adrenergen and the histamine-H1receptors." "" "" ""</seg>
<seg id="76">"" "" "" "during the gift of Aripiprazole in dosages from 0.5 to 30 mg once a day over 2 weeks of healthy volunteers showed a dosiscent target reduction of the bond of 11C-Racloprid, a D2 / D3 receptor-ligands, on the Nucleus caudatus and the Putamen." "" "" ""</seg>
<seg id="77">"" "" "" "in three placebo-controlled short-time studies (4 to 6 weeks), Aripiprazole showed a statistically significantly stronger improvement in psychotic symptoms compared to placebo." "" "" ""</seg>
<seg id="78">"" "" "" "in a Haloperidol study, 52% of patients responding to study medication was similar in both groups (Aripiprazole 77% and haloperidol 73%)." "" "" ""</seg>
<seg id="79">"" "" "" "current values from measuring shelves, which were defined as secondary studies, including PANSS and Montgomery-Asberg- depression scale, showed significantly stronger improvement than at Haloperidol." "" "" ""</seg>
<seg id="80">"" "" "" "in a placebo-controlled trial over 26 weeks in stabilised patients with chronic schizophrenia showed a significantly higher reduction of the return rate, which amounted to 34% in the Aripiprazole group and 57% among placebo." "" "" ""</seg>
<seg id="81">"" "" "" "in an olanzapine-controlled, multinational double-blind study included in schizophrenia (N = 18 or 13% of the most valuable patients) in significantly less patients (i.e. an increase of at least 5,6 kg in average weight)." "" "" ""</seg>
<seg id="82">"" "" "" "in two placebo-controlled monotherapy studies with a more flexible dosage of 3 weeks with a manic or mixed episode of bipolar-I disorder, Aripiprazole was compared to placebo over 3 weeks." "" "" ""</seg>
<seg id="83">"" "" "" "in a placebo-controlled monotherapy study over 3 weeks with fixed dosage with a manic or mixed episode of bipolar-I disorder, Aripiprazole showed no superior effectiveness." "" "" ""</seg>
<seg id="84">"" "" "" "in two placebo and active-controlled monotherapy trials over 12 weeks in patients with a manic or mixed episode of a bipolar-I-fault, with or without psychotic features, it was comparable to that of lithium or Haloperidol in week 12." "" "" ""</seg>
<seg id="85">"" "" "" "in addition, Aripiprazole also showed a comparable share of patients with symptomatic remission of the mania on how lithium or haloperidol." "" "" ""</seg>
<seg id="86">"" "" "" "in a placebo-controlled trial of 6 weeks with a manic or mixed episode of a bipolar-I-disorder, with or without psychotic symptoms, the accompanying therapy with Aripiprazole revealed a superior effectiveness in the reduction of chronic symptoms compared to monotherapy with lithium or Valproat." "" "" ""</seg>
<seg id="87">"" "" "" "10 In a placebo-controlled trial over 26 weeks followed by a long-term extension phase spanning a remission with Aripiprazole, predominantly in the prevention of a bipolar return, mainly in the prevention of a bipolar return." "" "" ""</seg>
<seg id="88">"" "" "" "based on in vitro studies, the CYP3A4 and CYP2D6 are responsible for the dehydration and hydroxylation of Aripiprazole, which is catalyzes by CYP3A4." "" "" ""</seg>
<seg id="89">The mean Eliminationshal period is approximately 75 hours for Aripiprazole with extensive metabolites for CYP2D6 and at approximately 146 hours in 'bad' (= "Poor") Metabolism over CYP2D6.</seg>
<seg id="90">"" "" "" "at Aripiprazole there are no differences in pharmacokinetics between male and female healthy subjects, as well as a pharmacokinetic examination had no gender dependent effects." "" "" ""</seg>
<seg id="91">Pre-specific evaluation of pharmacokinetics showed no indication of clinically significant differences in ethnic origin or effect of smoking at the pharmacokinetics of Aripiprazole.</seg>
<seg id="92">The pharmacokinetic characteristics of Aripiprazole and Dehydro-Aripiprazole were similar in patients with severe kidney disease compared to young healthy volunteers.</seg>
<seg id="93">"" "" "" "a single dose study with various engravings in liver cirrhosis (Child-Pugh Class A, B and C) showed no significant effect on liver cirrhosis of the class C, which does not suffice to draw conclusions on their metabolic capacity." "" "" ""</seg>
<seg id="94">"" "" "" "based on conventional studies on safety macology, toxicity in repeating gift, reproduction and carcinogenicity potential, the preventive data don't have any particular dangers for humans." "" "" ""</seg>
<seg id="95">"" "" "" "toxicologically significant effects were observed only in dosages or expositions which significantly exceeded the maximum dose or exposure to man, so they have limited or no meaning for clinical use." "" "" ""</seg>
<seg id="96">The effects converge a dosistive side-level toxicity (AUC) at the recommended maximum dose when humans and / or parenchymal exposure (AUC) at the recommended maximum dose for humans in 60 mg / kg / day (AUC) at the recommended maximum dose for people).</seg>
<seg id="97">It has also been noted as a result of the precipitation of the hydroxy- metabolism of the hydroxy- metabolites of hydroxy- Metabolism (AUC) in the recommended clinical dose or 16- to 81times the recommended maximum dose for people based on mg / m2.</seg>
<seg id="98">"" "" "" "however, in the human gall at the highest recommended daily dose of 30 mg of hydroxy- Aripiprazole not found more than 6 weeks in the gall of monkeys, they lie far among the values (6%) in vitro-solubility." "" "" ""</seg>
<seg id="99">"" "" "" "in rabbits, these effects were observed according to dosages, which led to expositions of 3- and 11x of the medium Steady State AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="100">"" "" "" "perforated blister for dispensing of single boxes made of aluminium in folding cartons with 14 x 1, 28 x 1, 56 x 1, 98 x 1 tablets." "" "" ""</seg>
<seg id="101">"" "" "" "15 late dyskinesies: in clinical trials which lasted one year or less, there were occasional reports during treatment with Aripiprazole." "" "" ""</seg>
<seg id="102">It is presumed that the effectiveness of Aripiprazole in schizophrenia and bipolar-I disorder is mediated on a combination of a partial sensory effect on dopamine D2- and serotonin 5HT1a- receptors and a antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="103">"" "" "" "22 After a placebo-controlled trial over 26 weeks, Aripiprazole had achieved a remission with Aripiprazole, compared to the prevention of a bipolar return, mainly in the prevention of a bipolar return." "" "" ""</seg>
<seg id="104">"" "" "" "27 late dyskinesies: in clinical trials which lasted one year or less, there were occasional reports during treatment with Aripiprazole." "" "" ""</seg>
<seg id="105">It is presumed that the effectiveness of Aripiprazole in schizophrenia and bipolar-I disorder is mediated on a combination of a partial sensory effect on dopamine D2- and serotonin 5HT1a- receptors and a antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="106">"" "" "" "34 After a placebo-controlled trial over 26 weeks, Aripiprazole had achieved a remission with Aripiprazole, predominantly in the prevention of a bipolar return, mainly in the prevention of a bipolar return." "" "" ""</seg>
<seg id="107">"" "" "" "39 late dyskinesies: in clinical trials which lasted one year or less, there were occasional reports during treatment with Aripiprazole." "" "" ""</seg>
<seg id="108">It is presumed that the effectiveness of Aripiprazole in schizophrenia and bipolar-I disorder is mediated on a combination of a partial sensory effect on dopamine D2- and serotonin 5HT1a- receptors and a antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="109">"" "" "" "46 In a placebo-controlled trial over 26 weeks followed by a long-term extension phase spanning a remission with Aripiprazole, predominantly in the prevention of a bipolar return, mainly in the prevention of a bipolar return." "" "" ""</seg>
<seg id="110">The recommended starting dose for Aripiprazole is 10 or 15 mg / day at a maintenance dose of 15 mg / day a day regardless of meals.</seg>
<seg id="111">Patients who have difficulties when swallowing ABILIFY tablets can take the melting tablets at an alternative to ABILIFY tablets (see Section 5.2).</seg>
<seg id="112">"" "" "" "in some cases, the occurrence of suicidal disorders is reported in some cases after the beginning or after changes of antipsychotic therapy, also in treatment with Aripiprazole (see section 4.8)." "" "" ""</seg>
<seg id="113">"" "" "" "late dyskinesien: in clinical trials which lasted one year or less, there were occasional reports during treatment with Aripiprazole." "" "" ""</seg>
<seg id="114">"" "" "" "clinical manifestations of a mns are high fever, muscle rigidity, varying levels of consciousness and signs of autonomous instability (irregular pulse, blood pressure, sweating and heart rhythm disorders)." "" "" ""</seg>
<seg id="115">"" "" "" "in general, a weight gain is generally observed in schizophrens patients and patients with bipolar mandities, the use of antipsychotics in which weight gain is known as a side effect and could lead to serious complications." "" "" ""</seg>
<seg id="116">"" "" "" "patients should be advised to notify your doctor if they become pregnant, or a pregnancy during treatment with Aripiprazole." "" "" ""</seg>
<seg id="117">The following adverse events were more common (≥ 1 / 100) than placebo or were classified as possible medically relevant effects of medicine (*):</seg>
<seg id="118">"" "" "" "in two placebo-controlled monotherapy studies with a more flexible dosage of 3 weeks with a manic or mixed episode of bipolar-I disorder, Aripiprazole was compared to placebo over 3 weeks." "" "" ""</seg>
<seg id="119">"" "" "" "58 In a placebo-controlled trial of 6 weeks with a manic or mixed episode of a bipolar-I-disorder, with or without psychotic symptoms that partly did not have a superior effectiveness in reducing deficiency of chronic symptoms compared to monotherapy with lithium or Valproat." "" "" ""</seg>
<seg id="120">"" "" "" "in a placebo-controlled trial over 26 weeks, Aripiprazole had achieved a remission with Aripiprazole during a stabilization phase before the prevention of a bipolar return, predominantly in the prevention of a bipolar return." "" "" ""</seg>
<seg id="121">"" "" "" "in rabbits, these effects were according to dosages, which are to expositions in 3 and 11 times of the mean steady State AUC at the recommended clinical trial." "" "" ""</seg>
<seg id="122">Patients who have difficulties when swallowing ABILIFY tablets can take the melting tablets at an alternative to ABILIFY tablets (see Section 5.2).</seg>
<seg id="123">"" "" "" "late dyskinesien: in clinical trials which lasted one year or less, there were occasional reports during treatment with Aripiprazole." "" "" ""</seg>
<seg id="124">"" "" "" "71 In a placebo-controlled trial of 6 weeks with a manic or mixed episode of a bipolar-I-disorder, with or without psychotic symptoms, the accompanying therapy with Aripiprazole, revealed a superior effectiveness in the reduction of chronic symptoms compared to monotherapy with lithium or Valproat." "" "" ""</seg>
<seg id="125">Patients who have difficulties when swallowing ABILIFY tablets can take the melting tablets at an alternative to ABILIFY tablets (see Section 5.2).</seg>
<seg id="126">"" "" "" "late dyskinesien: in clinical trials which lasted one year or less, there were occasional reports during treatment with Aripiprazole." "" "" ""</seg>
<seg id="127">84 In a placebo-controlled trial of 6 weeks with a manic or mixed episode of a bipolar-I-fault with or without psychotic symptoms that partly did not have a superior effectiveness in the reduction of chronic symptoms compared to monotherapy with lithium or Valproat.</seg>
<seg id="128">200 mg of fructose per ml 400 mg Sucrose by ml 1.8 mg methyl-4 hydroxybenzoat (E218) per ml per pyl-4 hydroxybenzoat (E216) per ml.</seg>
<seg id="129">The recommended starting dose for ABILIFY is 15 mg once a day regardless of the meals as monotherapy or combination therapy (see Section 5.1).</seg>
<seg id="130">"" "" "" "to prevention of recurrence of Manic Episodes in patients who have already received Aripiprazole, the therapy will be continued with the same dose." "" "" ""</seg>
<seg id="131">"" "" "" "late dyskinesien: in clinical trials which lasted one year or less, there were occasional reports during treatment with Aripiprazole." "" "" ""</seg>
<seg id="132">"" "" "" "hyperglycemia, in some cases extremely and associated with etoazide or hyperosmolarem coma or death, was reported in patients who were treated with atypical antipsychotic drugs including ABILIFY." "" "" ""</seg>
<seg id="133">"" "" "" "there are no precise risk assessment for hyperglycemia-related events associated with ABILIFY and other atypical antipsychotic drugs, which allow direct comparisons." "" "" ""</seg>
<seg id="134">92 In a clinical trial with healthy volunteers a highly effective CYP2D6 inhibitor (Chinidin) increased the AUC from Aripiprazole to 107% while the Cmax remained unchanged.</seg>
<seg id="135">Diaztiazem or Escitalopram) or CYP2D6 together with ABILIFY will be given together with an excessive increase in Aripiprazol- concentrations.</seg>
<seg id="136">"" "" "" "Manic Episodes in bipolar-I-disorder - In a controlled trial over 12 weeks, the incidence of EPS 23,5% was among patients under Aripiprazol-" "" "" ""</seg>
<seg id="137">It is presumed that the effectiveness of Aripiprazole in schizophrenia and bipolar-I disorder is mediated on a combination of a partial sensory effect on dopamine D2- and serotonin 5HT1a- receptors and a antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="138">"" "" "" "in an olanzapine-controlled, multinational double-blind study included in schizophrenia (N = 18 or 13% of the most valuable patients) in significantly less patients (i.e. an increase of at least 5,6 kg in average weight)." "" "" ""</seg>
<seg id="139">97 in a placebo-controlled monotherapy study with fixed dose of patients with a manic or mixed episode of bipolar-I disorder showed Aripiprazole versus placebo no superior effectiveness.</seg>
<seg id="140">In a relative Bioverfeed study in which the Pharmacokinetics of 30 mg Aripiprazole was compared to a intake of 30 mg Aripiprazole in pill form and the value of the tablets at 122% (N = 30).</seg>
<seg id="141">99 Thanks to the recommended dose of hydroxy- metabolites of hydroxy- metabolism in the bile from 25 to 125 mg / kg / day (AUC) in the recommended clinical dose or 16- to 81times the recommended maximum dose for people based on mg / m2.</seg>
<seg id="142">"" "" "" "in rabbits, these effects were observed according to dosages, which led to expositions of 3- and 11x of the medium Steady State AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="143">ABILIFY injection solution is used for quick control of immunogidity and behavioural disorders in patients with manic episodes of bipolar-I disorder when oral therapy is not appropriate.</seg>
<seg id="144">"" "" "" "once it is clinically appropriate, the treatment with Aripiprazole should be completed and started with the oral application of Aripiprazole." "" "" ""</seg>
<seg id="145">"" "" "" "to minimize the absorption and minimize variability, an injection in the M. deltoideus or deep in the gluteus-maximus muscle is recommended under conversion of adipous regions." "" "" ""</seg>
<seg id="146">"" "" "" "a lower dose of 5,25 mg (0.7 ml) depends on the individual clinical status taking into account which has already been given to the approximate or acute therapy (see section 4.5)." "" "" ""</seg>
<seg id="147">"" "" "" "if a further oral treatment is indexed using Aripiprazole, see the summary of the characteristics of the drug using ABILIFY tablets, ABILIFY melting tablets or ABILIFY solution." "" "" ""</seg>
<seg id="148">"" "" "" "there are no studies on efficacy of Aripiprazole injection solution in patients with anti-animal and behavioural disorders, which were different from schizophrenia and manic episodes of the bipolar-I disorder." "" "" ""</seg>
<seg id="149">"" "" "" "in addition to a parenteral therapy with benzodiazepine, in addition to the arithmetical injection solution, patients should be observed in extreme encoding or blood pressure (see section 4.5)." "" "" ""</seg>
<seg id="150">Examinations concerning the safety and effectiveness of Aripiprazole injection solution are not available for patients with alcohol or drug poisoning (caused by the prescribed or illegal drugs).</seg>
<seg id="151">Aripiprazole should be used with caution in patients with known cardiovascular disease (dehydration disorders), cerebrovascular diseases (dehydration disorders) or hypertonia (including acelogenous and malignant form).</seg>
<seg id="152">"" "" "" "late dyskinesien: in clinical trials which lasted one year or less, there were occasional reports during treatment with Aripiprazole." "" "" ""</seg>
<seg id="153">Clinical trials of a mns are high fever, muscle rigidity, variable levels of consciousness and signs of autonomous instability (irregular pulse or blood pressure, tating and heart rhythm disorders).</seg>
<seg id="154">Polydipsy (polyurie, polyphagie and weakness) are observed and patient with diabetes mellitus or with risk factors for diabetes mellitus should be regularly monitored in relation to deterioration of glucose levels.</seg>
<seg id="155">"" "" "" "in general, a weight gain is observed in schizophran patients and patients with bipolar mandities, the use of antipsychotics, in which weight gain is known as a side effect and could lead to serious complications." "" "" ""</seg>
<seg id="156">"" "" "" "nevertheless the intensity of the Sedation was greater compared to the only gift of Aripiprazole, in a study in the healthy subjects of Aripiprazole (15 mg dose) and simultaneously received Lorazepam (2 mg doses)." "" "" ""</seg>
<seg id="157">"" "" "" "105 The H2 antagonist Famotidine, a gastric-blockers, reduces the resorption of Aripiprazole, although this effect is regarded as clinically irrelevant." "" "" ""</seg>
<seg id="158">"" "" "" "in comparison to CYP2D6 'bad' (= 'Poor") Metabolism, the common application can result with high-effective inhibitors of CYP3A4 in higher plasma concentration of Aripiprazole. "" "" "" "</seg>
<seg id="159">Other highly effective inhibitors of CYP3A4 like Itraconazole and HIVA inhibitors that have similar effects may have similar effects.</seg>
<seg id="160">"" "" "" "after placing the CYP2D6- or 3A4 Inhibitors, the dose of ABILIFY should be raised to the dose height prior to the companion therapy." "" "" ""</seg>
<seg id="161">"" "" "" "106 Lorazepam (2 mg doses) intramuscular, the intensity of Sedation was greater compared to the sole gift of Aripiprazole." "" "" ""</seg>
<seg id="162">"" "" "" "the following adverse events were more common in clinical studies using Aripiprazole injection solution more common (≥ 1 / 100) than placebo or were classified as possible medically relevant effects (*):" "" "" ""</seg>
<seg id="163">"" "" "" "the frequency of the side-related side effects is defined according to the following criteria: frequently (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1.000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="164">107 The following adverse events were more common (≥ 1 / 100) as under placebo or were classified as possible medically relevant effects (*) in clinical trials (see Section 5.1):</seg>
<seg id="165">"" "" "" "in a placebo-controlled study for over 26 weeks, the incidence of EPS 19% was under Aripiprazol- treatment and 13.1% in patients under placebo." "" "" ""</seg>
<seg id="166">"" "" "" "in another study over 12 weeks, the incidence of EPS 26.6% was diagnosed with Aripiprazol- treatment and 17.6% for those under lithium-treatment." "" "" ""</seg>
<seg id="167">"" "" "" "during a period of 26 weeks during a placebo-controlled trial, the incidence of EPS is 18.2% for patients suffering from Aripiprazole treatment and 15.7% for placebo treated patients." "" "" ""</seg>
<seg id="168">"" "" "" "a comparison between the patient groups below Aripiprazole and placebo, in which potentially clinically significant changes of routinely controlled laboratory parameters came up, showed no medically significant differences." "" "" ""</seg>
<seg id="169">Enhancements of the Cpk (creatinphosphokinase) generally observed temporarily and asymptomatically, compared to 2.0% of patients treated with placebo.</seg>
<seg id="170">"" "" "" "the malignant neuroleptic syndrome, hyperglycemia and diabetes mellitus, hyperglycemia and diabetes mellitus, belong to the adverse effects associated with Aripiprazole, and diabetes mellitus (see Section 4.4)." "" "" ""</seg>
<seg id="171">"" "" "" "110 and behavioural disorders, the arithmetical injection solution, associated with statistically significant improvements of appracy / behavioural disorders were compared to placebo and similar to Haloperidol." "" "" ""</seg>
<seg id="172">"" "" "" "in a placebo-controlled short-time study (24 h) with bipolar disorder and behavioural problems associated with a statistically significant improvement of symptoms regarding the abnormality and behavioural disorders compared to placebo and similar to the Lorazepam- reference arm." "" "" ""</seg>
<seg id="173">The observed average improvement of the output value on the PANSS Excitement Component score at the primary 2-hour end point was 5.8 for placebo, 9.6 for Lorazepam and 8.7 for Aripiprazole.</seg>
<seg id="174">"" "" "" "in analyses of subgroups in patients with mixed episodes or patients with severe retinal specimens, a similar efficacy was observed on the overall population, but a statistical significance was observed due to a reduced patient number." "" "" ""</seg>
<seg id="175">"" "" "" "in three placebo-controlled short-time studies (4 to 6 weeks), Aripiprazole (oral) showed a statistically significantly stronger improvement in psychotic symptoms compared to placebo." "" "" ""</seg>
<seg id="176">"" "" "" "in a Haloperidol study, 52% of patients responding to study medication is similar in both groups (Aripiprazole 77%) and haloperidol 73%)." "" "" ""</seg>
<seg id="177">"" "" "" "current values from measuring shelves, which were defined as secondary studies, including PANSS and Montgomery-Asberg depression, showed significantly stronger improvement than at Haloperidol." "" "" ""</seg>
<seg id="178">In a placebo-controlled study on 26 weeks of stabilised patients with chronic schizophrenia (oral) showed significantly higher reduction of the return rate which amounted to 34% in the Aripiprazol- (oral) group and 57% among placebo.</seg>
<seg id="179">"" "" "" "in an olanzapine-controlled, multinational double-blind study on schizophrenia (N = 18 or 13% of ausvaluable patients) in significantly less patients had a weight gain of at least 5,6 kg (i.e. an average weight of at least 5,6 kg)." "" "" ""</seg>
<seg id="180">111 In a placebo-controlled trial of 6 weeks with a manic or mixed episode of a bipolar-I-fault with or without psychotic symptoms that partly did not have a superior effectiveness in the reduction of chronic symptoms compared to monotherapy with lithium or Valproat.</seg>
<seg id="181">"" "" "" "in a placebo-controlled trial over 26 weeks followed by a 74-week study extension, with Aripiprazole, compared to the prevention of a bipolar return, the prevention of a bipolar return, mainly in the prevention of a bipolar return." "" "" ""</seg>
<seg id="182">"" "" "" "in the first 2 hours after intramuscular injection, the Aripiprazole is 90% larger the AUC after the gift of the same dose as tablet; the systemic exposure was similar to the two formulations." "" "" ""</seg>
<seg id="183">"" "" "" "in 2 studies with healthy volunteers, the mean time until reaching the maximum plasma mask in 1 to 3 hours after application." "" "" ""</seg>
<seg id="184">"" "" "" "the gift of Aripiprazole injection solution was well tolerated by rats and monkeys, resulting in no direct toxicity of a response to a systemic exposure of 30 mg and 5 times over the maximum human therapeutic exposure of 30 mg." "" "" ""</seg>
<seg id="185">"" "" "" "in studies on reproduction of reproduction after intravenous application, no security concerns after maternal exposure took place in 15- (rats) and 29 times (rabbits) over the maximum human therapeutic exposure of 30 mg." "" "" ""</seg>
<seg id="186">"" "" "" "based on conventional studies using Aripiprazole (oral) for security macology, toxicity in repealed gift, reproduction and carcinogenicity potential, the preventive data don't have any particular dangers for humans." "" "" ""</seg>
<seg id="187">"" "" "" "toxicologically significant effects were observed only in dosages or expositions which significantly exceeded the maximum dose or exposure to man, so they have limited or no meaning for clinical use." "" "" ""</seg>
<seg id="188">The effects converge a dosistive side-level toxicity (AUC) at the recommended maximum dose for humans and / or parenchylic acid exposure (AUC) at the recommended maximum dose for humans in 60 mg / kg / day (AUC) at the recommended maximum dose for people).</seg>
<seg id="189">"" "" "" "in addition, an Choleliothiasis was found as a result of the precipitation of the hydroxy- metabolites of hydroxy- metabolites in the recommended clinical dose or 16- to 81 times the recommended maximum dose for people based on mg / m2." "" "" ""</seg>
<seg id="190">"" "" "" "in rabbits, these effects were observed according to dosages, which resulted in expositions of 3- and 11-times of the medium Steady state AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="191">"" "" "" "" "" "" "" "the approval holder needs to ensure that before and while the product is marketed, the pharmaceutical covigilance system, as described in version 1.0 of the application form, is set up and functional." "" "" ""</seg>
<seg id="192">"" "" "" "according to CHMP Guideline on Risk Management Systems for Human Use," the updated risk management plan must be submitted at the same time with the next periodic safety update Report (PSUR). "" "" "" "</seg>
<seg id="193">"" "" "" "in addition, a updated risk management plan must be submitted as new information is to be published, which was reached within 60 days after an important milestone of pharmaceutical covigilance or measures to risk management on request of the EMEA." "" "" ""</seg>
<seg id="194">14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets</seg>
<seg id="195">EU / 1 / 04 / 276 / 002 14 x 1 tablets EU / 1 / 04 / 276 / 002 49 x 1 tablets EU / 1 / 04 / 276 / 004 56 x 1 tablets EU / 1 / 04 / 276 / 005 98 x 1 tablets</seg>
<seg id="196">1 / 1 / 04 / 276 / 006 14 x 1 tablets EU / 1 / 04 / 276 / 276 / 008 56 x 1 tablets EU / 1 / 04 / 276 / 008 56 x 1 tablets EU / 1 / 04 / 276 / 010 98 x 1 tablets</seg>
<seg id="197">EU / 1 / 04 / 276 / 011 14 x 1 tablets EU / 1 / 04 / 276 / 013 28 x 1 tablets EU / 1 / 04 / 276 / 014 56 x 1 tablets EU / 1 / 04 / 276 / 015 98 x 1 tablets</seg>
<seg id="198">EU / 1 / 04 / 276 / 016 14 x 1 tablets EU / 1 / 04 / 276 / 018 28 x 1 tablets EU / 1 / 04 / 276 / 019 56 x 1 tablets EU / 1 / 04 / 276 / 020 98 x 1 tablets</seg>
<seg id="199">"" "" "" "if one of the listed side effects are significantly impaired or you will notice any side effects that are not listed in this user information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="200">"" "" "" "it is used for the treatment of adults who suffer from a sickness such as hearing, seeing or mills of things that are not present, mistrust, insulls, unrelated language, wirres behaviour and flatter mood." "" "" ""</seg>
<seg id="201">"" "" "" "ABILIFY is used in adults to treat a state with excessive feeling that feel excessive energy, much less sleep is needed than usually, very quick speech with quickly changing ideas and sometimes strong irritability." "" "" ""</seg>
<seg id="202">High blood sugar or cases of diabetes (diabetes) in the family attacks are not arbitrary or irregular muscle movements, especially in the face cardiac or vascular bleeding in the brain (transit or temporary ischaemic attack / TIA). abnormal blood pressure.</seg>
<seg id="203">"" "" "" "if you suffer from an older patient to dementia (loss of memory or other intellectual abilities), you should consult a stroke or a temporary managulation of the brain." "" "" ""</seg>
<seg id="204">"" "" "" "immediately inform your doctor if you suffer from rigidity or rigidity associated with high fever, sweating, modified mental state or very rapid heart beat." "" "" ""</seg>
<seg id="205">"" "" "" "children and young people ABILIFY are not applicable in children and adolescents, as it has not been examined in patients under 18 years of age." "" "" ""</seg>
<seg id="206">"" "" "" "when taking ABILIFY with other medicines please inform your doctor or pharmacist if you have taken other medicines / apply or used recently, even if it is not prescription drugs." "" "" ""</seg>
<seg id="207">Medicines for treatment of heart rhythmia antidepressants or herbal medicines used to treat depression and anxiety used drugs to treat diseases of HIV infection anticonvulva which are used to treat epilepsy.</seg>
<seg id="208">"" "" "" "pregnancy and breastfeeding should not take ABILIFY if you are pregnant, unless you have taken this to your doctor." "" "" ""</seg>
<seg id="209">"" "" "" "machines and use of machinery you should not drive a car, and operate no tools or machines until you know how ABILIFY works with you." "" "" ""</seg>
<seg id="210">"" "" "" "please take this medicine only after consultation with your doctor, if you know that you suffer from a tolerability towards certain sugars." "" "" ""</seg>
<seg id="211">"" "" "" "please contact your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or weak." "" "" ""</seg>
<seg id="212">"" "" "" "even if you feel better, change or use the daily dose of ABILIFY not to ask for your doctor before." "" "" ""</seg>
<seg id="213">If you have taken a larger amount of ABILIFY as you should find that you have taken more ABILIFY tablets as taken from your doctor (or if someone else has taken some of your ABILIFY tablets), please contact your doctor promptly.</seg>
<seg id="214">"" "" "" "if you forget the intake of ABILIFY If you have forgotten a dose, take the forgotten dose once you think, do not take the double dose in one day." "" "" ""</seg>
<seg id="215">"" "" "" "frequent side effects (in more than 1 out of 100, less than 1 out of 10 treated) uncontrollable accessibility, stipation, sleep problems, anxiety, sledity, trembling, and blurred vision." "" "" ""</seg>
<seg id="216">"" "" "" "occasional side effects (at more than 1 of 1,000, less than 1 of 100 treated) Some persons can feel dizzy, especially if they stand out of lying or sitting position, or can find an accelerated pulse." "" "" ""</seg>
<seg id="217">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will be significantly impaired or you will notice any side effects that are not listed in this manner." "" "" ""</seg>
<seg id="218">"" "" "" "like ABILIFY and content of the pack ABILIFY 5 mg tablets are rectangular and blue, with the embossing of A-007 and 5 on one page." "" "" ""</seg>
<seg id="219">"" "" "" "immediately inform your doctor if you suffer from rigidity or rigidity associated with high fever, sweating, modified mental state or very rapid heart beat." "" "" ""</seg>
<seg id="220">"" "" "" "even if you feel better, change or use the daily dose of ABILIFY not to ask for your doctor before." "" "" ""</seg>
<seg id="221">"" "" "" "like ABILIFY and content of the pack ABILIFY 10 mg tablets are rectangular and pink, with embossing from A-008 and 10 on one page." "" "" ""</seg>
<seg id="222">"" "" "" "immediately inform your doctor if you suffer from rigidity or rigidity associated with high fever, sweating, modified mental state or very rapid heart beat." "" "" ""</seg>
<seg id="223">"" "" "" "even if you feel better, change or use the daily dose of ABILIFY not to ask for your doctor before." "" "" ""</seg>
<seg id="224">"" "" "" "like ABILIFY and content of the pack ABILIFY 15 mg tablets are round and yellow, with embossing from A-009 and 15 on one page." "" "" ""</seg>
<seg id="225">"" "" "" "immediately inform your doctor if you suffer from rigidity or rigidity associated with high fever, sweating, modified mental state or very rapid heart beat." "" "" ""</seg>
<seg id="226">"" "" "" "even if you feel better, change or use the daily dose of ABILIFY not to ask for your doctor before." "" "" ""</seg>
<seg id="227">"" "" "" "like ABILIFY and content of the pack ABILIFY 30 mg tablets are round and pink, with embossing from A-011 and 30 on one page." "" "" ""</seg>
<seg id="228">"" "" "" "171 If you suffer as an older patient to dementia (loss of memory or other intellectual abilities), you should or a keeper / a relationship to your doctor if you ever had a stroke or temporary managulation of the brain." "" "" ""</seg>
<seg id="229">"" "" "" "immediately inform your doctor if you suffer from rigidity or rigidity associated with high fever, sweating, modified mental state or very rapid heart beat." "" "" ""</seg>
<seg id="230">Important information about certain other components of ABILIFY patients who have no phenylalanine may be allowed to take note that ABILIFY is contained as a source of phenylalanine.</seg>
<seg id="231">"" "" "" "take it immediately after opening the blister pack the tablet with dry hands, and put the melting tray in the whole on the tongue." "" "" ""</seg>
<seg id="232">"" "" "" "even if you feel better, change or use the daily dose of ABILIFY not to ask for your doctor before." "" "" ""</seg>
<seg id="233">If you have taken a larger amount of ABILIFY when you find that you have taken more ABILIFY melting tablets as taken from your doctor (or if someone else has taken some of your ABILIFY melting tray) please contact your doctor promptly.</seg>
<seg id="234">"" "" "" "calciumtrimetasilicat, Croscarmless sodium, Crospovidon, silicium dioxide, micro-crystalline, vanilla, magnesium, magnesium, magnesium, magnesium (III) - Oxide (E172)." "" "" ""</seg>
<seg id="235">"" "" "" "like ABILIFY and contents of the pack The ABILIFY 10 mg of melting tablets are round and pink, with embossing from" A "over" 640 "on one side and" 10 "on the other." "" "" ""</seg>
<seg id="236">"" "" "" "177 If you suffer from an older patient to dementia (loss of memory or other intellectual abilities), you should or a keeper / a relationship to your doctor if you ever had a stroke or temporary managulation of the brain." "" "" ""</seg>
<seg id="237">"" "" "" "immediately inform your doctor if you suffer from rigidity or rigidity associated with high fever, sweating, modified mental state or very rapid heart beat." "" "" ""</seg>
<seg id="238">"" "" "" "calciumtrimetasilicat, Croscarmless sodium, Crospovidon, silicon dioxide, microalline aroma, asylitol, asylitol, hydroxide gerate, iron (III) - hydroxid oxide x H2O (E172)." "" "" ""</seg>
<seg id="239">"" "" "" "as ABILIFY looks and content of the pack The ABILIFY 15 mg of melting tablets are round and yellow, with embossing from" A "over" 641 "on one side and" 15 "on the other." "" "" ""</seg>
<seg id="240">"" "" "" "183 If you suffer as an older patient to dementia (loss of memory or other intellectual abilities), you should consult a stroke or a temporary managulation of the brain." "" "" ""</seg>
<seg id="241">"" "" "" "immediately inform your doctor if you suffer from rigidity or rigidity associated with high fever, sweating, modified mental state or very rapid heart beat." "" "" ""</seg>
<seg id="242">"" "" "" "like ABILIFY and contents of the pack The ABILIFY 30 mg of melting tablets are round and pink, with embossing from" A "over" 643 "on one side and" 30 "on the other." "" "" ""</seg>
<seg id="243">"" "" "" "immediately inform your doctor if you suffer from rigidity or rigidity associated with high fever, sweating, modified mental state or very rapid heart beat." "" "" ""</seg>
<seg id="244">"" "" "" "machines and use of machinery you should not drive a car, and operate no tools or machines until you know how ABILIFY works with you." "" "" ""</seg>
<seg id="245">190 Important information about certain other components of ABILIFY each ml ABILIFY solution for insertion contains 200 mg of fructose and 400 mg Sucrose.</seg>
<seg id="246">"" "" "" "if your doctor has informed you that you suffer from intolerance to certain sugars, please contact your doctor before using this medicine." "" "" ""</seg>
<seg id="247">The dose to ABILIFY solution must be measured using the weighted measuring cup or the 2 ml tropicpipette that are contained in the package.</seg>
<seg id="248">"" "" "" "please contact your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or weak." "" "" ""</seg>
<seg id="249">If you have taken a larger amount of ABILIFY as you should determine that you have taken more ABILIFY solution as taken from your doctor (or if someone has taken ABILIFY solution to get taken), please contact your doctor promptly.</seg>
<seg id="250">"" "" "" "dinals, glycerol, glycerol, lacyl glycol, propyl-4 hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216)." "" "" ""</seg>
<seg id="251">How ABILIFY looks like and content of the pack ABILIFY 1 mg / ml solution for inserting is a clear, colored until light yellow liquid in bottles with a child-safe polypropylene locking flap and 50 ml; 150 ml or 480 ml</seg>
<seg id="252">"" "" "" "ABILIFY injection solution is applied to the rapid treatment of increased unrest and doubtful behavior that are identified as symptoms of a disease, which are not present, mistrust, insults, unrelated language, wirres behaviour and flatter mood." "" "" ""</seg>
<seg id="253">"" "" "" "people with this disease can also be depressed, anxious or strained. excessive energy to have much less sleep than usually, very fast speech with changing ideas and sometimes strong irritability." "" "" ""</seg>
<seg id="254">"" "" "" "immediately inform your doctor if you suffer from rigidity or rigidity associated with high fever, sweating, modified mental state or very rapid heart beat." "" "" ""</seg>
<seg id="255">"" "" "" "when using ABILIFY with other medicines please inform your doctor or pharmacist if you have taken other medicines / apply or used recently, even if it is not prescription drugs." "" "" ""</seg>
<seg id="256">Medicines for treatment of heart rhythmia antidepressants or herbal medicines used to treat depression and anxiety used drugs to treat diseases of HIV infection anticonvulva which are used to treat epilepsy.</seg>
<seg id="257">"" "" "" "196 pregnancy and breastfeeding should not apply ABILIFY if you are pregnant, unless you have taken this to your doctor." "" "" ""</seg>
<seg id="258">"" "" "" "machines and use of machinery you should not drive a car, and do not use tools or machines when you use ABILIFY injections." "" "" ""</seg>
<seg id="259">"" "" "" "if you have concerns that you get more ABILIFY injections than you need to believe, please contact your doctor or care about it." "" "" ""</seg>
<seg id="260">"" "" "" "frequent side effects (in more than 1 out of 100, less than 1 out of 10 treated) by ABILIFY injections are tiredness, dizziness, restlessness, nausea and vomiting." "" "" ""</seg>
<seg id="261">"" "" "" "occasional side effects (at more than 1 of 1000, less than 1 of 100 treated) Some people may feel a change of blood, especially when sitting out of lying or sitting, or having a fast pulse, a dry sense of dry or feel." "" "" ""</seg>
<seg id="262">"" "" "" "frequent side effects (in more than 1 out of 100, less than 1 out of 10 treated) uncontrollable accessibility, stipation, sleeping troubles, anxiety, sledity, trembling, and blurred vision." "" "" ""</seg>
<seg id="263">"" "" "" "if you need further information about your illness or treatment, please read the package directions (also part of the EPAR) or apply to your doctor or pharmacist." "" "" ""</seg>
<seg id="264">Abraxane ought to be used only under the supervision of a qualified oncologist at the application of cytostatika (killing of cells) specialised departments.</seg>
<seg id="265">"" "" "" "in patients with certain side effects on the blood or the nervous system, the dose can be reduced or the treatment is interrupted." "" "" ""</seg>
<seg id="266">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.eu http. "" "" "" "</seg>
<seg id="267">"" "" "" "the efficacy of Abraxane was studied in a main study, in which 460 women participated with metastatic breast cancer, of which approximately three quarters had obtained a Anthracycline." "" "" ""</seg>
<seg id="268">The effect of Abraxane (in sole discretion) was compared to a conventional Paclitaxel (given in combination with other medicines for reducing the side effects).</seg>
<seg id="269">"" "" "" "a total of 72 (31%) of 229 with Abraxane patients were treated in the treatment, compared with 37 (16%) of 225 patients, which contained conventional Paclitaxel drugs." "" "" ""</seg>
<seg id="270">"" "" "" "considering only the patients who were treated for the first time because of metastatic breast cancer, there were no difference between pharmaceuticals and survival." "" "" ""</seg>
<seg id="271">"" "" "" "in contrast, patients showed other treatments of their metastatic breast cancer in relation to these indicators that Abraxane acted as conventional Paclitaxel as conventional drug." "" "" ""</seg>
<seg id="272">"" "" "" "in addition, it must not be applied in patients who have low neutrophiles in the blood before the treatment." "" "" ""</seg>
<seg id="273">"" "" "" "the drug for human medicines (CHMP) proved that Abraxane contained the first treatment more effectively than conventional Paclitaxel, and that it has to be given more effective than other paclitaxel foods to reduce side effects." "" "" ""</seg>
<seg id="274">"" "" "" "" "" "" "" "from January 2008, the European Commission approved Abraxis BioScience Limited on the basis of the basis of Abraxane in the whole European Union." "" "" ""</seg>
<seg id="275">Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in patients with which the first-line therapy for metastatic breast cancer is not shown and is not displayed in a standard Anthracycline therapy (see also Section 4.4).</seg>
<seg id="276">"" "" "" "in patients with severe neutrropia (neutrophilenium &lt; 0,50 x 109 / l over a period of one week or longer) or severe sensorial neuropathy during the Abraxane therapy the dose should be reduced to 220 mg / m2." "" "" ""</seg>
<seg id="277">"" "" "" "at sensory Neuropathy Grad, 3 is the treatment to interrupt until an improvement is reached on degree 1 or 2, and with all subsequent cycles the dose must be reduced." "" "" ""</seg>
<seg id="278">There are currently no sufficient data for the recommendation of dosisadaptations in patients with mild to moderate impairment of the liver function (see Section 4.4. and 5.2).</seg>
<seg id="279">"" "" "" "there were no studies involving patients with impaired renal function, and there are currently no sufficient data on patients with impairment of the renal function (see Section 5.2)." "" "" ""</seg>
<seg id="280">Abraxane is not recommended for use in children under 18 years due to non-sufficient data for impemability and effectiveness.</seg>
<seg id="281">Abraxane is an albumin-bent nanoparist formulation of paclitaxel to be used as other pharmacological characteristics as other formulations by paclitaxel (see Section 5.1 and 5.2).</seg>
<seg id="282">"" "" "" "if an allergic reaction occurs, the medicine should be removed immediately and the patient may not be treated with paclitaxel." "" "" ""</seg>
<seg id="283">"" "" "" "in patients no longer Abraxane treatment cycles should be followed up until the neutrophilation number rose again to &gt; 1.5 x 109 / l, and the thrombooming count rose again to &gt; 100 x 109 / l." "" "" ""</seg>
<seg id="284">Patients with heavy liver function (Bilirubin &gt; 5 x ULN / ALT &gt; 10 x ULN) should not be treated with Abraxane.</seg>
<seg id="285">"" "" "" "while an unequivocal cardiominarity was not proven, kardials incidental incidents are not unusual, especially in patients with early Anthracycline treatment or arching heart disease or lung disease." "" "" ""</seg>
<seg id="286">"" "" "" "in case of patients after the gift of Abraxane nausea, vomiting and diarrhea, they can be treated with the usual antiemetic and constiptive means." "" "" ""</seg>
<seg id="287">Abraxane is not to be practised by pregnant women or women in a poor age which does not practise an effective contraception that does not apply to the treatment of the mother with paclitaxel turns unavoidable.</seg>
<seg id="288">Women in the age-capable age should apply during and up to 1 month after the treatment with Abraxane a reliable contraceptive method.</seg>
<seg id="289">Male patients who will be treated with Abraxane is advised to bear a child for up to six months after treatment.</seg>
<seg id="290">Male patients should advise themselves before the treatment of a sperm contours until the treatment with Abraxane is the possibility of irreversible infertility.</seg>
<seg id="291">Abraxane can cause side effects such as fatigue (very common) and dizziness (often) that can impact on the traffic and the ability to serve machines.</seg>
<seg id="292">"" "" "" "following are the most common and most important incidents of adverse events observed in 229 patients with metastatic breast cancer, which were treated in the pivotal clinical Phase III study every three weeks with 260 mg / m2 Abraxane." "" "" ""</seg>
<seg id="293">Neutropenie was the most striking important hematological toxicity (79% of patients reported) and was quick reversible and dosisdependent; Leukopenia was reported in 71% of patients.</seg>
<seg id="294">Anemia (Hb &lt; 10 g / dl) was observed in 46% of patients with Abraxane patients and was severe (Hb &lt; 8 g / dl).</seg>
<seg id="295">"" "" "" "in Table 1, the side effects are specified, which occurred in conjunction with the gift of Abraxane as monotherapy for each dose and indication (N = 789)." "" "" ""</seg>
<seg id="296">"" "" "" "very frequently (≥ 1 / 100, &lt; 1 / 100); occasionally (≥ 1 / 1000, &lt; 1 / 100); rare (≥ 1 / 1000, &lt; 1 / 1000); very rare (&lt; 1 / 10,000)." "" "" ""</seg>
<seg id="297">"" "" "" "occasionally: increased blood pressure, weight gain, increased lactic acid in the blood, increased phosphorus in the blood, increased phosphorus in the blood, reduced potassium in the blood of heart disease:" "" "" ""</seg>
<seg id="298">"" "" "" "dysphagie, bloating, tongue burning, dry mouth, pain in ophagus, ulcers in the mouth, oral pain, rectal bleeding, rectal bleeding, kidneys and urinary tract:" "" "" ""</seg>
<seg id="299">"" "" "" "pain in the chest wall, weakness of muscles, abdominal pain, sore throat, pain in limbs, muscle weakness, very common:" "" "" ""</seg>
<seg id="300">Restlessness 1 The frequency of hypersensitivity will be calculated based on a definitive case in a population of 789 patients.</seg>
<seg id="301">"" "" "" "as these events were reported on a voluntary basis during clinical practice, no estimates of the actual frequency are possible and no causal correlation was established with these events." "" "" ""</seg>
<seg id="302">Paclitaxel is an anti-microtubules that promotes the combination of the microtubules from the tubels and stabilizes the microtubules by inhibition of their deformation.</seg>
<seg id="303">"" "" "" "this stabilization leads to a inhibition of the normal dynamic reorganisation of the microtubular network, which is essential for the vital interphase and mitotic cell functions." "" "" ""</seg>
<seg id="304">It is known that Albumin imitates the transcytosis of plasma components into the endothelial cells and in the context of in-vitro studies that the presence of albumin has been promoting the transport of paclitaxel by the endothelial cells.</seg>
<seg id="305">It is assumed that this improved transendothelial transport by the GP-60-Albume receptor is communicated and caused by an Paclitaxel accumulation in cysteine) in cysteine in cysteine.</seg>
<seg id="306">"" "" "" "the application of Abraxane for metastatic breast cancer is supported by the data of 106 patients, in two single-blind studies and from 454 patients who were treated in a randomised Phase III comparative study." "" "" ""</seg>
<seg id="307">"" "" "" "in a study there were 43 patients with metastatic breast cancer, which was given in the form of an infusion about 30 minutes with a dose of 175 mg / m2." "" "" ""</seg>
<seg id="308">"" "" "" "in the second study, a dose of 300 mg / m2 was used as an infusion about 30 minutes on 63 patients with metastatic breast cancer." "" "" ""</seg>
<seg id="309">This multi-centric study was conducted in patients with metastatic breast cancer diagnosed with paclitaxel 75 mg / m2 as a 3-hour infusion with relief of an allergic reaction (N = 225) or in the form of Abraxane 260 mg / m2 as a 30-minute infusion without pretreatment (N = 229).</seg>
<seg id="310">During inclusion in the study 64% of patients had an impaired general condition (ECOG 1 or 2); 79% had visceral metastases and 76% had more than 3 metastases.</seg>
<seg id="311">"" "" "" "14% of patients had previously received chemotherapy, 27% had only a adjuvant chemotherapy, 40% only because of metastatic breast and a adjuvant treatment." "" "" ""</seg>
<seg id="312">"" "" "" "9. the results for the general response and time to progression of the disease as well as progression-free survival and survival for patients who received &gt; First-Line therapy, are shown below." "" "" ""</seg>
<seg id="313">"" "" "" "the neurotoxicity against paclitaxel was evaluated by a degree of patients who were evaluated during a period during therapy, peripheral Neuropathy Grad 3 were evaluated." "" "" ""</seg>
<seg id="314">The natural course of peripheral re-empathy for baseline regarding the cumulative Toxicity by Abraxane after &gt; 6 treatment courses was not evaluated and is still unknown.</seg>
<seg id="315">The Pharmacokinetics of the total-paclitaxel after 30- and 180-minute infusions from Abraxane with a dose of 80 to 375 mg / m2 was determined in clinical trials.</seg>
<seg id="316">"" "" "" "the process exposure (AUC) increased from 2653 to 16736 ng.h / ml, with a dose of 80 to 300 mg / m2." "" "" ""</seg>
<seg id="317">10 After intravenous treatment of Abraxane patients with metastatic breast cancer at the recommended clinical dose of 260 mg / m2 the paclitaxel plasma concentration took place in multiphassic ways.</seg>
<seg id="318">The average distribution volume was 632 l / m2; the high distribution volume points to an extensive extravascular distribution and / or grazing connection of paclitaxel.</seg>
<seg id="319">In a study of patients with advanced solid tumours the pharmacokinetic properties of paclitaxel were compared to intravenous 30-minute infusion of 175 mg / m2 weighing approximately 175 mg / m2 of solvent containing Paclitaxel.</seg>
<seg id="320">The Pacance of Paclitaxel was higher after the Abraxane administration higher (43%) than after a solvent containing Paclitaxel injection and the deployment volume was above Abraxane higher (53%).</seg>
<seg id="321">"" "" "" "in published literature about in-vitro studies of the human liver microsome and fabric coatings, paclitaxel appears primarily to be metabolized (3" -p hydroxypaclitaxel and 6000-3 "-p-Dihydroxypaclitaxel)." "" "" ""</seg>
<seg id="322">After a 30-minute infusion of 260 mg / m2 Abraxane in patients with metastatic breast cancer diagnosed with fewer than 1% of the used total dose with fewer than 1% of the metabolism of the Metabolite 665 -Hydroxypaclitaxel and 3 "-p Hydroxypaclitaxel.</seg>
<seg id="323">"" "" "" "however, over the age of over 75 years, only a few data are available, since only 3 patients participated in the pharmacokinetic analysis." "" "" ""</seg>
<seg id="324">The chemical and physical stability was proved at 2 ° C - 8 ° C in original box and light-protected light over 8 hours.</seg>
<seg id="325">Paclitaxel is a cytotoxic anticarcinogenic drug and as well as other potentially toxic substances should be maintained when dealing with Abraxane caution.</seg>
<seg id="326">"" "" "" "using a sterile syringe, injected slowly over a period of at least 1 minute 20 ml (0.9%) sodium chloride infusion solution into a Abraxane-breaking bottle." "" "" ""</seg>
<seg id="327">"" "" "" "after the complete encore of the solution, the tube should rest for at least 5 minutes to guarantee a good benchmark." "" "" ""</seg>
<seg id="328">"" "" "" "then the tube for a minimum of 2 minutes should be slow and carefully slipped and / or invert, until a complete reboard of the powder is done." "" "" ""</seg>
<seg id="329">"" "" "" "if fake or incts are visible, the water bottle must be gently repaired to achieve a complete reboard before the application." "" "" ""</seg>
<seg id="330">"" "" "" "the exact total dosisvolume of the 5 mg / ml suspension is calculated for the patient and injected into an empty, sterile PVC- or non-PVC infusion bag." "" "" ""</seg>
<seg id="331">"" "" "" "" "" "" "" "the holder of the vehicle permission must ensure the pharmaceutical covigilance system, as described in version 2.0 and is set up in Module 1.8.1. of the application form, and will work before and while the medicine is taken into the traffic." "" "" ""</seg>
<seg id="332">Risk-management plan The holder of the approval of the approval process is committed to implement the studies described in the pharmaceutical-vigilatory plan and as well as all subsequent updates of the RMP in the pharmaceutical company plan (RMP) as well as all subsequent updates of the RMP that will be agreed with CHMP.</seg>
<seg id="333">"" "" "" "according to the CHMP policy on risk-management systems for use on humans, the updated RMP is scheduled to be submitted at the same time with the next periodic safety update Report (PSUR)." "" "" ""</seg>
<seg id="334">"" "" "" "moreover, a updated RMP may be submitted as new information that may affect the current safety specification, the pharmaceutical-vigilatory plan or risk management (pharmaceutical-vigilance or risk management) • On request of the EMEA)" "" "" ""</seg>
<seg id="335">"" "" "" "8 hours in refrigerator in boiling bottle, when it is stored in the box to protect the content from light." "" "" ""</seg>
<seg id="336">Abraxane is used for the treatment of mammocarcinoma when other therapies were tried, but if you were not successful for Anthracycline-contained therapies.</seg>
<seg id="337">Abraxane is not to be used: • If you are sensitive to paclitaxel or any of the other components of Abraxane or if you are breastfeeding - if your white blood cells are degraded (initial values for neutrophiles of &lt; 1.5 x 109 / l - your doctor will inform you about it)</seg>
<seg id="338">Special caution when using Abraxane is necessary: • If you suffer a disturbance of kidney function • If you suffer a sensitive kidney function if you suffer from severe liver problems such as you have cardiac problems</seg>
<seg id="339">"" "" "" "when using Abraxane with other medicines please inform the doctor if you apply other medicines or recently used, since these may cause an alteration effect with Abraxane." "" "" ""</seg>
<seg id="340">Women in the age-capable age should apply during and up to 1 month after the treatment with Abraxane a reliable contraceptive method.</seg>
<seg id="341">"" "" "" "in addition, they should advise themselves before the treatment of a sperm contours, as the Abraxane treatment is the possibility of a lasting infertility." "" "" ""</seg>
<seg id="342">People Abraxane and the use of Machines Abraxane can cause side effects such as fatigue (very common) and dizziness (often) that can impact on the traffic and the ability to serve machines.</seg>
<seg id="343">"" "" "" "if you receive other medicines in your treatment, you should consult your doctor in terms of driving or using machines from your doctor." "" "" ""</seg>
<seg id="344">22 • Effect on peripheral nerves (pain and numbness) • pain in one or more joints • pain in the muscles • nausea, diarrhea • vomiting • weakness and fatigue</seg>
<seg id="345">"" "" "" "the frequent side effects (at least 1 of 100 patients reported) are: • skin rash, itching, dry skin, abdominal pain • infection, abdominal pain • infections, abdominal pain • sore throat, sore throat or sore tongue, painful mouth or sore tongue, oral soor • sleeping disorders" "" "" ""</seg>
<seg id="346">The rare side effects (in case of at least 1 of 10,000 patients) are: • Llung infection on a different substance to irradiation • blood clots</seg>
<seg id="347">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will be significantly impaired or you will notice any side effects that are not listed in this manner." "" "" ""</seg>
<seg id="348">"" "" "" "if it is not used immediately, it can be stored in a cylindrical bottle up to 8 hours in the refrigerator (2 ° C - 8 ° C), in order to protect the content from light." "" "" ""</seg>
<seg id="349">Each sorption bottle contains 100 mg of Paclitaxel. • After the reconstruction contains each ml of the suspension 5 mg of Paclitaxel. • The other component of the suspension solution of humans (contains sodium, sodium capillate and N Acetyltryptophan (Ph.D.)).</seg>
<seg id="350">Precautions for the preparation and application Paclitaxel is a cytotoxic anticarcinogenic drug and as well as other potentially toxic substances should be maintained when dealing with Abraxane caution.</seg>
<seg id="351">Using a sterile syringe should slowly be injected over a period of 1 minute 20 ml of a 9 mg / ml (0.9%) sodium chloride infusion solution into a Abraxane-breaking bottle.</seg>
<seg id="352">"" "" "" "then slowly pivot the tube for at least 2 minutes, slowly pivot and / or invert, until a complete reboard of the powder is done." "" "" ""</seg>
<seg id="353">"" "" "" "the exact total dosisvolume of the 5 mg / ml suspension and the corresponding amount of the reconstituent Abraxane is injected into an empty, sterile PVC infusion bag type IV." "" "" ""</seg>
<seg id="354">"" "" "" "parenteral drugs should be subjected to the application of a visibility to possible particles and discoloration, whenever the solution or containers will allow this." "" "" ""</seg>
<seg id="355">"" "" "" "stability Unfolding bottles with Abraxane are stored until the date indicated on the packaging, when the hole is stored in the box to protect the content from light." "" "" ""</seg>
<seg id="356">"" "" "" "stability of the prostitute in the bottle, After the first reconstruction, the suspension should immediately be filled into an infusion bag." "" "" ""</seg>
<seg id="357">"" "" "" "" "" "" "" "" "" "" "" "member states must ensure that the owner is provided to provide medical specialists in dialysis centres and retail chains with the following information and materials:" "" "" ""</seg>
<seg id="358">• Training-brochure • summary of the characteristics of the medicine by means of a clear imaging of the product's correct use of the product refilled cooling boxes for transport by the patient.</seg>
<seg id="359">This means that dialing is similar to a biological medicine that has already been approved in the European Union (EU) and the same active ingredient (also called "reference drug").</seg>
<seg id="360">"" "" "" "it is used in patients with normal blood-ferrous complications, which may occur in connection with a blood transfusion complications before the procedure is an self-bleeding not possible and with which a blood loss of 900 to 1 800 ml is expected." "" "" ""</seg>
<seg id="361">"" "" "" "treatment with seamed must be initiated under the supervision of a doctor, which has experience in the treatment of patients with disorders, which is indicated for the medicine." "" "" ""</seg>
<seg id="362">"" "" "" "in patients with kidney problems and in patients who want to make an self-bleeding, Abseamed into a Vene is injected." "" "" ""</seg>
<seg id="363">Injection can also be carried out by the patient or the care subject if they have received appropriate instruction.</seg>
<seg id="364">"" "" "" "in patients with chronic renal insufficiency or in patients who have received chemotherapy, the hemoglobster should always be in the recommended range (between 10 and 12 grams per decanting in adults and between 9.5 and 11 g / dl in children)." "" "" ""</seg>
<seg id="365">"" "" "" "the iron values of all patients are before treatment to ensure that no iron deficiency exists, and iron complexes should be administered during the entire treatment." "" "" ""</seg>
<seg id="366">"" "" "" "in patients who receive chemotherapy, or in patients with kidney problems, an anemia can be caused by a erythropoietindeficiency, or thereby that the body is not sufficient for the body's own erythropoietin." "" "" ""</seg>
<seg id="367">Erythropoietin is also used before surgery to increase the number of red blood cells and thus reduce the consequences of blood loss.</seg>
<seg id="368">It is produced by a cell that has been introduced into a gene (DNA) which works for the formation of epoxetine alfa.</seg>
<seg id="369">"" "" "" "by appointment as an injection, aboutamed into a vene in the framework of a main study of 479 patients caused by kidney problems caused by reference medicines." "" "" ""</seg>
<seg id="370">"" "" "" "all patients participating in this study were at least eight weeks later, Eprex / Erypo had been injected into a Vene prior to them or continued to receive Eprex / Erypo." "" "" ""</seg>
<seg id="371">Main indicator for efficacy was the change of hemoglobin values between the beginning of the study and the evaluation period in weeks 25 to 29.</seg>
<seg id="372">"" "" "" "in addition, the company provided the results of a study in which the effects of under the skin were injected using the ones of Eprex / Erypo with 114 cancer patients received chemotherapy." "" "" ""</seg>
<seg id="373">"" "" "" "in the study of patients who caused by kidney problems caused by kidney problems, hemoglobbinds were transferred to the same extent as with those patients who continued Eprex / Erypo." "" "" ""</seg>
<seg id="374">"" "" "" "in comparison with this, the patients continued to get Eprex / Erypo, an increase of 0.063 g / dl at the initial value of 12.0 g / dl." "" "" ""</seg>
<seg id="375">"" "" "" "the most frequent side effect of seisamed is an increase in blood pressure that can occasionally lead to symptoms of cephalopathy (brain problems) such as sudden, crawling headaches and confusion." "" "" ""</seg>
<seg id="376">"" "" "" "Abseamed must not be used in patients, which may be excessive (allergic) against epoetin alfa or any of the other components." "" "" ""</seg>
<seg id="377">"" "" "" "seisamed as injections under the skin is not recommended for treatment of kidney problems, as further studies are required to ensure that no allergic reactions are caused." "" "" ""</seg>
<seg id="378">"" "" "" "the Committee for Human Use (CHMP) reached the conclusion that the drug has been provided with a comparable quality, safety and efficacy profile, such as Eprex / Erypo." "" "" ""</seg>
<seg id="379">"" "" "" "the company, the seisamed, will provide information relating to medical specialists in all Member States and provide information about the safety of the drug." "" "" ""</seg>
<seg id="380">"" "" "" "in August 2007, the European Commission granted Medice drugs Pütter GmbH & Co KG, the European Commission granted authorisation of disagreements within the whole European Union." "" "" ""</seg>
<seg id="381">"" "" "" "treatment of anaemia and reduction of transfusion in adults with solid tumours, malignant lymphoma or multiplem myeloma who receive chemotherapy, or with which the risk of transfusion due to the general condition (e.g. cardiovasculular status, pre-existing anemia in the beginning of chemotherapy)." "" "" ""</seg>
<seg id="382">Treatment should be performed only in patients with moderate anemia (hemoglobin [hb] 10 - 13 g / l [6,2 - 8.1 mmol / l]; if blood-saving measures are not available or inadequate measures in case of planned greater surgical intervention (4 or more units blood for women; 5 or more units blood within men).</seg>
<seg id="383">"" "" "" "for reducing foreign blaming, seisamed from a major elective orthodontic procedure in adults can be used without iron deficiency, in which a high risk of transfusion income is expected." "" "" ""</seg>
<seg id="384">HB 10-13 g / dl) and an unexpected blood loss of 900-1800 ml can be applied not to participate in an autologated blood test program.</seg>
<seg id="385">The hemoglobin target concentration is between 10 and 12 g / dl (6,2 - 7.5 mmol / l) except for pediatric patients suffering from 9.5 and 11 g / dl (5.9 - 6.8 mmol / l).</seg>
<seg id="386">"" "" "" "symptoms and tortures can vary depending on age, gender and total disease of disease; therefore, the assessment of individual clinical practice and disease resistance is necessary." "" "" ""</seg>
<seg id="387">A rise in hemoglobins to be more than 2 g / dl (1.25 mmol / l) over a period of four weeks should be avoided.</seg>
<seg id="388">"" "" "" "due to the variability between patients, individual hemoglobin values can occasionally be observed with or under the hemogglobin- target concentration." "" "" ""</seg>
<seg id="389">"" "" "" "in view of these hemoglobin variability, a corresponding dose management should be tempted to achieve hemoglobin target concentration of 10 g / dl (6,2 mmol / l) to 12 g / dl (7,5 mmol / l)." "" "" ""</seg>
<seg id="390">If the hemoggloomy contains more than 2 g / dl (1.25 mmol / l) per month or if the permanent hemoglobin value 12 g / dl (7.5 mmol / l) exceeds the epoxin alfa dose to reduce 25%.</seg>
<seg id="391">"" "" "" "patients should be closely monitored to ensure that epoetin alfa is required in the lowest permitted dose, which is applied to control anaemia and anemia symptoms." "" "" ""</seg>
<seg id="392">The present clinical results indicate that patients with initial low Hb-value (&lt; 6 g / dl or &lt; 3.75 mmol / l) may require higher conservation of patients (Hb &gt; 8 g / dl or &gt; 5 mmol / l).</seg>
<seg id="393">The present clinical results indicate that patients with initial low Hb value (&lt; 6,8 g / dl or &lt; 4.25 mmol / l) may require higher conservation of patients (Hb &gt; 6,8 g / dl or &gt; 4.25 mmol / l).</seg>
<seg id="394">Starting dose 50 i.e. / kg three times a week by intravenous application if necessary with a dose of dose of 25 kg / kg (three times per week) until the desired goal is reached (this should be done by steps at least 4 weeks).</seg>
<seg id="395">"" "" "" "symptoms and symptoms can vary depending on age, gender and total disease of disease; therefore, the assessment of individual clinical practice and disease resistance is necessary." "" "" ""</seg>
<seg id="396">"" "" "" "in view of these hemoglobin variability, a corresponding dose management should be tempted to achieve hemoglobin target concentration of 10 g / dl (6,2 mmol / l) to 12 g / dl (7,5 mmol / l)." "" "" ""</seg>
<seg id="397">"" "" "" "patients should be close meshed in order to ensure that Epoettin alfa is in the lowest permitted dose, which is applied to control the anticancer symptoms." "" "" ""</seg>
<seg id="398">If after 4 treatment weeks of hemoglobin value by at least 1 g / dl (0.62 mmol / l) or the reverse oscopy ratio of ≥ 40.000 cells / µl per week or 450 kg / kg per week should be retained once a week.</seg>
<seg id="399">If the hemoglobin increase &lt; 1 g / l (&lt; 0.62 mmol / l) and the reverse oscopy of &lt; 40.000 cells / µl compared to the initial level has to be raised to 300 Hz / kg three times a week.</seg>
<seg id="400">If after additional 4 treatment weeks with 300 Mb / kg three times a week of hemogglobetrong around ≥ 1 g / l (≥ 0.62 mmol / l) or the reverse oscopy number by ≥ 0.62 mmol / l (≥ 0.62 mmol / l) or the reverse oscopy number by ≥ 0.62 mmol / l (≥ 0.62 mmol / l) or the reverse oscopy ratio should be retained by 300 mg / kg three times a week.</seg>
<seg id="401">If the hemoglobin value has risen by &lt; 1 g / l (&lt; 0,62 mmol / l) or the reverse oscopy of &lt; 40,000 cells / µl against the initial level is unlikely to be interrupted and the treatment should be interrupted.</seg>
<seg id="402">Patients with a slight anemia (hematocrit 33 - 39%) in which the preventive invitations of ≥ 4 blood-conservative is required should be deduced in a dose of 600 i.e. / kg body weight twice weekly for 3 weeks before the surgical procedure.</seg>
<seg id="403">"" "" "" "with the Iron substitution, as early as possible - for example, a few weeks before the start of the autologous blood test program - can be started so before the start of the seamed therapy great iron reserves are available." "" "" ""</seg>
<seg id="404">"" "" "" "6 The recommended dosage is 600 g / kg epoxetine alfa which should be given once a week for three weeks (day 21, 14 and 7) before the operational procedure and the day of the intervention (day 0)." "" "" ""</seg>
<seg id="405">"" "" "" "here the ephertin alfa preoperatively 300 i.e. / kg each 10 consecutive days before, on the day of the intervention and 4 days immediately afterwards." "" "" ""</seg>
<seg id="406">"" "" "" "alternatively, injection can be given at the end of dialysis via the hose of a diocelnadel, followed by 10 ml isotonic cooking solution to ensure the hose and ensure adequate injection of the medication through the circulation." "" "" ""</seg>
<seg id="407">Patients who received with any erythropoetin (Pure Red Cell Aplasia, PRCA) should be obtained (see Section 4.4 - Erythrobberopenia).</seg>
<seg id="408">Heart attack or stroke within a month before the treatment of unstable angina pectoris, increased risk of deep venous thrombosis (e.g. anamnestic Thromboembolia).</seg>
<seg id="409">"" "" "" "in patients who are intended to participate in an autologous cardiac procedure, the application of epoxic cardiac disease is contraindicated: severe coronary heart disease, peripheral arterial disease, peripheral disease, vasculary heart attack, or cerebrovascular event." "" "" ""</seg>
<seg id="410">Erythrobberopenia (PRCA) Very rarely has been reported on the appearance of an antistatic PRCA to monate- to years of treatment with subcutaneous Erythropoetin.</seg>
<seg id="411">"" "" "" "in patients with sudden action loss, defined as a reduction in hemoglobin values (1-2 g / dl per month) and the usual causes of failure (iron, follicacid or vitamin B12 deficiency, infections or infections, blood loss and hemmolyse)." "" "" ""</seg>
<seg id="412">"" "" "" "if the reagent value, taking into consideration of anemia (i.e. the reverse ulocytes" index "), the thrombobtin and leukzytends are determined, and if no other reason of active loss should be considered (&lt; 20.000 / mm3 or &lt; 20.000 / microliter or &lt; 0.5%)." "" "" ""</seg>
<seg id="413">Data for immunogenicity in subcutaneous application of seamed patients with a risk for an anti-induced PRCA (patients with renal anemia) are not sufficient.</seg>
<seg id="414">"" "" "" "8 In cases of chronic renal insufficiency, this should not exceed the recommended upper limit of hemoglobin concentration in section 4.2." "" "" ""</seg>
<seg id="415">"" "" "" "in clinical trials, an increased mortality risk and risk of severe cardiovascular disease (ESA) were given with a hemoglobin target concentration of more than 12 g / dl (7,5 mmol / l)." "" "" ""</seg>
<seg id="416">"" "" "" "controlled clinical trials have shown no significant benefit, which is attributable to the gift of epoxins and the prevention of blood transfusions and prevention of blood transfusions is increased." "" "" ""</seg>
<seg id="417">The hemoglow rise should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="418">"" "" "" "in case of chronic renal insufficiency and clinical evidence which should not be exceeded under Section 4.2, the lower limit of hemoglobin disease should not be exceeded." "" "" ""</seg>
<seg id="419">"" "" "" "according to present knowledge, it is not accelerated by the treatment of anemia with epoxetine alfa in adults with kidney insufficiency, which are not accelerated." "" "" ""</seg>
<seg id="420">Patients with cancer patients should be taken into account for the assessment of therapy efficiency of ephertin alfa a 2-3-week delay between epoxetine alfa's gift and the erythropoetin response (patients who may have transfungible).</seg>
<seg id="421">If the Hb increase is greater than 2 g / dl (1.25 mmol / l) per month or a Hb value of 13 g / dl (8.1 mmol / l) which is necessary to minimize the risk of possible thrombotic events (see section 4.2 of patients with instipected anemia / dl and 12 g / dl).</seg>
<seg id="422">"" "" "" "the decision for the application recombinant erythropoetine should be based on a benefit-risk reduction in the patient's participation, which should also consider the specific clinical context." "" "" ""</seg>
<seg id="423">"" "" "" "in patients who are intended for a greater electric orthopaedic procedure, if possible, before the epoxetine alfa therapy the cause of anemia should be studied and treated accordingly." "" "" ""</seg>
<seg id="424">"" "" "" "patients who accompanied themselves to a greater electric orthodontic procedure, should have an increased risk of thrombotic and vascular diseases, particularly with a worshipable cardiovascular disease." "" "" ""</seg>
<seg id="425">"" "" "" "in addition, it cannot be excluded that with epoxetine alfa for patients with a starting point of &gt; 13 g / dl provides an increased risk of postoperative thrombotic / vasculular events." "" "" ""</seg>
<seg id="426">"" "" "" "in several controlled trials, epoetine was not proven that they can reduce the overall survival or reduce the risk of tumor progression." "" "" ""</seg>
<seg id="427">"" "" "" "4 months in patients with metastatic breast cancer which received chemotherapy was resumed, if a hemoglobin target concentration of 12 to 14 g / dl (7.5 - 8,7 mmol / l) was stripped." "" "" ""</seg>
<seg id="428">Is used ephertin alfa along with Ciclosporin and should regulate the blood level of Ciclosporin and should be adapted to Ciclosporous osis of the increasing hematocrit.</seg>
<seg id="429">"" "" "" "in-vitro examination, there are no indications on a interaction between epoxetine alfa and G-CSF or GM CSF with regard to hematological differentiation or proliferation." "" "" ""</seg>
<seg id="430">"" "" "" "thrombosis, vascularthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, retinalthrombosis, arterial thrombosis, retinalthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, osis." "" "" ""</seg>
<seg id="431">The most common adverse effect during treatment with epoxalfa is a dosistive increase in blood pressure or deterioration of an existing hypertonia.</seg>
<seg id="432">An increased incidence of thrombovasculular events (see section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="433">"" "" "" "regardless of the erythropoetin treatment, surgical patients with cardiovascular disease can occur after repeated blood donations to thrombotic and vasculular complications." "" "" ""</seg>
<seg id="434">"" "" "" "the genetically modified Epoettin alfa is identical to the amino acids and carbohydrates of carbohydrates, identical to the endogenous human erythropoetin, which was isolated from the urine." "" "" ""</seg>
<seg id="435">"" "" "" "it could be shown with the help of cultures of human bone marrow cells, that ephertin alfa stimulates the erythropoesis and the leucopogenesis is not affected." "" "" ""</seg>
<seg id="436">389 patients with hemostblasts (221 multiple myelomas) and 332 patients with solid tumours (172 native percolomas) and 332 patients with solid tumours (172 prostate cancer, 22% gastrocarcinomas, 21 gastrointestinal tumors, 21 gastrointestinal carcinomas and 30 other).</seg>
<seg id="437">"" "" "" "1895 patients with solid tumours (683 mammocarcinomas, 260 bronchial carcinomas, 174 gynaecological tumours, 300 gastrointestinal tumours and 802 patients with hemostblasts." "" "" ""</seg>
<seg id="438">Survival and progression-progression were examined in five major controlled trials with a total of 2833 patients; four of these studies were double-blind placebo-controlled trials and</seg>
<seg id="439">In the open study there was no difference in overall survival between patients treated with recombinant erythropoetin patients and patients.</seg>
<seg id="440">"" "" "" "in these studies, patients treated with recombinant human erythropoetin showed a clarifying, statistically significant higher mortality than with the controls." "" "" ""</seg>
<seg id="441">Overall survival in the studies could not be explained by differences in the incidence of thrombosis and related complications with recombinant human erythropoetin patients and with controls.</seg>
<seg id="442">"" "" "" "there is an increased risk of thromboembollic events of tumor patients who are treated with recombinant human erythropoetin, and a negative effect on the overall survival cannot be excluded." "" "" ""</seg>
<seg id="443">"" "" "" "it is not clear how far this results can be transferred to the application of recombinant human erythropoetin, using chemotherapy, as a few patients with these characteristics were included in the checked data." "" "" ""</seg>
<seg id="444">Epoxetine alfa provisions after repeated intravenous application showed a half-life of approximately 4 hours in healthy volunteers and an extended half-life of approximately 5 hours in patients with kidney failure.</seg>
<seg id="445">"" "" "" "after subcutaneous injection, the serum levels of epoxetine alfa are much lower than the serum levels that are reached after intravenous injection." "" "" ""</seg>
<seg id="446">"" "" "" "there are no cumulation: the serum levels remain the same, regardless of whether they are determined 24 hours after the first gift or 24 hours after the last gift." "" "" ""</seg>
<seg id="447">(bone marfibrous is a well-known compilation of chronic renal insufficiency in humans and could be attributable to secondary hyperparathyreoidism or unknown factors.</seg>
<seg id="448">"" "" "" "in a study on hemostalysis patients who were treated with epoxy alfa, the incidence of bone marfibrous patients who were not treated with epoxsealfa was not increased)." "" "" ""</seg>
<seg id="449">"" "" "" "14 In experimental studies with close to 20s of the adoption of subjects recommended by man, ephertin alfa led to diminished federal weight, with a delay of ossification and an increase in killing mortality." "" "" ""</seg>
<seg id="450">"" "" "" "these reports rely on in vitro studies with cells from human tumor tissue samples, which are of uncertain significance for the clinical situation." "" "" ""</seg>
<seg id="451">"" "" "" "during an outpatient application, the patient dieting is possible to store a maximum of 3 days outside the cooling case and not above 25 ° C." "" "" ""</seg>
<seg id="452">"" "" "" "syringes are provided with graduation rings and the filling volume is indicated by a glued label, so if necessary, the measurement of particles is possible." "" "" ""</seg>
<seg id="453">"" "" "" "treatment with seamed must be initiated under the supervision of doctors, experience in the treatment of patients with the mentioned indications." "" "" ""</seg>
<seg id="454">"" "" "" "21 The recommended dosage is 600 g / kg epoxetine alfa which should be given once a week for three weeks (day 21, 14 and 7) before the operational procedure and the day of the intervention (day 0)." "" "" ""</seg>
<seg id="455">"" "" "" "23 If patients suffering from chronic renal insufficiency should not be exceeded under Section 4.2, the lower limit of hemoglobin concentration." "" "" ""</seg>
<seg id="456">The hemoglow rise should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="457">"" "" "" "thrombosis, vascularthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, retinalthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, osis." "" "" ""</seg>
<seg id="458">An increased incidence of thrombovasculular events (see section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="459">389 patients with hemostblasts (221 multiple myelomas) and 332 patients with solid tumours (172 native percolomas) and 332 patients with solid tumours (172 prostate cancer, 22% gastrocarcinomas, 21 gastrointestinal tumors, 21 gastrointestinal carcinomas and 30 other).</seg>
<seg id="460">"" "" "" "29 In experimental studies with close to 20s of age required, ephertin alfa led to diminished federal weight, with a delay of ossification and an increase in killing mortality." "" "" ""</seg>
<seg id="461">"" "" "" "during an outpatient application, the patient dieting is possible to store a maximum of 3 days outside the cooling case and not above 25 ° C." "" "" ""</seg>
<seg id="462">"" "" "" "36 The recommended dosage is 600 g / kg epoxetine alfa which should be given once a week for three weeks (day 21, 14 and 7) before the operational procedure and the day of the intervention (day 0)." "" "" ""</seg>
<seg id="463">"" "" "" "38 In case of chronic renal insufficiency, the number of hemoglobin disease should not be exceeded under Section 4.2." "" "" ""</seg>
<seg id="464">The hemoglow rise should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="465">"" "" "" "thrombosis, vascularthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, retinalthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, osis." "" "" ""</seg>
<seg id="466">An increased incidence of thrombovasculular events (see section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="467">389 patients with hemostblasts (221 multiple myelomas) and 332 patients with solid tumours (172 native percolomas) and 332 patients with solid tumours (172 prostate cancer, 22% gastrocarcinomas, 21 gastrointestinal tumors, 21 gastrointestinal carcinomas and 30 other).</seg>
<seg id="468">"" "" "" "44 In animal studies with nearly the 20s of the adoption of subjects recommended by man, ephertin alfa led to diminished federal weight, with a delay of the ossification and an increase in killing mortality." "" "" ""</seg>
<seg id="469">"" "" "" "during an outpatient application, the patient dieting is possible to store a maximum of 3 days outside the cooling case and not above 25 ° C." "" "" ""</seg>
<seg id="470">51 The recommended dosage is 600 g / kg epoxetine alfa which should be given once a week for three weeks (day 21: 14 and 7) before the operational procedure and on the day of the intervention (day 0).</seg>
<seg id="471">"" "" "" "53 In case of chronic renal insufficiency, in case of maintenance therapy the lower upper limit of hemoglobin concentration should not be exceeded." "" "" ""</seg>
<seg id="472">The hemoglow rise should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="473">"" "" "" "thrombosis, vascularthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, retinalthrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, osis." "" "" ""</seg>
<seg id="474">An increased incidence of thrombovasculular events (see section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="475">389 patients with hemostblasts (221 multiple myelomas) and 332 patients with solid tumours (172 native percolomas) and 332 patients with solid tumours (172 prostate cancer, 22% gastrocarcinomas, 21 gastrointestinal tumors, 21 gastrointestinal carcinomas and 30 other).</seg>
<seg id="476">59 "" "" "" "59 In the experimental studies with nearly 20x of the patients recommended during the application, ephertin alfa led to diminished federal weight, with a delay of ossification and an increase in killing mortality." "" "" ""</seg>
<seg id="477">"" "" "" "during an outpatient application, the patient dieting is possible to store a maximum of 3 days outside the cooling case and not above 25 ° C." "" "" ""</seg>
<seg id="478">"" "" "" "66 The recommended dosage is 600 m / kg Epoettin alfa, which should be given once a week for three weeks (day 21, 14 and 7) before the operational procedure and the day of the intervention (day 0)." "" "" ""</seg>
<seg id="479">68 In patients with chronic renal insufficiency should not be exceeded under section 4.2 of the recommended upper limit of hemoglobin target concentration.</seg>
<seg id="480">The hemoglow rise should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="481">"" "" "" "thrombosis, vascularthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, retinalthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, osis." "" "" ""</seg>
<seg id="482">An increased incidence of thrombovasculular events (see section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="483">389 patients with hemostblasts (221 multiple myelomas) and 332 patients with solid tumours (172 native percolomas) and 332 patients with solid tumours (172 prostate cancer, 22% gastrocarcinomas, 21 gastrointestinal tumors, 21 gastrointestinal carcinomas and 30 other).</seg>
<seg id="484">"" "" "" "74 In experimental studies with close to 20s of the adoption of subjects recommended during the use of the human body, ephertin alfa led to diminished federal weight, with a delay of the Ossification and an increase in killing mortality." "" "" ""</seg>
<seg id="485">"" "" "" "during an outpatient application, the patient dieting is possible to store a maximum of 3 days outside the cooling case and not above 25 ° C." "" "" ""</seg>
<seg id="486">"" "" "" "81 The recommended dosage is 600 g / kg Epoettin alfa, which should be given once a week for three weeks (day 21, 14 and 7) before the operational procedure and the day of the intervention (day 0)." "" "" ""</seg>
<seg id="487">83 "" "" "" "83 in patients with chronic renal insufficiency, in case of maintenance therapy the lower upper limit of hemoglobin concentration should not be exceeded." "" "" ""</seg>
<seg id="488">The hemoglow rise should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="489">"" "" "" "thrombosis, vascularthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthropoetin treatment." "" "" ""</seg>
<seg id="490">An increased incidence of thrombovasculular events (see section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="491">389 patients with hemostblasts (221 multiple myelomas) and 332 patients with solid tumours (172 native percolomas) and 332 patients with solid tumours (172 prostate cancer, 22% gastrocarcinomas, 21 gastrointestinal tumors, 21 gastrointestinal carcinomas and 30 other).</seg>
<seg id="492">"" "" "" "89 In experimental studies with close to 20s of the adoption of subjects recommended by man, ephertin alfa led to diminished federal weight, with a delay of the ossification and an increase in killing mortality." "" "" ""</seg>
<seg id="493">"" "" "" "during an outpatient application, the patient dieting is possible to store a maximum of 3 days outside the cooling case and not above 25 ° C." "" "" ""</seg>
<seg id="494">96 The recommended dosage is 600 g / kg epoxetine alfa which should be given once a week for three weeks (day 21: 14 and 7) before the operational procedure and on the day of the intervention (day 0).</seg>
<seg id="495">"" "" "" "98 In cases of chronic renal insufficiency, in case of maintenance therapy the lower upper limit of hemoglobin concentration should not be exceeded." "" "" ""</seg>
<seg id="496">The hemoglow rise should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="497">"" "" "" "thrombosis, vascularthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, retinalthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, osis." "" "" ""</seg>
<seg id="498">An increased incidence of thrombovasculular events (see section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="499">389 patients with hemostblasts (221 multiple myelomas) and 332 patients with solid tumours (172 native percolomas) and 332 patients with solid tumours (172 prostate cancer, 22% gastrocarcinomas, 21 gastrointestinal tumors, 21 gastrointestinal carcinomas and 30 other).</seg>
<seg id="500">"" "" "" "104 In animal studies with close to 20s of age required, ephertin alfa led to diminished federal weight, with a delay of ossification and an increase in killing mortality." "" "" ""</seg>
<seg id="501">"" "" "" "during an outpatient application, the patient dieting is possible to store a maximum of 3 days outside the cooling case and not above 25 ° C." "" "" ""</seg>
<seg id="502">111 The recommended dosage is 600 g / kg epoxetine alfa which should be given once a week for three weeks (day 21: 14 and 7) before the operational procedure and on the day of the intervention (day 0).</seg>
<seg id="503">113 "" "" "" "113 In cases of chronic renal insufficiency, which should not be exceeded in section 4.2 below the recommended upper limit of hemoglobin target concentration." "" "" ""</seg>
<seg id="504">The hemoglow rise should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="505">"" "" "" "thrombosis, vascularthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, retinalthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, osis." "" "" ""</seg>
<seg id="506">An increased incidence of thrombovasculular events (see section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="507">389 patients with hemostblasts (221 multiple myelomas) and 332 patients with solid tumours (172 native percolomas) and 332 patients with solid tumours (172 prostate cancer, 22% gastrocarcinomas, 21 gastrointestinal tumors, 21 gastrointestinal carcinomas and 30 other).</seg>
<seg id="508">"" "" "" "119 In the experimental studies, according to the age of 20s the ephertin alfa has led to diminished federal weight, with a delay of ossification and an increase in killing mortality." "" "" ""</seg>
<seg id="509">"" "" "" "during an outpatient application, the patient dieting is possible to store a maximum of 3 days outside the cooling case and not above 25 ° C." "" "" ""</seg>
<seg id="510">126 The recommended dosage is 600 g / kg epoxetine alfa which should be given once a week for three weeks (day 21: 14 and 7) before the operational procedure and on the day of the intervention (day 0).</seg>
<seg id="511">128 in patients with chronic renal insufficiency should not be exceeded under section 4.2 of the recommended upper limit of hemoglobin target concentration.</seg>
<seg id="512">The hemoglow rise should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="513">"" "" "" "thrombosis, vascularthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, retinalthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, osis." "" "" ""</seg>
<seg id="514">An increased incidence of thrombovasculular events (see section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="515">389 patients with hemostblasts (221 multiple myelomas) and 332 patients with solid tumours (172 native percolomas) and 332 patients with solid tumours (172 prostate cancer, 22% gastrocarcinomas, 21 gastrointestinal tumors, 21 gastrointestinal carcinomas and 30 other).</seg>
<seg id="516">"" "" "" "134 In the experimental studies with nearly the 20s of the adoption of subjects recommended during the use of the human body, ephertin alfa led to diminished federal weight, with a delay of the Ossification and an increase in killing mortality." "" "" ""</seg>
<seg id="517">"" "" "" "during an outpatient application, the patient dieting is possible to store a maximum of 3 days outside the cooling case and not above 25 ° C." "" "" ""</seg>
<seg id="518">141 The recommended dosage is 600 g / kg epoxetine alfa which should be given once a week for three weeks (day 21: 14 and 7) before the operational procedure and on the day of the intervention (day 0).</seg>
<seg id="519">143 In patients with chronic renal insufficiency should not be exceeded under section 4.2 of the recommended upper limit of hemoglobin target concentration.</seg>
<seg id="520">The hemoglow rise should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="521">"" "" "" "thrombosis, vascularthrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis, retinalthrombosis, retinalthrombosis, retinalthrombosis, osis patients suffering from epythropoetin." "" "" ""</seg>
<seg id="522">An increased incidence of thrombovasculular events (see section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="523">389 patients with hemostblasts (221 multiple myelomas) and 332 patients with solid tumours (172 native percolomas) and 332 patients with solid tumours (172 prostate cancer, 22% gastrocarcinomas, 21 gastrointestinal tumors, 21 gastrointestinal carcinomas and 30 other).</seg>
<seg id="524">149 The experimental studies with nearly the 20s of the patients recommended during the use of the recommended number of weeklyosis the ephertin alfa led to a delay of the Ossification and an increase in killing mortality.</seg>
<seg id="525">"" "" "" "during an outpatient application, the patient dieting is possible to store a maximum of 3 days outside the cooling case and not above 25 ° C." "" "" ""</seg>
<seg id="526">"" "" "" "prior to the market entry and agreement with the competent authorities of the following information provided with the competent authorities in dialysis centres and retail chains with the following information and materials: • Training brochure • summary of the characteristics of the product, with clear imaging of the product." "" "" ""</seg>
<seg id="527">"" "" "" "the approval of the approval process is set up and functional in version 3.0 and is operational in version 1.8.1. by the application form, before the drug is applied in the traffic and as long as it is applied to the traffic." "" "" ""</seg>
<seg id="528">"" "" "" "the approval of the approval of the Risk Management Plan (RMP) specified in the pharmaceutical covigilance schedule, as defined in version 5 of the application form (RMP) as well as according to any subsequent implementation of the risk management plan." "" "" ""</seg>
<seg id="529">A updated RMP should be provided in accordance with the "CHMP Guideline on Risk Management Systems for Human Use" at the same time with the next updated report on the incomparability of the medicine (periodic safety update Report, PSUR).</seg>
<seg id="530">"" "" "" "in addition, a updated RMP should be submitted as a result of the current security specifications (Safety specification), the pharmaceutical-vigilatory plan or risk reduction in the EMEA) to achieve an important (the pharmaceutical covigilance or risk reduction)." "" "" ""</seg>
<seg id="531">"" "" "" "• If you suffer a heart attack or stroke within a month prior to your treatment, • If you suffer from an unstable angina pectoris (for the first time occurring or reinforced chest pain)" "" "" ""</seg>
<seg id="532">They suffer from severe bleeding disorders of the heart (coronary heart disease); the arteries of the legs or arms (peripheral arterial disease) of the cervical or cerebrovascular illness) suffer from a heart attack or stroke.</seg>
<seg id="533">"" "" "" "during treatment with dismations, it may come back to a slight dosisent increase in blood platescount, which will return to another treatment again." "" "" ""</seg>
<seg id="534">"" "" "" "if necessary, your doctor may conduct regular blood tests to monitor the number of platelets during the first 8 weeks of treatment." "" "" ""</seg>
<seg id="535">"" "" "" "deficiencies, dissolution of red blood cells (hemmolyse), blood pressure, vitamin B12 or Folacidic deficiency, should take into account and be treated prior to treatment with discourses." "" "" ""</seg>
<seg id="536">Very rarely has been reported on the appearance of an antique semi-robberopenia after monate- to years of subcutaneous treatment with subcutaneous (under the skin speckled) erythropoetin.</seg>
<seg id="537">"" "" "" "if you suffer from Erythrobberopenia, it will break your therapy with dismations and determine how your anaemia will be treated best." "" "" ""</seg>
<seg id="538">"" "" "" "therefore, seisamed through injection into a vene (intravenously) must be given if you are treated because of an anemia due to a kidney disease." "" "" ""</seg>
<seg id="539">"" "" "" "a high hemoggloomy contains the risk of problems with heart or blood vessels, and the death of death could be increased." "" "" ""</seg>
<seg id="540">"" "" "" "for increased or increasing potassium, your doctor may take an interruption of treatment with dismations until the potassium values are back in the norm range." "" "" ""</seg>
<seg id="541">"" "" "" "if you suffer from chronic kidney illness and clinically apparent coronary heart disease, your doctor will ensure that your hemoglobin mirror will not exceed a particular value." "" "" ""</seg>
<seg id="542">"" "" "" "according to the present knowledge, it is not accelerated by the treatment of bleeding in adults with chronic kidney disease (renal insufficiency), which are not accelerated." "" "" ""</seg>
<seg id="543">A 2-3-week delay between epoxetine alfa's gift and the desired effect should be taken into account for the evaluation of the effectiveness of seeding needs.</seg>
<seg id="544">200 Your doctor will regularly determine your values of the red blood dye (hemoglobin) and adjust their deriving dose accordingly to keep the risk of blood croping formation (thrombotic event).</seg>
<seg id="545">"" "" "" "this risk should be carefully weighed from the treatment with epoxetine alfa drugs, especially if you have an increased risk of thromboteric vascular events (e.g. a deep clesiosis or pneembolie)." "" "" ""</seg>
<seg id="546">"" "" "" "in case you are cancer patients, consider that sedentals work as a growth factor for blood cells and under certain circumstances may affect the tumor." "" "" ""</seg>
<seg id="547">"" "" "" "if a major orthopedic operation is imminated, the treatment of your anaemia should be studied and treated accordingly." "" "" ""</seg>
<seg id="548">"" "" "" "if your values of the red blood dye (hemoglobin) are too high, you should not get dismations as there is an increased risk of hemorrhaformation after surgery." "" "" ""</seg>
<seg id="549">"" "" "" "please inform your doctor or pharmacist if you have taken other medicines / apply or used recently, even if it is not prescription drugs." "" "" ""</seg>
<seg id="550">"" "" "" "if you take Ciclosporin (means to suppression the immune system) during your therapy with seisamed, your doctor may apply certain blood tests to measure blood levels of Ciclosporin." "" "" ""</seg>
<seg id="551">Laboratory investigations have shown no interaction between epoxetine alfa and G-CSF or GM CSF (G-CSF) and GM CSF (G-CSF) and GM CSF (for example with cancer or HIV).</seg>
<seg id="552">"" "" "" "depending on how your blood clergy (anemia) is related to the treatment, the dose may be adjusted for about every four weeks until your condition is under control." "" "" ""</seg>
<seg id="553">"" "" "" "if necessary, your doctor will examine regular blood tests to check the treatment success and ensure that the medicine works correctly and does not exceed a particular value." "" "" ""</seg>
<seg id="554">"" "" "" "once you are well set, you will receive regular doses of seamed between 25 and 50 i.e. / kg twice weekly, distributed on two equally large injections." "" "" ""</seg>
<seg id="555">"" "" "" "if necessary, your doctor will examine regular blood tests to check the treatment success and ensure that your hemoglobin value does not exceed a certain value." "" "" ""</seg>
<seg id="556">"" "" "" "depending on how the anemia should apply to treatment, the dose may be adjusted for approximately every four weeks until the condition is under control." "" "" ""</seg>
<seg id="557">"" "" "" "to ensure this and ensure that the hemoglobin value does not exceed a certain value, the treated doctor will perform regular blood tests." "" "" ""</seg>
<seg id="558">"" "" "" "if it is necessary to shorten the treatment time before surgery, a dose of 300 i.e. / kg can be given at 10 consecutive days before surgery, on the day of the intervention and another 4 days after the surgery." "" "" ""</seg>
<seg id="559">"" "" "" "however, you can, if your doctor holds this for appropriate, also learn how to splash out the skin under the skin." "" "" ""</seg>
<seg id="560">"" "" "" "heart disease, cardiac arthrombosis, arterial thrombosis, arterial thrombosis, lung expansions, arterial thrombosis, vrombosis of the retina and blood clots in artificial kidneys were reported in patients under Erythropoetin treatment." "" "" ""</seg>
<seg id="561">Eyelids and lips (Quincke-Ödem) and shock-like allergic reactions with symptoms such as cribbles, redness, itching and accelerated pulse have been reported in rare cases.</seg>
<seg id="562">Erythrobberopenia means that no more sufficient red blood cells in the bone marrow can be formed (see section "Special prudence in the use of seisamed is required").</seg>
<seg id="563">After repeated blood donations it may come - regardless of the treatment with sedentals (thrombotic vascular events).</seg>
<seg id="564">Treatment with sedentals can occur with an increased risk of hemorrhage after surgery (postoperative thrombotic vascular events) when your starting point is too high.</seg>
<seg id="565">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will significantly affect you or if you notice side effects that are not listed in this user information." "" "" ""</seg>
<seg id="566">"" "" "" "when a syringe has been taken from the fridge and the room temperature has been reached (up to 25 ° C), it must be used either within 3 days or rejected." "" "" ""</seg>
<seg id="567">Aclasta is used to treat the following diseases: • osteoporosis (a disease which makes the bones brittle) both in women after menopause and in men.</seg>
<seg id="568">"" "" "" "it is applied to patients with a high risk of risk (bone fractures), including patients who recently suffered a small traumatic shift in the bone; • Morbus Paget of the bone has changed the normal course of bone growth." "" "" ""</seg>
<seg id="569">"" "" "" "in addition, patients with Morbus Paget should take at least 500 mg. of calcium twice daily for at least 10 days after treatment; patients with hip fracture should receive a great dose of vitamin D (50 000 to 125 000 IE) before the first infusion." "" "" ""</seg>
<seg id="570">"" "" "" "the administration of paracetamol or ibuprofen (means against inflammation) shortly after the application of Aclasta can reduce symptoms of symptoms such as fever, muscle pain, flu-like symptoms, joint pain and headache." "" "" ""</seg>
<seg id="571">"" "" "" "for treating the Morbus Paget, Aclasta may only be prescribed by doctors, experience in treating this disease." "" "" ""</seg>
<seg id="572">"" "" "" "since the active ingredient in Aclasta is the same as in Zometa, a part of the data material for Zometa was attracted to assessing Aclasta." "" "" ""</seg>
<seg id="573">"" "" "" "in the first study almost 8 000 older women were involved with osteoporosis, and the number of vertebrates and hip fractures were examined over a period of three years." "" "" ""</seg>
<seg id="574">"" "" "" "the second study included 2 127 male women and women with osteoporosis over 50 years, who recently investigated a hill fractures over a period of up to five years." "" "" ""</seg>
<seg id="575">"" "" "" "at Morbus Paget, Aclasta has been tested in two studies involving 357 patients and compared with Risedronate (another bisphosphonate)." "" "" ""</seg>
<seg id="576">"" "" "" "the main indicator of the efficacy was whether the content of alkaline phosphatase in the serum (an enzyme, the bone substance), normalized or reduced at least 75% compared to the initial value." "" "" ""</seg>
<seg id="577">"" "" "" "in the study with older women, the risk of vertebrates in patients with Aclasta (excluding other osteoporosis) was reduced by 70% over a period of three years." "" "" ""</seg>
<seg id="578">"" "" "" "compared to people suffering from Aclasta (with or without other osteoporosis), the risk of hip fractures was reduced by 41%." "" "" ""</seg>
<seg id="579">In the study with men and women with hip fracture 9% of patients under Aclasta had a fracture (92 from 1 065) compared to 13% of patients under placebo (139 of 1 062).</seg>
<seg id="580">"" "" "" "most of the side effects of Aclasta occur within the first three days after infusion, and are less frequent with repeated infusions." "" "" ""</seg>
<seg id="581">Aclasta may not be used in patients who may be sensitive (allergic) against Zoledronric acid or other bisphosphonate or any of the other ingredients.</seg>
<seg id="582">"" "" "" "like all bisphosphonates patients at Aclasta's risk of kidney problems, reactions on the infusion and steelondrose (extinction of bone tissue) in pine." "" "" ""</seg>
<seg id="583">"" "" "" "the manufacturers of Aclasta provide clarifying material for physicians who use Aclasta to treat osteoporosis, as well as similar material for patients who explains the side effects of the drug and referred to it as if they should consult the doctor." "" "" ""</seg>
<seg id="584">"" "" "" "in April 2005, the European Commission granted Novartis Europemas Limited a permit for the transport of Aclasta in the European Union." "" "" ""</seg>
<seg id="585">"" "" "" "conditions OR Restrictions regarding THE SHING AND SHORY THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE SHING OF THE YOU ARE." "" "" ""</seg>
<seg id="586">"" "" "" "treatment of osteoporosis in postmenopausal women and men with an increased risk of fractures, including patients with a recently noted low-traumatic hip fracture." "" "" ""</seg>
<seg id="587">"" "" "" "the patient information package should be provided and the following core messages include: • The packing of calcium and vitamin D, appropriate physical activity, Non-smoking signs and symptoms of severe side effects • When on medical or nursing aid" "" "" ""</seg>
<seg id="588">Treatment of osteoporosis • postmenopausal women • in men with an increased risk of fractures included in patients with a recent low-traumatic hip fracture.</seg>
<seg id="589">"" "" "" "for the treatment of postmenopausal osteoporosis and osteoporosis in men, an intravenous infusion of 5 mg aclasta is once a year recommended." "" "" ""</seg>
<seg id="590">"" "" "" "in patients with a low-traumatic hip fracture, the administration of the infusion of Aclasta two or more weeks after surgical care is recommended (see Section 5.1)." "" "" ""</seg>
<seg id="591">"" "" "" "for the treatment of Morbus Paget, Aclasta should only be prescribed by doctors, experience in the treatment of Morbus Paget." "" "" ""</seg>
<seg id="592">"" "" "" "after a treatment of the Morbus Paget, Aclasta treatment was observed in patients who have addressed the therapy (see Section 5.1)." "" "" ""</seg>
<seg id="593">"" "" "" "in addition, it is very advisable to ensure patients with Morbus Paget an adequate supply of calcium, correspondingly twice daily at least 500 mg of elemental calcium, for at least 10 days after the gift of Aclasta (see Section 4.4)." "" "" ""</seg>
<seg id="594">"" "" "" "in patients with a recently noted low-traumatic hip fracture, an initial dose of 50.000 to 125,000, i.e. oral or intramuscular vitamin D is recommended before the first Aclasta infusion." "" "" ""</seg>
<seg id="595">"" "" "" "the incidence of symptoms that occur within the first three days after administration of Aclasta, can be reduced shortly after the use of Aclasta." "" "" ""</seg>
<seg id="596">Patients with kidney interference (see section 4.4) In cases of patients with a creatinine Clearance &lt; 35 ml / min Aclasta is not recommended as a limited clinical experience for these patient group is available.</seg>
<seg id="597">"" "" "" "older patients (≥ 65 years) A dose adjustment is not necessary because the bioavailability, distribution and elimination in elderly patients is similar to younger ones." "" "" ""</seg>
<seg id="598">"" "" "" "children and young people Aclasta is not recommended for use in children and adolescents under the age of 18, because data is missing for the inconceivable and effectiveness." "" "" ""</seg>
<seg id="599">Aclasta is not recommended in patients with severe kidney failure (creatinine Clearance &lt; 35 ml / min) because of these patient population only limited clinical experiences.</seg>
<seg id="600">An existing hypokalemia is used prior to treatment with Aclasta by adequate supply of calcium and vitamin D (see section 4.3).</seg>
<seg id="601">"" "" "" "due to rapid inhalation of the effect of zoledronric acid on bone marumine, a temporary, mitogen symptomatic hypokalemia may develop, usually within the first 10 days after the infusion of Aclasta. (see section 4.8)." "" "" ""</seg>
<seg id="602">"" "" "" "in addition, it is very advisable to ensure patients with Morbus Paget an adequate supply of calcium, correspondingly twice daily at least 500 mg of elemental calcium, for at least 10 days after the gift of Aclasta (see Section 4.2)." "" "" ""</seg>
<seg id="603">Cancer disease (chemotherapy, treatment with corticosteroid arthritis, treatment with corticosteroid arthritis) should be considered a dental examination with a reasonable relief valve.</seg>
<seg id="604">"" "" "" "for patients receiving dental handles, no data are available whether the interruption of treatment with bisphosphonates reduce the risk of osteonecrosen in jaw areas." "" "" ""</seg>
<seg id="605">"" "" "" "the clinical assessment by the treatments doctor should be based on each patient's treatment plan, and based on an individual benefit-risk assessment." "" "" ""</seg>
<seg id="606">"" "" "" "the incidence of symptoms that occur within the first three days after administration of Aclasta, can be reduced shortly after the use of Aclasta (see Section 4.2)." "" "" ""</seg>
<seg id="607">"" "" "" "the overall incidence of adverse adverse events was increased by patients who received Aclasta (1.3%) (51%) (51 of 3,862) in comparison to patients with placebo (0.6%)." "" "" ""</seg>
<seg id="608">"" "" "" "in the osteoporosis studies (PFT, HORIZON - Recurrent Fracture Trial [RFT]) was comparable to total circulation between Aclasta (2.6%) and placebo (2.1%)." "" "" ""</seg>
<seg id="609">"" "" "" "very frequent (≥ 1 / 10, &lt; 1 / 100, &lt; 1 / 100, &lt; 1 / 100), rare (≥ 1 / 1000, &lt; 1 / 1000), rare (≥ 1 / 1000), rare (≥ 1 / 1000), rare (≥ 1 / 1000), rare (≥ 1 / 1000), rare (≥ 1 / 1000)." "" "" ""</seg>
<seg id="610">"" "" "" "kidney disturbance Zoledron acid was associated with kidney function, which is in combination of the kidney function (i.e. an increase in serum creatinins) and in rare cases as acute kidney failure." "" "" ""</seg>
<seg id="611">"" "" "" "the change in the creatinine Clearance (measured every year before administration) and the occurrence of kidney function as well as a restricted kidney function, were similar to osteoporosis over three years between the Aclasta- and the placebo group." "" "" ""</seg>
<seg id="612">A temporary increase in serum creatinins within 10 days of gift was observed with 1.8% of patients treated with Aclasta patients compared to 0.8% of patients treated with placebo-treated patients.</seg>
<seg id="613">"" "" "" "based on the evaluation of the laboratory sores, the temporary asymptomatic calcium values showed up to 21% of patients treated with Aclasta in a large clinical study compared to 21% of patients treated with Aclasta in patients." "" "" ""</seg>
<seg id="614">"" "" "" "all patients received adequate amounts of vitamin D and calcium in the study on postmenopausal osteoporosis, in the study on avoiding clinical fractures after a hip fracture and in Morbus-Paget studies (see Section 4.2)." "" "" ""</seg>
<seg id="615">"" "" "" "in the study on avoiding clinical fractures after a recently lapidated hip fracture, the majority of patients received an initial dose of vitamin D prior to administration of Aclasta (see Section 4.2)." "" "" ""</seg>
<seg id="616">"" "" "" "local reactions After accepting Zoledron acid in a large clinical study was reported about local reactions at the infusion agency, such as redness, swelling and / or pain, reported (0.7%)." "" "" ""</seg>
<seg id="617">"" "" "" "Osteonekrosen in the jaw range was articulated above all in cancer patients, above Osteonekrosen (primarily in the jaw range), with bisphosphonate, including coledron acid." "" "" ""</seg>
<seg id="618">"" "" "" "many of these patients had signs for local infections including Osteomyelitis, and the majority of the reports apply to cancer patients to dental tractions or other dental attacks." "" "" ""</seg>
<seg id="619">"" "" "" "7 study with 7,736 patients joined Osteonekrosis in the jaw area with Aclasta and with placebo-treated patients." "" "" ""</seg>
<seg id="620">"" "" "" "in case of overdosing, which leads to a clinically relevant hypokalemia, can be obtained by the gift of oral calcium and / or a intravenous infusion of calcium gluconate." "" "" ""</seg>
<seg id="621">Clinical efficacy during treatment of postmenopausal osteoporosis (PFT) The efficacy and safety of Aclasta 5 mg once a year in postmenopausal women (7.736 females aged between 65 and 89 years) with either two light or a medium-weight spinal cord to ≤ -2.5 with or without signs of existing vertebral fracture tincture.</seg>
<seg id="622">Effects on morphometric spinal fractures Aclasta sensed significantly over a period of three years as well as after one year the frequency of one or several new vertebrates fractures (see table 2).</seg>
<seg id="623">Aclasta treated patients of 75 years and older had a 60% reduced risk of spinal fractures compared to placebo patients (p &lt; 0.0001).</seg>
<seg id="624">Effects on hip fractures Aclasta showed a constant effect over three years based on a reduced risk of 41% (95% CI and 17% to 58%) reduced risk of hip fractures.</seg>
<seg id="625">"" "" "" "effect on the bone density (BMD) Aclasta increased the bone density on the luminal staylic acid, hips and distal radius (6, 12, 24 and 36 months)." "" "" ""</seg>
<seg id="626">9 Increase the bone density of the lumbar counter by 6.7% of the total hill by 5.1% and the distal radius rose by 3.2%.</seg>
<seg id="627">Bone histology of 152 postmenopausal osteoporosis patients who were treated with Aclasta (N = 82) or placebo (N = 70) were taken from the pelvic dose.</seg>
<seg id="628">A microcomputer tomography (µCT) analysis showed up with Aclasta patients in comparison to placebo a increase of the trainsular bone volume and the receipt of the trainsular bone architecture.</seg>
<seg id="629">Bone-related alkaline phosphatase (BSAP) in serum and the beta-C-Telopeptid (b-CTX) in serum and the beta-C-Telopeptid (b-CTX) in serum were determined in sub-groups from 517 to 1.246 patients in periodically intervals.</seg>
<seg id="630">"" "" "" "treatment with an annual 5 mg dose of Aclasta decreased by 30% compared to initial output and was held at 28% below the initial value for up to 36 months." "" "" ""</seg>
<seg id="631">P1NP was significantly reduced by 61% below the initial value after 12 months and was held at 52% below the initial value for up to 36 months.</seg>
<seg id="632">B-CTX has been significantly reduced by 61% below the initial value after 12 months and was kept at 55% below the initial value for up to 36 months.</seg>
<seg id="633">"" "" "" "the vitamin D mirrors were not routinely measured, but the majority of patients received an initial dose of vitamin D (50.000 to 125,000, oral or intramuscular) 2 weeks before infusion." "" "" ""</seg>
<seg id="634">"" "" "" "the total mortality was 10% (101 patients) in the treated group, compared with 13% (141 patients) in the placebo group." "" "" ""</seg>
<seg id="635">Effect on the bone mineral density (BMD) in the HORIZON-RFT study increased the Aclasta treatment compared to placebo-treatment for BMD at the overall heat and snakes.</seg>
<seg id="636">The Aclasta treatment conducted over 24 months in comparison to placebo-treatment to an increase of BMD by 5.4% on the overall heat and 4,3% at the Schenkelheck.</seg>
<seg id="637">"" "" "" "clinical efficacy in men In the HORIZON-RFT study were randomized, and in 185 patients the BMD was assessed after 24 months." "" "" ""</seg>
<seg id="638">The study was not designed to show a reduction in clinical fractures in men; the frequency of clinical fractures amounted to 7.5% in Aclasta-treated males compared to 8.7% for placebo.</seg>
<seg id="639">"" "" "" "in another study by men (study CZOL446M2308), the once annual administration of Aclasta was given to the percentage change of lumbar BMD after 24 months compared to the initial value." "" "" ""</seg>
<seg id="640">Clinical efficacy of treatment at Morbus Paget of the bone Aclasta has been examined in patients with radiologically confirmed earlier (mean serum levels of alkaline phosphatase correspondingly to 2.6x up to 3.0ies-specific upper level taken in the study).</seg>
<seg id="641">"" "" "" "11 The effectiveness of an infusion of 5 mg of Zoledron acid compared to taking 30 mg. of risedronate once a day during 2 months, was demonstrated in two six months of comparison studies." "" "" ""</seg>
<seg id="642">"" "" "" "for the combined results, a similar decrease in pain relief and pain control was observed in comparison to the initial value for Aclasta and Risedron." "" "" ""</seg>
<seg id="643">"" "" "" "patients, which were classified by six months as a result of the six-month trial (applied to therapy), could be included in a follow-up phase." "" "" ""</seg>
<seg id="644">"" "" "" "from the 143 with Aclasta and 107 with risedronate patients, the therapeutic approach could be treated with Aclasta, compared with 71 patients treated with risedron treatment, compared with a mean duration of the follow-up period of 18 months." "" "" ""</seg>
<seg id="645">"" "" "" "one-time and multiple 5 and 15 minutes lasting infusions from 2, 4, 8 and 16 mg of Zoledronric acid in 64 patients showed the following pharmacokinetic data that proved to be dosisindependent." "" "" ""</seg>
<seg id="646">"" "" "" "after that, the plasma level decreased rapidly to &lt; 10% of the maximum value after 4 h and &lt; 1% after 24 h, followed by a long lasting phase, no more than 0.1% of the maximum value." "" "" ""</seg>
<seg id="647">Surprise biphassic disappearance of the big cycle with half-life cycle t ½ -0.24 and t ½. 1.87 hours followed by a long elimination phase with a season of elimination stages of ½ g 146 hours.</seg>
<seg id="648">"" "" "" "the early stages of distribution (α and β, with the above-called ½ -values) represent a rapid resorption in bones and excretion over the kidneys." "" "" ""</seg>
<seg id="649">"" "" "" "in the first 24 hours, 39 ± 16% of the adult dose, while the rest is bound to bone tissue." "" "" ""</seg>
<seg id="650">"" "" "" "the total body-Clearance is irrespective of the dose 5.0 ± 2.5 l / h and remains unaffected by gender, age, race or body weight." "" "" ""</seg>
<seg id="651">An extension of the infusion period from 5 to 15 minutes led to the decrease of the Zoledron acid concentration by 30% at the end of the infusion, but had no effect on the surface under the curve (plasma concentration at time).</seg>
<seg id="652">A reduced clearing of metabolic syndrome is unlikely to metabolized by cytochrom-P450 substances and because zoledronic acid is not metabolized because it is a weak or even direct and / or irreversible, active inhibitor of the P450-</seg>
<seg id="653">Special patient groups (see section 4.2) The renal clearing of the Zoledronic acid correlated with the Kreatinine Clearance, namely 75 ± 33% of the creatinine Clearance and in the 64 evaluated patients in the mean 84 ± 29 ml / min (range 22 to 143 ml / min).</seg>
<seg id="654">This makes it possible that a light (Clone = 50- 80 ml / min) and a moderate renal interference up to a creatinine clearing up to 35 ml / min does not require dosisadaption of the Zoledron acid.</seg>
<seg id="655">"" "" "" "since heavy kidney interference (Kreatinine Clearance &lt; 30 ml / min) is only limited, no conclusions are possible for this population." "" "" ""</seg>
<seg id="656">Acute toxicity The highest non-acting intravenous single dose amounted to 10 mg / kg of body weight and at rats 0.6 mg / kg of bodyweight.</seg>
<seg id="657">"" "" "" "in dogs, individual doses of 1.0 mg / kg (based on AUC) were given the 6fold of the recommended humane therapeutic exposure), administered over a period of 15 minutes, good and without renal influence." "" "" ""</seg>
<seg id="658">"" "" "" "chronic and chronic toxicity studies with intravenous application was administered at intervals of 2 times a 15-minute infusion in 3-day intervals, administered in intervals of 2- 3 weeks (a cumulated dose, which applies to the 7x of the Human-therapeutic exposure, relative to AUC, corresponds to)." "" "" ""</seg>
<seg id="659">"" "" "" "in long-term studies with repeated use in cumulated exposures, which exceeded the maximum of the intended human exposure, including the gastrointestinal tract and the liver, as well as at the intravenous injection site." "" "" ""</seg>
<seg id="660">"" "" "" "the most frequent occurrence in studies with repeated use was an increased primary Spongiosa in the metaphyse of the long bone with animals in the growth phase with virtually all dosages, a result reflects the pharmacological, antiresortive effect of the substance." "" "" ""</seg>
<seg id="661">"" "" "" "at rats, a teratogenicity at doses ranging from 0.2 mg / kg as external and inner (visceral) abnormalities and such skeletops." "" "" ""</seg>
<seg id="662">"" "" "" "rabbits were observed in rabbits were observed no teratogenous effects or an embryo-fetal effects, although the maternal toxicity was pronounced at 0.1 mg / kg as a result of reduced serum calcium mirror." "" "" ""</seg>
<seg id="663">"" "" "" "if the medicine is not directly used, the user is responsible for the storage time and conditions before the application; normally 24 hours at 2 ° C can not be exceeded." "" "" ""</seg>
<seg id="664">Aclasta is supplied as a pack with a pack as package unit or as bundle pack consisting of 5 packs each containing a bottle.</seg>
<seg id="665">"" "" "" "treatment of osteoporosis in postmenopausal women and men with an increased risk of fractures, including patients with a recently noted low-traumatic hip fracture." "" "" ""</seg>
<seg id="666">"" "" "" "the patient information package should be provided and the following core messages include: • The packing of calcium and vitamin D, appropriate physical activity, Non-smoking and symptoms of severe side effects • When to be patient or used for medical help" "" "" ""</seg>
<seg id="667">"" "" "" "July 29, 2007, completed on 29 September 2006, in the 1.8.1 of the approval application of the pharmaceutical covigilance system in power and works before and while the product is marketed." "" "" ""</seg>
<seg id="668">"" "" "" "Risco-Management Plan The holder of the approval of the approval process is obligated to implement the studies and the additional activities of the risk management plan (RMP) in the pharmaceutical covigilance plan, and all the following versions of the RMP grants." "" "" ""</seg>
<seg id="669">"" "" "" "according to the CHMP Directive on risk management systems for human medicines, the revised RMP should be submitted together with the next" periodic safety update Report (PSUR). "" "" "" "</seg>
<seg id="670">"" "" "" "a revised RMP should be submitted as new information, which could influence the current statements on security, the pharmaceutical-vigilance plan or activities for minimizing risk factors." "" "" "" • On the requirements of the EMEA. "" "" "" "</seg>
<seg id="671">"" "" "" "Zoledronic acid is a representative of substanzas, which is called bisphosphonate and is used for the treatment of osteoporosis in postmenopausal women, osteoporosis in men and the Morse Paget of the bone." "" "" ""</seg>
<seg id="672">"" "" "" "decreasing blood levels of sex hormones, predominantly oestrogens, which are formed from androgens, play a role in a rather progressive loss of bone mass who is observed in men." "" "" ""</seg>
<seg id="673">"" "" "" "at Morbus Paget, the bone structure is too fast, and new bone material is subjected to subordinate which makes the bone material weaker than normal." "" "" ""</seg>
<seg id="674">"" "" "" "Aclasta has a effect in normalized bone formation, ensuring normal bone formation and thus gives the bone again giving strength." "" "" ""</seg>
<seg id="675">"" "" "" "if you are in dental treatment or to undergo a dental surgery, tell your doctor that you will be treated using Aclasta." "" "" ""</seg>
<seg id="676">"" "" "" "when applying Aclasta with other medicines please inform your doctor, pharmacist or nursing staff when using other medicines or used recently, even if it is not prescription drugs." "" "" ""</seg>
<seg id="677">"" "" "" "for your doctor, it is particularly important to know if you are using medicine, which is known by the kidneys." "" "" ""</seg>
<seg id="678">"" "" "" "when applying Aclasta along with food and drink, you worry that you will be sufficient liquid before and after the treatment with Aclasta." "" "" ""</seg>
<seg id="679">Osteoporosis is the usual dose is 5 mg once a year that is given to you by your doctor or the nursing staff as infusion in a vene.</seg>
<seg id="680">"" "" "" "when you have broken the hip, it is recommended to take the administration of Aclasta two or more weeks after surgical care." "" "" ""</seg>
<seg id="681">"" "" "" "Morbus Paget The usual dose is 5 mg, which is given to you by your doctor or the nursing staff as infusion in a vene." "" "" ""</seg>
<seg id="682">"" "" "" "since Aclasta has worked for a long time, you may need a further dose until one year or longer." "" "" ""</seg>
<seg id="683">"" "" "" "it is important to follow these instructions, so that the calcium mirror in your blood is not too low in the period following the infusion." "" "" ""</seg>
<seg id="684">"" "" "" "at Morbus Paget, Aclasta can work longer than a year, and your doctor will inform you if you need a renewed treatment." "" "" ""</seg>
<seg id="685">"" "" "" "if administration was missed by Aclasta, you will get in touch with your doctor or hospital in order to make a new appointment." "" "" ""</seg>
<seg id="686">"" "" "" "prior to completion of the treatment with Aclasta Falls, please consider the completion of the treatment with Aclasta and discuss this with your doctor." "" "" ""</seg>
<seg id="687">"" "" "" "side effects associated with the first infusion occur very often (with more than 30% of patients), but are less frequent after the subsequent infusion." "" "" ""</seg>
<seg id="688">Fever and chills; muscle or joint pain and headaches that occur within the first three days after administration of Aclasta.</seg>
<seg id="689">"" "" "" "currently it is unclear whether Aclasta causes this irregular heartbeat, but you should notice it to your doctor if you have received such symptoms when you get Aclasta." "" "" ""</seg>
<seg id="690">"" "" "" "physical signs because of a low calcium deficiency in the blood, such as muscle cramps or cribes feeling, especially in the field around the mouth." "" "" ""</seg>
<seg id="691">"" "" "" "flu, sleeplessness, fatigue, glaciousness, flaps, mouths, rubbing, skin pain, skin pain, skin pain, skin pain, skin pains, skin pain, skin pains, rubbing, rubbing, skin burns and thirst." "" "" ""</seg>
<seg id="692">Prolonged pain and / or not healing wounds in the mouth or jaws were reported primarily in patients who were treated with bisphosphonates for other diseases.</seg>
<seg id="693">"" "" "" "allergic reactions, including rare cases of respiratory problems, hives rash and angioedema (such as swelling in the face, tongue or throat), was reported." "" "" ""</seg>
<seg id="694">"" "" "" "please inform your doctor, pharmacist or nursing staff when one of the listed side effects will significantly affect or you will notice any side effects that are not listed in this user information." "" "" ""</seg>
<seg id="695">"" "" "" "if the medicine is not directly used, the user is responsible for the storage time and conditions up to the application; normally 24 hours at 2 ° C can not be exceeded." "" "" ""</seg>
<seg id="696">"" "" "" "in patients with a short-traumatic hip fracture, patients are advised to make the infusion of Aclasta two or more weeks after the surgical care of the hip fracture." "" "" ""</seg>
<seg id="697">"" "" "" "before and after administration of Aclasta patients need to be sufficient with fluid, this is particularly important in patients who receive diuretic therapy." "" "" ""</seg>
<seg id="698">"" "" "" "due to rapid inhalation of the effect of Zoledronic acid on bone marumming, a temporary, sometimes symptomatically interctively develop, whose maximum usually occurs within the first 10 days after the infusion of Aclasta." "" "" ""</seg>
<seg id="699">"" "" "" "in addition, it is very advisable to ensure patients with Morbus Paget an adequate supply of calcium, according to at least twice daily 500 mg of elemental calcium, for at least 10 days after the gift of Aclasta." "" "" ""</seg>
<seg id="700">"" "" "" "in patients with a short-traumatic hip fracture, a starting dose of 50.000 to 125,000 is i.e. oral or intramuscular vitamin D is recommended before the infusion of Aclasta." "" "" ""</seg>
<seg id="701">"" "" "" "if you need further information about your illness or treatment, please read the package directions (also part of the EPAR) or apply to your doctor or pharmacist." "" "" ""</seg>
<seg id="702">"" "" "" "ACOMPLIA is used in addition to a diet and movement for the treatment of adult patients (body mass index - BMI) of 30 kg / m ² or above, or above (BMI of 27 kg / m ²) and over one or more." "" "" ""</seg>
<seg id="703">"" "" "" "in addition, four trials over 7 000 patients were conducted in which ACOMPLIA was used as a supporting means for setting the smoking." "" "" ""</seg>
<seg id="704">"" "" "" "in contrast to study on smoking, no uniform results showed that the effect of ACOMPLIA was difficult to assess on this application." "" "" ""</seg>
<seg id="705">"" "" "" "what risk is associated with ACOMPLIA? the most common effects of ACOMPLIA were observed during studies (nausea) and infections of the upper respiratory tract. ng The complete listing of associated with ACOMPLIA reported side effects, the package deals." "" "" ""</seg>
<seg id="706">"" "" "" "it may also not be applied to patients who suffer loss of severe depression or treat antidepressants, since it can reinforcements the risk of depression and among others by a small minority of patients." "" "" ""</seg>
<seg id="707">Caution is advisable while using ACOMPLIA with medicines such as Ketoconazole or Itraconazole (medicines for fungal infections), rite-mycin or clotthromycin (antibiotics). LN</seg>
<seg id="708">The Committee for Human Use (CHMP) concluded that the effectiveness of ACOMPLIA in terms of weight reduction in patients with obesity or overweight people</seg>
<seg id="709">"" "" "" "medicines used in patients, which require health and non-cosmetic reasons (by providing surveillance packages for patients and doctors), and around the Arz" "" "" ""</seg>
<seg id="710">He is an addition to diet and exercise for the treatment of obesity (BMI ≥ 30 kg / m ²) or overimportant patients (BMI &gt; 27 kg / m ²) in addition to one or more risk factors (see Section 5.1).</seg>
<seg id="711">"" "" "" "ACOMPLIA is not recommended for use in children and adolescents under 18 years of age, due to the lack of data for efficacy and impemability." "" "" ""</seg>
<seg id="712">"" "" "" "La depressive diseases or mood changes with depressive symptoms have been reported in up to 10% of patients who received Rimonabant in up to 1%, (see section 4.8)." "" "" ""</seg>
<seg id="713">"" "" "" "and with depressive disorders, Rimonabant may not be applied, unless the benefit of treatment in individual cases is the risk (see section 4.3 and 4.8)." "" "" ""</seg>
<seg id="714">"" "" "" "in addition to patients who have - besides obesity - no recognizable risks, can occur depressed reactions." "" "" ""</seg>
<seg id="715">"" "" "" "members or other nearby people) are indicated that it is necessary to monitor new symptoms of such symptoms and get immediate medical advice, if these symptoms are occurring." "" "" ""</seg>
<seg id="716">• Elder patients The efficacy and lack of Rimonabant in the treatment of patients over 75 years were not sufficiently shown.</seg>
<seg id="717">Patients with a cardiovascular event (myocardial infarction or stroke etc.) before less than 6 months were outdated by studies with Rimonabant. ln</seg>
<seg id="718">"" "" "" "rifampicin, phenytoin, phenobarbital, carbamazepine, Carbamazepine, Carbamazepine, Johanniswort is assumed that the simultaneous gift of potent CYP3A4-induction included the plasma concentration of Rimonabant." "" "" ""</seg>
<seg id="719">"" "" "" "in addition, patients with obesity have examined the important patient and in addition to 3800 patients in other indications." "" "" ""</seg>
<seg id="720">"" "" "" "the following table (table 1) shows the unwanted effects in placebo-controlled trials in patients who were treated for weight reduction and accompanied metabolic diseases." "" "" ""</seg>
<seg id="721">If the incidence was statistically significant higher than the corresponding effects of placeborate (for unwanted effects (1%) or if they were clinically relevant (for unwanted effects &lt; 1%) or when they were clinically relevant (for adverse effects the following skins are basically reduced):</seg>
<seg id="722">Very common (≥ 10%); frequently (≥ 1, &lt; 10%); occasionally (≥ 0.1, &lt; 1%); rare (≥ 0.01, &lt; 0.1%); very t lä</seg>
<seg id="723">"" "" "" "in a tolerable study, in which a limited number of persons having administered up to 300 mg were observed, only slight symptoms were observed." "" "" ""</seg>
<seg id="724">Patients had a BMI ≥ 30 kg / m ² or BMI &gt; 27 kg / m ² and one at the same time existing hypertonia and / or Dyslipimia.</seg>
<seg id="725">N weight reduction after one year was used for ACOMPLIA 20 mg / 6.5 kg. compared to 1.6 kg for the placebo (difference -4.9 kg CI95% -5.3; -4.4, p &lt; 0.001).</seg>
<seg id="726">Patients who were treated with ACOMPLIA 20 mg and 1.2 kg in the placebo group (difference -3.8 kg; CI95% -4.4; -3.3; p &lt; 0.001).</seg>
<seg id="727">"" "" "" "after 2 years, the difference in total weight reduction between ACOMPLIA and placebo-4.2 kg (CI95% -5.0%; -3.4, p &lt; 0.001)." "" "" ""</seg>
<seg id="728">"" "" "" "9 weight reduction and further risk factors In the studies of patients without diabetes, in which a mixed population of patients with" "" "" ""</seg>
<seg id="729">Under Rimonabant 20 mg an average trglyceride of 6.9% was seen (output value triglyceride 1.62 mmol / l) as compared to a rise of 5.8%</seg>
<seg id="730">"" "" "" "in a second study of patients with obesity and previously untreated type 2 diabetes (serenade), the absolute change of the HbA1c value (with an output value of 7.9% for both groups) was 20 mg and 0.3 under placebo" "" "" ""</seg>
<seg id="731">The percentage of patients who reached HbA1c- value of &lt; 7% was 51% in the Rimonabant Group and 35% in the placebo group.</seg>
<seg id="732">The difference of medium weight change between the 20 mg- and placebo group was 3.8 kg (CI95% -5.0, -2.6 p &lt; 0.001). LN</seg>
<seg id="733">Improving the HbA1c value in patients who had taken Rimonabant 20 mg were explained about 50% by direct effects of Rimonabant and about 50% by weight reduction. n EIM Arz</seg>
<seg id="734">2 hours reached that the Steady-state plasma level have been reached after 13 days (Cmax = 196 ± 28.1 ng / ml; Ctk = 91.6 ± 14.1 ng / ml; CC0-24 = 2960 ± 268 ng.h / ml).</seg>
<seg id="735">Influence of food: he subjects and Rimonabant were either obtained in the sober-condition or after a low-fat meal. in case of food intake a Cmax or by 48% increased ng AUC up to 48%.</seg>
<seg id="736">Patients with black skin color can result in a reduction of up to 31% lower Cmax and a reduction of 43% lower AUC as patients other ethnic populations.</seg>
<seg id="737">N-populationist analysis (age range 18- 81 years) is estimated that a 75 - year-old patient is one by 21% higher Cmax and one by 27% higher AUC has a 40-year-old</seg>
<seg id="738">"" "" "" "5.3 Identification of clinical data concerning the resulting unwanted effects which were not observed in clinical trials, however, were considered to be relevant for clinical application:" "" "" ""</seg>
<seg id="739">"" "" "" "in some, but not in all cases the beginning of the convulsions seems to be associated with proceeding stress as dealing with animals." "" "" ""</seg>
<seg id="740">"" "" "" "in Rimonabant, Rimonabant was given for a longer period before the combination (9 weeks) which allowed a recovery from the initial effects of Rimonabant, so no unwanted effects were observed on fertilization or cycle disorders." "" "" ""</seg>
<seg id="741">The influence of Rimonabant on pre- and postnatal development was examined at the rat in dosages of up to 10 mg / kg / day.</seg>
<seg id="742">Exposition with Rimonabant in utero and postnatal development created a exposition with Rimonabant in utero and through lactation no changes when learning or in memory.</seg>
<seg id="743">Detailed information about this medicine are available on the website of the European Medicines Agency (EMEA) http: / / www.emea.europa.eu / available</seg>
<seg id="744">"" "" "" "La On the treatment situation of the pharmaceutical, name and address of the manufacturer, which are responsible for approval of the respective charge." "" "" ""</seg>
<seg id="745">26 "" "" "" "26 Several psychiatric events such as depression or mood changes were reported in patients with ACOMPLIA (see paragraph, which NEBENWIRKECTS were reported)" "" "" ""</seg>
<seg id="746">"" "" "" "sse If with you symptoms of a depression (see below) during treatment with ACOMPLIA, turn to your doctor and break the treatment." "" "" ""</seg>
<seg id="747">"" "" "" "dizziness, diarrhea, anxiety, itching, transitions, pain ache (hedalgia), change sensitivity, back pain (hedalgia), changed sensitivity (diminished sensation or indelible), heat loss, joint pain, joint pain." "" "" ""</seg>
<seg id="748">Sse Informing to your doctor or pharmacist if one of the listed side effects will be significantly impaired or you will notice any side effects that are not listed in this use.</seg>
<seg id="749">Abstract of the EPAR for the public: the present document is a summary of the European Public Directorate (EPAR) which explains how the Committee for Human Use (CHMP) is discussed in order to get recommendations concerning the application of medicine.</seg>
<seg id="750">Actos is used for treatment of type 2 diabetes (also known as non-insulin-dependent diabetes). • It can not be used in patients (in particular overweight patients). • It can be used together with another diabetric medicine (dualtherapy).</seg>
<seg id="751">"" "" "" "it can also be applied in addition to metformin in patients (in particular overweight patients), which can not be satisfactory in the highest tolerable dose." "" "" ""</seg>
<seg id="752">"" "" "" "in combination with a Sulfonylresin material or insulin, the old dose of the sulfa drugs and insulin can be reduced compared to patients with hypoglycaemia (low blood sugar); this should be reduced to the dose of the sulfa drugs and the insulin." "" "" ""</seg>
<seg id="753">"" "" "" "this means that the body's body is better utilized and the blood sugar level drops, which allows Type 2 diabetes." "" "" ""</seg>
<seg id="754">"" "" "" "with more than 1 400 patients, the effectiveness of Actos in Tripletherapy was investigated, thereby the patients received a combination of metformin with a sulphil resin, in addition they received either Actos or placebo for up to 3.5 years." "" "" ""</seg>
<seg id="755">"" "" "" "in the studies the concentration of a substance in blood (glycoaxial hemoglobin, HbA1c) was measured, which shows how good blood sugar is adjusted." "" "" ""</seg>
<seg id="756">"" "" "" "Actos led to a lowering of the HbA1c value, which suggests that blood sugar levels were lowered by 15 mg, 30 mg and 45 mg." "" "" ""</seg>
<seg id="757">"" "" "" "at the end of the Triplea study, the effect of the additional treatment of Actos to the existing treatment with metformin and a sulfolic wavy showed up 0.94%, while the extra gift of placebo resulted in a reduction of 0.35%." "" "" ""</seg>
<seg id="758">"" "" "" "in a small study, in which the combination of Actos and insulin were examined in 289 patients, the patients received additional insulin amounts of 0.69% after 6 months, compared with 0.14% in patients who also took placebo." "" "" ""</seg>
<seg id="759">"" "" "" "the most common adverse events related to actos were vision disorders, infections of the upper respiratory tract (colds), weight gain, and hypoesthesia (diminished sensitivity to irritation)." "" "" ""</seg>
<seg id="760">"" "" "" "Actos should not be used in patients who may be sensitive to patients (allergic) to pioglitazon or any of the other components, nor in patients with liver problems, heart failure or diabetic calvetia." "" "" ""</seg>
<seg id="761">"" "" "" "it was decided that Actos should serve as an alternative to the standard treatment with metformin in patients, where metformin is not displayed." "" "" ""</seg>
<seg id="762">"" "" "" "in October 2000, the European Commission granted Takeda Europe R & D Centre Limited authorization of account of the account of Actos in the European Union." "" "" ""</seg>
<seg id="763">"" "" "" "the tablets are white until whitish, round, curved and carry on one side the marking" 15 "and on the other side the inscription" Actos. "" "" "" ""</seg>
<seg id="764">"" "" "" "Pioglitazon is also indicated for the combination with insulin for patients with type 2 diabetes mellitus, whose blood sugar is insufficient and inadequately (see section 4.4)." "" "" ""</seg>
<seg id="765">"" "" "" "for use of pioglitazon in patients under 18 years of age, no data is available, therefore application is not recommended in this age group." "" "" ""</seg>
<seg id="766">"" "" "" "in patients who develop at least one risk factor (e.g. earlier heart attack or symptomatic coronary heart disease), the doctor should start treatment with the lowest available dose and increase the dose." "" "" ""</seg>
<seg id="767">"" "" "" "patients should be observed in signs and symptoms of congestive heart failure, weight gain or oedema, especially those with reduced cardiovascular reserve." "" "" ""</seg>
<seg id="768">"" "" "" "patients should be observed in signs and symptoms of congestive heart failure, weight gain and oedema when Pioglitazon is used in combination with insulin." "" "" ""</seg>
<seg id="769">A cardiovascular outcome study with Pioglitazon in patients under 75 years with type 2 diabetes mellitus and pre-existing advanced macrorovascular illness was performed.</seg>
<seg id="770">"" "" "" "in this study, an increase in reports of congestive heart failure - which however did not lead to an increase in mortality rate in the study." "" "" ""</seg>
<seg id="771">In patients with increased output liver enzymes (ALT &gt; 2.5 x upper limit of the norm) or with other signs of liver disease may not be used as Pioglitazon.</seg>
<seg id="772">"" "" "" "when the ALT mirror increases to 3 times the upper limit of the norm, liver enzyms are as soon as possible to control." "" "" ""</seg>
<seg id="773">"" "" "" "if a patient symptoms develops to point to a hepatic dysfunction, such as unexplained nausea, vomiting, torso problems, fatigue, loss of appetite and / or darker hardn, are the liver enzymatic values." "" "" ""</seg>
<seg id="774">"" "" "" "the decision on whether the treatment of patients with Pioglitazon is continued, should be led to the preferences of the laboratory parameters of clinical assessment." "" "" ""</seg>
<seg id="775">"" "" "" "in clinical studies using Pioglitazon, a dosistive weight gain has been proven that may differ from grease deposits and in some cases connected with liquid retention." "" "" ""</seg>
<seg id="776">As a result of hemogalignes under the therapy with Pioglitazon (relative reduction of 4%) and hematocrits (relative reduction by 4.1%).</seg>
<seg id="777">Similar changes were observed in comparative controlled trials with pioglitazon in patients under metformin (relative reduction of hemoglobin to 1-4% and hematocrits by 1-2% and hematocrits by 1-3.2%).</seg>
<seg id="778">As a result of increased insulin sensitivity to patients who obtain Pioglitazon as oral twin or triple combination therapy with a sulphil resin or as a twin combination therapy with insulin-dependent hypoglycaemia.</seg>
<seg id="779">"" "" "" "after the introduction of the introduction of thiacolidindions, Pioglitazon, one occurrence or deterioration of a diabetic macular hole was reported." "" "" ""</seg>
<seg id="780">"" "" "" "it is unclear whether there is a direct connection between taking Pioglitazon and the occurrence of macular edema, but unsording doctors should be aware of the possibility of visual acuity; a suitable ophthalmological examination should be considered." "" "" ""</seg>
<seg id="781">"" "" "" "in a summarizing analysis of notifying adverse events in randomised, controlled, double-blind clinical trials over a period of up to 3.5 years with more than 8.100 patients treated with Pioglitazon." "" "" ""</seg>
<seg id="782">"" "" "" "the calculated fracture incidence was 1,9 Fractures, with Pioglitazon treated women and 1.1 Fracontours of women who were treated with a comparative medication." "" "" ""</seg>
<seg id="783">"" "" "" "in the ProActive study, a study conducted over 3.5 years for examining kardiovasculine events, fractures were treated with Pioglitazon, compared with 23 / 905 (2.5%; 0,5 fractures per 100 patient years) in patients with a comparative medication." "" "" ""</seg>
<seg id="784">"" "" "" "patients should be aware of the possibility of pregnant women, and if a patient wish a pregnancy or this entry is necessary (see Section 4.6)." "" "" ""</seg>
<seg id="785">"" "" "" "studies on the study of interactions have shown that Pioglitazon has no relevant effects on pharmacokinetics or pharmacodynamics of Digoxin, warfarin, phenprocoumon and metformin." "" "" ""</seg>
<seg id="786">Interactions with medicines that are metabolized by these enzymes, e.g. oral contraceptives, cyclosporin, calcium metabolism and HMGCoA-reductasselmer are not expected.</seg>
<seg id="787">The simultaneous application of Pioglitazon with gemfibrozil (a cytochrome P450 2C8- inhibitor) resulted in an increase of AUC from Pioglitazon to match 3 times.</seg>
<seg id="788">Simultaneous application of Pioglitazone with rifampicin (a Cytochrom P450 2C8-Inductor) resulted in a reduction in AUC from Pioglitazon by 54%.</seg>
<seg id="789">"" "" "" "this is attributable to maloculinemia and increased insulin resistance in the pregnancy, reducing the availability of metabolic substrates for reddish growth." "" "" ""</seg>
<seg id="790">Very frequently &gt; 1 / 10; frequently &gt; 1 / 100; &lt; 1 / 1000; &lt; 1 / 1000; rare &gt; 1 / 1000; single cases: unknown (not invaluable from this data).</seg>
<seg id="791">"" "" "" "these lead to a temporary change of the lens and the refractive index of the lens, as it can also be seen in other hypoglycemic drugs." "" "" ""</seg>
<seg id="792">"" "" "" "in clinical trials with Pioglitazon stepped up to three times the upper limit of the standard range often occurs as under placebo, but less commonly known as in comparison sections under metformin or sulfolic." "" "" ""</seg>
<seg id="793">"" "" "" "in an outcome study in patients with pre-existing macrorovascular illness, the frequency of severe heart failure under Pioglitazon was 1.6% higher than in placebo when Pioglitazon bzw." "" "" ""</seg>
<seg id="794">"" "" "" "since the market introduction, when Pioglitazone has been reported in combination with insulin or in combination with insulin or in patients with heart failure." "" "" ""</seg>
<seg id="795">"" "" "" "a summarizing analysis of data adverse events in randomised, controlled, double-blind clinical trials over a period of up to 3.5 years with more than 8.100 patients were treated in patients with comparative medication." "" "" ""</seg>
<seg id="796">"" "" "" "in over a period of 3.5 years of ongoing ProActive study, Fracontours were treated with Pioglitazon, compared with 23 / 905 (2.5%) in patients with a comparative medication." "" "" ""</seg>
<seg id="797">"" "" "" "when taking the maximum dose of 120 mg / day over four days, after 180 mg / day over seven days there were no symptoms." "" "" ""</seg>
<seg id="798">Pioglitazon seems to work on a activation of specific kernel receptors (peroxisome Proliferation and Receptor-g (PPAR-g)) which leads to an increased insulin sensitivity of liver, fat and skeleton cells.</seg>
<seg id="799">It could be shown that Pioglitazon reduces the glucose production in the liver and the peripheral Glucoseverings increases in the case of insulin resistance.</seg>
<seg id="800">A clinical study of pioglitazon versus Gliclaicide as monotherapy was continued in two years to examine the time until leaving the therapeutic effect (defined as HbA1c ≥ 8.0% after the first 6 treatment).</seg>
<seg id="801">"" "" "" "at the time after two years after the therapy, blood sugar control (defined as HbA1c &lt; 8.0%) was maintained by Pioglitazon in 69% of patients (compared to 50% of patients under Gliclacidal)." "" "" ""</seg>
<seg id="802">"" "" "" "in a placebo-controlled trial over 12 months, patients whose blood sugar have been insufficient despite thirty-month optimum phase with insulin, to Pioglitazon or placebo." "" "" ""</seg>
<seg id="803">In case of patients under Pioglitazon the mean HbA1c was reduced by 0.45% compared with the patients who continued to get insulin; a reduction of insulin-treated patients with Pioglitazon had been observed.</seg>
<seg id="804">"" "" "" "in clinical trials over one year, a statistically significant decrease in the album / creatinine quotiate showed a statistically significant decrease compared to the initial values." "" "" ""</seg>
<seg id="805">The effect of pioglitazon (monotherapy with 45 mg versus placebo) was tested in a small area laid out examination of type 2 diabetikern.</seg>
<seg id="806">"" "" "" "in most clinical trials a reduction of the overall plasma triglyceride and free fatty acids and a rise of HDL- Cholesterinspiegel as well as minor, but clinically significant increased LDL cholesterol was observed." "" "" ""</seg>
<seg id="807">"" "" "" "in clinical trials over a period of up to two years, Pioglitazon reduced the total plasmatriglyceride and the free fatty acids and increased the HDL Cholesterinspiegel." "" "" ""</seg>
<seg id="808">"" "" "" "compared to Plazebo, a statistically significant increase in LDL cholesterol was observed, while under metformin and gliclacidal values were observed." "" "" ""</seg>
<seg id="809">"" "" "" "in a study over 20 weeks, Pioglitazon did not only produce the sober triglyceride levels, but also improved the postprandial triglyceride levels as well as to the triglyceride absorption as well as to the hepatic triglyceride synthesis." "" "" ""</seg>
<seg id="810">"" "" "" "in the ProActive study, a cardiovascular risk study, 5238 patients were randomized with type 2 diabetes mellitus and pre-existing advanced and cardiovascular therapy, either Pioglitazon or placebo." "" "" ""</seg>
<seg id="811">"" "" "" "after an oral application Pioglitazon is quickly resorbited, whereby the peak concentrations in the plasma is usually accomplished 2 hours after application." "" "" ""</seg>
<seg id="812">"" "" "" "based on this basis, the M-IV contribution corresponds to efficacy in about the threefold efficacy of pioglitazon, whereas the relative efficacy of M-II is minimal." "" "" ""</seg>
<seg id="813">"" "" "" "in interactions studies, Pioglitazon has no relevant impact on pharmacokinetics or pharmacodynamics of Digoxin, warfarin, phenprocoumon and metformin." "" "" ""</seg>
<seg id="814">The simultaneous application of Pioglitazon with gemfibrozil (a cytochrome P450 2C8- inhibitor) or with rifampicin (a cytochrome P450 2C8-Inctor) or lowers the plasma concentration of Pioglitazon (see section 4.5).</seg>
<seg id="815">"" "" "" "after an oral application of radioactive pioglitazon in humans, the marker was found mainly in the rotting (55%) and at a lower extent in Harn (45%)." "" "" ""</seg>
<seg id="816">"" "" "" "the medial plasma elimination period of unchanging pioglitazon amounts to 5-6 hours, and the total active metabolism is 16-23 hours." "" "" ""</seg>
<seg id="817">"" "" "" "the Plasmaconcentrations of Pioglitazon and its metabolism are lower than in patients with reduced kidney function, but the rates of oral Clearance of motherhood are similar." "" "" ""</seg>
<seg id="818">"" "" "" "in toxicological studies in mice, rats, dogs and monkeys have agreed upon repeating plasma volume magnification with hemostal ccentric cardiac hypertrophie." "" "" ""</seg>
<seg id="819">"" "" "" "this is attributable to maloculinemia and increased insulin resistant hyperinsulinemia and increased insulin resistance into the breast reduction and thus reducing the availability of metabolic substrates for reddish growth." "" "" ""</seg>
<seg id="820">Long-term studies (up to 2 years) were induced at the rat of hyperplasia (in male and female rats) and tumors (in male rats) of the urinary bladder.</seg>
<seg id="821">In an animal model of family-family polyposis polyposis (FAP) carried the treatment with two other Thiazolidindions to increased frequency of collagen.</seg>
<seg id="822">"" "" "" "the tablets are white to whitish, round, flat and carry on one side the marking" 30 "and on the other side the inscription" Actos. "" "" "" ""</seg>
<seg id="823">"" "" "" "the calculated fracture incidence was 1,9 Fractures, with Pioglitazon treated women and 1.1 Fracontours of women who were treated with a comparative medication." "" "" ""</seg>
<seg id="824">"" "" "" "in the ProActive study, a study conducted over 3.5 years for examining kardiovasculine events, fractures were treated with Pioglitazon, compared with 23 / 905 (2.5%; 0,5 fractures per 100 patient years) in patients with a comparative medication." "" "" ""</seg>
<seg id="825">"" "" "" "in another study over two years, the effects of a combination therapy of metformin were examined with either Pioglitazon or gliclaicide." "" "" ""</seg>
<seg id="826">"" "" "" "in clinical trials over 1 year, a statistically significant decrease in the album / creatinine quotiate showed a statistically significant decrease compared to the initial values." "" "" ""</seg>
<seg id="827">"" "" "" "in a study over 20 weeks, Pioglitazon did not only produce the sober triglyceride levels, but also improved the postprandial triglyceride absorption as well as to the hepatic Tryglizerid synthesis." "" "" ""</seg>
<seg id="828">"" "" "" "although the study lacked the goal of their primary endpoint, stroke, acute coronarsyndrome, leg amputation of the leg arteries, coronary reascularisation and reascularisation of the leg arteries that are not associated with the intake of Pioglitazon's long-term risks." "" "" ""</seg>
<seg id="829">"" "" "" "the tablets are white to whitish, round, flat and carry on one side the marking" 45 "and on the other side the inscription" Actos. "" "" "" ""</seg>
<seg id="830">"" "" "" "in a summarizing analysis of reports adverse events in randomised, controlled, double-blind clinical trials were treated with pioglitazon and over 7,400 patients who received comparative coincidence in women." "" "" ""</seg>
<seg id="831">"" "" "" "in the ProActive study, a study conducted over 3.5 years for examining kardiovasculine events, fractures were treated with Pioglitazon, compared with 23 / 905 (2.5%; 0,5 fractures per 100 patient years) in patients with a comparative medication." "" "" ""</seg>
<seg id="832">"" "" "" "in a study over 20 weeks, Pioglitazon did not only produce the sober triglyceride levels, but also improved the postprandial triglyceride levels as well as to the triglyceride absorption as well as to the hepatic triglyceride synthesis." "" "" ""</seg>
<seg id="833">"" "" "" "on the packing placement of the pharmaceutical, name and address of the manufacturer, which is responsible for the approval of the respective charge." "" "" ""</seg>
<seg id="834">"" "" "" "in September 2005, the Pharmaceutical Company will submit an additional 6 month Periodic Table Report (PSUR) and later annual PSURs, up to a different decision of CHMP." "" "" ""</seg>
<seg id="835">There must be an updated risk management plan according to the CHMP Guideline on Risk Management Systems for Human Use.</seg>
<seg id="836">"" "" "" "if you are ill with type 2 diabetes, Actos are developing 15 mg tablets to control your blood sugar level by making better exploitation of body's own insulin." "" "" ""</seg>
<seg id="837">"" "" "" "if you know that you are suffering from a sugar, please contact Actos 15mg tablets your doctor." "" "" ""</seg>
<seg id="838">"" "" "" "please inform your doctor or pharmacist if you have further drugs or until recently taken, even if it is not prescription drugs." "" "" ""</seg>
<seg id="839">"" "" "" "if you use Actos 15 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chlorine propellamide, gliclaciamide, glicas, certanamide, is your doctor to tell you whether to reduce the dose of your medicines." "" "" ""</seg>
<seg id="840">"" "" "" "in some patients with longitudinal type 2 diabetes mellitus, cardiac disease or early stroke, which were treated with Actos and insulin, a heart failure evolved." "" "" ""</seg>
<seg id="841">"" "" "" "in clinical studies, in which Pioglitazon was compared with other oral antidiabetics or placebo (active-free tablets) showed up to a higher number of bones." "" "" ""</seg>
<seg id="842">"" "" "" "if you accidentally have taken too many tablets, or if another or a child has taken your medicine, you must immediately get in touch with a doctor or pharmacist." "" "" ""</seg>
<seg id="843">"" "" "" "like Actos and content of the pack Actos 15 mg tablets are white to whitish, round, curved tablets with the marking" 15 "on one side and the inscription" Actos "on the other hand." "" "" ""</seg>
<seg id="844">"" "" "" "if you are ill with type 2 diabetes, Actos are saved 30 mg tablets to control your blood sugar level by making a better utilisation of the body's own insulin." "" "" ""</seg>
<seg id="845">"" "" "" "if you know that you suffer from a sugar, please contact Actos 30mg tablets your doctor before taking account." "" "" ""</seg>
<seg id="846">"" "" "" "if you use Actos 30 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chlorine propellamide, gliclaciamide, glicas, certanamide, is your doctor to tell you whether to reduce the dose of your medicines." "" "" ""</seg>
<seg id="847">"" "" "" "61 Includes as soon as possible your doctor if you find signs of congestive heart failure, such as unusual short breathing or swift weight gain or local answelling (oedema)." "" "" ""</seg>
<seg id="848">"" "" "" "in clinical studies, in which Pioglitazon was compared with other oral antidiabetics or placebo (active-free tablets) showed up to a higher number of bones." "" "" ""</seg>
<seg id="849">"" "" "" "like Actos and content of the pack Actos 30 mg tablets are white to whitish, round, flat tablets with marking" 30 "on one side and the inscription" Actos "on the other hand." "" "" ""</seg>
<seg id="850">"" "" "" "when you are ill with type 2 diabetes, Actos are 45 mg tablets to control your blood sugar level by making a better utilisation of the body's own insulin." "" "" ""</seg>
<seg id="851">"" "" "" "if you know that you are suffering from a sugar, please contact Actos 45mg tablets your doctor." "" "" ""</seg>
<seg id="852">"" "" "" "if you use Actos 45 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chlorine propellamide, gliclaciamide, glicas, certanamide, is your doctor to tell you whether to reduce the dose of your medicines." "" "" ""</seg>
<seg id="853">"" "" "" "66 In some patients with longitudinal type 2 diabetes mellitus, cardiac disease or early stroke, which were treated with Actos and insulin, a congestive heart failure evolved." "" "" ""</seg>
<seg id="854">"" "" "" "as soon as possible, inform your doctor if you find signs of congestive heart failure as an unusual short breathing or swift weight gain or local answelling (oedema)." "" "" ""</seg>
<seg id="855">"" "" "" "in clinical studies, in which Pioglitazon was compared with other oral antidiabetics or placebo (active-free tablets) showed up to a higher number of bones." "" "" ""</seg>
<seg id="856">"" "" "" "67 If any of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this user information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="857">"" "" "" "like Actos and content of the pack Actos 45 mg tablets are white to whitish, round, flat tablets with the marking" 45 "on one side and the inscription" Actos "on the other hand." "" "" ""</seg>
<seg id="858">"" "" "" "the present document is a summary of the European Public Department report (EPAR), which is explained as the Committee for Human Use (CHMP) to get recommendations concerning the application of medication." "" "" ""</seg>
<seg id="859">"" "" "" "if you need further information about your medical condition or treatment of your disease, please read the package directions (which is also part of the EPAR) or apply to a doctor or pharmacist." "" "" ""</seg>
<seg id="860">"" "" "" "if you wish more information on the basis of the CHMP recommendations, please read the scientific discussion (which is also part of the EPAR)." "" "" ""</seg>
<seg id="861">Actraphane 10: solubphane insulin 10% Actraphane insulin 10% Actraphane insulin: 80% Actraphane insulin: 80% Actraphane insulin: 80% Actraphane insulin 50% Actraphane II: soluble insulin 50% and Isophan insulin insulin</seg>
<seg id="862">Actraphane is usually used once or twice a day when a rapid initiating effect is desired along with a longer lasting effect.</seg>
<seg id="863">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.eu.int © EMEA 2006 Reproduction and / or Distribution of this document is Authorised for non business-only in the EMEA (rDNA) and is produced using the so-called "recombinant technology."</seg>
<seg id="864">"" "" "" "Actuphane was diagnosed with type 1 diabetes in total of 294 patients with type 1 diabetes, in which the pancreas is not able to use insulin to use insulin." "" "" ""</seg>
<seg id="865">"" "" "" "after 12 weeks, the concentration of a substance (glycoaxial hemoglobin (HbA1c) was measured, which shows how good blood sugar is adjusted." "" "" ""</seg>
<seg id="866">Actraphane led to a decrease in the HbA1c mirror that hinted on it that blood sugar levels were cut similar to a other humaninsulin.</seg>
<seg id="867">Actraphane should not be used in patients who may be sensitive to humankind (allergic) to humaninsulin (rDNA) or any of the other components.</seg>
<seg id="868">"" "" "" "moreover, the doses of Actraphane must be adjusted if it is administered together with a number of other medicines that can affect blood sugar (the full list is the package)." "" "" ""</seg>
<seg id="869">"" "" "" "the Committee for Human Use (CHMP) reached the conclusion that the benefits of Actraphane, in the treatment of diabetes, reached the risks." "" "" ""</seg>
<seg id="870">"" "" "" "in October 2002, the European Commission approved the European Commission of Novo Nordisk A / S for approval of the transport of Actraphane in the entire European Union." "" "" ""</seg>
<seg id="871">"" "" "" "premixed insulin products are usually applied once or twice a day, if a fast initiating effect is desired along with a longer lasting effect." "" "" ""</seg>
<seg id="872">"" "" "" "the injection needle must be used under the skin for at least 6 seconds, to ensure that the entire dose injected injected." "" "" ""</seg>
<seg id="873">"" "" "" "patients whose blood sugar levels have improved significantly, for example through an intense insulin therapy, the hypoglycaemia warning symptoms can be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="874">Any changes regarding strength, brand (manufacturer), insulin type (fast acting, biphasic, long-effective insulin for insulin) and / or production method (by recombinant DNA compared to insulin of animal origin) can cause a change of dosage.</seg>
<seg id="875">"" "" "" "if switching to Actraphane is required when switching to Actraphane, it can be necessary in the first dose or months after the changeover." "" "" ""</seg>
<seg id="876">"" "" "" "some patients, with hypoglycemic reactions after a change from animal to human insulin, reported that the early warning symptoms of a hypoglycaemia reported less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="877">"" "" "" "prior to travelling that go over several time zones, the patient should be advised to catch the Council of his doctor, as such trips can lead to other times and have to be taken." "" "" ""</seg>
<seg id="878">"" "" "" "the doctor must therefore consider possible interactions in the therapy, and his patients always ask for other medicines used by them." "" "" ""</seg>
<seg id="879">"" "" "" "4 Both hypoglycaemia as well as hyperglycemia, which can occur with a non-controlled Diabetric therapy, increase the risk of abnormalities and fruit tod in utero." "" "" ""</seg>
<seg id="880">"" "" "" "severe hypoglycemic bodies can lead to lessness and / or varicfancies, and with temporary or permanent disturbances of brain function and even death." "" "" ""</seg>
<seg id="881">Diseases of the nervous system Skip - peripheral newropathy A rapid improvement of blood sugar control can be connected with discomfort which are called acute painful neuropathy and are usually reversible.</seg>
<seg id="882">5. an intensification of the insulin therapy with a corrupt improvement of blood sugar may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="883">"" "" "" "diseases of the skin and the lower abdomen tissue - Lipodystrophy at the injection site, a light podystrophy may arise when failed to switch inside the injection area within the injection area." "" "" ""</seg>
<seg id="884">"" "" "" "general disorders and complaints at the adoption of money - local hypersensitivity action on the injections during the insulin delivery can occur local hypersensitivity reactions (redness, swelling, itching, pain and hematoma)." "" "" ""</seg>
<seg id="885">"" "" "" "diseases of the immune system Gelego.- Urtikaria, Exanthem Very rarely - Anaphylakic reactions symptoms generated, gastrointestinal gas, respiratory diseases, cardiovascular problems, low blood pressure and impotence." "" "" ""</seg>
<seg id="886">"" "" "" "however, hypoglycemia can be gradually developed: • Easy hypoglycemic bodies can be treated by oral supplements of glucose and glucose levels." "" "" ""</seg>
<seg id="887">Diabetics should therefore have always treated grapes that are treated with tumours or subcutaneous fruit juice and are treated with an intramuscular or subcutaneous injection of glucose (0.5 to 1.0 mg) by an intramuscular or subcutaneous injection of glucose (0.5 to 1,0 mg) by an intramuscular or subcutaneous injection.</seg>
<seg id="888">"" "" "" "the effect begins within half an hour, the maximum maximum is reached within 2 to 8 hours and the total duration of the duration is up to 24 hours." "" "" ""</seg>
<seg id="889">"" "" "" "resorption The Resorption profile lies in it, that it is necessary in the product to provide a mix of insulin products with faster or delayed resorption." "" "" ""</seg>
<seg id="890">A series of splits (hydrolysis) places on the humaninsulin molecules were raised in consideration; none of the metaboites formed by the division is active.</seg>
<seg id="891">"" "" "" "based on conventional studies on Safety Pharmacology, Toxicity at repeating gift, Genotoxicity, to carcinogenous potential and Reproductive data are no particular dangers to recognize for humans." "" "" ""</seg>
<seg id="892">"" "" "" "it is recommended - after the Actraphane line is taken from the fridge, increasing the temperature of the insulin to room temperature (not above 25 ° C) before it is dispensed in the manual for the first use." "" "" ""</seg>
<seg id="893">"" "" "" "some patients, with hypoglycemic reactions after a change from animal to human insulin, reported that the early warning symptoms of a hypoglycaemia reported less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="894">"" "" "" "the doctor must therefore consider possible interactions in the therapy, and his patients always ask for other medicines used by them." "" "" ""</seg>
<seg id="895">"" "" "" "12 Both hypoglycaemia as well as hyperglycemia, which can occur with a non-controlled Diabetric therapy, increase the risk of abnormalities and fruit tod in utero." "" "" ""</seg>
<seg id="896">13. an intensification of the insulin therapy with a corrupt improvement of blood sugar may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="897">The terminale half-life (t ½) is therefore rather a measure of the absorption than a measure of the elimination of the insulin to the plasma (insulin has a t ½ of only a few minutes).</seg>
<seg id="898">"" "" "" "it is recommended - after the Actraphane line is taken from the fridge, increasing the temperature of the insulin to room temperature (not above 25 ° C) before it is dispensed in the manual for the first use." "" "" ""</seg>
<seg id="899">"" "" "" "some patients, with hypoglycemic reactions after a change from animal to human insulin, reported that the early warning symptoms of a hypoglycaemia reported less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="900">"" "" "" "20 Both hypoglycaemia as well as hyperglycemia, which can occur with a non-controlled Diabetric therapy, increase the risk of abnormalities and fruit tod in utero." "" "" ""</seg>
<seg id="901">21 An intensification of the insulin therapy with a corrupt improvement of blood sugar may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="902">"" "" "" "diseases of the immune system Gelego.- Urtikaria, Exanthem Very rarely - Anaphylakic reactions symptoms generated, gastrointestinal gas, respiratory diseases, cardiovascular problems, low blood pressure and impotence." "" "" ""</seg>
<seg id="903">Cartridges may only be used together with products that are compatible with them and ensure a safe and effective function of cartridge.</seg>
<seg id="904">It is recommended - after the actraphane penfill from the fridge was taken - the temperature of the insulin has to rise to room temperature (not above 25 ° C) before it is added to the manual for the first use.</seg>
<seg id="905">"" "" "" "some patients, with hypoglycemic reactions after a change from animal to human insulin, reported that the early warning symptoms of a hypoglycaemia reported less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="906">"" "" "" "28 trunks of hypoglycaemia as well as hyperglycemia, which can occur with a non-controlled Diabetric therapy, increase the risk of abnormalities and fruit tod in utero." "" "" ""</seg>
<seg id="907">29 A intensification of the insulin therapy with a corrupt improvement of blood sugar may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="908">"" "" "" "some patients, with hypoglycemic reactions after a change from animal to human insulin, reported that the early warning symptoms of a hypoglycaemia reported less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="909">"" "" "" "36 Both hypoglycaemia as well as hyperglycemia, which can occur with a non-controlled Diabetric therapy, increase the risk of abnormalities and fruit tod in utero." "" "" ""</seg>
<seg id="910">37. an intensification of the insulin therapy with a corrupt improvement of blood sugar may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="911">"" "" "" "44 Both hypoglycaemia as well as hyperglycemia, which can occur with a non-controlled Diabetric therapy, increase the risk of abnormalities and fruit tod in utero." "" "" ""</seg>
<seg id="912">45 An intensification of the insulin therapy with a corrupt improvement of blood sugar may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="913">"" "" "" "some patients, with hypoglycemic reactions after a change from animal to human insulin, reported that the early warning symptoms of a hypoglycaemia reported less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="914">52 Both hypoglycaemia as well as hyperglycemia which can occur in a non-controlled Diabetric therapy - increase the risk of abnormalities and fruit tod in utero.</seg>
<seg id="915">53 A intensification of the insulin therapy with a corrupt improvement of blood sugar may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="916">"" "" "" "injection units have to be prepared prior to injection, that the dose controller is reset to zero and a insulin drop at the tip of the injection needle appears." "" "" ""</seg>
<seg id="917">"" "" "" "59 patients whose blood sugar levels have improved significantly, for example through an intense insulin therapy, the hypoglycemic warning symptoms can be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="918">"" "" "" "both hypoglycemia and hyperglycemia, which can occur with a non-controlled Diabetric therapy, increase the risk of abnormalities and fruit tod in utero." "" "" ""</seg>
<seg id="919">Intensification of the insulin therapy with a corrupt improvement of blood sugar may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="920">"" "" "" "diseases of the immune system Gelego.- Urtikaria, Exanthem Very rarely - Anaphylakic reactions symptoms generated, gastrointestinal gas, respiratory diseases, cardiovascular problems, low blood pressure and impotence." "" "" ""</seg>
<seg id="921">"" "" "" "these finished products may only be used together with products that are compatible with them, and ensure a safe and effective function of fabrication." "" "" ""</seg>
<seg id="922">"" "" "" "it is recommended - after Actraphane Novolet was taken from the fridge, increasing the temperature of the insulin to room temperature (not above 25 ° C) before it is dispensed in the manual for the first use." "" "" ""</seg>
<seg id="923">67 "" "" "" "67 patients whose blood sugar levels have improved significantly, for example, inhibit hypoglycemic warning symptoms, and should be advised accordingly." "" "" ""</seg>
<seg id="924">"" "" "" "75 patients whose blood sugar levels have improved significantly, for example, inhibit hypoglycemic warning symptoms, and should be advised accordingly." "" "" ""</seg>
<seg id="925">"" "" "" "83 patients whose blood sugar levels have improved significantly, for example through an intense insulin therapy, the hypoglycaemia warning symptoms can be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="926">"" "" "" "91 patients whose blood sugar levels have improved significantly, for example through an intense insulin therapy, the hypoglycaemia warning symptoms can be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="927">"" "" "" "99 patients whose blood sugar levels have improved significantly, for example through an intense insulin therapy, the hypoglycaemia warning symptoms can be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="928">"" "" "" "any changes regarding strength, brand (manufacturers), insulin type (quickly effective, biphasic, langinsulin analogue) and / or production method (by recombinant DNA compared to insulin of animal origin) can cause a change of dosage." "" "" ""</seg>
<seg id="929">It is recommended - after Actraphane Innography is taken from the fridge - the temperature of the insulin should rise to room temperature (not above 25 ° C) before it is added to the manual for the first use.</seg>
<seg id="930">It is recommended - after Actraphane FlexPen has been taken from the fridge - the temperature of the insulin should rise to room temperature (not above 25 ° C) before it is added to the manual for the first use.</seg>
<seg id="931">"" "" "" "on the packing placement of the pharmaceutical, name and address of the manufacturer, which is responsible for the approval of the respective charge." "" "" ""</seg>
<seg id="932">Keep in the refrigerator (2 ˚ C - 8 ˚ C) Not to freeze The tucking bottle in the box to protect the content from light after dawn: not in the refrigerator or at 25 ° C</seg>
<seg id="933">Subcutaneous application Penfill cartridges are intended for use with insulin-injections of Novo Nordisk with the instructions of the instructions. note Actraphane 10 pension fill may only be used by a person</seg>
<seg id="934">"" "" "" "store in the refrigerator (2 ˚ C - 8 ˚ C) Not to store the cartridge against light, in order to protect the contents from light; not in the refrigerator, or over 30 ° C." "" "" ""</seg>
<seg id="935">Subcutaneous application Penfill cartridges are intended for use with insulin-injections of Novo Nordisk with the instructions of the package dispensing. note Actraphane 20 Penfill must only be used by a person</seg>
<seg id="936">Subcutaneous application Penfill cartridges are intended for use with insulin-injections of Novo Nordisk with the instructions of the package dispensing. note Actraphane 30 penfill may only be used by a person</seg>
<seg id="937">Subcutaneous application Penfill cartridges are intended for use with insulin-injections of Novo Nordisk with the instructions of the instructions. actraphane 40 penfill may only be used by a person</seg>
<seg id="938">Subcutaneous application Penfill cartridges are intended for use with insulin-injections of Novo Nordisk with the instructions of the instructions. actraphane 50 Penfill may only be used by a person</seg>
<seg id="939">Subcutaneous application To use Actraphane 10 Novoddles are intended to be used with Actraphane 10 Novoddles due to the instructions of resuspane 10 Novoddlers only be used by one person</seg>
<seg id="940">Keep in the refrigerator (2 ˚ C - 8 ˚ C) Not to freeze light after opening hours: keep in the refrigerator or about 30 ° C</seg>
<seg id="941">Subcutaneous application To use Actraphane 20 Novoung are intended to be used with Actraphane 20 Novoung to the instructions of the instructions. note Actraphane 20 Novolet should be used only by one person</seg>
<seg id="942">Subcutaneous application For use with Actraphane 30 Novoddles are intended to be used with Actraphane 30 Novoddles due to the instructions of resusphane 30 Novoddler must be used only by one person</seg>
<seg id="943">Subcutaneous application To use Actraphane 40 Novoung are intended to be used with Actraphane 40 Novoung to the instructions of the instructions. actraphane 40 Novolet should be used only by one person</seg>
<seg id="944">Subcutaneous application For use with Actraphane 50 Novoddles are intended for use with Actraphane 50 Novoddles due to the instructions of resuspane 50 Novoddlers only must be used by one person</seg>
<seg id="945">Subcutaneous application For use with Actraphane 30 Innouns are intended for using Actraphane S injections according to the instructions of resuspane 30 Innod must only be used by a person</seg>
<seg id="946">"" "" "" "this means approximately half an hour after you have applied it to sink your blood sugar, and that the effect will stop about 24 hours." "" "" ""</seg>
<seg id="947">"" "" "" "► if you are allergic to this insulin product, metacresol or any of the other components (see section 7 more information)." "" "" ""</seg>
<seg id="948">Pay attention to the among 5 which side effects are possible? described symptoms of an allergy if you feel the first signs of hypoglycemia (symptoms of subtying).</seg>
<seg id="949">"" "" "" "if your doctor has caused a change from insulin or brand to another, possibly the dose must be adjusted by your doctor." "" "" ""</seg>
<seg id="950">► Check the label with the label whether it is about the right insulin type. disinfect the rubber membrane with an medical tupfer.</seg>
<seg id="951">If this is not completely unusual if you have got the water bottle back to your pharmacy. (see 6 How is Actraphane) or frozen (see 6 How is Actraphane).</seg>
<seg id="952">"" "" "" "use injection technique to advise you your doctor or diabetesconsultant. ► Move the injection needle for at least 6 seconds under your skin, to ensure that the complete dose injected." "" "" ""</seg>
<seg id="953">"" "" "" "suddenly the warning signs of a subcking can occur suddenly and can be: cold sweat, cold pears, nausea, great appetite, anxiety or trembling, anxiety, confusion, concentration difficulties." "" "" ""</seg>
<seg id="954">"" "" "" "tell your relatives, friends and close colleagues to secure you in the case of a lessness of consciousness in the stable side position and immediately need to communicate a doctor." "" "" ""</seg>
<seg id="955">"" "" "" "you may not give you anything to eat or drink, as you could choke it. ► If a heavy flush may not be treated if you have a subcking or even occurring disturbing, search your doctor." "" "" ""</seg>
<seg id="956">"" "" "" "you can regain awareness faster, if the hormone is glucagon of a person who is familiar with its gift." "" "" ""</seg>
<seg id="957">"" "" "" "this can happen, • If you can add too much insulin to eat or take a meal • if you need more than usual physically." "" "" ""</seg>
<seg id="958">"" "" "" "increased urinary tract, thirst, loss of appetite, nausea, or vomiting, fatigue or fatigue, purified dry skin, mouth drying and fruity (after acetone) irritating breath." "" "" ""</seg>
<seg id="959">• You have a insulin injecting and repeating instances of less insulin than you need • infection or fever - more food than usual • less physical exercise than usual.</seg>
<seg id="960">"" "" "" "if you give yourself an injection at the same place, the subjunctival tissue can shrink (lipatrophy) or to take (Lipohypertrophie)." "" "" ""</seg>
<seg id="961">"" "" "" "if you notice deepenings or thickening of your skin at the injection point, tell your doctor or your diabetesConsultant, as these reactions can affect you in such a place." "" "" ""</seg>
<seg id="962">"" "" "" "immediately look for a doctor if the symptoms of an allergy increase to other parts of the body, or if you suddenly have penetrations, nausea (vomiting), breathing difficulties, heart attacks, or you have the impression to become unconscious." "" "" ""</seg>
<seg id="963">They possibly have a very rare allergic reaction to actraphane or one of its components (such as systemic or allergic reaction).</seg>
<seg id="964">"" "" "" "if one of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet counselor, or pharmacist." "" "" ""</seg>
<seg id="965">What Actraphane 30 contains - the active substance is associated with recombinant DNA technology from insulin-generated insulin (30% as insulin insulin and 70% as isophan insulin).</seg>
<seg id="966">"" "" "" "like Actraphane and contents of the package The injections are delivered as deceptive, white, watery suspension with 5 ml or a bundling pack with 5 holes, each 10 ml each." "" "" ""</seg>
<seg id="967">"" "" "" "use injection technique to advise you your doctor or diabetesconsultant. ► Move the injection needle for at least 6 seconds under your skin, to ensure that the complete dose injected." "" "" ""</seg>
<seg id="968">"" "" "" "it is recommended - after being taken from the fridge, increase the temperature of the water temperature to room temperature before the insulin is used for the first use." "" "" ""</seg>
<seg id="969">"" "" "" "like Actraphane and contents of the package The injections are delivered as deceptive, white, watery suspension with 5 ml or a bundling pack with 5 holes, each 10 ml each." "" "" ""</seg>
<seg id="970">► Check the label with the label whether it is about the right insulin type. always check the penumfill cartridge including the rubber pistol.</seg>
<seg id="971">"" "" "" "do not use it if any damage is visible or a gap between the rubber piston and the white bond of the label is visible." "" "" ""</seg>
<seg id="972">"" "" "" "for further information, refer to the manual of your insulin injector. ► disinfect the rubber membrane with an medical tupfer. ► Use a new injection needle to avoid contamination." "" "" ""</seg>
<seg id="973">► to use insulin pump ► if the fill-fill or the device that contains the bular (see 6 How is Actraphane) or frozen. (see 6 How is Actraphane) or frozen.</seg>
<seg id="974">"" "" "" "if you are treated with Actraphane 10 pendular fill and a different insulin in pension cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="975">"" "" "" "before you use the cartridge to the insulin injections, you move at least 20 times between the positions a and b up and down (see figure), so that the glass spheres move from one end of the cartridge to another." "" "" ""</seg>
<seg id="976">"" "" "" "use injection technique to help you remove your doctor or your diabetesconsultant and use the injection needle for at least 6 seconds under your skin, allowing the injection needle to remove and remove actraphane without absorbing injection needle." "" "" ""</seg>
<seg id="977">"" "" "" "in 183, you will put your relatives, friends and close colleagues to meet you in the case of a lessness of consciousness in the stable side position and immediately need to communicate a doctor." "" "" ""</seg>
<seg id="978">• You have a insulin injecting and repeating instances of less insulin than you need • infection or fever - more food than usual • less physical exercise than usual.</seg>
<seg id="979">"" "" "" "if one of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet counselor, or pharmacist." "" "" ""</seg>
<seg id="980">"" "" "" "it is recommended - after being taken from the fridge, the temperature of the fill cartridge is to rise to room temperature before the insulin is used for the first use." "" "" ""</seg>
<seg id="981">"" "" "" "185 Make the cartridges always in box, if you do not use it to protect them from light." "" "" ""</seg>
<seg id="982">What Actraphane 10 contains - the active substance is associated with recombinant DNA technology-generated insulin (10% as insulin insulin and 90% as isophan insulin).</seg>
<seg id="983">"" "" "" "like Actraphane and contents of the package The injections are delivered as blackish, white, watery suspension in packs of 1, 5 or 10 cartridges per 3 ml each." "" "" ""</seg>
<seg id="984">"" "" "" "for further information, refer to the manual of your insulin injector. ► disinfect the rubber membrane with an medical tupfer. ► Use a new injection needle to avoid contamination." "" "" ""</seg>
<seg id="985">"" "" "" "if you are treated with Actraphane 20 Penfill and a different insulin in pension cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="986">"" "" "" "189 Saw your relatives, friends and close colleagues to deliver you in the case of a lessness of consciousness in the stable side position and immediately need to communicate a doctor." "" "" ""</seg>
<seg id="987">"" "" "" "if one of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet counselor, or pharmacist." "" "" ""</seg>
<seg id="988">191 Watch the cartridges always in box when you do not use them to protect them from light.</seg>
<seg id="989">What Actraphane 20 contains - the active substance is associated with recombinant DNA technology used insulin (20% as insulin insulin and 80% as isophan insulin).</seg>
<seg id="990">"" "" "" "like Actraphane and contents of the package The injections are delivered as blackish, white, watery suspension in packs of 1, 5 or 10 cartridges per 3 ml each." "" "" ""</seg>
<seg id="991">"" "" "" "for further information, refer to the manual of your insulin injector. ► disinfect the rubber membrane with an medical tupfer. ► Use a new injection needle to avoid contamination." "" "" ""</seg>
<seg id="992">"" "" "" "if you are treated with Actraphane 30 penfill and a different insulin in pension cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="993">"" "" "" "195 Saw your relatives, friends and close colleagues to deliver you in the case of a lessness of consciousness in the stable side position and immediately need to communicate a doctor." "" "" ""</seg>
<seg id="994">"" "" "" "if one of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet counselor, or pharmacist." "" "" ""</seg>
<seg id="995">"" "" "" "197 Pull the cartridges always in box, if you do not use it to protect them from light." "" "" ""</seg>
<seg id="996">"" "" "" "manufacturers of the manufacturer can be identified through the batch name, which is printed on the flap of the carton and printed on the label:" "" "" ""</seg>
<seg id="997">"" "" "" "if on the second and third place of the Chargen designation W5, S6, P5, K7 or ZF appears, the manufacturer Novo Nordisk A / S, Novo Allé, DK- 2880 Bagsvaerd, Denmark" "" "" ""</seg>
<seg id="998">"" "" "" "if on the second and third place of the Chargen designation H7 or T6, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F-28002 Chartres, France." "" "" ""</seg>
<seg id="999">"" "" "" "for further information, refer to the instruction of your Insul inox system. ► disinfect the rubber membrane with an medical tupfer. ► Use a new injection needle to avoid contamination." "" "" ""</seg>
<seg id="1000">"" "" "" "if you are treated with Actraphane 40 Penfill and a different insulin in pension cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1001">"" "" "" "201 Saw your relatives, friends and close colleagues to secure you in the case of a lessness of consciousness in the stable side position and immediately need to communicate a doctor." "" "" ""</seg>
<seg id="1002">"" "" "" "if one of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet counselor, or pharmacist." "" "" ""</seg>
<seg id="1003">203 Maintainments your cartridges always in box when you do not use them to protect them from light.</seg>
<seg id="1004">What Actraphane 40 contains - The substance is associated with recombinant DNA technology hereditary insulin technology (40% as insulin insulin and 60% as isophan insulin).</seg>
<seg id="1005">"" "" "" "for further information, refer to the instruction of your Insul inox system. ► disinfect the rubber membrane with an medical tupfer. ► Use a new injection needle to avoid contamination." "" "" ""</seg>
<seg id="1006">"" "" "" "if you are treated with Actraphane 50 Penfill and a different insulin in pension cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1007">"" "" "" "before you use the penetration cartridge to the insulin injector, you move at least 20 times between the positions a and b up and down (see picture), so that the glass ball is moved from one end of the cartridge to another." "" "" ""</seg>
<seg id="1008">"" "" "" "207 Saw your relatives, friends and close colleagues to secure you in the case of a lessness of consciousness in the stable side position and immediately need to communicate a doctor." "" "" ""</seg>
<seg id="1009">"" "" "" "if one of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet counselor, or pharmacist." "" "" ""</seg>
<seg id="1010">209 Maintainments your cartridges always in box when you do not use them to protect them from light.</seg>
<seg id="1011">What Actraphane 50 contains - the active substance is associated with recombinant DNA technology-generated insulin (50% as insulin insulin and 50% as isophan insulin).</seg>
<seg id="1012">Oral antidiabetics (for insertion), monoaminoxida (MAO inhibitor) inhibitor steroids, sulfa drugs, beta-corticosteroids, anti-corticosteroids, beta-coronetiomimetika, beta-coronetiomimetika, beta-coricomimetika, bacterial pathogens, Danazole, Octaotide or Lanreotide. "" "" "" "</seg>
<seg id="1013">► Check the label if it is around the right Insul-type. use a new injection needle for any injection to avoid contamination.</seg>
<seg id="1014">► to lose insulin pump ► if the Novolet was dropped or broken down when it was not stored properly or frozen (see 6 How is Actraphane) or frozen.</seg>
<seg id="1015">"" "" "" "suddenly the warning signs of a subcking can occur suddenly and can be: cold sweat, cold pears, nausea, great appetite, anxiety or trembling, anxiety, confusion, concentration difficulties." "" "" ""</seg>
<seg id="1016">"" "" "" "214 If any of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet adviser or pharmacist." "" "" ""</seg>
<seg id="1017">"" "" "" "in use, Novolet manufacturing and such that will be used shortly or as a substitute, are not stored in the refrigerator." "" "" ""</seg>
<seg id="1018">"" "" "" "it is recommended - after being taken from the fridge, the temperature of the Novolet finished pens to room temperature before the insulin is used for the first use." "" "" ""</seg>
<seg id="1019">"" "" "" "release the closing folder of your Novolet production pens always when Novoass is not in use, to protect the insulin from light." "" "" ""</seg>
<seg id="1020">"" "" "" "like Actraphane and contents of the package The injsuspension suspension is delivered as blackish, white, aqueous suspension in packs of 5 or 10 ready to 3 ml each." "" "" ""</seg>
<seg id="1021">"" "" "" "prior to each injection, check if there are still least 12 units of insulin into the cartridge that a uniform mixture is ensured." "" "" ""</seg>
<seg id="1022">"" "" "" "follow the way to avoid the injection of air and ensure a correct dosage: • Keep Actraphane 10 Novoddles with the injection needle to the top • Add a couple of times with fingers slightly against the cartridge." "" "" ""</seg>
<seg id="1023">"" "" "" "while air bubbles are present, the cartridge will continue in the cartridge (figure D) While you keep the injection needle in the direction of the arrow (figure D) • During the tip of the injection pin, press a drop in insulin." "" "" ""</seg>
<seg id="1024">"" "" "" "• Put the closing folder again on the finished tracks, that the digit is 0 compared to the metering mark (Figure E)." "" "" ""</seg>
<seg id="1025">If not, turn off the closing folder until the push button is completely pushed through • Keep your Actraphane 10 Novolet horizontally.</seg>
<seg id="1026">"" "" "" "if the pressure button cannot move freely to the outside, insulin is pressed out of the injection cap • The scale on the closing folder shows 0, 2, 4, 8, 8, 12, 14 and 18 units." "" "" ""</seg>
<seg id="1027">"" "" "" "the push button is moving towards the outside while you turn the closing plate • The scale under the push button shows 20, 40 and 60 units." "" "" ""</seg>
<seg id="1028">"" "" "" "check the adjusted dose • Read the number on the closing folder directly next to the dosing mark • If you have set the maximum number, turn the adjusted dose, turn forward or backwards until you have set the right number of units." "" "" ""</seg>
<seg id="1029">"" "" "" "otherwise, insulin injected from the injection needle and the adjusted dose will not be correct • If you have tried to adjust a dose of more than 78 units, run the following steps:" "" "" ""</seg>
<seg id="1030">"" "" "" "then take the closing folder and put it up again, that the 0 of the dosing brand is opposite." "" "" ""</seg>
<seg id="1031">"" "" "" "make sure to press the pressure button on the pressure button. • Keep the push button after injection, until the injection needle has been drawn from the skin." "" "" ""</seg>
<seg id="1032">"" "" "" "if not, turn off the closing folder, until the push button is completely broken down and then proceed as described in pre-use • Possible, when pressing the push button." "" "" ""</seg>
<seg id="1033">"" "" "" "it may be incorrect - you can't set any dose, which is higher than the number of remaining ones remaining in the cartridge, as much insulin is still remaining." "" "" ""</seg>
<seg id="1034">Oral antidiabetics (for insertion), monoaminoxida (MAO inhibitor) inhibitor steroids, sulfa drugs, beta-corticosteroids, anti-corticosteroids, beta-coronetiomimetika, beta-coronetiomimetika, beta-coricomimetika, bacterial pathogens, Danazole, Octaotide or Lanreotide. "" "" "" "</seg>
<seg id="1035">"" "" "" "224 If any of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet adviser or pharmacist." "" "" ""</seg>
<seg id="1036">226 "" "" "" "226 Pre-injection • Check that there are still at least 12 units of insulin into the cartridge, ensuring a smooth mix." "" "" ""</seg>
<seg id="1037">"" "" "" "follow the way to avoid the injection of air and ensure correct dosage: • Keep Actraphane 20 NovoLet with the injection needle for a couple of times with fingers easily against the cartridge." "" "" ""</seg>
<seg id="1038">"" "" "" "while bubbles appear in the cartridge, the cartridge will continue in the cartridge (figure D) While you keep the injection needle in the direction of the arrow (figure D) • During the tip of the injection needle the button is necessary to drop into a drop insulin." "" "" ""</seg>
<seg id="1039">If not, turn off the closing folder until the push button is completely pushed through • Keep your Actraphane 20 Novolet horizontally.</seg>
<seg id="1040">Oral antidiabetics (for insertion), monoaminoxida (MAO inhibitor) inhibitor steroids, sulfa drugs, beta-corticosteroids, anti-corticosteroids, beta-coronetiomimetika, beta-coronetiomimetika, beta-coricomimetika, bacterial pathogens, Danazole, Octaotide or Lanreotide. "" "" "" "</seg>
<seg id="1041">"" "" "" "234 If any of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet adviser or pharmacist." "" "" ""</seg>
<seg id="1042">236 Before each injection • Check that there are still at least 12 units of insulin into the cartridge that a uniform mixture is ensured.</seg>
<seg id="1043">"" "" "" "follow the way to avoid the injection of air and ensure correct dosage: • Keep Actraphane 30 NovoLet with the injection needle for a couple of times with fingers easily against the cartridge." "" "" ""</seg>
<seg id="1044">"" "" "" "while air bubbles are present, the cartridge will continue in the cartridge (figure D) While you keep the injection needle in the direction of the arrow (figure D) • During the tip of the injection pin, press a drop in insulin." "" "" ""</seg>
<seg id="1045">If not, turn off the closing folder until the push button is completely pushed through • Keep your Actraphane 30 Novolet horizontally.</seg>
<seg id="1046">Oral antidiabetics (for insertion), monoaminoxida (MAO inhibitor) inhibitor steroids, sulfa drugs, beta-corticosteroids, anti-corticosteroids, beta-coronetiomimetika, beta-coronetiomimetika, beta-coricomimetika, bacterial pathogens, Danazole, Octaotide or Lanreotide. "" "" "" "</seg>
<seg id="1047">"" "" "" "244 If any of the listed side effects are significantly impaired or you may notice adverse events, please inform your doctor, your diet counselor, or pharmacist." "" "" ""</seg>
<seg id="1048">"" "" "" "246 In any injection, check if there are still least 12 units of insulin into the cartridge that ensure an even mix." "" "" ""</seg>
<seg id="1049">"" "" "" "follow the way to avoid the injection of air and ensure correct dosage: • Keep Actraphane 40 NovoLet with the injection needle for a couple of times with fingers easily against the cartridge." "" "" ""</seg>
<seg id="1050">"" "" "" "while bubbles appear in the cartridge, the cartridge will continue in the cartridge (figure D) While you keep the injection needle in the direction of the arrow (figure D) • During the tip of the injection needle the button is necessary to drop into a drop insulin." "" "" ""</seg>
<seg id="1051">If not, turn off the closing folder until the push button is completely broken down • Keep your Actraphane 40 Novolet horizontally.</seg>
<seg id="1052">Oral antidiabetics (for insertion), monoaminoxida (MAO inhibitor) inhibitor steroids, sulfa drugs, beta-corticosteroids, anti-corticosteroids, beta-coronetiomimetika, beta-coronetiomimetika, beta-coricomimetika, bacterial pathogens, Danazole, Octaotide or Lanreotide. "" "" "" "</seg>
<seg id="1053">"" "" "" "254 If any of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet counselor, or pharmacist." "" "" ""</seg>
<seg id="1054">"" "" "" "it is recommended - after being taken from the fridge, the temperature of the Novolet finished pens to room temperature before the insulin is used for the first use." "" "" ""</seg>
<seg id="1055">256 before each injection • Check that even at least 12 units of insulin are left in the cartridge so that a uniform mixture is ensured.</seg>
<seg id="1056">"" "" "" "follow the way to avoid the injection of air and ensure correct dosage: • Keep Actraphane 50 NovoLet with the injection needle for a couple of times with fingers easily against the cartridge." "" "" ""</seg>
<seg id="1057">"" "" "" "while air bubbles are present, the cartridge will continue in the cartridge (figure D) While you keep the injection needle in the direction of the arrow (figure D) • During the tip of the injection pin, press a drop in insulin." "" "" ""</seg>
<seg id="1058">If not, turn off the closing folder until the push button is completely broken down • Keep your Actraphane 50 Novolet horizontally.</seg>
<seg id="1059">Oral antidiabetics (for insertion), monoaminoxida (MAO inhibitor) inhibitor steroids, sulfa drugs, beta-corticosteroids, anti-corticosteroids, beta-coronetiomimetika, beta-coronetiomimetika, beta-coricomimetika, bacterial pathogens, Danazole, Octaotide or Lanreotide. "" "" "" "</seg>
<seg id="1060">► to lose insulin pump ► if the Innolet was dropped or broken down when it was not stored properly or frozen (see 6 How is Actraphane) or frozen.</seg>
<seg id="1061">"" "" "" "suddenly the warning signs of a subcking can occur suddenly and can be: cold sweat, cold pears, nausea, great appetite, anxiety or trembling, anxiety, confusion, concentration difficulties." "" "" ""</seg>
<seg id="1062">"" "" "" "264 If any of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet adviser or pharmacist." "" "" ""</seg>
<seg id="1063">"" "" "" "in use, Innolet manufacturing and such that will be used shortly or as a substitute, are not stored in the refrigerator." "" "" ""</seg>
<seg id="1064">"" "" "" "it is recommended - after being taken from the fridge, the temperature of the InnoLet finished pens to room temperature before the insulin is used for the first use." "" "" ""</seg>
<seg id="1065">"" "" "" "release the closing folder of your Innolet production pens always when InnoLet is not in use, to protect the insulin from light." "" "" ""</seg>
<seg id="1066">"" "" "" "like Actraphane and contents of the package The injsuspension suspension is delivered as blackish, white, watery suspension in packs of 1, 5 or 10 ready to 3 ml each." "" "" ""</seg>
<seg id="1067">"" "" "" "the movement must be repeated until the liquid is evenly white and muddy. after the reset, you lead all the following steps of injection without delay." "" "" ""</seg>
<seg id="1068">• disinfect the rubber membrane with an medical tupfer • Use a new injection needle for injections of a NovoFine S injector needle in order to remove the injection needle and pull off the large external injection pin and the internal injection pin.</seg>
<seg id="1069">"" "" "" "• Check that the pressure button is completely broken down, and the dose controller is zero. adjust the number of units that you must injected by pushing the dose controller to clockwise (Figure 2)." "" "" ""</seg>
<seg id="1070">Do not use the residual scale on the measure of your insulin dose • you can hear a click noise for each one individually.</seg>
<seg id="1071">"" "" "" "perform injection technique from your doctor, • Specify the dose by pressing the press button in the press (Figure 3)." "" "" ""</seg>
<seg id="1072">"" "" "" "the dose controller is back to zero, and you stop click on the skin to ensure that the dose controller must not be blocking after injection, as the dose controller must not stall when you press on the pressure button • remove the injection needle after injection." "" "" ""</seg>
<seg id="1073">"" "" "" "medical personnel, family members and other caregers need to consider general precautions for removal and disposal of injections to avoid unintentional stitches with the injection needle." "" "" ""</seg>
<seg id="1074">Oral antidiabetics (for insertion), monoaminoxida (MAO inhibitor) inhibitor steroids, sulfa drugs, beta-corticosteroids, anti-corticosteroids, beta-coronetiomimetika, beta-coronetiomimetika, beta-coricomimetika, bacterial pathogens, Danazole, Octaotide or Lanreotide. "" "" "" "</seg>
<seg id="1075">► to lose insulin pump ► when the flexpen has been dropped or broken it has been damaged or frozen (see 6 How is Actraphane) or frozen.</seg>
<seg id="1076">"" "" "" "if you notice deepenings or thickening of your skin at the injection point, tell your doctor or your diabetesConsultant, as these reactions can affect you in such a place." "" "" ""</seg>
<seg id="1077">"" "" "" "274 If any of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet counselor, or pharmacist." "" "" ""</seg>
<seg id="1078">"" "" "" "in use flexest flexpen and such, which will be used shortly or as a substitute, are not stored in the refrigerator." "" "" ""</seg>
<seg id="1079">"" "" "" "it is recommended - after being taken from the fridge, increase the temperature of flexpen finished to room temperature before the insulin is used for the first use." "" "" ""</seg>
<seg id="1080">"" "" "" "leave your FlexPen's locking flap always when fleece is not in use, to protect the insulin from light." "" "" ""</seg>
<seg id="1081">"" "" "" "like Actraphane and contents of the package The injsuspension suspension is delivered as blackish, white, watery suspension in packs of 1, 5 or 10 ready to 3 ml each." "" "" ""</seg>
<seg id="1082">"" "" "" "manufacturers of the manufacturer can be identified through the batch name, which is printed on the flap of the carton and printed on the label:" "" "" ""</seg>
<seg id="1083">"" "" "" "275 • Falls on the second and third place of the Chargen designation W5, S6, P5, K7 or ZF is the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France." "" "" ""</seg>
<seg id="1084">"" "" "" "B Move the fabrication between positions 1 and 2 and 2 times, so that the glass ball is moved from one end of the cartridge to another." "" "" ""</seg>
<seg id="1085">"" "" "" "move at least 10 times between positions 1 and 2 between positions 1 and 2, until the liquid appears opaque and deceped." "" "" ""</seg>
<seg id="1086">"" "" "" "• To reduce the risk of unintentionally conifers, you never put the inner cover back into the injection needle after taking it once." "" "" ""</seg>
<seg id="1087">"" "" "" "279 G Keep the flexpen with the injection needle to the top and knock a few times with the fingers slightly against the cartridge, so that air bubbles up in the cartridge." "" "" ""</seg>
<seg id="1088">"" "" "" "the dose can be corrected both upwards and downwards, by rotating the dose of the dose to the marking up to the correct dose." "" "" ""</seg>
<seg id="1089">"" "" "" "the present document is a summary of the European Public Department report (EPAR), which explains how the studies for human medicines will be assessed in order to get recommendations concerning the application of medication." "" "" ""</seg>
<seg id="1090">"" "" "" "the veterinary is effective in acetone, insulin and human (rDNA), is produced using the" recombinant technology "process:" "" "" ""</seg>
<seg id="1091">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.europe.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.</seg>
<seg id="1092">Actrapid is not allowed to be used in patients who possibly are overweight to insulin (rDNA) or any of the other components.</seg>
<seg id="1093">"" "" "" "moreover, the doses of Actrapid have to be adjusted if it is administered together with a number of other medicines that may affect blood sugar." "" "" ""</seg>
<seg id="1094">"" "" "" "in October 2002, the European Commission approved the European Commission of Novo Nordisk A / S for approval of the transport of Actrapid throughout the European Union." "" "" ""</seg>
<seg id="1095">"" "" "" "when two types of insulin are mixed, the amount of the quickly effective insulin must first be removed, then the amount of the very effective insulin." "" "" ""</seg>
<seg id="1096">"" "" "" "3 If switching to Actrapid treatment, dosing can be required when switching to Actrapid, it can be necessary in the first dose or months after the changeover." "" "" ""</seg>
<seg id="1097">"" "" "" "prior to travelling that go over several time zones, the patient should be advised to catch the Council of his doctor, as such trips can lead to other times and have to be taken." "" "" ""</seg>
<seg id="1098">"" "" "" "5 General diseases and complaints at the adoption of money - local hypersensitivity action on the injections during the insulin delivery can occur local hypersensitivity reactions (redness, swelling, itching, pain and hematoma)." "" "" ""</seg>
<seg id="1099">Diabetics should therefore have always treated grapes that are treated with tumours or subcutaneous fruit juice and are treated with an intramuscular or subcutaneous injection of glucose (0.5 to 1.0 mg) by an intramuscular or subcutaneous injection of glucose (0.5 to 1,0 mg) by an intramuscular or subcutaneous injection.</seg>
<seg id="1100">A clinical trial in an intensive care for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic patients (blood sugar 4.4 to 6.1 mmol / l) reduced the mortality rate by 42% (8% vs 4.6%).</seg>
<seg id="1101">"" "" "" "the effect begins within half an hour, the maximum number will be reached within 1.5 to 3,5 hours and the total duration is about 7 to 8 hours." "" "" ""</seg>
<seg id="1102">Children and adolescents The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescents.</seg>
<seg id="1103">"" "" "" "data is limited, however, however, the assumption is close that the pharmacokinetic profile is similar to children and adolescents." "" "" ""</seg>
<seg id="1104">Fusion systems with Actrapid concentrations in concentrations 0.05 / ml - 1.0 1% sodium chloride, 5% D-glucose and 10% D- glucose with 40 mmol / l potassium-chloride are stable at room temperature for 24 hours.</seg>
<seg id="1105">"" "" "" "11 If switching to Actrapid treatment, dosing can be required when switching to Actrapid, it can be necessary in the first dose or months after the changeover." "" "" ""</seg>
<seg id="1106">"" "" "" "prior to travelling that go over several time zones, the patient should be advised to catch the Council of his doctor, as such trips can lead to other times and have to be taken." "" "" ""</seg>
<seg id="1107">"" "" "" "13 General diseases and complaints at the adoption of money - local hypersensitivity to the injections during the insulin delivery can occur local hypersensitivity reactions (redness, swelling, itching, pain and hematoma at the injection station)." "" "" ""</seg>
<seg id="1108">Diabetics should therefore have always treated grapes that are treated with tumours or subcutaneous fruit juice and are treated with an intramuscular or subcutaneous injection of glucose (0.5 to 1.0 mg) by an intramuscular or subcutaneous injection of glucose (0.5 to 1,0 mg) by an intramuscular or subcutaneous injection.</seg>
<seg id="1109">Children and adolescents The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescents.</seg>
<seg id="1110">"" "" "" "the intravenous use of Actrapid from manufacturing or cartridges should represent an exception, and only in situations where no deposit bottles are available." "" "" ""</seg>
<seg id="1111">"" "" "" "if switching to Actrapid is required when switching to Actrapid, it can be necessary in the first dose or in the first weeks or months after the changeover." "" "" ""</seg>
<seg id="1112">"" "" "" "21 disorders of the skin and the lower abdomen tissue on the injection site can emerge a liystrophy at the injection site, if failed to switch inside the injection area within the injection area." "" "" ""</seg>
<seg id="1113">Children and adolescents The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescents.</seg>
<seg id="1114">"" "" "" "29 diseases of the skin and the lower abdomen tissue - Lipodystrophy at the injection site, a light podystrophy may arise when failed to switch inside the injection area within the injection area." "" "" ""</seg>
<seg id="1115">"" "" "" "diseases of the immune system Gelego.- Urtikaria, Exanthem Very rarely - Anaphylakic reactions symptoms generated, gastrointestinal gas, respiratory diseases, cardiovascular problems, low blood pressure and impotence." "" "" ""</seg>
<seg id="1116">Children and adolescents The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescents.</seg>
<seg id="1117">"" "" "" "diseases of the immune system Gelego.- Urtikaria, Exanthem Very rarely - Anaphylakic reactions symptoms generated, gastrointestinal gas, respiratory diseases, cardiovascular problems, low blood pressure and impotence." "" "" ""</seg>
<seg id="1118">38 A clinical trial in an intensive care for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic patients (blood sugar 4.4 to 6.1 mmol / l) reduced the mortality rate by 42% (8% vs 4.6%).</seg>
<seg id="1119">"" "" "" "diseases of the immune system Gelego.- Urtikaria, Exanthem Very rarely - Anaphylakic reactions symptoms generated, gastrointestinal gas, respiratory diseases, cardiovascular problems, low blood pressure and impotence." "" "" ""</seg>
<seg id="1120">46 A clinical trial in an intensive care for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic patients (blood sugar 4.4 to 6.1 mmol / l) reduced the mortality rate by 42% (8% vs 4.6%).</seg>
<seg id="1121">Refrigerate in the fridge (2 ° C - 8 ° C) Not to freeze The sag in the box; in order to protect the contents from light after quarry: keep in the fridge or over 25 ° C</seg>
<seg id="1122">Subcutaneous application Penfill cartridges are intended for use with Novo Nordisk insulin injections according to Actrapid Penfill may only be used by a person</seg>
<seg id="1123">"" "" "" "store in the fridge (2 ° C - 8 ° C) Not to store the cartridge against light, in order to protect the contents from light after dawn: not in the refrigerator or about 30 ° C." "" "" ""</seg>
<seg id="1124">Subcutaneous application For use with Actrapid Novolet are included in NovoFine injections according to Actrapid Novolet not only be used by a person</seg>
<seg id="1125">Keep in the fridge (2 ° C - 8 ° C) Not to freeze. protect against light: not in the refrigerator or about 30 ° C</seg>
<seg id="1126">Subcutaneous application For use with Actrapid Innolet measures NovoFine S injections according to Actrapid Innod must be used only by a person</seg>
<seg id="1127">"" "" "" "this means approximately half an hour after you have applied it to sink your blood sugar, and that the effect will stop about 8 hours." "" "" ""</seg>
<seg id="1128">► Check the label with the label whether it is about the right insulin type. ► disinfect the rubber membrane with an medical tupfer.</seg>
<seg id="1129">If this is not completely unusual if you have got the water bottle back to your pharmacy. if it was not stored properly or frozen (see 6 How is Actrapid?) ► if it looks like water and colorless.</seg>
<seg id="1130">"" "" "" "use injection technique to advise you your doctor or diabetesconsultant. ► Move the injection needle for at least 6 seconds under your skin, to ensure that the complete dose injected." "" "" ""</seg>
<seg id="1131">83 "" "" "" "83 Saw your relatives, friends and close colleagues to bring you in the case of a lessness of consciousness in the stable side position and immediately need to communicate a doctor." "" "" ""</seg>
<seg id="1132">They possibly have a very rare allergic reaction to actrapid or one of its components (such as systemic or allergic reaction).</seg>
<seg id="1133">"" "" "" "the injection solution is supplied as clear, colorless, aqueous solution in packs of 1 or 5 holding bottles, each 10 ml or a bundle packs of 5 ml each." "" "" ""</seg>
<seg id="1134">"" "" "" "89 Say on your relatives, friends and close colleagues to bring you in the case of a lessness of consciousness in the stable side position and immediately need to communicate a doctor." "" "" ""</seg>
<seg id="1135">► Check the label with the label whether it is about the right insulin type. check the cartridge including the rubber tissue (stoppers).</seg>
<seg id="1136">► to wear insulin pump ► if the fill-fill or the device that contains the bular (see 6 How is Actrapid) or frozen (see 6 How is Actrapid?) ► if it looks like water and colorless.</seg>
<seg id="1137">"" "" "" "if you are treated with Actrapid Penfill and other insulin into pension cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1138">"" "" "" "use injection technique to help you remove the injection needle for at least 6 seconds under your skin, to ensure that the complete dose injected and remove the injection needle without removing the injection needle without absorbing injection needle." "" "" ""</seg>
<seg id="1139">"" "" "" "• In the second and third place of the Chargen designation W5, S6, P5, K7 or ZF appears, the manufacturer Novo Nordisk A / S, Novo Allé, DK-2880 Bagsvaerd, Denmark" "" "" ""</seg>
<seg id="1140">"" "" "" "• In the second and third place of the Chargen designation H7 or T6, the manufacturer Novo Nordisk Production SAS, 45, Avenue d" Orléans, F- 28002 Chartres, France. "" "" "" "</seg>
<seg id="1141">Oral antidiabetics (for insertion), monoaminoxida (MAO inhibitor) inhibitor steroids, sulfa drugs, beta-corticosteroids, anti-corticosteroids, beta-coronetiomimetika, beta-coronetiomimetika, beta-coricomimetika, bacterial pathogens, Danazole, Octaotide or Lanreotide. "" "" "" "</seg>
<seg id="1142">"" "" "" "► Check the label with the label, whether it is about the right insulin type." "" "" "" ► to use a new injection needle to avoid contamination. "" "" "" "</seg>
<seg id="1143">► to lose insulin pump ► if the Novolet was dropped or broken; it is not stored correctly or frozen (see 6 How is Actrapid?) ► if it looks like water and colorless.</seg>
<seg id="1144">"" "" "" "this can happen when you injecting too much insulin, if you eat too little or take a meal if you need more than usual physically." "" "" ""</seg>
<seg id="1145">"" "" "" "release the closing folder of your Novolet production pens always when it is not in use to protect it from light." "" "" ""</seg>
<seg id="1146">"" "" "" "• Use the rubbing cap. • Use a new injection needle for injection of a new injection needle in order to avoid contamination of the injection needle in order to avoid contamination. • Take off the large external cap of the injection needle and the internal cap of the injection needle." "" "" ""</seg>
<seg id="1147">"" "" "" "follow the way to avoid the injection of air and ensure a correct dosage: • Keep Actrapid NovoLet with the injection needle for a couple of times with fingers easily against the cartridge." "" "" ""</seg>
<seg id="1148">"" "" "" "while bubbles appear in the cartridge, the cartridge is still upwards in the cartridge (figure B) • While the injection needle continues upwards, press the button-button in the direction of the pin (figure C) • During the tip of the injection needle a drop insulin." "" "" ""</seg>
<seg id="1149">"" "" "" "• Put the closing folder to the fabripen, that the digit is 0 compared to the metering mark (Figure D)." "" "" ""</seg>
<seg id="1150">"" "" "" "if the pressure button is not able to move freely, insulin is pressed out of the injection cap • The scale on the closing folder shows 0, 2, 4, 8, 8, 12, 14 and 18 units." "" "" ""</seg>
<seg id="1151">Pressure button is moving towards the outside while you turn the closing flap • The scale under the push button (pushbutton) shows 20, 40 and 60 units.</seg>
<seg id="1152">"" "" "" "107 • Make the highest number you can get on the pressure button • If you have set the two numbers in order to set the adjusted dose, turn the thumb forward or backwards until you have set the right number of units." "" "" ""</seg>
<seg id="1153">"" "" "" "turn right down until the push button is down and you take a resistor, and put it up again that the 0 of the dosing brand is over." "" "" ""</seg>
<seg id="1154">"" "" "" "make sure to press the pressure button on the pressure button, push the pressure button to the injection until the injection needle has been drawn from the skin." "" "" ""</seg>
<seg id="1155">"" "" "" "it may be incorrect - you can't adjust the dose, which is higher than the number of insulin-remaining units, but you can't use the amount of insulin too much, but you can't use it to stop or select your dose." "" "" ""</seg>
<seg id="1156">Oral antidiabetics (for insertion), monoaminoxida (MAO inhibitor) inhibitor steroids, sulfa drugs, beta-corticosteroids, anti-corticosteroids, beta-coronetiomimetika, beta-coronetiomimetika, beta-coricomimetika, bacterial pathogens, Danazole, Octaotide or Lanreotide. "" "" "" "</seg>
<seg id="1157">► to lose insulin pump ► if the Innolet was dropped or broken; it is not stored correctly or frozen (see 6 How is Actrapid?) ► if it looks like water and colorless.</seg>
<seg id="1158">"" "" "" "leave the closing folder of your InnoLet finished pens, when it is not in use to protect it from light." "" "" ""</seg>
<seg id="1159">• disinfect the rubber membrane with an medical tupfer • Use a new injection needle for injection of a new injection needle in order to avoid contamination of the injection needle and the internal cap of the injection nadel and the internal cap of the injection needle.</seg>
<seg id="1160">"" "" "" "the dose controller is back to zero, and you stop click on the skin to ensure that the dose controller must not stall after injection, as the dose controller must not stall when you push to the pressure button • removing the injection needle after each injection." "" "" ""</seg>
<seg id="1161">Oral antidiabetics (for insertion), monoaminoxida (MAO inhibitor) inhibitor steroids, sulfa drugs, beta-corticosteroids, anti-corticosteroids, beta-coronetiomimetika, beta-coronetiomimetika, beta-coricomimetika, bacterial pathogens, Danazole, Octaotide or Lanreotide. "" "" "" "</seg>
<seg id="1162">121 ► if it was not stored properly or frozen (see 6 How is Actrapid to keep up?) ► if it looks like water and colorless.</seg>
<seg id="1163">"" "" "" "if one of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this manual information, please inform your doctor, your diet counselor, or pharmacist." "" "" ""</seg>
<seg id="1164">"" "" "" "leave your FlexPen's locking flap always when it is not in use to protect it from light." "" "" ""</seg>
<seg id="1165">"" "" "" "F Keep the flexpen with the injection needle and knock up a few times with the fingers slightly against the cartridge, so that air bubbles up in the cartridge." "" "" ""</seg>
<seg id="1166">"" "" "" "the dose can be corrected both upwards and downwards, by rotating the dose fixing button in the appropriate direction until the correct dose is up to the marking of the dose display." "" "" ""</seg>
<seg id="1167">Adenuric is used in patients who have already used signs of crystallization deposits including arthritis (pain and inflammation in the joints) or plaster notes ("stones") or higher primorate deposits; which can lead to joint and bone damage).</seg>
<seg id="1168">"" "" "" "if the urinary acid is still more than 6 mg per decency, the dose may be increased to 120 mg once a day." "" "" ""</seg>
<seg id="1169">"" "" "" "during the first treatment months, poisons may still occur; therefore, patients at least during the first six months of treatment with adenuric will still take more medicines for prevention of poisoning." "" "" ""</seg>
<seg id="1170">"" "" "" "the medicine is not recommended for children and in patients who had an organ transplantation, as it was not investigated for those groups." "" "" ""</seg>
<seg id="1171">"" "" "" "in the first study enrolled at 1 072 patients, the efficacy of three different adenic doses (once daily 80, 120 and 240 mg) were compared with the placebo (headlight drug) and Allopurinol (other medicines for hyperurikaemia)." "" "" ""</seg>
<seg id="1172">In the second study two doses of adenuric (once daily 80 and 120 mg) were compared to 762 patients each with Allopurinol.</seg>
<seg id="1173">"" "" "" "in both studies, Allopurinol was used in a dose of 300 mg per day; patients with kidney problems received only 100 mg per day." "" "" ""</seg>
<seg id="1174">"" "" "" "the main indicator for efficacy was the number of patients whose urinary acid was in the blood for the last three measurements under 6 mg / dl." "" "" ""</seg>
<seg id="1175">"" "" "" "in the first study 48% (126 of 262) of patients, Adenuric had a daily dose of 80 mg, and 65% (175 of 269) of patients who once daily intake a uric acid level in the blood of under 6 mg / dl." "" "" ""</seg>
<seg id="1176">"" "" "" "in comparison to this, it was 22% (60 of 268) of patients under Allopurinol and none of the 134 patients under placebo." "" "" ""</seg>
<seg id="1177">The most common side effects of adenuric (observed at 1 to 10 of 100 patients) are headaches, diarrhoea, nausea (nautical sea), rash and normal liver values.</seg>
<seg id="1178">"" "" "" "especially in patients with cardiac pain in history, perhaps an increased risk of certain side effects that affect the heart and blood vessels." "" "" ""</seg>
<seg id="1179">"" "" "" "the Committee for Human Use (CHMP) reached the conclusion that adenuric acid was effective in the blood, but also a higher risk of side effects in connection with heart and blood vessels." "" "" ""</seg>
<seg id="1180">Treatment of chronic hyperuricaemia in diseases which have already led to prehistoric deposits (including one from the health history or at present present deparations and / or a toxicity).</seg>
<seg id="1181">Dosage intake after 2-4 weeks is still possible &gt; 6 mg / dl (357 µnl / l) for 2-4 weeks and can be considered a dose of dosage to ADENURIC 120 mg daily.</seg>
<seg id="1182">"" "" "" "in patients with severe kidney illness, efficacy and safety have not been completely investigated (creatinine Clearance &lt; 30 ml / min, see Section 5.2)." "" "" ""</seg>
<seg id="1183">"" "" "" "children and adolescents When there are no experiences in children and adolescents, the application of Febuxostat is not recommended in this patient group." "" "" ""</seg>
<seg id="1184">Organ transplant recipients no experiences yet with organ transplants. the application of Febuxostat is not recommended in this patient group (see Section 5.1).</seg>
<seg id="1185">Cardiovascular diseases in patients with ischemia cardiac disease or decompensated heart failure the treatment with Febuxeat is not recommended (see section 4.8).</seg>
<seg id="1186">"" "" "" "as with other harpacidic medicines, it can occur during the treatment to a acute toxicity because due to the lowering of the serum acid level, urea can first be mobilized in the tissues." "" "" ""</seg>
<seg id="1187">"" "" "" "B. with malignant diseases and their treatment, Lesch- Nyhan syndrome), the absolute concentration of xanthin in the urine is so far reaching that it comes to a deposit in the urinary tract." "" "" ""</seg>
<seg id="1188">"" "" "" "during clinical trials of Phase 3, liver clinical trials were observed with Febuxostat patients (3,5%)." "" "" ""</seg>
<seg id="1189">"" "" "" "therefore, it is recommended to implement the Febuxostatment and in further course depending on clinical report and a liver function (see Section 5.1)." "" "" ""</seg>
<seg id="1190">"" "" "" "Theophyllin Zwasn't any alteration studies into Febuxostat, but it is known that the XO inhibiting has been reported to a rise of the metabolism of theophylline (also reported for other XO inhibitors)." "" "" ""</seg>
<seg id="1191">Subjects were associated with the simultaneous gift of Febuxostat and naproxen 250 mg twice daily with a rise in Febuxfocus exposure (Cmax 28%, AUC 41% and t1 / 2 26%).</seg>
<seg id="1192">"" "" "" "in clinical trials, the application of naproxen or other NSAR / Cox-2 inhibitors were not related to a clinically significant increase of unwanted events." "" "" ""</seg>
<seg id="1193">Colchicin / Indometacin / Hydrochlorthiazide / Warfarin Febuxeat can be used together with Colchicin or Indometacin without requiring a dose of dose for Febuxeat or at the same time necessary active substance.</seg>
<seg id="1194">In a study of subjects performed 120 mg ADENURIC 1 x daily a mean 22% increase in AUC of Desipramine, a CYP2D6-Substrate which indicates the potential-weak orographic effect of Febuxostat to the CYP2D6-enzyme for vivo.</seg>
<seg id="1195">"" "" "" "Antazida It was shown that the simultaneous taking of an antazium, the magnesium hydroxide and aluminum hydroxide (about 1 hour) were delayed, but no significant change in AUC caused." "" "" ""</seg>
<seg id="1196">Pregnancy data on a very limited number of exponated pregnancies may not close side effects from Febuxostat to the pregnancy or health of the fetus / newborns.</seg>
<seg id="1197">"" "" "" "experimental studies do not apply to direct or indirect effects on pregnancy, embryonic / fetal development or birth (see Section 5.3)." "" "" ""</seg>
<seg id="1198">"" "" "" "patients should be careful when taxation of a vehicle, serving machines or exercising dangerous actions, until they can be reasonably affected by the ADENURIC." "" "" ""</seg>
<seg id="1199">A numerical incidence of higher incidence was observed in the overall statecal study in phase 3 (1.3 versus 0.7 events per 100 patient years) and in long-term efficacy studies (1,4 versus 0.7 events per 100 patients years) and no causal correlation was found and no causal correlation could be found.</seg>
<seg id="1200">The risk factors associated with these patients were an arterioserotic disease and / or a myocardial infarction or a decompensated heart failure in health.</seg>
<seg id="1201">(≥ 1 / 100 to &lt; 1 / 10) and rare (≥ 1 / 1000 to &lt; 1 / 100) and rare (≥ 1 / 1000 to &lt; 1 / 100) and rare (≥ 1 / 1000 mg of Febuxostat) and the (test assessment) in connection with the drug may be reported more than once reported in all Febuxostat treatment groups.</seg>
<seg id="1202">Diarrhoea, nausea and vomiting are more common in patients who at the same time are treated with colchicin. * * In clinical trials no severe skin eruptions or severe hypersensitivity reactions were observed.</seg>
<seg id="1203">"" "" "" "7 days long-term renewal studies in the open long-term renewal studies, 906 patients were treated with Febuxeat 80 mg / 120 mg for up to 4 years." "" "" ""</seg>
<seg id="1204">"" "" "" "during the long-term - renewal studies, those related events were similar to those that were reported in phase 3 studies (see table 1)." "" "" ""</seg>
<seg id="1205">The following treatment-related events have been reported in all Febuxostat- treatment groups a total of more than once and appeared in patients suffering from the Febuxeat 80 mg / 120 mg in long-term renewal studies (up to 4 years with an exposure time of &gt; 1.900 patients).</seg>
<seg id="1206">"" "" "" "the following treatment-related events were either reported in the PivotalStudies Phase 3 for these cans, or at lower frequency:" "" "" ""</seg>
<seg id="1207">"" "" "" "diabetes, hyperlipidemia, insomnia, hypesthetic, skin discoloration, skin discoloration, skin rash, skin discoloration, skin disorders, skin discoloration in the blood, decline of blood cells, reduction in number of white blood cells." "" "" ""</seg>
<seg id="1208">The mechanism of uric acid is the end product of the purine metabolic and arises in the context of the reaction-ade Hypoxanthin → Xanthin → uric acid.</seg>
<seg id="1209">Febuxeat is a powerful, non-selective inhibitor of the XO (NP-SIxO) with a Ki-value for the in vitro inhibition that is below the nanomolar range.</seg>
<seg id="1210">Clinical study results The efficacy of ADENURIC was shown in two pivotal studies of phase 3 (APEX study and FACT study as described below) which were performed with hyperhiikaemia and gout using 1.832 patients.</seg>
<seg id="1211">"" "" "" "in every study, the primary efficacy endpoint was the patients' proportion (357 mg / dl (357 µnl / l)." "" "" ""</seg>
<seg id="1212">Placebo (n = 134) and ADENURIC 120 mg 1 x daily (n = 269) and ADENURIC 120 mg daily (n = 269) for patients with a serum increment at the beginning of study of &gt; 1.5 mg / dl and ≤ 2.0 mg / dl.</seg>
<seg id="1213">The APEX-study showed the statistically significant superiority of 6 mg / dl (357 µnl / l) (see table 2 and Figure 1) as well as with ADENURIC 120 mg daily (n = 258) / 100 mg (n = 258) / 100 mg (n = 10).</seg>
<seg id="1214">The FACT study showed a statistically significant superiority in the treatment with ADENURIC 80 mg 1 x daily as well as with ADENURIC 120 mg 1 x daily compared to the treatment with the usual dose Allopurinol 300 mg.</seg>
<seg id="1215">Patients with serum microorganisms &gt; 1.5 and ≤ 2.0 mg / dl) or 300 mg 1 x daily (n = 509) were summarised for the analysis. * p &lt; 0.001 versus Allopurinol, # p &lt; 0.001 versus 80 mg.</seg>
<seg id="1216">The lowering of the serum acid level at &lt; 6.0 mg / dl (357 µmol / l) was observed during the medical visit in week 2 and maintain permanently over the entire treatment.</seg>
<seg id="1217">509 patients received Allopurinol 300 mg 1 x daily; 10 patients with serum increments &gt; 1.5 and &lt; 2.0 mg / dl received 100 mg 1 x daily.</seg>
<seg id="1218">"" "" "" "the primary endpoint in the sub-group of patients with renal function limiting The APEX study evaluated the effectiveness of 40 patients with kidney retention." "" "" ""</seg>
<seg id="1219">With ADENURIC the primary efficacy endpoint was reached 44% (80 mg 1 x daily) and 45% (120 mg 1 x daily) and 60% (240 mg 1 x daily) of patients.</seg>
<seg id="1220">There were no clinically significant differences in the percentage of the percentage of serum diseases (58% in the group with normal kidney function and 55% in the group with heavy kidney function).</seg>
<seg id="1221">Primary endpoint in the sub-group of patients with serum harnacid concentrations observed 40% of patients (APEX- and FACT study) at the beginning of the study (Baseline) had a serum concentration of ≥ 10 mg / dl.</seg>
<seg id="1222">The data collected in two years showed the data collected by the open extension study of phase 3 that resulted in a decrease in the incidence of cases required at &lt; 6 mg / dl (&lt; 357 µnl / l) in the months of 16-24 months (i.e. more than 97% of patients needed no treatment against a feed).</seg>
<seg id="1223">This was associated with a reduction of gadh size which resulted in 54% of patients a complete disappearance of the nodes nodes up to month 24.</seg>
<seg id="1224">Increased tSH- values (&gt; 5.5 µIE / ml) were observed in patients who received a long-term treatment with Febuxostat (5.8%) in the open long-term renewal studies (see Section 4.4).</seg>
<seg id="1225">In healthy volunteers the maximum plasma concentrations (Cmax) and the surface under the plasma concentration time curve (AUC) increased by Febuxostat to be ordered and multi-coupler doses ranging from 10 mg to 120 mg dosisproportional.</seg>
<seg id="1226">"" "" "" "for cans between 120 mg and 300 mg, a rise in AUC is observed, which is greater than the dosisproportional increase." "" "" ""</seg>
<seg id="1227">"" "" "" "after taking easier or multi-stroke doses of 80 and 120 mg 1 x daily, the Cmax is 2.8-3.2 µg / ml and 5.0-5.3 µg / ml." "" "" ""</seg>
<seg id="1228">"" "" "" "however, no clinically significant change was observed in the percentage of serum molecules, if this has been tested (multiple doses of 80 mg)." "" "" ""</seg>
<seg id="1229">Distribution The apparent Steady state power distribution volume (Vss / F) of Febuxostat lies in the range from 29 to 75 l after taking part of doses of 10-300 mg.</seg>
<seg id="1230">"" "" "" "the plasma-binding of Febuxeat amounts to approximately 99.2% (primary relationship to Albumin) and is about the concentration range, which is achieved with doses ranging from 80 to 120 mg." "" "" ""</seg>
<seg id="1231">"" "" "" "in vitro studies in human liver microsomen, CYP1A2, CYP1A2, CYP2C8 or CYP2C9, CYP2C8 or CYP2C9, CYP2C8 or CYP2C9, and that Febuxostatglucuronid arises mainly through UGT 1A1, 1A8 and 1A9." "" "" ""</seg>
<seg id="1232">After taking a 80 mg rate of 14C-marked Febuxeat (3%), Acylglukuronid of the active substance (30%) and its well-known oxidative metabolites and their conjugate (13%) as well as other unknown metabolites (3%).</seg>
<seg id="1233">In addition to excretion over the urine we found approximately 45% of the dose in the chair as unaltered Febuxeat (12%) which is known as a non-known oxidative metabolites and their conjugate (25%) as well as other unknown Metabolites (7%).</seg>
<seg id="1234">"" "" "" "special patients group renal insufficiency After taking multifocal doses of 80 mg of ADENURIC in patients with mild, moderate or severe kidney disease, the Cmax of Febuxeat did not change in relation to subjects with normal kidney function." "" "" ""</seg>
<seg id="1235">"" "" "" "the mean total AUC of Febuxostat increased about the 1.8-times of 7,5 μ, in the group with normal kidney function on 13.2 μ g / ml in the group with severe kidney function." "" "" ""</seg>
<seg id="1236">12 liver failure according to taking multifocal doses of 80 mg of ADENURIC in patients with lighter (Child- Pugh classification B) or moderate (child-dgh classification B) liver failure not significantly changed compared to subjects with normal liver function.</seg>
<seg id="1237">Age There were no significant changes in terms of AUC of Febuxostat or its metabolites after taking multifocal doses of ADENURIC when compared to younger subjects.</seg>
<seg id="1238">"" "" "" "carcinogenesis, mutagenesis, impairment of Fertility In male rats, a statistically significant increase of urinary bladder and carcinomas) was found only in connection with Xanthin stones in the highly-dosed group, with approximately 11 times the exposure to humans." "" "" ""</seg>
<seg id="1239">"" "" "" "these findings are seen as a result of a specialist Purinmetallization and urine, and is not considered to be relevant for clinical application." "" "" ""</seg>
<seg id="1240">It was noted that Febuxeat in oral doses of up to 48 mg / kg / day has no effect on fertility and reproduction performance of male and female rats.</seg>
<seg id="1241">"" "" "" "with high doses, the undertaking about 4,3 fold of the human toxicity, the maternal toxicity stepped up with a reduction in raising performance and a development delay in the offspring of rats." "" "" ""</seg>
<seg id="1242">"" "" "" "Teratological studies on supporting rats with expositions, which emphasize the 4.3-times and with supporting rabbits with expositions which have been underpinned by the 13-times of the human-therapeutic exposure." "" "" ""</seg>
<seg id="1243">Colchicin / Indometacin / Hydrochlorthiazide / Warfarin Febuxeat can be used together with Colchicin or Indometacin without requiring a dose of dose for Febuxeat or at the same time necessary active substance.</seg>
<seg id="1244">Diarrhoea, nausea and vomiting are more common in patients who at the same time are treated with colchicin. * * In clinical trials no severe skin eruptions or severe hypersensitivity reactions were observed.</seg>
<seg id="1245">"" "" "" "in the open long-term renewal studies, 906 patients were treated with Febuxeat 80 mg / 120 mg for up to 3 years." "" "" ""</seg>
<seg id="1246">"" "" "" "in every study, the primary efficacy endpoint was the patients' proportion (357 mg / dl (357 µnl / l)." "" "" ""</seg>
<seg id="1247">The data collected in two years showed the data collected by the open extension study of phase 3 that resulted in a decrease in the incidence of cases required at &lt; 6 mg / dl (&lt; 357 µnl / l) in the months of 16-24 months (i.e. more than 97% of patients needed no treatment against a feed).</seg>
<seg id="1248">26 as unaltered Febuxeat (3%), Acylglues of the active substance (30%) with its well-known oxidative metabolites and their conjugate (13%) as well as other unknown metabolites (3%).</seg>
<seg id="1249">Liver limiting After taking multifocal doses of 80 mg of ADENURIC in patients with lighter (Child- Pugh classification B) or moderate (child-dgh classification B) liver failure not significantly changed compared to subjects with normal liver function.</seg>
<seg id="1250">"" "" "" "carcinogenesis, mutagenesis, impairment of Fertility In male rats, a statistically significant increase of urinary bladder and carcinomas) was found only in connection with Xanthin stones in the highly-dosed group, with approximately 11 times the exposure to humans." "" "" ""</seg>
<seg id="1251">"" "" "" "the approval of the approval of the approval process is to ensure that a pharmaceutical covigilance system is described as described in version 2.0 module 1.8.1 for the approval of the application, and so long is available as the medicine is placed in the traffic." "" "" ""</seg>
<seg id="1252">A updated RMP is provided with the CHMP Guideline to risk management systems for human medicines with the next periodic safety update Report (PSUR).</seg>
<seg id="1253">"" "" "" "additionally, an update of the RMP is required • If new information is available, which have an impact on the security data, the pharmaceutical coilance plan or activities in 60 days after reaching an important milestones (pharmaceutical covigilance or risk management) • on request of the EMEA)" "" "" ""</seg>
<seg id="1254">"" "" "" "in some people, uric acid occurs in the blood and can achieve levels that are so high that uric acid is insoluble." "" "" ""</seg>
<seg id="1255">"" "" "" "if you keep the urine of urine by the 1 x daily intake of ADENURIC, the crystalline formation is prevented and in this way reducing the discomfort." "" "" ""</seg>
<seg id="1256">ADENURIC may not be taken if you are sensitive to the active substance Febuxostat or any of the other components of ADENURIC.</seg>
<seg id="1257">Inform your doctor before taking this medicine by taking care of this medication or if you suffer a cardiac disease or in a other heart problem. • When you suffer from a high blood pressure cancer or the Lesch-Nyhan-Syndroms (a rare innate condition) treated with too much uric acid in the blood.</seg>
<seg id="1258">"" "" "" "if you have a toxin at the moment (sudden appearance of severe pain, pressure sensitivity, redness, heat-feeling and joint vibration), before you begin with the treatment of ADENURIC." "" "" ""</seg>
<seg id="1259">"" "" "" "this does not have to be with everyone, but may also occur with you, especially during the first treatment weeks or monate, occur if you are using ADENURIC." "" "" ""</seg>
<seg id="1260">"" "" "" "your doctor will treat you other medicines, in order to prevent poisoning, or to treat the associated symptoms (such as pain and joint vibration)." "" "" ""</seg>
<seg id="1261">"" "" "" "please inform your doctor or pharmacist if you have taken other medicines / apply or used recently, even if it is not prescription drugs." "" "" ""</seg>
<seg id="1262">"" "" "" "it is particularly important that you may use your doctor or pharmacist when using ADENURIC (for the treatment of cancer) • Azathioprine (for the treatment of cancer) • pigeophylin (for the treatment of asthma) • Warfarin (for the treatment of diseases)" "" "" ""</seg>
<seg id="1263">There were no studies on the effects of ADENURIC on the traffic and the ability to serve machines.</seg>
<seg id="1264">"" "" "" "therefore, please take ADENURIC after consultation with your doctor if you know that you suffer from a tolerability towards certain sugars." "" "" ""</seg>
<seg id="1265">"" "" "" "on the back of the blister, the individual weekdays are printed if you have taken a tablet every day. • The tablets need to be swallowed and can be taken with or without food." "" "" ""</seg>
<seg id="1266">"" "" "" "if you have taken an overdose should be taken intentionally, please contact your doctor or at the intake of the nearest hospital." "" "" ""</seg>
<seg id="1267">"" "" "" "if you have forgotten the consumption of ADENURIC, take this as soon as possible, unless the next intake is shortly before." "" "" ""</seg>
<seg id="1268">"" "" "" "when taking ADENURIC's consumption, your urinary acid may rise again and your complaints can worsen, because new urine was able to form all in your joints and kidneys as well as their surroundings." "" "" ""</seg>
<seg id="1269">Frequent side effects (more than 1 out of 100 treated, but less than 1 out of 10 treated): • Smooth liver test • diarrhea • headache • nausea</seg>
<seg id="1270">"" "" "" "rare side effects (more than 1 out of 10,000 treated, but less than 1 of 1,000 treated): • weakness • nervousness • Durstness • heart beat" "" "" ""</seg>
<seg id="1271">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will be significantly impaired or you will notice any side effects that are not listed in this manner." "" "" ""</seg>
<seg id="1272">ADENURIC is available in 2 blister packages with 14 tablets (Pack of 28 tablets) or in 6 eyes packs each with 14 tablets (Pack of 84 tablets).</seg>
<seg id="1273">Forwarded to the Ipsen Pharma 24 rue Erlong F-75781 Paris Cedex 16 France Tél: + 33 - 1 - 44 96 13 13</seg>
<seg id="1274">Danmark, Norge, Suomi / Finland, Sverige, Ísland Institute eiits synthèse (IPSEN) AB Kista Sverige / Ruotsi / Svíky jóvarjój / Puh / Sími / Puh / Sími: + 46 8 588 370 70 "" "" "" "</seg>
<seg id="1275">"" "" "" "ADROVANCE is used for the treatment of osteoporosis (one disease, in which the bones are fragile) in women after menopause, with which there is a risk for a low vitamin D mirror." "" "" ""</seg>
<seg id="1276">"" "" "" "the patient must take the tablet with a full glass of water (no mineral water) at least 30 minutes before eating, drinking or taking other medicines (including antazida, calcium and vitamin supplement)." "" "" ""</seg>
<seg id="1277">"" "" "" "in order to avoid irritation of the esophagus, the patient may take place after the first food intake of the day, which should take place 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1278">"" "" "" "since Alendronate and vitamin D3 are already separately approved in medicines that are approved in the European Union, the company submitted data from previous studies and published literature." "" "" ""</seg>
<seg id="1279">"" "" "" "the company also conducted a study involving 35 men and 682 postmenopausal women with osteoporosis, in order to prove the efficacy of ADROVANCE in terms of increasing vitamin D levels." "" "" ""</seg>
<seg id="1280">"" "" "" "after a 15-week treatment, patients with a low vitamin D mirror was treated with ADROVANCE (11%) than those with ADROVANCE (32%)." "" "" ""</seg>
<seg id="1281">"" "" "" "the company also provided data that the Alendronate dose contained in ADROVANCE is exactly the dose, which is needed for preventing a bone loss." "" "" ""</seg>
<seg id="1282">"" "" "" "the most common side effects (observed in 1 to 10 of 100 patients) are headaches, pain, bones, or joints) and symptoms of digestive problems, dysphagia, ulcers (ulcers), ulcers (blogging) and hemorrhagia." "" "" ""</seg>
<seg id="1283">In patients with any hypersensitivity (allergy) against Alendronate, vitamin D3 and one of the other components ADROVANCE cannot be applied.</seg>
<seg id="1284">"" "" "" "it must not be used in diseases of the esophagus, in patients with hypocalcemia (low calcium level) or in patients who can't stand or sit for at least 30 minutes." "" "" ""</seg>
<seg id="1285">"" "" "" "in January 2007, the European Commission granted approval by the company Merck Sharp and Dohme Ltd., a approval of ADROVANCE in the European Union." "" "" ""</seg>
<seg id="1286">"" "" "" "capsulations, white to broken white tablets, marked with the outline of a bone on one side and" 710 "on the other side." "" "" ""</seg>
<seg id="1287">ADROVANCE is only with water (not with mineral water) at least 30 minutes before the first eat or drink of medicines (including antazida, calcium and vitamin supplementary products) for the day.</seg>
<seg id="1288">"" "" "" "the following indicators are to follow exactly, in order to reduce the risk of malophageal irritations and related side effects (see Section 4.4):" "" "" ""</seg>
<seg id="1289">• ADROVANCE should be thrown after the emergence of the day only with a full glass of water (at least 200 ml) and the tablet is not supposed to take place before the first food intake of the day that should take place 30 minutes after taking the tablet.</seg>
<seg id="1290">"" "" "" "B. peptic ulcus, active gastrointestinal bleeding or surgical interventions in the upper Gastrointestinal tract except Pyloroplastic, are only be given under special caution (see Section 4.3)." "" "" ""</seg>
<seg id="1291">"" "" "" "oesopgeal reactions, such as esteshagia, malophageal Ulzera and malophageal seizations, were seldom followed by malophagetic strokes, some were severe and required a hospital order." "" "" ""</seg>
<seg id="1292">"" "" "" "the doctor should therefore refer to all signs and symptoms that refer to potential malophageal reactions like dysphagia, pain during swallowing or retroactive heartburn to obtain medical advice (see section 4.8)." "" "" ""</seg>
<seg id="1293">"" "" "" "3 The risk of severe cancer effects appear to be increased in patients, which does not take the medicine correctly and / or after the occurrence of symptoms that are on a malophageal irritation." "" "" ""</seg>
<seg id="1294">It is very important that all dosing instructions can be passed on to patients and be understood by the patient (see Section 4.2).</seg>
<seg id="1295">"" "" "" "while in large-wide clinical trials with Alendronat no higher risk was found, including some grave and complications, reported (see section 4.8)." "" "" ""</seg>
<seg id="1296">"" "" "" "Osteonekrosis of the Pine, usually reported in connection with a dental reduction and / or local infection (including Osteomyelitis), whose treatment courses predominantly administered intravenously and called bisphosphonate." "" "" ""</seg>
<seg id="1297">"" "" "" "there are no data available to provide evidence whether the absorption of a bisphosphonattherapy in patients, which reduces the risk of osteonatrosis of the jaw." "" "" ""</seg>
<seg id="1298">"" "" "" "clinical assessment by the treated doctor is authoritative for treatment planning in each patient based on an individual benefit-risk assessment." "" "" ""</seg>
<seg id="1299">"" "" "" "patients must be dependent on the intake of a dose of ADROVANCE the tablet in the next morning, after having noticed their legacy." "" "" ""</seg>
<seg id="1300">"" "" "" "you should not take two tablets on the same day, but taking the intake of one tablet per week as originally planned on the day of the week." "" "" ""</seg>
<seg id="1301">Other diseases affecting the mineral metabolism (such as vitamin D deficiency and hypoparathyreoidism) should also be treated with ADROVANCE therapy.</seg>
<seg id="1302">"" "" "" "alendronate Food and beverages (including mineral water), calcium supplements, antazida and some oral drugs may affect the absorption of alendronate if they are taken at the same time." "" "" ""</seg>
<seg id="1303">"" "" "" "therefore, patients must wait at least 30 minutes after taking Alendronat before taking other medicines (see sections 4.2 and 5.2)." "" "" ""</seg>
<seg id="1304">"" "" "" "although specific interactions studies were not performed, Alendronate was taken in clinical trials together with a wide range of usually prescribed medicines, without that clinically relevant interactions were present." "" "" ""</seg>
<seg id="1305">ADROVANCE is intended only for the application in postmenopausal women and is therefore neither necessary during the pregnancy of lactating women.</seg>
<seg id="1306">Animal studies with alendronat leave no indication of directly shabdicting effects in terms of pregnancy, the embryonic / fetal or postnatal development.</seg>
<seg id="1307">Osteonekrosis reported in patients with bisphosphonates; most reports are reported in cancer patients but also in osteoporosis.</seg>
<seg id="1308">Nevertheless the serum increased to &lt; 8.0 mg / dl (2.0 mmol / l) and the serum phosphats up to ≤ 2.0 mg / l (0.65 mmol / l) in both treatment groups.</seg>
<seg id="1309">Alendronat insequence of an oral overdose can occur hypocalcemia, hypophicatanemia and side effects in the upper Gastrointestinal tract like stomach upset, ostritis or Ulzera.</seg>
<seg id="1310">"" "" "" "in the skin, Colecalciferol (vitamin D3) Vitamin D3 is produced in the skin by UV light about the conversion of 7 elongydroces to vitamin D3." "" "" ""</seg>
<seg id="1311">The main action of 1.25-Dihydroxyvitamin D3 is the increasing intestinal absorption of calcium and phosphate and regulating calcium and phosphate.</seg>
<seg id="1312">"" "" "" "in heavy cases, a lack of secondary hyperparathyreoidism, weakness of the proximal musculature and Osteomalazie and thus resulted in an increased risk for falls and bones in osteoporosis." "" "" ""</seg>
<seg id="1313">"" "" "" "Bone material density) on spine or hip, which is 2.5 standard deviations under the mean value for a normal, young population, or regardless of the bone density as present pathological fracture." "" "" ""</seg>
<seg id="1314">Patients received ADROVANCE in lower strength (70 mg / 2.800 g) (n = 350) or FOSAMAX (n = 332); further vitamin D supplements were prohibited.</seg>
<seg id="1315">After 15 weeks of treatment the medium serum levels of 25-hydroxygen (70%) were significantly higher in the group under ADROVANCE (70 mg / l [23 ng / l]) (46 nmol / l [18,2 ng / ml]).</seg>
<seg id="1316">ADROVANCE (70 mg / 2.800) significantly reduced the proportion of patients with vitamin D insufficiency (serum value of 25-Hydroxyvitamin D &lt; 37,5 nmol / l [&lt; 15 ng / l]) by 62.5% compared to Alendronate alone (12% vs.</seg>
<seg id="1317">"" "" "" "studies with Alendronat once a weekly 70 mg (n = 519) and Alendronat 10 mg daily (n = 370), has been demonstrated to postmenopausal women with osteoporosis." "" "" ""</seg>
<seg id="1318">The effects of alendronate on bone mass and fragment in postmenopausal women were examined in two phase III studies of identical design (n = 944) as well as in the Fraktur-Interventional Study (FIT: n = 6.459).</seg>
<seg id="1319">"" "" "" "in phase III studies, the BMD Group's mid-III studies were set to 8.8% in relation to placebo after 3 years and 7.8% at the spine." "" "" ""</seg>
<seg id="1320">"" "" "" "in comparison with the placebo group a reduction of 48% (Alendronate 3.2% compared to placebo 6.2%) were achieved in the number of patients, one or several vertebrates." "" "" ""</seg>
<seg id="1321">"" "" "" "in the two-year extension of these studies, the climbs of the BMD of spine and trowelders continued to maintain the BMD of the Female halses and the entire body." "" "" ""</seg>
<seg id="1322">"" "" "" "fit consisted of two plazeboy trials in which Alendronate was daily taken daily (5 mg daily for 2 years and then 10 mg daily, either over 1 or 2 years):" "" "" ""</seg>
<seg id="1323">"" "" "" "in this study, the daily gift of Alendronat reduced 47% (Alendronate 7.9% compared to the placebo 15.0%)." "" "" ""</seg>
<seg id="1324">Resorption after a monthly reference dose was the mean oral bioavailability of alendronate at women 0.64% for cans between 5 and 70 mg after nightly fast and two hours before recording of a standardized breakfast.</seg>
<seg id="1325">"" "" "" "bioavailability increased to about 0.46% and 0.39%, when Alendronate was taken one or half an hour before a standardized breakfast." "" "" ""</seg>
<seg id="1326">"" "" "" "in osteoporosis, Alendronate was effective when it was taken at least 30 minutes before the first meal or drink of the day." "" "" ""</seg>
<seg id="1327">"" "" "" "in healthy volunteers, the gift of oral prednisone (20 mg three times daily) resulted in no clinically significant alteration of oral bioavailability of Alendronate (increase in the range from 20% to 44%)." "" "" ""</seg>
<seg id="1328">"" "" "" "9 distribution studies on rats have yielded that Alendronat is distributed after intravenous injection of 1 mg / kg, but then quickly spread in the bones or excreted with urine." "" "" ""</seg>
<seg id="1329">"" "" "" "excretion After intravenous gift of a single dose of 14C-Alendronate were eliminated about 50% of the radioactive substance within 72 hours, with urine and not found radioactivity." "" "" ""</seg>
<seg id="1330">After intravenous gift of a single dose of 10 mg the renal clearing of Alendronat 71 ml / min and Systemic Clearance exceeded 200 ml / min.</seg>
<seg id="1331">"" "" "" "Alendronat is not excreted over the acid or alkaline transport system of the kidneys, and therefore it is not accepted that by humans the excretion of other medicines by these transport systems is affected." "" "" ""</seg>
<seg id="1332">Resorption of healthy adult subjects (women and men) was after the gift of ADROVANCE after nightly fast and two hours before taking a meal the average surface under the serum concentration time curve (AUC0-120 h) for vitamin D3 296.4 ng • h / ml (without consideration of endogenous vitamin D3 mirror).</seg>
<seg id="1333">The average maximum concentration in serum (Cmax) of vitamin D3 was 5.9 ng / ml and the median age until reaching the maximum serum concentration (Tmax) 12 hours.</seg>
<seg id="1334">"" "" "" "Biotranslation Vitamin D3 is rapidly used in the liver to 25-hydroxygen D3 hydroxygen, D3, biologically active form, metabolized." "" "" ""</seg>
<seg id="1335">"" "" "" "excretion In the gift of radioactive vitamin D3 in healthy subjects, the average discharge of radioactivity in the urine was 2.4% in the urine after 4 days 4.9%." "" "" ""</seg>
<seg id="1336">"" "" "" "characteristics of clinical trials showed that the share of Alendronate, which is not stored in the bone, is quickly excreted over the urine." "" "" ""</seg>
<seg id="1337">"" "" "" "although there is no clinical data available, it is still that the renal elimination of alendronate as in the animal try to be reduced in patients with reduced kidney function." "" "" ""</seg>
<seg id="1338">"" "" "" "therefore, in patients with reduced kidney function, a slightly increased cumulation of alendronate in bone can be expected (see section 4.2)." "" "" ""</seg>
<seg id="1339">"" "" "" "alendronate Non-clinical data based on conventional safety macology, for chronic toxicity, to Genotoxicity and to canogenic potential don't realize any special dangers." "" "" ""</seg>
<seg id="1340">"" "" "" "studies on rats showed that the gift of alendronate was evocative rats with the occurrence of Dystokie near the motherhood, which was attributable to a hypocalcemia." "" "" ""</seg>
<seg id="1341">Micro-crystalline Cellulose (E 460) Lactose medium-chain triglyceride gel sodium hydroxytoluol (Ph.D.) (E 321) starch, modified (corn) Aluminium natrigerate (E 554)</seg>
<seg id="1342">Etui with sealed aluminium / aluminum blister packs into circulation on 2 (1 Etui with 2 tablets), 6 (1 Etuis with 2 tablets) and 12 (3 Etuis with 4 tablets) or 40 (10 tablets) tablets.</seg>
<seg id="1343">EU / 1 / 06 / 364 / 06 / 364 / 002 - 2 tablets EU / 1 / 06 / 364 / 004 - 6 tablets EU / 1 / 06 / 364 / 004 - 12 tablets EU / 1 / 06 / 364 / 005 - 40 tablets</seg>
<seg id="1344">"" "" "" "rectangular, white to broken white tablets, marked with the outline of a bone on one side and" 270 "on the other side." "" "" ""</seg>
<seg id="1345">13 • The patients will not take least 30 minutes after taking ADROVANCE. • ADROVANCE should not be taken before bedtime or before the first rise of the day.</seg>
<seg id="1346">"" "" "" "the risk of severe ösophageal side effects seems to be increased in patients, which does not take the medicine correctly and / or after the occurrence of symptoms that refer to a malophageal irritation." "" "" ""</seg>
<seg id="1347">"" "" "" "while in large-wide clinical trials with Alendronat no higher risk was found, including some grave and complications, reported (see section 4.8)." "" "" ""</seg>
<seg id="1348">"" "" "" "18 Colecalciferol (vitamin D3), vitamin D3 is produced in the skin by UV light about the transformation of 7 elongydroces to vitamin D3." "" "" ""</seg>
<seg id="1349">Patients received ADROVANCE in lower strength (70 mg / 2.800 g) (n = 350) or FOSAMAX (n = 332); further vitamin D supplements were prohibited.</seg>
<seg id="1350">"" "" "" "vitamin D3 (the amount of vitamin D3 in the higher dose of ADROVANCE) is once a week, was shown in a 24-week extension study with osteoporosis." "" "" ""</seg>
<seg id="1351">After 24 weeks treatment the medium serum levels of 25-Hydroxyvitamin D was significantly higher in the 5.600-I.E.-vitamin D3 group (69 nmol / l [27.6 ng / l]) than in the 2.800-I.E.-vitamin D3 group (64 nmol / l [25,5 ng / ml]).</seg>
<seg id="1352">There was no statistically significant difference between the treatment groups with hypercalciurie at the end of the 24-week extension.</seg>
<seg id="1353">"" "" "" "3.1% of the hips in the group with 70 mg once a week, or 10 mg. a day." "" "" ""</seg>
<seg id="1354">"" "" "" "in this study, the daily gift of Alendronat reduced 47% (Alendronate 7.9% compared to the placebo 15.0%)." "" "" ""</seg>
<seg id="1355">"" "" "" "bioavailability increased to about 0.46% and 0.39%, if Alendronate one or half an hour before a standardized breakfast." "" "" ""</seg>
<seg id="1356">"" "" "" "distribution studies on rats have yielded that Alendronat is distributed after intravenous injection of 1 mg / kg, but then quickly spread in the bones or excreted with urine." "" "" ""</seg>
<seg id="1357">Resorption of healthy adult subjects (women and men) were according to the gift of ADROVANCE (70 mg / 5.600 g) after nightly and two hours before taking a meal the average surface under the serum concentration time curve (AUC0-80 h) for vitamin D3 490.2 ng • h / ml (without consideration of endogenous vitamin D3 mirror).</seg>
<seg id="1358">The average maximum concentration in serum (Cmax) of vitamin D3 was 12.2 ng / ml and the median age until reaching the maximum serum concentration (Tmax) 10.6 hours.</seg>
<seg id="1359">Smaller quantities are spread in fat and muscle tissue and are stored there as vitamin D3 in order to be placed in the circulation.</seg>
<seg id="1360">"" "" "" "21 vitamin D3 is rapidly used in the liver to 25-hydroxygen vitamin D3, a vitamin D3, the biologically active form, metabolized." "" "" ""</seg>
<seg id="1361">No indications for the saturation of the bone of the bone after long-term dose of cumulative intravenous doses of up to 35 mg / kg found in animals.</seg>
<seg id="1362">Etui with sealed aluminium / aluminum blister packs into circulation on 2 (1 Etui with 2 tablets), 4 (1 Etui with 4 tablets) or 40 (10 tablets with 4 tablets) tablets.</seg>
<seg id="1363">"" "" "" "" "" "" "" "pharmaceutical-vigilance System The owner of approval for the transport system is to be sure that a pharmaceutical covigilance system is described as described in version 2 module, before it is available as long as the market will be marketed in the traffic." "" "" ""</seg>
<seg id="1364">"" "" "" "risk management plan The holder of the approval of the pharmaceutical company is committed to conduct studies and further pharmaceutical-vigilance activities in the risk management plan (RMP) and its corresponding updates in accordance with Version 1, 1.8.2 of the application documents." "" "" ""</seg>
<seg id="1365">A updated RMP is provided with the CHMP Guideline to risk management systems for human medicines with the next periodic Saftey Update Report (PSUR).</seg>
<seg id="1366">"" "" "" "in addition, an update of the RMP is required - if new information is required to have an impact on the security data, pharmaceutical covigilance or risk activities − within 60 days of achieving important milestones (pharmaceutical covigilance or risk management) − on the requirements of the EMEA" "" "" ""</seg>
<seg id="1367">"" "" "" "take a ADROVANCE tablet as well as before the first food and drink and before taking any other medicine, swallow the tablet with a full glass of water (not chewing and not lapped)." "" "" ""</seg>
<seg id="1368">"" "" "" "perhaps you would like to read this later again. • If you have further questions, please contact your doctor or pharmacist. • This medicine was given to you personally." "" "" ""</seg>
<seg id="1369">"" "" "" "in the menopause, the ovaries produce no female hormones, oestrogen, more, which help skeleton of women healthy." "" "" ""</seg>
<seg id="1370">"" "" "" "the fractures usually occur on the hip, the spine or the wrist and can not only cause pain, but also substantial problems such as tilated postage") and loss of mobility. "" "" "" "</seg>
<seg id="1371">"" "" "" "ADROVANCE does not only prevent loss of bone mass, but also helps to reduce bone loss again and reduce the risk of spinal and hips." "" "" ""</seg>
<seg id="1372">"" "" "" "correction of esophagus or swallowing disorders, (3) if it is not possible to sit or stand at least 30 minutes if your doctor has established that your calcium content is degraded in the blood." "" "" ""</seg>
<seg id="1373">"" "" "" "40 • If you have problems with swallowing or digestion, • If you have cancels when you have cancer or radiation treatment, • If you have cancer or radiation treatment, • If you do not routinely go to dental care." "" "" ""</seg>
<seg id="1374">"" "" "" "these complaints may appear in particular, if the patients take the ADROVANCE tablet with a full glass of water and / or take it 30 minutes before taking it." "" "" ""</seg>
<seg id="1375">"" "" "" "when taking ADROVANCE with other medicines Calcium supplements, Antazida and some other medicines for intake, the effectiveness of ADROVANCE can be disabled." "" "" ""</seg>
<seg id="1376">"" "" "" "certain medicines or food additives contained the absorption of vitamin D in the body, including artificial fats, mineral oils, orlistat and the cholesterinsenkenden medicines cholestyramin and Colonpol." "" "" ""</seg>
<seg id="1377">"" "" "" "please inform your doctor or pharmacist if you have taken other medicines / apply or used recently, even if it is not prescription drugs." "" "" ""</seg>
<seg id="1378">"" "" "" "please take this medicine only after consultation with your doctor, if you know that you suffer from a tolerability towards certain sugars." "" "" ""</seg>
<seg id="1379">Please follow the references (2) (3) and 5) to ease the transport of the ADROVANCE tablet into the stomach and to reduce potential irritation of the esophagus (esophagus - tube that connects your mouth with the stomach).</seg>
<seg id="1380">(2) Take the ADROVANCE tablet as well as before taking any food or drink as well as before taking any other medicine with a full glass (at least 200 ml) water (not with mineral water). • Do not take with coffee or tea. • Do not take with juice or milk.</seg>
<seg id="1381">"" "" "" "(3) Do not go away - stay completely upright (sitting, standing or walking), for at least 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1382">"" "" "" "(5) If any difficulties or pain in swallowing, pain behind the sternum, re-use or deteriorating heartburn, take ADROVANCE and search your doctor." "" "" ""</seg>
<seg id="1383">"" "" "" "(6) Wait for at least 30 minutes after the swallowing of your ADROVANCE pill before you take your first food, beverages or other medicines such as antazida (magenacid drugs), calcium- or vitamin supplement to that day." "" "" ""</seg>
<seg id="1384">"" "" "" "should you accidentally have taken many tablets at once, drink a full glass of milk and turn right at your doctor." "" "" ""</seg>
<seg id="1385">"" "" "" "if you have missed the intake of a tablet, take one tablet in the next morning after you have noticed your legacy." "" "" ""</seg>
<seg id="1386">"" "" "" "often: • suction heaps; swallowing pain; jaw pain, sore throat and / or joint pain, • abdominal pain; constipation; constipation; interference-up; diarrhea; bloating, • headache." "" "" ""</seg>
<seg id="1387">Occasionally: • nausea; vomiting, • irritation and inflammation of the esophagus (esophagus - the tube that connects your mouth with your stomach) or the stomach mucosa; • skin rash; skin rash; reddish skin; purified skin.</seg>
<seg id="1388">"" "" "" "the following adverse events were reported (frequency not known): • (rotation) dizziness, • fatigue, • hair loss, • jaw problems (osteonsneak) in combination with delayed wound healing and infections, often after the drag of teeth, • swelling of hands or legs." "" "" ""</seg>
<seg id="1389">"" "" "" "43 It is helpful when you note that which complaints you had, when they started and how long they stopped." "" "" ""</seg>
<seg id="1390">The other components are microcrystalline Cellulose (E 460), lactose, medium-chained triglyceride, gelatine hydroxytoluol (Ph.D.) (E 321), magnesium hydroxytoluol (E 572). (E 572).</seg>
<seg id="1391">The tablets are available in Etuis with sealed aluminium / aluminum blister packages in the following packages: • 2 tablets (1 Etuis with 2 tablets in aluminum blister packages) • 6 tablets (3 pills in aluminum blister packs) • 40 tablets (10 tablets per 4 tablets in aluminum blister packs).</seg>
<seg id="1392">"" "" "" "in the menopause, the ovaries produce no female hormones, oestrogen, more, which help skeleton of women healthy." "" "" ""</seg>
<seg id="1393">"" "" "" "48 If you have allergies, if you have problems in swallowing or with the digestive process, • When you have cancer or radiation treatment, • If you have cancer or radiation treatment, • If you do not routinely go to dental care." "" "" ""</seg>
<seg id="1394">"" "" "" "when taking ADROVANCE with other medicines Calcium supplements, Antazida and some other medicines for intake, the effectiveness of ADROVANCE can be disabled." "" "" ""</seg>
<seg id="1395">2) Take the ADROVANCE tablet as well as before taking any food or drink as well as before taking any other medicine with a full glass (at least 200 ml) water (not with mineral water). • Do not take with coffee or tea. • Do not take with juice or milk.</seg>
<seg id="1396">"" "" "" "3) Do not go away - stay completely upright (sitting, standing or walking), for at least 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1397">"" "" "" "5) If any difficulties or pain in swallowing, pain behind the sternum, re-use or deteriorating heartburn, take ADROVANCE and search your doctor." "" "" ""</seg>
<seg id="1398">"" "" "" "6) Wait for at least 30 minutes after the swallowing of your ADROVANCE pill before you take your first food, beverages or other medicines such as antazida (magenacid drugs), calcium- or vitamin supplement to that day." "" "" ""</seg>
<seg id="1399">"" "" "" "• (revolt) swingle, • articulation, • fatigue, • hair loss, • jaw problems (osteonekrosis) in combination with delayed wound healing and infections, often after the drag of teeth, • swelling of hands or legs." "" "" ""</seg>
<seg id="1400">"" "" "" "tablets are available as rightful, white to broken white tablets, labelled with the outline of a bone on one side and" 270 "on the other side." "" "" ""</seg>
<seg id="1401">"" "" "" "Advagraf is administered to adult patients who transplanted a kidney or liver, to prevent transplanted organ by the immune system." "" "" ""</seg>
<seg id="1402">"" "" "" "since Tacrolimus and Prograf / Prograf has already been deployed in the EU, the company has presented the results of previously conducted studies with Prograf / Programming as well as data from published literature." "" "" ""</seg>
<seg id="1403">"" "" "" "furthermore, the results of a clinical study submitted to 668 patients with kidney transplantation, whereby the application of Advagraf has been compared with Prograf / Prograft or Ciclosporin." "" "" ""</seg>
<seg id="1404">"" "" "" "the main indicator of the effectiveness was the number of patients due to which the transplant was dead after a treatment duration of one year, as often an improved organ transplantation or a resumption of dialysis was required)." "" "" ""</seg>
<seg id="1405">"" "" "" "in addition, recent studies were conducted in 119 patients with kidney transplantation and 129 patients with liver transplantation and examines how Advague is absorbed by the body as compared to Prograf / Programmer." "" "" ""</seg>
<seg id="1406">"" "" "" "Treber (tremors), headaches, nausea, vomiting, diarrhea (hyperglycemia), hypertension, increased blood sugar levels (hypertension), hypertension, and insomnia (insomnia)." "" "" ""</seg>
<seg id="1407">"" "" "" "in patients with any hypersensitivity (allergy) against tacrolimus, macro lens antibiotics (such as erythromycin) or other ingredients may not be applied." "" "" ""</seg>
<seg id="1408">Patients and doctors must be cautious if others (especially several herbal) drugs should be taken simultaneously with Advague as the prescribed medication should be adjusted accordingly.</seg>
<seg id="1409">"" "" "" "in red ink, hard capsules, retarded yellow-orange, printed in red ink on the light yellow capsule part with" 647 "; they contain white powder." "" "" ""</seg>
<seg id="1410">Only physicians who are familiar with the immune suppressive therapy and treatment of transplantation patients should be used to classify this drug or alter changes in immunossuppressive therapy.</seg>
<seg id="1411">"" "" "" "due to clinically relevant differences of systemic exposure of tacrolimus, this can lead to transplant attacks or an increased incidence of side effects, including under- or overimmunosuppression." "" "" ""</seg>
<seg id="1412">Patients should always maintain the same Tacrolimus formulation and the appropriate daily dosage; modifications of the formulation or regime should only be made under the close control of an experienced medical device (see sections 4.4 and 4.8).</seg>
<seg id="1413">"" "" "" "in a consequence of a transition to an alternative formulation, a therapeutic drug monitoring and corresponding dose can be carried out to ensure that the systemic exposure of tacrolimus remains intact." "" "" ""</seg>
<seg id="1414">"" "" "" "the dosage of Advagraf should be primarily based on clinical assessment of sharpening and tolerability in individual cases, and to blood pressure regulations (see below" recommendations "" "" "" "</seg>
<seg id="1415">"" "" "" "after the conversion from programming to Advagraf, the tacrolimus Talers should be controlled before switching and over two weeks after switching." "" "" ""</seg>
<seg id="1416">"" "" "" "on day 4, the systemic exposure, measured as a drop mirror, was comparable with both formulations both in case of liver transplanted patients." "" "" ""</seg>
<seg id="1417">Careful and repeated inspections of the Tacrolimus Talers are recommended during the first two weeks after transplantation under Advagraf; to ensure proper substance exposure in the immediate aftertransplantation phase.</seg>
<seg id="1418">"" "" "" "since Tacrolimus is a substance with low clearing, an adjustment of the vague can take several days until the Steady State is reached." "" "" ""</seg>
<seg id="1419">"" "" "" "if the patient's condition is not permitted in the first post-surgical phase, the tacrolimus treatment intravenously (prograf 5 mg / ml concentrate on the production of an infusion solution) can be initiated with a dose of ca." "" "" ""</seg>
<seg id="1420">"" "" "" "duration of the application for oppression of transplantation must be maintained; therefore, therefore, the maximum duration of oral therapy cannot be specified." "" "" ""</seg>
<seg id="1421">Dosages - kidney transplantation prophylaxis and transplantation The oral Advague therapy should begin with 0.20 - 0.30 mg / kg / day as once daily gift in the morning.</seg>
<seg id="1422">Further dosisadaptations may be required later as the Pharmacokinetics of Tacrolimus can change in the course of stabilization of the patient after transplantation.</seg>
<seg id="1423">Dose recommendation - liver transplantation prophylaxis and transplantation The oral Advague therapy should begin with 0.10 - 0.20 mg / kg / day as once daily gift in the morning.</seg>
<seg id="1424">"" "" "" "dosisrecommended - conversion from Prograf to Advague must be taken into a transplant of twice daily dosage of Prograf capsules at once daily intake of Advagraf, so this change in relation to the whole daily dose may be made." "" "" ""</seg>
<seg id="1425">"" "" "" "after a transition from other immunogressiva to advague, after a transition from other immunogressiva to advague, treatment with liver transplantation will be recommended daily for the prophylaxis of transplantation." "" "" ""</seg>
<seg id="1426">"" "" "" "heart transplantation In adult patients who are questioned on Advague, is an oral initial dose of 0.15 mg / kg / day daily at once." "" "" ""</seg>
<seg id="1427">Other transplant receptors Obwell there are no clinical experience with Advagraf in lung cancer and darmtransplanted patients in an oral initial dose of 0.2 mg / kg / day and in an oral initial dose of 0.3 mg / kg / day and in an oral initial dose of 0.3 mg / kg / day.</seg>
<seg id="1428">Dosisadaptations in special patient groups with reduced liver function for maintaining blood reflections in the target range can be charged in patients with heavy liver function.</seg>
<seg id="1429">Patients with reduced kidney function Since the kidney function does not affect the pharmacokinetics of tacrolimus can be assumed that a dose can not be required.</seg>
<seg id="1430">"" "" "" "however, due to the nephrlioxic potentials of tacrolimus, however, a careful monitoring of the kidney function (including a regular determination of the serum infiltration and monitoring of urine volume) is recommended." "" "" ""</seg>
<seg id="1431">Conversion of Ciclosporin to Advague When switching from a Ciclosporine to a Tacrolimus-based therapy is advisable (see sections 4.4 and 4.5).</seg>
<seg id="1432">Recommendations of the drop-level in full blood The dose should be primarily based on clinical assessment of cavity and tolerability in individual cases of full blood-radirolimus-levels inspections.</seg>
<seg id="1433">It is recommended to perform frequent inspections of the Tacrolimus Talers during the first two weeks after transplantation, followed by periodic checks during maintenance therapy.</seg>
<seg id="1434">Blood-Talers of Tacrolimus should also change after changing Prograf to Advagraf, Dosisadaption, changes of immunosuppressive therapy or for simultaneous use of substances which may change the tacrolimus blood-blood concentration (see Section 4.5).</seg>
<seg id="1435">"" "" "" "as Advague is a drug with a low clearing, adaptations of the dose may require several days until the Steady State has entered." "" "" ""</seg>
<seg id="1436">"" "" "" "the data in clinical studies indicate that a successful treatment in most cases is possible, if the tallow level does not exceed 20 ng / ml." "" "" ""</seg>
<seg id="1437">In clinical practice the Talers of Tacrolimus are usually lying in the first time after liver transplants in the range of 5 - 20 ng / ml and in case of liver transplanted patients at 10 - 20 ng / ml.</seg>
<seg id="1438">"" "" "" "during the following maintenance therapy of liver, kidney and heart transplantation, blood concentrations tend to be used in the range of 5 - 15 ng / ml." "" "" ""</seg>
<seg id="1439">"" "" "" "this has led to serious adverse events, including transplant attacks or other side effects that occur in sequence of tacrolimus or overexposure." "" "" ""</seg>
<seg id="1440">Patients should always maintain the same Tacrolimus formulation and the appropriate daily dosage; modifications of the formulation or regime should only be made under the close control of an experienced medical device (see sections 4.2 and 4.8).</seg>
<seg id="1441">"" "" "" "5 For the treatment of adult patients with transplanting pointer, which proved to be treated against other immunogressiva, no clinical data for the retarded formulation of Advagraf." "" "" ""</seg>
<seg id="1442">"" "" "" "to prevent prophylaxis, transplanting and grafts in adult heart transplants are not yet submitted to clinical data for the retarded formulation of Advagraf." "" "" ""</seg>
<seg id="1443">"" "" "" "because of possible interactions which can lead to a reduction of tacrolimuscle levels in the blood and a weakening of the clinical effect of tacrolimus, or other plant remedies during treatment with Advague (see section 4.5)." "" "" ""</seg>
<seg id="1444">"" "" "" "in patients with diarrhoea, a particularly careful monitoring of the Tacrolimush concentrations in the blood is advisable because the tacrolimus blood levels can be subject to considerable variations in these circumstances." "" "" ""</seg>
<seg id="1445">In rare cases a cardiomyopathy was referred to as cardiomyopathy which can therefore be found under Advagraf.</seg>
<seg id="1446">"" "" "" "further factors that increase the risk of such clinical disorders, are an already existing heart disease, high blood pressure, kidney or liver disorders, infections, fluid circulating and oils." "" "" ""</seg>
<seg id="1447">"" "" "" "as with other immunogressiva, the effect of sunlight or UV light should be restricted because of the possible risk of malignant skin changes with a high protection factor." "" "" ""</seg>
<seg id="1448">"" "" "" "when patients take the tacrolimus, symptoms for Pres such as headaches, changes of consciousness, cramps and vision problems, should be a radiological examination (eg." "" "" ""</seg>
<seg id="1449">"" "" "" "as Advague Hartkapass, retarded, lactose, is recommended in patients with the rare hereditary Galactose-intolerance, lactose deficiency or glucose vlactose special absorption." "" "" ""</seg>
<seg id="1450">"" "" "" "the simultaneous application of medicines or herbal remedies, which are known as inhibitor or inductors of CYP3A4, can increase the metabolism of tacrolimus or lower the blood values of tacrolimus." "" "" ""</seg>
<seg id="1451">"" "" "" "it is therefore advisable to monitor the Tacrolimus- blood level, while able to monitor the CYP3A metabolism and adjust the tacrolimus dose for maintaining uniform concentrations accordingly (see sections 4.2 and 4.4)." "" "" ""</seg>
<seg id="1452">"" "" "" "a strong interaction between ketoconazole, fluconazole, and voriconazole, as well as with the Macrolid antibiotic Erythromycin and HIV proteastia (z)." "" "" ""</seg>
<seg id="1453">Pharmacokinetics studies resulted in the rise of blood levels mainly from the increased oral bioavailability of tacrolimus caused by inhibition of gastrointestinal gases.</seg>
<seg id="1454">High-dosed prednisolone or methyl prednisolone as it is used for acute absorption reactions, can increase or lower the concentration of tacrolimus in the blood.</seg>
<seg id="1455">"" "" "" "the effect of tacrolimus on metabolism of other medicines Tacrolimus can be known as CYP3A4 inhibitors; therefore, the simultaneous application of tacrolimus can be metabolized by CYP3A4, whose metabolism can affect the metabolism." "" "" ""</seg>
<seg id="1456">"" "" "" "because tacrolimus can reduce the Clearance of steroid contraceptives, and thereby increase hormonal exposure, is particularly cautious regarding perceptive measures." "" "" ""</seg>
<seg id="1457">"" "" "" "the results of animal experiments have shown that tacrolimus can reduce the Clearance of Pentobarbital and phenazon and extend their half-time." "" "" ""</seg>
<seg id="1458">"" "" "" "the results of a small number of transplant patients provide no indication that under Tacrolimus can provide an increased risk of unwanted events regarding the course and result of pregnancy." "" "" ""</seg>
<seg id="1459">"" "" "" "in utero exposure, a monitoring of the newborn effects of tacrolimus are recommended (especially regarding its effect on the kidneys)." "" "" ""</seg>
<seg id="1460">There is the risk of an early birth (&lt; Week 37) and hypercalibremia of the newborn (incidence 8 of 111 newborns):</seg>
<seg id="1461">"" "" "" "the side-acting profile of immunosressiva is often not closely associated with a variety of other medicines, with a variety of other medicines." "" "" ""</seg>
<seg id="1462">"" "" "" "below: very frequently (≥ 1 / 100, ≤ 1 / 100, ≤ 1 / 100, ≤ 1 / 100, ≤ 1 / 100, ≤ 1 / 100, ≤ 1 / 100, ≤ 1 / 100, ≤ 1 / 100, ≤ 1 / 100, ≤ 1 / 10), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000, ≤ 1 / 100), very rare (≥ 1 / 1000,</seg>
<seg id="1463">Cardiac disorders of coronary vessels and cardiac arrhythmia and cardiac arrhythmia, myocardiopathy, aquatic tropics, supreventricular arrhythmia, palpitatio in the ECG, abnormal heart and pulse rate.</seg>
<seg id="1464">"" "" "" "diarrhea, nausea, gastrointestinal composition, bleeding from the stomach-intestine, stomatitis, and symptoms, obtaination, flatulence, bloating and symptoms in the stomach intestine - range and symptoms." "" "" ""</seg>
<seg id="1465">"" "" "" "infections and parasitic diseases As well known in other highly effective immunosuressants, patients who are treated with tactics (viral, bacterial, mycotic, protozoic) frequently increases." "" "" ""</seg>
<seg id="1466">Cases of BK-Virus-associated Nephropathy and JC-Virus associated progressive multifocal leukencephalopathy (PML) were reported in patients with immunodeficiency therapy.</seg>
<seg id="1467">It has been reported about benign or malignant Neoplasmic diseases and skin tumors associated with the treatment of tacrolimus.</seg>
<seg id="1468">"" "" "" "due to its high molecular weight, its low water solubility and plasma rotation can be accepted that tacrolimus can not dialyzed." "" "" ""</seg>
<seg id="1469">"" "" "" "on the molecular level, the effects of tacrolimus can be conveyed by its liaison to a cytostic protein (FKBP12), which is responsible for the enrichment of the connection in the cellular memory." "" "" ""</seg>
<seg id="1470">This leads to a calciumdependent inhibiting of signal transmission due to the T-cell and prevents transcription of a certain number of lymphakin genes.</seg>
<seg id="1471">Tacrolimus are suppressed the T-cells activating T-cells and the formation of lymphocytes (such as interleukin-2, interleukin-3 and g-interferon) as well as the expression of the interleukin-2 receptors.</seg>
<seg id="1472">"" "" "" "12 confirmed acute attacks during the first 24 weeks in the vague Group (N = 237), 32.6% and in the program group (N = 234) 29.3%." "" "" ""</seg>
<seg id="1473">Patients survival rates after 12 months were enrolled at 89.2% for Advague and 90.8% for programming; in the vague arm 25 (14 women, 11 men) and in the program arm 24 (5 women, 19 men) deaths.</seg>
<seg id="1474">"" "" "" "kidney transplantation The efficacy and safety of Advagraf and Prograf was compared with mycophenolatmofetil (MMF) and corticosteroids, in 667 de Novo kidney transplantation." "" "" ""</seg>
<seg id="1475">Patients survival rates after 12 months were enrolled 96.9% for the vague and 97.5% for programming; in the vague arm 10 (3 women, 7 men) and in the program arm 8 (3 women, 5 men) deaths.</seg>
<seg id="1476">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf has been compared in combination with Basiliximab antibody, MMF and corticosteroids, in 638 de Novo kidney transplantation." "" "" ""</seg>
<seg id="1477">The incidence of therapy results after 12 months (defined as death, graft loss, biopsy-confirmed deducting or missing follow-up data) amounted to 15.0% in the program group (N = 212) and 17.0% in the Ciclosporin Group (N = 212).</seg>
<seg id="1478">The treatment difference was -3.0% (Advaguf- Ciclosporin) (95.2%) for Advagraf vs Ciclosporin and -1.9% (programing of Ciclosporin) (95.2%, 5.2%]) for Prograf vs Ciclosporin.</seg>
<seg id="1479">"" "" "" "in the vague arm 3 (men), in the program arm 10 (3 women, 7 men) and at Ciclosporin arm 6 (3 women, 3 men) deaths." "" "" ""</seg>
<seg id="1480">"" "" "" "published results of primary immunosuppression with tactics in the form of twice daily, after other primary organ transplants, developed into a recognized primary immune response to pancreas, lung and intestinal transplants." "" "" ""</seg>
<seg id="1481">"" "" "" "175 subjects transplanted patients, at 475 patients who had subjected to a pancreatic transplantation and in 630 cases were used as a primary immune soup." "" "" ""</seg>
<seg id="1482">"" "" "" "overall, the safety profile of oral programme in these published studies contained the observations in the large studies in which programme was used in liver, kidney and heart transplantation." "" "" ""</seg>
<seg id="1483">"" "" "" "in an interim analysis, Lungrafting Study has reported a multi-centric study conducted over 110 patients who received either Tacrolimus or Ciclosporin." "" "" ""</seg>
<seg id="1484">"" "" "" "the bronchiolitis bargain, bronchiolitis, was also observed in the first year after transplantation was often observed (2.86% versus 8.57%)." "" "" ""</seg>
<seg id="1485">"" "" "" "the survival rate after one year was 80,8% in the Tacrolimus- and 83% in Ciclosporin Group (Treede et al., 3rd ICI San Diego, USA, 2004; abstract 22)." "" "" ""</seg>
<seg id="1486">"" "" "" "in the patients treated with Tacrolimus, patients came to the formation of a bronchiolitis in comparison to 38.0% below Ciclosporin (p = 0,025)." "" "" ""</seg>
<seg id="1487">The number of cases where Ciclosporin had to be converted to Ciclosporin (n = 0.02) as the number of patients suffering from Tacrolimus on Ciclosporin (n = 2) (Keenan et al., Ann Thoracic Surg 1995; 60: 580).</seg>
<seg id="1488">The number of cases where it came to no acute graft. after 6 months (57.7% versus 45.8%) and after 1 year (50% vs 33.3%) and after 1 year (50% vs 33.3%) and after 1 year (50% vs 33.3%) and after 1 year (Treede et al.; J Heart Lung Transplant 2001; 20: 511).</seg>
<seg id="1489">In a study the frequency of the birth of a bronchiolitis was significantly lower in patients with Tacrolimus patients.</seg>
<seg id="1490">"" "" "" "a multi-centric study conducted with oral programming was subjected to 205 patients who have been subjected to a pancreas and kidney transplantation, which were randomised to randomised procedures Tacrolimus (n = 103) or Ciclosporin (n = 102)." "" "" ""</seg>
<seg id="1491">The initial initial dose (by protocol) of Tacrolimus was 0.2 mg / kg / day and after reaching the targeted field level from 8 to 15 ng / ml was 5.</seg>
<seg id="1492">Recapal transplantation The published clinical results of a monocentric study conducted by 155 patients (65 only intestine and 25 multivisceral transplants) showed an updated survival rate of 75% after 1 year, 5% after 5 years and 42% after 10 years.</seg>
<seg id="1493">Methods for early detection of Epstein-Barr (EBV) - and CMV infections (EBV) and CMV infections of Tacrolimus which lead to Talkin method (Abu-Elmagd et al., Ann Surg 2001; 234: 404).</seg>
<seg id="1494">Factors such as low hematocrites and low protein concentrations lead to an increase in the inexplicable faction of Tacrolimus or by treatment with corticosteroid reinforcements of the metabolism of the higher Clearance rates.</seg>
<seg id="1495">"" "" "" "this makes it close to that Tacrolimus is almost completely metabolized before the excretion, with the excretion primarily via the bile." "" "" ""</seg>
<seg id="1496">In case of stable patients who were taken by Prograf (twice daily) on Advague (once daily) in relation to the total daily dose of Tacrolimus (AUC0-24) was nearly 10% lower than a program.</seg>
<seg id="1497">It is recommended to perform frequent inspections of the Tacrolimus Talers during the first two weeks after transplantation, followed by periodic checks during maintenance therapy.</seg>
<seg id="1498">"" "" "" "21 For the treatment of adult patients with transplant pipes, which proved to be treated against other immunogressiva, no clinical data for the retarded formulation of Advagraf." "" "" ""</seg>
<seg id="1499">"" "" "" "further factors that increase the risk of such clinical disorders, are an already existing heart disease, high blood pressure, kidney or liver disorders, infections, fluid circulating and oils." "" "" ""</seg>
<seg id="1500">"" "" "" "28 confirmed acute attacks during the first 24 weeks in the Advague Group (N = 237), 32.6% and in the program group (N = 234) 29.3%." "" "" ""</seg>
<seg id="1501">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf has been compared in combination with Basiliximab antibody, MMF and corticosteroids, in 638 de Novo kidney transplantation." "" "" ""</seg>
<seg id="1502">"" "" "" "beech trees, retarnish red-orange gelatin, printed in red ink on the grass top with" 5 mg "and the orange capsubottom part with" "687" they contain white powder. "" "" "" "</seg>
<seg id="1503">It is recommended to perform frequent inspections of the Tacrolimus Talers during the first two weeks after transplantation, followed by periodic checks during maintenance therapy.</seg>
<seg id="1504">"" "" "" "37 For the treatment of adult patients with transplant pipes, which proved to be treated against other immunogressiva, no clinical data for the retarded formulation of Advagraf." "" "" ""</seg>
<seg id="1505">"" "" "" "further factors that increase the risk of such clinical disorders, are an already existing heart disease, high blood pressure, kidney or liver disorders, infections, fluid circulating and oils." "" "" ""</seg>
<seg id="1506">44 confirmed acute attacks during the first 24 weeks in the Advague Group (N = 237) and 32.6% and in the programming group (N = 234) and 29.3%.</seg>
<seg id="1507">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf has been compared in combination with Basiliximab antibody, MMF and corticosteroids, in 638 de Novo kidney transplantation." "" "" ""</seg>
<seg id="1508">A total of 34 patients were killed by Ciclosporin on Tacrolimus while only 6 Tacrolimus patients were needed (Bechstein et al.) transplant 2004; 77: 1221).</seg>
<seg id="1509">Recapal transplantation The published clinical results of a monocentric study conducted by 155 patients (65 only intestine and 25 multivisceral transplants) showed an updated survival rate of 75% after 1 year, 5% after 5 years and 42% after 10 years.</seg>
<seg id="1510">"" "" "" "this makes it close to that Tacrolimus is almost completely metabolized before the excretion, with the excretion primarily via the bile." "" "" ""</seg>
<seg id="1511">"" "" "" "risk management plan The holder of approval of the approval process is obligated to be accepted, as described in version 3.2 of the Risk Management Plan, as well as all other updates of the RMP, which are approved by CHMP." "" "" ""</seg>
<seg id="1512">"" "" "" "according to the CHMP-guideline for pharmaceuticals for use in humans, the updated RMP must be submitted with the next periodic safety report (periodic safety update Report, PSUR)." "" "" ""</seg>
<seg id="1513">"" "" "" "perhaps you will also get Advagraf to treat your liver, kidney or heart transplant or other transplanted organs, or because the immune response of your body could not be ruled by a prescribed treatment." "" "" ""</seg>
<seg id="1514">"" "" "" "when taking Advagraf with other medicines please inform your doctor or pharmacist if you have taken other medicines or recently taken, even if it is not prescription drugs or remedies of herbal origin." "" "" ""</seg>
<seg id="1515">Amiloride, triamier or spironolacton (so-called non-steroidal antiinflammatory drugs like ibuprofen), anticoagulants or medicines for treatment of diabetes mellitus.</seg>
<seg id="1516">"" "" "" "pregnancy and breastfeeding When a pregnancy is planned or already exists, ask before taking all drugs to your doctor or pharmacist for advice." "" "" ""</seg>
<seg id="1517">"" "" "" "if you are not allowed to use the wheel of a vehicle or to use tools or machines, if you feel dizzy or sleepy after taking off." "" "" ""</seg>
<seg id="1518">"" "" "" "important information about certain other components of Advague Please contact Advagraf after consultation with your doctor if you know, that you suffer from an intolerance towards certain sugars." "" "" ""</seg>
<seg id="1519">"" "" "" "make sure you always receive the same Tacrolimus medicine if you redeem your prescription, unless your specialist has explicitly agreed with a change of tacrolimus preparation." "" "" ""</seg>
<seg id="1520">"" "" "" "if you obtain a medicine, whose appearance may deviate from the customary or the metering instructions, please do so quickly as possible with your doctor or pharmacist allowing you to get the right medicine." "" "" ""</seg>
<seg id="1521">"" "" "" "so that your doctor may determine the correct dose and time to time, he then needs to perform blood tests regularly." "" "" ""</seg>
<seg id="1522">"" "" "" "if you have taken a larger amount of vague, if you accidentally have taken a larger amount of vague, seek your doctor or emergency department at the nearest hospital." "" "" ""</seg>
<seg id="1523">"" "" "" "if you forgot taking the intake of Advagraf, If you forgot to take the capsules, please get this at the same day at the earliest possible time." "" "" ""</seg>
<seg id="1524">"" "" "" "when taking the intake of Advagraf, you can increase the risk of your transplant at the end of the treatment with Advague." "" "" ""</seg>
<seg id="1525">"" "" "" "Advague 0,5 mg of hard capsules, retarded, are hard-yellow top with" 0.5 mg "and their orange bottom part with" "647" each are printed with white powder and are filled with white powder. "" "" "" "</seg>
<seg id="1526">"" "" "" "Advague 1 mg of hard capsules, retarded, the white top with" 1 mg "and their orange bottom part with" "677" are printed with red powder and are filled with white powder. "" "" "" "</seg>
<seg id="1527">"" "" "" "Advague 5 mg of hard capsules, retarded, are hard-coloured with" 5 mg "and their orange bottom part with" sp687 "each are printed with white powder and are filled with white powder." "" "" ""</seg>
<seg id="1528">România Astellas Pharma Internavel Detalii de contact pentru România Parks ti-Ploieu România ementoseaua Bucureş ti tel. 42-44 - Bucureş ti Tel: + 40 (0) 21 361 0495</seg>
<seg id="1529">Slovenska Republika Astellas Pharma s.r.o. and organizač ná - Galvániho 15 / C SK- 821 04 Bratislava 2 Tel: + 421 2 4444 2157</seg>
<seg id="1530">Advate is used for the treatment and prevention of bleeding in patients with hemophilia A (one by the lack of factor VIII related to congenital disturbing).</seg>
<seg id="1531">"" "" "" "the dosage and frequency of the application are then directed, whether Advate is applied to the treatment of hemorrhage or to the prevention of hemorrhages." "" "" ""</seg>
<seg id="1532">"" "" "" "patients with hemophilia A suffer from a factor VIII deficiency, which causes blood problems such as bleeding in joints, muscles, or inner organs." "" "" ""</seg>
<seg id="1533">"" "" "" "Octocog alfa is not extracted from human plasma, but according to a method that is called" recombinant DNA technology. "" "" "" ""</seg>
<seg id="1534">It is produced by a cell where a gene (DNA) has been introduced to educate it for the formation of the human clan factor VIII.</seg>
<seg id="1535">"" "" "" "Advate is the drug approved in the European Union (Recombinate, similar), but does not contain proteins of human or animal origin." "" "" ""</seg>
<seg id="1536">"" "" "" "in three additional studies of patients with severe to moderate hemophilia A, among them a study of 53 children under six years, the application of the drug was examined for the prevention of bleeding and surgical procedures." "" "" ""</seg>
<seg id="1537">"" "" "" "in the main study, Advate was the efficacy of bleeding in 86% of 510 new blood cerides with" excellent "resp." "" "" "" "</seg>
<seg id="1538">The most common side effects from Advate (observed at 1 to 10 of 100 patients) are dizziness, headaches, pyrexie (fever) and the formation of antibodies against factor VIII.</seg>
<seg id="1539">Advate is not allowed to be used in patients who may be sensitive (allergic) against the human gerinness factor VIII, mouse or hamster protein or any of the other ingredients.</seg>
<seg id="1540">"" "" "" "in March 2004, the European Commission granted authorization to Baxter AG an approval of the establishment of Advates throughout the European Union." "" "" ""</seg>
<seg id="1541">"" "" "" "dosing and duration of the substitution therapy is based on the severity of the factor VIII-Mangels, following the place and the extent of blood and the clinical condition of patients." "" "" ""</seg>
<seg id="1542">"" "" "" "in the following hemorrhagic events, the factor VIII in the corresponding period shall not fall into the specified plasma level (in% of the norm or in i.e. / dl)." "" "" ""</seg>
<seg id="1543">Injection: every 12-24 hours (8-24 hours in patients below 6 years) can be repeated for 3-4 days or longer until the pain and acute impairment removed.</seg>
<seg id="1544">Injection: repeat every 8-24 hours (6-12 hours in patients under 6 years) until the danger is over.</seg>
<seg id="1545">"" "" "" "during treatment, to control the dose and frequency of injections a reasonable determination of the factor VIII plasma level is stimulated." "" "" ""</seg>
<seg id="1546">Individual patients can differ in their reaction to factor VIII different in vivo Recovery and have different half-ups.</seg>
<seg id="1547">3 Prevention for long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 i.e. by factor VIII per kg of body weight within 2-3 days.</seg>
<seg id="1548">"" "" "" "if the expected factor VIII plasma-activities cannot be reached or if the bleeding is not governed by an appropriate dose, a test must be performed to prove a inhibitor." "" "" ""</seg>
<seg id="1549">"" "" "" "in patients with high inhibitors it is possible that the factor VIII therapy is not effective, so that other therapeutic interventions must be considered." "" "" ""</seg>
<seg id="1550">"" "" "" "should the adoption of the patient should be addressed, the maximum injection rate of 10 ml / min should not be exceeded." "" "" ""</seg>
<seg id="1551">The formation of neutralising antibodies (inhibitors) against factor VIII is a well-known complication in treating patients with hemophilia A.</seg>
<seg id="1552">These inhibitors are always directed against the procoagulatory activity of factor VIII (B.E.) per ml plasma using modified Bethesda Assay.</seg>
<seg id="1553">"" "" "" "the risk, inhibitors to develop, correlated with the extent of exposure to factor VIII, whereby the risk within the first 20 expositions of the greatest is and depends on genetic and other factors." "" "" ""</seg>
<seg id="1554">"" "" "" "for pre-treated patients (PTPs) with more than 100 expositions and anamneser inhibitors, the rerecombinant of the inhibitors was observed from another recombinant factor VIII product." "" "" ""</seg>
<seg id="1555">"" "" "" "due to the rare setting of hemophilia A in women, there are no experiences about the application of factor VIII during pregnancy and breastfeeding." "" "" ""</seg>
<seg id="1556">"" "" "" "the inhibitors of patients who have occurred in the largest number of patients (5 patients) showed a higher risk for the formation of inhibitors, involving headaches (5 patients), fever and dizziness (3 patients)." "" "" ""</seg>
<seg id="1557">"" "" "" "very frequently (≥ 1 / 100 to &lt; 1 / 10), occasionally (≥ 1 / 1000 to &lt; 1 / 100), very rare (≥ 1 / 1000 to &lt; 1 / 1000), very rare (frequencies on the basis of available data not invaluable)." "" "" ""</seg>
<seg id="1558">A) The percentage of patients was calculated using the sum of individual patients (234) (b). the unexpected drop of the blood coagulation factor VIII (10 - 14 postoperatively) was postoperatively in a patient under continuous ADVATE infusion.</seg>
<seg id="1559">"" "" "" "the blood clotting was maintained throughout the time, and both the factor VIII- mirror in the plasma and the Clearance rate showed sufficient values on the 15th post-operational day." "" "" ""</seg>
<seg id="1560">In clinical trials with ADVATE to 145 children and adults 2 with mild to moderate hemophilia A (FVIII &lt; 2%) and prior exposure to factor VIII- concentrates (≥ 150 days) showed a low inhibitors with ADVATE (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1561">"" "" "" "in addition, not a 53 pediatric patients with an age of under 6 years and diagnosed with severe hemophilia A (FVIII ≤ 2%) after previous exposure to factor VIII- concentrates (≥ 50 days) a FVIII Inhibitor." "" "" ""</seg>
<seg id="1562">Patients treated with ADVATE treated patients inhibitors were treated against factor VIII in previously untreated patients with ADVATE treated patients.</seg>
<seg id="1563">"" "" "" "the immune response of patients on traces of contamination of proteins was analyzed by the investigation of antibodies against these proteins, laboratory parameters and reported side effects." "" "" ""</seg>
<seg id="1564">"" "" "" "however, a patient showed a statistically significant impact resistance as well as an ongoing peak of anti-Cho cell remedies, but otherwise there were no symptoms or symptoms that showed an allergic reaction, or hypersensitivity." "" "" ""</seg>
<seg id="1565">"" "" "" "in four patients, the occurrence of Urtikaria, Pruritus, rash and increased number of eosinophiles Granulocytes reported on several repeated product expositions within the study." "" "" ""</seg>
<seg id="1566">7 How other intravenous products have been reported in ADVATE about hypersensitivity reactions from allergic type, including anaphylactic / anaphylaktoider reactions (frequency not known).</seg>
<seg id="1567">"" "" "" "the activated factor VIII works as a factor for activating factor IX, and accelerates the formation of activated factor X from factor X." "" "" ""</seg>
<seg id="1568">All pharmacokinetics studies with ADVATE have been performed pre-treated patients with severe or moderate hemophilia A (base value of factor VIII (2%).</seg>
<seg id="1569">The pharmacokinetic parameters come from a cross-over-study with ADVATE in 100 previously treated patients or &gt; 10 years and are listed in the table below.</seg>
<seg id="1570">Table 3 Summary of the pharmacokinetic parameters of ADVATE with severe to moderate hemophilia A (factor VIII &lt; 2%) PK parameters (Pharmacokinetics)</seg>
<seg id="1571">"" "" "" "non-clinical data, based on studies on security macology, too acute, repeats and local toxicity and to Genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1572">Each pack consists of a tube-like bottle containing powder and water vapour with 5 ml of solvent (both glass type I with chlorobutyl rubber stamps) and a device for reconstitution (BAXJECT II).</seg>
<seg id="1573">"" "" "" "if the product is still stored in the refrigerator, remove both cap and solvents from the refrigerator at room temperature (between 15 and 25 ° C)." "" "" ""</seg>
<seg id="1574">A significant increase in the pulse rate can be reduced by slow or temporarily breaking the injection can be reduced immediately (see sections 4.4 and 4.8).</seg>
<seg id="1575">14 prophylaxis concerning high-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 i.e. by factor VIII per kg of body weight within 2-3 days.</seg>
<seg id="1576">"" "" "" "due to the rare setting of hemophilia A in women, there are no experiences about the application of factor VIII during pregnancy and breastfeeding." "" "" ""</seg>
<seg id="1577">"" "" "" "3 newborn infants (aged 0-1 month), infants (aged 2-12 years), children (at the age of 12-16), adults (over 16 years)" "" "" ""</seg>
<seg id="1578">In clinical trials with ADVATE to 145 children and adults 4 with significant severe to moderate hemophilia A (FVIII &lt; 2%) and prior exposure to factor VIII- concentrates (≥ 150 days) showed a low inhibitors with ADVATE (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1579">"" "" "" "18 As with other intravenous products, ADVATE has been reported on hypersensitivity reactions from allergic type, including anaphylactic / anaphylaktoider reactions (frequency not known)." "" "" ""</seg>
<seg id="1580">Table 3 Summary of the pharmacokinetic parameters of ADVATE with severe to moderate hemophilia A (factor VIII &lt; 2%) PK parameters (Pharmacokinetics)</seg>
<seg id="1581">"" "" "" "non-clinical data, based on studies on security macology, too acute, repeats and local toxicity and to Genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1582">25 prophylaxis concerning high-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 i.e. by factor VIII per kg of body weight within 2-3 days.</seg>
<seg id="1583">5 newborn infants aged 0-1 month); infants (aged 1 to 12 years); children (aged 2-12 years); children (aged 12-16 years); adults (over 16 years)</seg>
<seg id="1584">In clinical trials with ADVATE to 145 children and adults 6 with mild to moderate hemophilia A (FVIII &lt; 2%) and prior exposure to factor VIII- concentrates (≥ 150 days) showed a low inhibitors with ADVATE (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1585">"" "" "" "29 As with other intravenous products, ADVATE has been reported on hypersensitivity reactions from allergic type, including anaphylactic / anaphylaktoider reactions (frequency not known)." "" "" ""</seg>
<seg id="1586">"" "" "" "non-clinical data, based on studies on security macology, too acute, repeats and local toxicity and to Genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1587">36 Prevention for long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 i.e. by factor VIII per kg of body weight within 2-3 days.</seg>
<seg id="1588">"" "" "" "7 newborn infants (ages 0-1 month), infants (aged 2-12 years), children (at the age of 12-16), adults (over 16 years)" "" "" ""</seg>
<seg id="1589">In clinical trials with ADVATE to 145 children and adults 8 with mild to moderate hemophilia A (FVIII &lt; 2%) and prior exposure to factor VIII- concentrates (≥ 150 days) showed a low inhibitors with ADVATE (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1590">"" "" "" "40 As with other intravenous products, ADVATE has been reported on hypersensitivity reactions from allergic type, including anaphylactic / anaphylaktoider reactions (frequency not known)." "" "" ""</seg>
<seg id="1591">"" "" "" "non-clinical data, based on studies on security macology, too acute, repeats and local toxicity and to Genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1592">47 Prevention concerning the long-term prophylactic of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 i.e. by factor VIII per kg of body weight within 2-3 days.</seg>
<seg id="1593">9 babies (aged 0-1 month); infants (aged 1 to 12 years); children (aged 2-12 years); children (aged 12-16 years); adults (over 16 years)</seg>
<seg id="1594">In clinical trials with ADVATE to 145 children and adults 10 with mild to moderate hemophilia A (FVIII &lt; 2%) and prior exposure to factor VIII- concentrates (≥ 150 days) showed a low inhibitors with ADVATE (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1595">"" "" "" "51 As with other intravenous products, ADVATE has been reported on hypersensitivity reactions from allergic type, including anaphylactic / anaphylaktoider reactions (frequency not known)." "" "" ""</seg>
<seg id="1596">"" "" "" "non-clinical data, based on studies on security macology, too acute, repeats and local toxicity and to Genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1597">58 prophylaxis concerning the long-term prophylactic of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 i.e. by factor VIII per kg of body weight within 2-3 days.</seg>
<seg id="1598">11 newborn infants (aged 0-1 month); infants (aged 2-12 years); children (aged 2-12 years); children (aged 12-16 years); adults (over 16 years)</seg>
<seg id="1599">In clinical trials with ADVATE to 145 children and adults 12 with mild to moderate hemophilia A (FVIII &lt; 2%) and prior exposure to factor VIII- concentrates (≥ 150 days) showed a low inhibitors with ADVATE (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1600">62 As with other intravenous products have been reported in ADVATE about hypersensitivity reactions from allergic type, including anaphylactic / anaphylaktoider reactions (frequency not known).</seg>
<seg id="1601">"" "" "" "non-clinical data, based on studies on security macology, too acute, repeats and local toxicity and to Genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1602">"" "" "" "" "" "" "" "the approval process has to ensure a pharmaceutical covigilance system, as described in paragraph 1.1 of the RID 1.8.1 of pharmaceutical approval, and that this system remains in the market during the entire period of time in which the product remains in force." "" "" ""</seg>
<seg id="1603">"" "" "" "as specified in the CHMP Directive on the risk management plan for human medicine, these updates should be submitted at the same time with the next periodic safety update Report (PSUR)." "" "" ""</seg>
<seg id="1604">"" "" "" "• If new information is available, the influence on the valid safety guidelines, the pharmaceutical covigilance plan or the measures for risk minimizing might have become an important event within 60 days of an important event (regarding the risk minimization)" "" "" ""</seg>
<seg id="1605">1 endix bottle containing ADVATE 500 i.e Octocog alfa, 1 hole tube with 5 ml sterilised water for injections, 1 BAXJECT II medical device.</seg>
<seg id="1606">1 endix bottle containing ADVATE 1000 i.e Octocog alfa, 1 hole tube with 5 ml sterilised water for injections; 1 BAXJECT II medical device</seg>
<seg id="1607">"" "" "" "special caution when applying ADVATE is required to notify your doctor if you recently have been treated with factor VIII products, especially when you have developed inhibitors." "" "" ""</seg>
<seg id="1608">"" "" "" "these symptoms can be an early sign of anaphylaktic shocks which can additionally include the following symptoms: extreme vertigo, awareness of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1609">"" "" "" "when taking other medicines please inform your doctor if you have taken other medicines or have recently taken, even if it is not prescription drugs." "" "" ""</seg>
<seg id="1610">Your doctor will calculate your dose of ADVATE (in international units or i.e.) depending on your body weight and body weight and whether it is used for the prevention or treatment of bleeding.</seg>
<seg id="1611">"" "" "" "patients who are able to develop factor VIII in your plasma using ADVATE, or bleeding may not be governed by the expected factor VIII-" "" "" ""</seg>
<seg id="1612">"" "" "" "in conjunction with Operation catheter infections, lower number of red blood cells, swelling of limbs and joints, extended bleeding after removal of drainage, diminished factor VIII and postoperative hematoma." "" "" ""</seg>
<seg id="1613">Rare side effects since the introduction of drug on the market has been awarded heavy and potentially life-threatening reactions (Anaphylaia) and other allergic reactions (see above).</seg>
<seg id="1614">Inform your doctor if one of the listed side effects will significantly affect you or if you notice side effects that are not listed in this package.</seg>
<seg id="1615">Portugal Baxter Médico Farmacêutica LDA Sintra Business Park Zona Industrial da Abrunhera, Edifício 10 P-2710-089 Sintra Tel: + 351 21 925 25 00</seg>
<seg id="1616">"" "" "" "clues to the production of the solution • Do not use the expiration date, unless its sterile barrier is broken up, its packaging is damaged or signs of manipulation, as in the symbol" "" "" ""</seg>
<seg id="1617">"" "" "" "important note: • Don't be able to say before you receive the special training from your doctor or nurse. • Before you check the product on pig iron or discolouration." "" "" ""</seg>
<seg id="1618">"" "" "" "the solution should slowly occur with an infusion speed, which is negligible to the patient and will not exceed 10 ml per minute." "" "" ""</seg>
<seg id="1619">106 "" "" "" "106 In the case of blood cells, the factor VIII, within the corresponding period of time, should not fall under the specified plasma activity (in% or in meaning / ml)." "" "" ""</seg>
<seg id="1620">"" "" "" "these symptoms can be an early sign of anaphylaktic shocks which can additionally include the following symptoms: extreme vertigo, awareness of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1621">"" "" "" "patients who are able to develop factor VIII in your plasma using ADVATE, or bleeding may not be governed by the expected factor VIII-" "" "" ""</seg>
<seg id="1622">"" "" "" "occasional side effects Juckching, Increasing sweating, indignation, diarrhea, diarrhea, nausea, vomiting, inflammations, inflammations, skin inflammations, skin eruptions, extreme sweating," "" "" ""</seg>
<seg id="1623">"" "" "" "116 In the case of blood cells, the factor VIII, within the corresponding period of time, should not fall under the specified plasma activity (in% or in meaning / ml)." "" "" ""</seg>
<seg id="1624">"" "" "" "these symptoms can be an early sign of anaphylaktic shocks which can additionally include the following symptoms: extreme vertigo, awareness of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1625">"" "" "" "patients who are able to develop factor VIII in your plasma using ADVATE, or bleeding may not be governed by the expected factor VIII-" "" "" ""</seg>
<seg id="1626">126 In case of blood conditions the factor VIII mirror should not fall within the corresponding period under the specified plasma activity (in% or in meaning / ml).</seg>
<seg id="1627">"" "" "" "these symptoms can be an early sign of anaphylaktic shocks which can additionally include the following symptoms: extreme vertigo, awareness of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1628">"" "" "" "patients who are able to develop factor VIII in your plasma using ADVATE, or bleeding may not be governed by the expected factor VIII-" "" "" ""</seg>
<seg id="1629">"" "" "" "136 In case of blood conditions, the factor VIII mirror should not fall within the corresponding period under the specified plasma activity (in% or i.e., i.e. / ml)." "" "" ""</seg>
<seg id="1630">"" "" "" "these symptoms can be an early sign of anaphylaktic shocks which can additionally include the following symptoms: extreme vertigo, awareness of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1631">"" "" "" "patients who are able to develop factor VIII in your plasma using ADVATE, or bleeding may not be governed by the expected factor VIII-" "" "" ""</seg>
<seg id="1632">"" "" "" "146 In the case of blood cells, the factor VIII (in the corresponding period of time) should not fall under the specified plasma activity (in% or i.e., i.e. / ml)." "" "" ""</seg>
<seg id="1633">"" "" "" "these symptoms can be an early sign of anaphylaktic shocks which can additionally include the following symptoms: extreme vertigo, awareness of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1634">"" "" "" "patients who are able to develop factor VIII in your plasma using ADVATE, or bleeding may not be governed by the expected factor VIII-" "" "" ""</seg>
<seg id="1635">"" "" "" "occasional side effects Juckching, Increasing sweating, indignation, diarrhea, diarrhea, nausea, vomiting, inflammations, inflammations, skin inflammations, skin eruptions, extreme sweating," "" "" ""</seg>
<seg id="1636">Rare side effects since the introduction of drug on the market has been awarded heavy and potentially life-threatening reactions (Anaphylaia) and other allergic reactions (see above).</seg>
<seg id="1637">"" "" "" "156 In the case of blood cells, the factor VIII in the corresponding period should not fall under the specified plasma activity (in% or i.e., i.e. / ml)." "" "" ""</seg>
<seg id="1638">"" "" "" "based on the data available since the first approval of the CHMP, CHMP has further evaluated the benefit-risk assessment as positive but in consideration that the safety profile must be closely monitored by the following reasons:" "" "" ""</seg>
<seg id="1639">"" "" "" "therefore, the CHMP needs on the basis of the security profile of ADVATE, which makes a filing of PSURs every 6 months, decided that the authorisation holder should apply for another renewal procedure in 5 years." "" "" ""</seg>
<seg id="1640">"" "" "" "in December 2008, Gendux Molecular Limited adopted the Committee for Human Use (CHMP), that the company accepts his application for the treatment of Li-Fraumeni cancer." "" "" ""</seg>
<seg id="1641">"" "" "" "however, normally the breast, the brain, bone or body parts (tissue, which combines other structures in the body, surrounds and supports) of it." "" "" ""</seg>
<seg id="1642">"" "" "" "this is a kind of virus, the genetically modified that it can wear a gene into the cells of the body." "" "" ""</seg>
<seg id="1643">"" "" "" "in Advocin, the virus is a" Adenovirus "which was so modified that there are no copies of itself and therefore no infections can trigger the human." "" "" ""</seg>
<seg id="1644">"" "" "" "Advocin could have injected directly into the tumors and thus enable the cancer cells to form the normal p53 protein." "" "" ""</seg>
<seg id="1645">"" "" "" "the p53 protein, which is made from the defect in the human body existing p53 gene, is usually used to restore corrupt DNA and to kill the cells when the DNA cannot be recovered." "" "" ""</seg>
<seg id="1646">"" "" "" "at Li-Fraumeni cancer, the p53 protein doesn't work properly, and the cancer cells continue to grow and share." "" "" ""</seg>
<seg id="1647">"" "" "" "the company presented data from a study involving a patient prior to the Li-Fraumeni cancer, in the bone and in the brain." "" "" ""</seg>
<seg id="1648">"" "" "" "after the CHMP has examined the answers by the company, questions were still unsolved." "" "" ""</seg>
<seg id="1649">"" "" "" "based on the examination of the initial documents, the CHMP grants a list of questions that will be sent to the company." "" "" ""</seg>
<seg id="1650">"" "" "" "according to CHMP, the injection of Advantin has been documented in Li-Fraumeni-Tumors benefits for the patient." "" "" ""</seg>
<seg id="1651">"" "" "" "furthermore, the committee had concerns regarding the processing of medication in the body, the type of appointments as well as the safety of medication." "" "" ""</seg>
<seg id="1652">"" "" "" "in addition, the company was not sufficiently proven that Advocin can be produced in a reliable manner and that there is neither for the environment nor for people who come in touch with the patient which is harmful." "" "" ""</seg>
<seg id="1653">"" "" "" "the company was not aware of the CHMP, whether the withdrawal of the patient has been involved in clinical trials or" Compassionate-Use "programs with Advexin." "" "" ""</seg>
<seg id="1654">"changed mode of action" means that the tablets are so composed of that the effective components are immediately released and the other slowly released over a few hours.</seg>
<seg id="1655">Aerinaze is used to treat symptoms of seasonally allergic rhinitis (hay fever) caused by an allergy against pollen (nasal membranes) in patients with rhincantile vibration (clogged nose).</seg>
<seg id="1656">"" "" "" "in adults and youths over 12 years, the recommended dose of Aerinaze is twice daily with a glass of water with or without food." "" "" ""</seg>
<seg id="1657">"" "" "" "the duration of treatment should be as short as possible and end as soon as the symptoms, especially the swelling of the nose smucosa (clogged nose), are cloned." "" "" ""</seg>
<seg id="1658">"" "" "" "a treatment duration of more than 10 days is not recommended, because the effects of the medication can be impaired with the constipation of the nose." "" "" ""</seg>
<seg id="1659">"" "" "" "the main dimensions were the changes of gravity of the fever blister symptoms, which were reported from the patients prior to treatment and during the 15-day treatment." "" "" ""</seg>
<seg id="1660">"" "" "" "during the study, patients carried out their symptoms every 12 hours a journal and rated with a standard scale, how difficult the symptoms were in the last 12 hours." "" "" ""</seg>
<seg id="1661">"" "" "" "upon consideration of all hypocrisy symptoms except the constipation of the nose reported the patients, the aerobaze reported, on a decrease in the symptoms of 46.0% compared with 35.9% compared to patients receiving pseudoephedrine alone." "" "" ""</seg>
<seg id="1662">"" "" "" "if only the swelling of the rsmucosa was considered, patients suffering from aerobaze showed a relieving of the symptoms by 37.4% compared to 26.7% in patients suffering from the disintegrate." "" "" ""</seg>
<seg id="1663">The most common side effects of aerobaze (observe at 1 to 10 of 100 patients) are speediness (heart chase), stipiness, psychomotor, psychomotor (sleeplessness), somnolence (sleeplessness), somnolence and nervousness.</seg>
<seg id="1664">"" "" "" "Aerinaze is allowed to be sensitive to patients who possibly are oversensitive (allergic) against desloratadin, pseudoephedrine or any of the other components, against adrendoephedrine or any other medicines for allergies) are not applied." "" "" ""</seg>
<seg id="1665">"" "" "" "Aerinaze may also not suffer from patients who suffer from a stroke of pressure (hypertension), cardiac or vascular diseases (hypertension) or hyperthyroid (hypertension) or a hemorrhage stroke (hypertension) or a risk of hemorrhage stroke." "" "" ""</seg>
<seg id="1666">"" "" "" "on 30 July 2007, the European Commission approved the SP Europe Commission for approval for the transport of Aerinaze throughout the European Union." "" "" ""</seg>
<seg id="1667">"" "" "" "the tablet may be taken with a glass of water, but should swallow in the whole (i.e. without biting, break or chewing)." "" "" ""</seg>
<seg id="1668">Aerinaze should not be applied to children under 12 years due to the lack of data for impemability and efficacy (see Section 5.1).</seg>
<seg id="1669">"" "" "" "the duration of the application is as short as possible, and should not be continued after closing of the symptoms." "" "" ""</seg>
<seg id="1670">"" "" "" "it is recommended to limit the application time to 10 days, since long-term application can take the activity of pseudoephedrine with time." "" "" ""</seg>
<seg id="1671">"" "" "" "after a decrease in the swelling of the mucous membranes in the upper respiratory system, the treatment can be continued with desloratadin as monotherapy." "" "" ""</seg>
<seg id="1672">"" "" "" "as an aerobaze contains pseudoephedrine, the medicine is also contraindicated in patients who are treated with a monoamoxidase (MAO) inhibitors or within 2 weeks following completion of such therapy." "" "" ""</seg>
<seg id="1673">"" "" "" "this is due to the alphamimetic activity in combinated application of pseudoephedrine, pergol, lull or nasal as abyss of Rhinocets (phenylpropanolamin, phenylephrine, ephedrine, oxidation, etc.)." "" "" ""</seg>
<seg id="1674">"" "" "" "the safety and efficacy of these combination therapy were not checked for this patient group, and the data are not sufficient to address appropriate recommendations." "" "" ""</seg>
<seg id="1675">"" "" "" "the safety and efficacy of aerobaze were not checked in patients with kidney or liver interference, and the data are not sufficient to address appropriate recommendations." "" "" ""</seg>
<seg id="1676">"" "" "" "patients need to be informed about the treatment of the treatment of hypertonia or a tachycartridge, cardiac arrhythmia, nausea, or any other neurological symptoms (such as headaches or a gain of headache)." "" "" ""</seg>
<seg id="1677">Patients suffering from the following patient groups are advised to beware: • Patients with cardiac arrhythmic problems • Patients with a myocardial infarction in the Anamnese (diabetes mellitus) or bronchospasmus in the Anamnese.</seg>
<seg id="1678">"" "" "" "Aerinaze, at least 48 hours before performing dermatologic tests, as antihistamines otherwise can prevent positive reactions on indicators for skin reactions or reduce their extent." "" "" ""</seg>
<seg id="1679">"" "" "" "in the context of clinical trials with desloratadin, in which Erythromycin or ketoconazole were additionally given, however, no clinically relevant alternating or alterations of the plasma concentration of desloratadine were observed." "" "" ""</seg>
<seg id="1680">"" "" "" "the results of psychomotor testing were detected no significant differences between the patients' discereal patients and the placebo-treated patients, regardless of whether the procesatadine alone or with alcohol was taken." "" "" ""</seg>
<seg id="1681">"" "" "" "the enzyme responsible for the metabolism has not been identified, so that interactions with other medicines cannot be excluded entirely." "" "" ""</seg>
<seg id="1682">"" "" "" "in vivo CYP3A4 does not inhibit, and in-vitro studies that the drug CYP2D6 does not inhibits and neither a substrate nor a inhibitor of the P glycoproteins)." "" "" ""</seg>
<seg id="1683">"" "" "" "the inconsistency of the application of Aerinaze during pregnancy is not secured, but gained from a large number of affected pregnancies however no increase in frequency of abnormalities compared with the normal population." "" "" ""</seg>
<seg id="1684">"" "" "" "since recurring studies on animals are not always transferred to humans, due to the vasoconstrictor characteristics of pseudoephedrine, aerobaze should not be used in pregnancy." "" "" ""</seg>
<seg id="1685">"" "" "" "however, patients should be clarified that in very rare cases it may come to a benefit of the transport capability or the ability to serve machinery." "" "" ""</seg>
<seg id="1686">"" "" "" "the symptoms may vary between a CNS depression (sedation, apnee, reduced mental attention, cyanosis, coma, cardiovascular disease, treach, concvulsions) with possible leaps." "" "" ""</seg>
<seg id="1687">"" "" "" "headaches, anxiety, kill miction, muscle weakness, nausea, vomiting, breathing, nausea, vomiting, precordious pain, vertigo, tattaches, dysfunctions, hypertonia or hypotonia." "" "" ""</seg>
<seg id="1688">"" "" "" "a CNS stimulation is particularly likely with children, as well as Atropin typical symptoms (mouth dryers, pupil rigid and dileatation, skin consolation, hyperthermia, gastrointestinal symptoms)." "" "" ""</seg>
<seg id="1689">They include both the inhibition of inflammatory cytokines such as IL-4, IL-6, IL-8 and IL-13 from human mastine cells / basophiles as well as the inhibiting of the expression of the blood cells P-selectin in endothelial cells.</seg>
<seg id="1690">"" "" "" "in a single dose study with adults, Desloratadin 5 mg showed no effect on standard measurement values of the fluctuation including the reinforcement of subjective injuries and tasks that are connected with the flies." "" "" ""</seg>
<seg id="1691">"" "" "" "in controlled clinical trials, at the recommended dose of 5 mg a day no increased incidence of drowsiness was found compared to placebo." "" "" ""</seg>
<seg id="1692">The oral application of pseudoephedrine in the recommended dosage can cause additional likomimetic effects such as an increase in blood pressure or tachycartridge or manifestations of a ZNS arousal.</seg>
<seg id="1693">"" "" "" "1,248 patients participated in the age between 12 and 78 years with seasonal allergic rhinitis, with 414 patients with Aerinaze tablets." "" "" ""</seg>
<seg id="1694">"" "" "" "in both studies the histamine efficacy of Aerinaze tablets, determined based on the overall score for the symptom (except nose smucosal swelling), was significantly higher than under a monotherapy with pseudoephedrine above the 2-week treatment period." "" "" ""</seg>
<seg id="1695">"" "" "" "the effectiveness of Aerinaze tablets in terms of the detecting effect, determined based on the nose-mucosal swelling, was significantly higher than under a monotherapyadin over the 2-week treatment time." "" "" ""</seg>
<seg id="1696">"" "" "" "the effectiveness of Aerinaze tablets showed no significant differences in terms of sex, age or ethnic origin." "" "" ""</seg>
<seg id="1697">"" "" "" "within a single dose study for pharmacokinetics of aerobaze, Desloratadin is verifiable within 30 minutes after administration in the plasma." "" "" ""</seg>
<seg id="1698">"" "" "" "following the peroral application of Aerinaze at healthy subjects over 14 days, the flow weight of the lorries was reached in 3-hydroxydesloratadin and pseudoephedrine in day 10." "" "" ""</seg>
<seg id="1699">"" "" "" "as part of a pharmacokinetic multi-dosiscence study conducted with the formulation as a tablet to healthy adult subjects, four subjects of desloratadine was found badly." "" "" ""</seg>
<seg id="1700">A component interaction study shows that exposure (Cmax and AUC) by pseudoephedrine is as the sole gift of pseudoephedrine bioequivalent to the gift of an Aerinaze tablet.</seg>
<seg id="1701">"" "" "" "based on conventional studies on security macology, for toxicity in repeated administration, to gene otoxicity and reproduction of reproduction, genetic data may be recognized with desloratadin." "" "" ""</seg>
<seg id="1702">"" "" "" "the combination had no greater toxicity than its individual components, and the observed effects were generally related to the compound of pseudoephedrine." "" "" ""</seg>
<seg id="1703">The combination of Loratadin / pseudoephedrine was the combination of rinsulin / pseudoephedrine in a dose of up to 150 mg / kg / day and is not teratogenic in a dose of up to 120 mg / kg / day.</seg>
<seg id="1704">"" "" "" "March 2007 and in Module 1.8.1 of the approval process, the pharmaceutical covigilance system is established and works before and while the product is on the market." "" "" ""</seg>
<seg id="1705">"" "" "" "antihistamines contribute to the relief of allergic symptoms by preventing histamine, a substance that can unfold its effect." "" "" ""</seg>
<seg id="1706">"" "" "" "Aerinaze tablets left symptoms that occur in connection with seasonal allergic rhinitis (hay fever), like nighes, striving or juckling eyes, while constipation, constipation of the nose." "" "" ""</seg>
<seg id="1707">"" "" "" "20 In certain circumstances, you can be particularly sensitive to the mucosa drug pivedephedrine, which is contained in this medicine." "" "" ""</seg>
<seg id="1708">"" "" "" "(diabetes), a stenogenous stomach ulcer, a clasp of stomach bleeding or the dusty intestine (intestines), a blister clasp, bronchospasch in the patient's history, a prostate enlargement or problems with the liver, kidneys or bladder." "" "" ""</seg>
<seg id="1709">"" "" "" "notify your doctor if you occur under the use of Aerinaze symptoms or diseases or are diagnosed: • hypertension • Heart chase, cardiac problems • nausea and headache or a reinforcement of existing headaches." "" "" ""</seg>
<seg id="1710">"" "" "" "when taking Aerinaze with other medicines please inform your doctor or pharmacist if you have taken other medicines or recently taken, even if it is not prescription drugs." "" "" ""</seg>
<seg id="1711">"" "" "" "machines In the recommended dosage and use of machines In the recommended dosage, it is not possible to calculate that aerobaze leads to dizziness or put down attention." "" "" ""</seg>
<seg id="1712">"" "" "" "if you have taken a larger amount of Aerinaze, as you should Inform your doctor or pharmacist immediately when you should have taken a larger amount of Aerinaze as you should." "" "" ""</seg>
<seg id="1713">"" "" "" "if you forget the intake of Aerinaze if you forgot to take a dose in time, get the application as soon as possible and apply the next dose at the intended time." "" "" ""</seg>
<seg id="1714">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will be significantly impaired or you will notice any side effects that are not listed in this manner." "" "" ""</seg>
<seg id="1715">"" "" "" "cardiac chase, restlessness with increased physical activity, mouth drunkiness, constipation, sugar in urine, increased blood sugar, thirst, headaches, nervousness, nervousness and dizziness." "" "" ""</seg>
<seg id="1716">"" "" "" "cardiac pain, skin-inflammatory, nausea, bowel movements, nausea, bleeding, nasal-inflammations, nausea, bowel movements, nausea, bleeding, nasal sinking, nausea, bleeding, nasal sinking, troublestion, anxiety, anxiety, anxiety, irritability, irritability, anxiety and irritability." "" "" ""</seg>
<seg id="1717">"" "" "" "after the launch of Desloratadin it has been reported very rarely about cases of severe allergic reactions (respiratory emergency, itching, itching or swelling) or skin rash." "" "" ""</seg>
<seg id="1718">"" "" "" "about cases of heart palpitations, cardiac pain, nausea, vomiting, stomach pain, diarrhoea, hallucinations, muscle pain, diarrhoea, hallucinations, diarrhoea, hallucinations etc." "" "" ""</seg>
<seg id="1719">It is available as 5 mg tablets or 5 mg- lyophilisat (tablets that dissolve in the mouth), 0.5 mg / ml syrup and as 0,5 mg / ml solution.</seg>
<seg id="1720">"" "" "" "for children aged one to five years, the dose is 1.25 mg once a day, which in the form of 2.5 ml syrup or bzw." "" "" ""</seg>
<seg id="1721">"" "" "" "for children aged six to eleven years, the dose is 2.5 mg once a day, either in the form of 5 ml syrup or bzw." "" "" ""</seg>
<seg id="1722">"" "" "" "Aerius was examined in eight studies involving roughly 4 800 adults and adolescents with allergic rhinitis (among them four studies of seasonal allergic rhinitis, and two trials of patients who also had asthma)." "" "" ""</seg>
<seg id="1723">"" "" "" "the efficacy was measured by the change of symptoms (itching, number and size of torches, impairment of sleep and efficiency in days) before and after six weeks treatment was determined." "" "" ""</seg>
<seg id="1724">"" "" "" "further studies were presented to prove that the body evaluates the syrup, the solution to remove and the melting tablets in the same manner as the tablets and the application of children is harmless." "" "" ""</seg>
<seg id="1725">"" "" "" "in allergic rhinitis, when the results of all trials were taken together, the two-week treatment with 5 mg of Aerius were obtained by 25 to 32%, compared with the decrease of 12 to 26% in patients receiving a placebo." "" "" ""</seg>
<seg id="1726">"" "" "" "in the two trials in Urtikaria, the decline of symptoms after six weeks of treatment with Aerius 58 and 67% compared with 40 and 33% compared with placebo-treated patients." "" "" ""</seg>
<seg id="1727">"" "" "" "Aerius may not be applied to patients who possibly have excessive (allergic) against desloratadin, lauatadin or any of the other ingredients." "" "" ""</seg>
<seg id="1728">"" "" "" "in January 2001, the European Commission granted the SP Europe corporation to approve an approval of the establishment of Aerius throughout the European Union." "" "" ""</seg>
<seg id="1729">"" "" "" "one tablet once daily, with one or without a meal, to alleviate symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see section 5.1)." "" "" ""</seg>
<seg id="1730">"" "" "" "there are limited experiences from clinical trials for efficacy in the use of desloratadine for young people from 12 to 17 years (see sections 4.8 and 5.1)." "" "" ""</seg>
<seg id="1731">"" "" "" "treatment of intermittent allergic rhinitis (occurrence of symptoms for less than 4 days per week or less than 4 weeks) should be performed according to the previous disease, and can be resumed in subsequent corrections." "" "" ""</seg>
<seg id="1732">"" "" "" "in the persistent allergic rhinitis (occurrence of symptoms at 4 or more days per week and more than 4 weeks), patients may be recommended during the allergy time." "" "" ""</seg>
<seg id="1733">Clinically relevant interactions were not detected in the context of clinical trials involving Desclatadin tablets in which Erythromycin or ketoconazole were administered in addition (see Section 5.1).</seg>
<seg id="1734">"" "" "" "in a clinical pharmacological study, intoxication of Aerius and alcohol was not increasingly reinforced by alcohol (see Section 5.1)." "" "" ""</seg>
<seg id="1735">"" "" "" "however, patients should be clarified that in very rare cases it may come to benefit the transport capability or the ability to serve machinery." "" "" ""</seg>
<seg id="1736">"" "" "" "clinical trials in various indications, including allergic rhinitis and chronically idiopathic matikaria, were reported daily 3% more side effects in patients with Aerius when patients who were treated with placebo." "" "" ""</seg>
<seg id="1737">"" "" "" "the most commonly used side effects, more than common in placebo, were fatigue (1,2%), mouth-dryer (0.6%) and headaches (0.6%)." "" "" ""</seg>
<seg id="1738">"" "" "" "with a clinical study involving 578 youthful patients from 12 to 17 years, the most common adverse effect of patients having been treated with desloratadine and 6.9% of patients who were treated with placebo." "" "" ""</seg>
<seg id="1739">"" "" "" "in a multi-dose study, administered up to 45 mg of Desloratadin (Neunfold clinical dose), no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1740">This includes both the inhibiting of proinflammatory cytokines such as IL-4, IL-6, IL-8 and IL-13 from human mastine cells / basophiles as well as the inhibiting of the expression of the blood cells P-selectin in endothelial cells.</seg>
<seg id="1741">"" "" "" "in the context of a clinical study involving multiple agents, administered in the desloratadin in a dose of up to 20 mg daily over 14 days, no statistically significant or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1742">"" "" "" "in a clinical pharmacological study, in the desloratadin in a dose of 45 mg daily (the Neunfold of the clinical dose) has been administered for ten days, no extension of the QTc interval." "" "" ""</seg>
<seg id="1743">"" "" "" "in a single dosis- study with adults, Desloratadin 5 mg showed no effect on standard measurement values of the fluctuation including the reinforcement of subjective injuries and tasks that are connected with the flies." "" "" ""</seg>
<seg id="1744">"" "" "" "in patients with allergic rhinitis, Aerius was effective in relieving symptoms such as nifying, nose secretion and itching of the nose, itching, tear and redness of the eyes and itching on the palate." "" "" ""</seg>
<seg id="1745">"" "" "" "in addition to the established classification in seasonal and perennial, allergic rhinitis may be divided into intermittent allergic rhinitis and perennial allergic to allergic symptoms." "" "" ""</seg>
<seg id="1746">Intermittent allergic rhinitis is defined as the occurrence of symptoms for less than 4 days a week or less than 4 weeks.</seg>
<seg id="1747">"" "" "" "Persian allergic rhinitis is defined as the appearance of symptoms of 4 or more days a week, and more than 4 weeks." "" "" ""</seg>
<seg id="1748">"" "" "" "as with the overall score of quality of life in Rhino-conjunctivitis, Aerius effectively reduces those caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1749">"" "" "" "the chronically idiopathic matikaria was investigated for further forms of primitive ideology, since the underlying pathophysiology of various forms is similar to chronic patients and easier prospectively." "" "" ""</seg>
<seg id="1750">"" "" "" "as the histamine is a causal factor in all ancestral diseases, it is expected that Desloratadin is also confirmed in other forms of Urtikaria to improve the symptoms; this is confirmed by the recommendations of clinical guidelines." "" "" ""</seg>
<seg id="1751">"" "" "" "in two placebo-controlled trials over 6 weeks in patients with chronic idiopathic matikaria, Aerius was effective in improving the size and number of paddles at the end of the first dose intervals." "" "" ""</seg>
<seg id="1752">"" "" "" "like in other studies with antihistamines in chronic idiopathic matikaria, the minority of patients who did not react to antihistamines from the study." "" "" ""</seg>
<seg id="1753">"" "" "" "an improvement in the vertical resistance of more than 50% was observed at 55% of the treated patients, compared to 19% of patients treated with placebo-treated patients." "" "" ""</seg>
<seg id="1754">"" "" "" "the treatment with Aerius reduced the disturbance of sleep and wax importantly, as measured by a 4-point scale on evaluation of these variables." "" "" ""</seg>
<seg id="1755">"" "" "" "in a pharmacokinetic study, in which the patients demoographics were comparable with the general seasonal allergic rhinitis population, in 4% of patients a higher concentration of desloratadine was achieved." "" "" ""</seg>
<seg id="1756">There are no clues for a clinically relevant cumulation after a daily use of desloratadin (5- 20 mg) over 14 days.</seg>
<seg id="1757">"" "" "" "however, the enzyme responsible for metabolites was not yet identified, so that interactions with other medicines cannot be excluded entirely." "" "" ""</seg>
<seg id="1758">"" "" "" "Desloratadin inhibits CYP3A4 and in-vitro studies, that the drug CYP2D6 does not inhibits and neither a substrate nor a inhibitor of the P glycoproteins)." "" "" ""</seg>
<seg id="1759">"" "" "" "in a single dosing study with desloratadin in an dosage of 7.5 mg, meals (fatty food and calorie-rich breakfast) does not apply to the availability of desloratadin." "" "" ""</seg>
<seg id="1760">"" "" "" "the clinical studies carried out with desloratadin and Loratadin performed in a comparable degree of exposure of desloratadin, no qualitative or quantitative differences in the toxicity of desloratadin and Loratadin." "" "" ""</seg>
<seg id="1761">"" "" "" "based on conventional studies on Safety Pharmacology, Toxicity at repeating gift, Genotoxicity and Reproductive data to detect no particular dangers for human beings." "" "" ""</seg>
<seg id="1762">"" "" "" "coloured film (contains lactose-Monohydrat, hyprowless, titanium dioxide, Macrogocarmin (E 132)), colourless film (contains Hyprowless, Macrogol 400), carnauba wax, light wax." "" "" ""</seg>
<seg id="1763">"" "" "" "Aerius can be taken regardless of meals, to alleviate symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see section 5.1)." "" "" ""</seg>
<seg id="1764">"" "" "" "the prescription doctor should be aware that most cases of rhinitis in children under 2 years of age can be caused by an infection (see under Section 4.4) and that no data is received, which support treatment of a infective rhinitis with Aerius." "" "" ""</seg>
<seg id="1765">"" "" "" "in addition to the exclusion of upper respiratory infections or anatomical anomalies, the diagnosis of anamnesis, physical investigations and related laboratory and skin studies should play a role." "" "" ""</seg>
<seg id="1766">About 6% of adults and children between 2 and 11 years of metabolic deslorries are reduced and experienced a higher subsection load (see section 5.2).</seg>
<seg id="1767">"" "" "" "the safety of Aerius Sirup in children between 2 and 11 years, which are limited to metabolic, is identical to children that are normal to metabolic." "" "" ""</seg>
<seg id="1768">"" "" "" "this medicine contains saccharose and sorbitol; therefore, patients with hereditary problems should not take care of fructose intoleration or saccharase isomaltase- insufficiency of this medicine." "" "" ""</seg>
<seg id="1769">Clinically relevant interactions were not detected in the clinical trials involving Aerius tablets in which Erythromycin or ketoconazole were administered in addition (see Section 5.1).</seg>
<seg id="1770">"" "" "" "in a clinical pharmacological study, intoxication of Aerius tablets and alcohol did not amplify the beneficial effects of alcohol (see Section 5.1)." "" "" ""</seg>
<seg id="1771">"" "" "" "the total ruthness of the side effects in children between 2 and 11 years was similar to the Aerius Sirup Group, similar to the placebo group." "" "" ""</seg>
<seg id="1772">"" "" "" "clinical trials involving adults and adolescents in various indications, including allergic rhinitis and chronically idiopathic matikaria, were reported in the recommended dose 3% more side effects in patients with Aerius when patients treated with placebo." "" "" ""</seg>
<seg id="1773">"" "" "" "in a multi-dose study of adults and youth, administered up to 45 mg of Desloratadin (Neunfold clinical dose), no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1774">"" "" "" "children aged between 1 and 11, who came into question for an antihistamine therapy, received a daily disintegrate dose of 1.25 mg (aged between 1 and 5 years) or 2.5 mg (aged between 6 and 11 years)." "" "" ""</seg>
<seg id="1775">Because the course of allergic rhinitis / chronic idiopathic matikaria and the profile of desloratadine in adults and children can be extrapolated to the children's population.</seg>
<seg id="1776">"" "" "" "as part of a clinical study involving multiple agents of adults and youths, in the desloratadine in a dose of up to 20 mg daily, no statistically significant or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1777">"" "" "" "in a clinical pharmacological study enrolled in adults and adolescents, in a dose of 45 mg daily (the Neunfold of the clinical dose) has been applied for ten days in adults, no extension of the QTc interval." "" "" ""</seg>
<seg id="1778">"" "" "" "in controlled clinical studies the recommended dose of 5 mg daily for adults and adolescents, no increased incidence of drowsiness compared to placebo." "" "" ""</seg>
<seg id="1779">"" "" "" "with an individual daily dose of 7,5 mg Aerius tablets in adults and juveniles in clinical trials have no impairment of psychomotor." "" "" ""</seg>
<seg id="1780">"" "" "" "in clinically-pharmacological studies, it was caused by the simultaneous taking of alcohol to an increase of alcohol-induced effectiveness." "" "" ""</seg>
<seg id="1781">"" "" "" "in adult and adolescent patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as Niesen, nasal secretion and itching of the nose, itching and redness of the eyes and itching on the palate." "" "" ""</seg>
<seg id="1782">"" "" "" "as with the overall score of quality of life in Rhino-conjunctivitis, Aerius tablets effectively produce those caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1783">"" "" "" "in two placebo-controlled trials over 6 weeks in patients with chronic idiopathic matikaria, Aerius was effective in improving the size and number of paddles at the end of the first dose intervals." "" "" ""</seg>
<seg id="1784">The spread of this limited metabolic phenotype was comparable in adults (6%) and children between 2 and 11 years (6% adults and 16% children) than in Caucasia (2% adults and 3% children).</seg>
<seg id="1785">"" "" "" "similar pharmacokinetic parameters were observed in a pharmacokinetic multi-dose study of children between 2 and 11 years with allergic rhinitis, which are limited." "" "" ""</seg>
<seg id="1786">"" "" "" "the load (AUC) caused by Desloratadin was approximately 6 to 6 hours approximately 6 times higher, and the Cmax. 3 to 4times higher with a terminal half-time of about 120 hours." "" "" ""</seg>
<seg id="1787">"" "" "" "there are no clues for a clinically relevant drug cumulation after once daily use of desloratadin (5- 20 mg) over 14 days in adults and youth." "" "" ""</seg>
<seg id="1788">"" "" "" "12 In different individual dose studies, AUC- and Cmax-values of desloratadine in pediatric patients were comparable with those of adults who received the deserhoatadin syrup in a dose of 5 mg." "" "" ""</seg>
<seg id="1789">"" "" "" "however, the enzyme responsible for metabolites was not yet identified, so that interactions with other medicines cannot be excluded entirely." "" "" ""</seg>
<seg id="1790">"" "" "" "Aerius Sirup is offered in type III plastic bottles with child-safe Polypropylene cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1791">"" "" "" "equipped with a rigid, transparent polystyrene measuring spoon, calibrated with 2.5 ml and 5 ml or with a application spection for insertion from 2.5 ml and 5 ml (only for 150 ml bottle)." "" "" ""</seg>
<seg id="1792">A dose of Aerius Lyophilisat to insert once daily in the mouth to alleviate symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see section 5.1).</seg>
<seg id="1793">"" "" "" "immediately before the application, the blister should be carefully opened and the dose of lyophikers can be removed without damaging them." "" "" ""</seg>
<seg id="1794">Clinically relevant interactions were not determined under clinical trials involving Aerius tablets in which Erythromycin or ketoconazole were also applied (see section 5.1).</seg>
<seg id="1795">"" "" "" "clinical trials in various indications, including allergic rhinitis and chronically idiopathic matikaria, were reported daily 3% more side effects in patients with Aerius tablets, when patients treated with placebo." "" "" ""</seg>
<seg id="1796">"" "" "" "in a multi-dose study, which were applied up to 45 mg of Desloratadin (Neunfold clinical dose), no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1797">"" "" "" "in two single dose studies, Aerius Lyophilisat became well tolerated; this was documented by clinical laboratory results, medical surveys and ECG intervals." "" "" ""</seg>
<seg id="1798">"" "" "" "in the context of a clinical study involving multiple agents, in which Desloratadin has been applied in a dose of up to 20 mg daily over 14 days, no statistically significant or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1799">"" "" "" "in a clinical pharmacological study, in the desloratadin in a dose of 45 mg daily (the Neunfold of the clinical dose) has been applied for ten days, no extension of the QTc interval." "" "" ""</seg>
<seg id="1800">"" "" "" "in controlled clinical trials, at the recommended dose of 5 mg a day no increased incidence of drowsiness was found compared to placebo." "" "" ""</seg>
<seg id="1801">"" "" "" "at a 17 single dose study with adults, Desloratadin 5 mg showed no effect on standard measurement parameters including the reinforcement of subjective injuries and tasks that are connected with the flies." "" "" ""</seg>
<seg id="1802">"" "" "" "in patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as Niesen, nasal secretion and itching of the nose, itching and redness of the eyes and itching on the palate." "" "" ""</seg>
<seg id="1803">"" "" "" "as with the overall score of quality of life in Rhino-conjunctivitis, Aerius effectively reduces those caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1804">"" "" "" "18 In a pharmacokinetic study, in which the patient Demographics were comparable with the general seasonal allergic rhinitis in population, was achieved in 4% of patients a higher concentration of desloratadine." "" "" ""</seg>
<seg id="1805">Food does not have any significant impact on AUC and Cmax from Aerius Lyophilisat to get out while food Tmax of Desloratadin from 2.5 to 4 hours and Tmax of 3-OH desloratadin from 4 to 6 hours.</seg>
<seg id="1806">Gelatine Mannitol Aspartame (E 951) polacrilin potassium pigment Opatint red (contains iron (III) -oxide (E 464) and Hypromless (E 464)) aroma Tutti-Frutti water free citric acid</seg>
<seg id="1807">"" "" "" "an Aerius 2.5 mg of melting tray once a day in the mouth, to alleviate symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see section 5.1)." "" "" ""</seg>
<seg id="1808">"" "" "" "two Aerius 2,5 mg of melting tablets a day in the mouth to alleviate symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see section 5.1)." "" "" ""</seg>
<seg id="1809">"" "" "" "there are limited experiences from clinical trials for efficacy in the use of desloratadine for young people from 12 to 17 years (see sections 4.8 and 5.1)" "" "" ""</seg>
<seg id="1810">"" "" "" "immediately before the application, the blister should be carefully open and the dose of melting tray is removed without damaging them." "" "" ""</seg>
<seg id="1811">"" "" "" "efficacy and inconsistency of Aerius 2.5 mg of melting tablets at the treatment of children under 6 years have not been proven so far." "" "" ""</seg>
<seg id="1812">"" "" "" "the total ruthness of the side effects between the distillatadine syrup and the placebo group was equal, and did not significantly reduce safety profile from the adult patients." "" "" ""</seg>
<seg id="1813">"" "" "" "at the recommended dose, Aerius melting tray proved to be bioequivalent to the Aerius 5 mg of conventional tablets formulation and the Aerius 5 mg Lyophilisat for the adoption of deserts." "" "" ""</seg>
<seg id="1814">"" "" "" "in the context of a clinical study involving multiple agents, in which Desloratadin has been applied in a dose of up to 20 mg daily over 14 days, no statistically significant or clinical study was clinically significant." "" "" ""</seg>
<seg id="1815">"" "" "" "in a single dose study with adults, Desloratadin 5 mg showed no effect on standard measurement parameters including the reinforcement of subjective injuries and tasks that are connected with the flies." "" "" ""</seg>
<seg id="1816">The spread of this poorly metabolic phenotype was comparable to adult (6%) and Pediatric patients (6%) and Pediatric patients aged between 2 and 11 (children 16%) and the safety profile of these patients was not deviated from the general population.</seg>
<seg id="1817">"" "" "" "in single dose crossover study of Aerius melting tray with Aerius 5 mg of conventional tablets or Aerius 5 mg Lyophilisat, the formulations were bioequivalent." "" "" ""</seg>
<seg id="1818">"" "" "" "Aerius 2.5 mg tablets were not examined in pediatric patients, but in connection with the dose studies in children, however, the pharmacokinetic data for Aerius melting tablets can be used for children from 6 to 11 years." "" "" ""</seg>
<seg id="1819">Food does not have any significant impact on AUC and Cmax of Aerius Aerius Lyophilisat for intake during food Tmax of Desloratadin from 2.5 to 4 hours and Tmax of 3-OH- desloratadin from 4 to 6 hours.</seg>
<seg id="1820">"" "" "" "the overall analysis of the pre-clinical and clinical irritation tests for melting, revealed that the formulation is a unlikely risk for local irritation in clinical application." "" "" ""</seg>
<seg id="1821">Microcrystalline Cellulose pre-disguised force Carboxymethylmethyl methacrylate-polymethyl methacrylate Hydrooxide Hydroitol Aspartame (E951) aroma Tutti Frutti</seg>
<seg id="1822">The cold formidable film consists of polyvinyl chloride (PVC) laminated for a-related polyamide (OPA) film, cling to a aluminium foil and cling to a polyvinyl chloride (PVC) film.</seg>
<seg id="1823">"" "" "" "an Aerius 5 mg of melting tray once a day in the mouth, to alleviate symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see section 5.1)." "" "" ""</seg>
<seg id="1824">At the recommended dose Aerius 5 mg of melting tray as a bioequivalent to the Aerius 5 mg of conventional tablets formulation and the Aerius 5 mg Lyophilisate to the waning formulation of Desloratadin.</seg>
<seg id="1825">"" "" "" "in the context of a clinical study involving multiple agents, in which Desloratadin has been applied in a dose of up to 20 mg daily over 14 days, no statistically significant or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1826">"" "" "" "at a 30 single dose study with adults, Desloratadin 5 mg showed no effect on standard measurement parameters including the reinforcement of subjective injuries and tasks that are connected with the flies." "" "" ""</seg>
<seg id="1827">"" "" "" "in patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as Niesen, nasal secretion and itching of the nose, itching and redness of the eyes and itching on the palate." "" "" ""</seg>
<seg id="1828">"" "" "" "in single dose crossover study of Aerius 5 mg of melting tray with Aerius 5 mg of conventional tablets or Aerius 5 mg Lyophilisat, the formulations were bioequivalent." "" "" ""</seg>
<seg id="1829">"" "" "" "the overall analysis of the pre-clinical and clinical irritation tests for melting, revealed that the formulation is a unlikely risk for local irritation in clinical application." "" "" ""</seg>
<seg id="1830">"" "" "" "the safety of desloratadin among children between 2 and 11 years, which are limited to metabolic, is identical to children that are normal to metabolic." "" "" ""</seg>
<seg id="1831">"" "" "" "this medicine contains sorbitol; therefore, patients should not take care of hereditary problems of fructose intolerance or saccharase-isomaltase insufficiency of this medicine." "" "" ""</seg>
<seg id="1832">"" "" "" "the total ruthness of the side effects in children between 2 and 11 years was similar to the deserhoatadin group, similar to the placebo group." "" "" ""</seg>
<seg id="1833">"" "" "" "for infants between 6 and 23 months the most common side effects were reported, more than common in placebo, diarrhoea (3.7%), fever (2,3%) and insomnia (2.3%)." "" "" ""</seg>
<seg id="1834">"" "" "" "in an additional study, 2.5 mg of Desloratadin solution were observed in a solution of no side effects in patients aged between 6 and 11 years." "" "" ""</seg>
<seg id="1835">At the recommended doses the plasma concentration of desloratadin (see Section 5.2) were comparable in child and adult population.</seg>
<seg id="1836">"" "" "" "in controlled clinical studies the recommended dose of 5 mg daily for adults and adolescents, no increased incidence of drowsiness compared to placebo." "" "" ""</seg>
<seg id="1837">"" "" "" "in addition to the established classification in seasonal and perennial, allergic rhinitis may vary depending on the duration of symptoms as well as in intermittent allergic rhinitis." "" "" ""</seg>
<seg id="1838">"" "" "" "as with the overall score of quality of life in Rhino-conjunctivitis, Aerius tablets could be effectively caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1839">The spread of this limited metabolic phenotype was comparable in adults (6%) and children between 2 and 11 years (6% adults and 16% children) than in Caucasia (2% adults and 3% children).</seg>
<seg id="1840">"" "" "" "since Aerius solution incorporates the same concentration of desloratadin, no bioequivalent study was necessary and it is expected that it matches the syrup and the tablets." "" "" ""</seg>
<seg id="1841">"" "" "" "in various single dose studies, AUC- and Cmax-values of desloratadine in pediatric patients were comparable with those of adults who received the deserhoatadin syrup in a dose of 5 mg." "" "" ""</seg>
<seg id="1842">"" "" "" "Sorbitol, propylene glycol, Sucralose E 955, Hyprowless E 2910, sodium citrate 2 H2O, natural and artificial flavours (Bubble-Gum), water free citric acid, sodium ed. (Ph.D.), purified water." "" "" ""</seg>
<seg id="1843">"" "" "" "Aerius solution to insert is offered with 30, 50, 60, 100, 120, 150, 225 and 300 ml in type III Braunglabottles with a child-secure screw cover." "" "" ""</seg>
<seg id="1844">All packages except the 150 ml packet size are offered with a measuring spoon for dosages of 2.5 ml and 5 ml.</seg>
<seg id="1845">"" "" "" "the 150 ml packet size is a measuring spoon or application injection for preparations for intake with scaling ranging from 2,5 ml and 5 ml." "" "" ""</seg>
<seg id="1846">"" "" "" "after the approval of the approval, the authorisation holder receives regularly updated reports on the inconceivable reports of an medication every two years, unless there is something different from CHMP." "" "" ""</seg>
<seg id="1847">1 movie tray for 2 film tablets (5 film tablets) tablets: 14 film tablets. 60 film tablets. 60 film tablets. 60 film tablets.</seg>
<seg id="1848">1 movie tray for 2 film tablets (5 film tablets) tablets: 14 film tablets. 60 film tablets. 60 film tablets. 60 film tablets.</seg>
<seg id="1849">Measuring 30 ml with 1 measuring spoon for 60 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon for 150 ml with 1 measuring spoon for measuring 225 ml with 1 measuring spoon 300 ml with 1 measuring spoon</seg>
<seg id="1850">30 ml with 1 measuring spoon for 60 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon for 150 ml with 1 measuring spoon for measuring 225 ml with 1 measuring spoon 300 ml with 1 measuring spoon</seg>
<seg id="1851">1 dose Lyophilisat for inserting 2 doses Lyophilisat for inserting 10 cans Lyophilisat for inserting 30 cans Lyophilisat for inserting 50 cans Lyophilisat for inserting 50 cans Lyophilisat to take up to 50 cans Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilisat to insert 100 doses Lyophilisat for inserting 100 doses Lyophilis</seg>
<seg id="1852">"" "" "" "5 melting tray for 6 melting tablets, 1 melting tray; 1 melting tray for 60 hot tablets, 60 hot tablets." "" "" ""</seg>
<seg id="1853">Solution for inserting 30 ml with 1 measuring spoon + 1 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon for 150 ml with 1 measuring spoon for measuring 225 ml with 1 measuring spoon 300 ml with 1 measuring spoon</seg>
<seg id="1854">Pregnancy and nursing ask questions during pregnancy and breastfeeding before taking all drugs to your doctor or pharmacist for advice.</seg>
<seg id="1855">"" "" "" "machines In the recommended dosage and use of machines In the recommended dosage, it is not possible to calculate that Aerius leads to dizziness or decreases the attention." "" "" ""</seg>
<seg id="1856">"" "" "" "if you have said of your doctor you have to have an intolerance against certain sugars, ask your doctor before using this medicine." "" "" ""</seg>
<seg id="1857">"" "" "" "concerning the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer and will then decide how long you should take Aerius." "" "" ""</seg>
<seg id="1858">"" "" "" "if your allergic rhinitis is intermittent (the symptoms occur less than 4 days a week or less than 4 weeks last, your doctor will advise you, depending on your previous disease course." "" "" ""</seg>
<seg id="1859">"" "" "" "if your allergic rhinitis persist (the symptoms appear on 4 or more days a week, and more than 4 weeks last, your doctor may recommend you longer lasting treatment." "" "" ""</seg>
<seg id="1860">"" "" "" "if you forget the intake of Aerius If you forgot your dose, take it as soon as possible, and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1861">"" "" "" "71 After the market launch of Aerius, very rarely about cases of severe allergic reactions (difficulties in breathing, hitting, itching, hives and swelling) and skin rash was reported." "" "" ""</seg>
<seg id="1862">"" "" "" "about cases of heart palpitations, cardiac pain, nausea, vomiting, stomach upset, diarrhea, diarrhea, insomnia, insomnia, insomnia, insomnia and unusual liver function has also been reported very rarely." "" "" ""</seg>
<seg id="1863">Tablet coating consists of coloured film (contains Lactosite Monohydrat, hyprowless, titanium dioxide), colorgocarmin (E 132)), colourless film (contains Hyprowless, Macrogol 400), carnauba wax, light wax. "" "" "" "</seg>
<seg id="1864">"" "" "" "Aerius 5 mg film tablets are individually wrapped in blister packages with 1, 2, 3, 5, 7, 20, 20, 20, 50, 50 or 100 tablets." "" "" ""</seg>
<seg id="1865">"" "" "" "Aerius Sirup is indicated for children aged 1 to 11 years, adolescents (12 years and older) and adults, elderly people included." "" "" ""</seg>
<seg id="1866">Important information about certain other components of Aerius you should not take Aerius Sirup if you are allergic to the E 110 dye.</seg>
<seg id="1867">"" "" "" "if your doctor has informed you that you own an intolerance to some sugars, please contact your doctor before using this medicine." "" "" ""</seg>
<seg id="1868">"" "" "" "when the syrup is injected into the application of application with scalability, you can use it alternatively to take up the corresponding amount of syrup." "" "" ""</seg>
<seg id="1869">"" "" "" "concerning the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer and will then determine how long you should take Aerius Sirup." "" "" ""</seg>
<seg id="1870">"" "" "" "however, in children under 2 years of diarrhea, fever, and sleeplessness side effects, while in adults, fatigue, mouth dries and headache more often than placebo have been reported." "" "" ""</seg>
<seg id="1871">"" "" "" "after the market launch of Aerius very rarely about cases of severe allergic reactions (difficulties in breathing, hitting, itching, hives and swelling) and skin rash was reported." "" "" ""</seg>
<seg id="1872">"" "" "" "77 Aerius Sirup is available in bottles with child-safe closing folder with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1873">Aerius Lyophilisat to adopt the symptoms of allergic rhinitis (caused by an allergy-caused inflammation of the nose (for example hay fever or house dust allergy).</seg>
<seg id="1874">Intake of Aerius Lyophilisat to insert together with food and drink Aerius Lyophilisat for intake does not need to be taken with water or any other liquid.</seg>
<seg id="1875">"" "" "" "concerning the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer, and will then decide how long you should take Aerius Lyophilisate." "" "" ""</seg>
<seg id="1876">"" "" "" "81 If you forget the intake of Aerius Lyophilisat, If you forgot your dose, take it as soon as possible, and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1877">"" "" "" "after the market launch of Aerius very rarely about cases of severe allergic reactions (difficulties in breathing, hitting, itching, hives and swelling) and skin rash was reported." "" "" ""</seg>
<seg id="1878">"" "" "" "Aerius Lyophilisat for insertion is individually packaged in blister packages with 1, 2, 3, 5, 15, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 15, 20, 15, 20, 15, 20." "" "" ""</seg>
<seg id="1879">Aerius melting tray improves symptoms of allergic rhinitis (caused by an allergy of allergic inflammation, for example hay fever or house dust allergy).</seg>
<seg id="1880">"" "" "" "when taking Aerius melting tray together with food and drink Aerius melting tray, does not need to be taken with water or any other liquid." "" "" ""</seg>
<seg id="1881">"" "" "" "concerning the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer and will then determine how long you should take Aerius melting tablets." "" "" ""</seg>
<seg id="1882">"" "" "" "86 If you forget the intake of Aerius melting tray when you forgot your dose, take it as soon as possible, and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1883">"" "" "" "Aerius melting tray is individually packaged in blister packages with 5, 6, 10, 12, 15, 20, 20, 50, 60, 60, 60, 90 and 100." "" "" ""</seg>
<seg id="1884">"" "" "" "when taking Aerius melting tray together with food and drink Aerius melting tray, does not need to be taken with water or any other liquid." "" "" ""</seg>
<seg id="1885">"" "" "" "if you forget the intake of Aerius melting tray you have forgotten your dose, take it as soon as possible, and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1886">"" "" "" "after the market launch of Aerius very rarely about cases of severe allergic reactions (difficulties in breathing, hitting, itching, hives and swelling) and skin rash was reported." "" "" ""</seg>
<seg id="1887">"" "" "" "Aerius solution to take is indicated for children aged 1 to 11 years, adolescents (12 years and older) and adults, elderly people included." "" "" ""</seg>
<seg id="1888">"" "" "" "if the solution for inserting a application spection is enclosed with scaling, you can alternatively use it to take the appropriate quantity solution." "" "" ""</seg>
<seg id="1889">"" "" "" "concerning the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer and will then decide how long you should take Aerius solution." "" "" ""</seg>
<seg id="1890">"" "" "" "however, in children under 2 years of diarrhea, fever, and sleeplessness side effects during adult fatigue, mouth-drying and headache more often than placebo have been reported." "" "" ""</seg>
<seg id="1891">"" "" "" "use 97 Aerius solution to insert is available in bottles with child-safe closing folder with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1892">"" "" "" "the 150 ml packet size is a measuring spoon or application injector, added with scaling ranging from 2.5 ML- and 5 ml cans." "" "" ""</seg>
<seg id="1893">"" "" "" "in June 2008, Novartis Vaccines and Diagnostics S.r.l. officially shared the Committee for Human Use for the Compiration of Aflunov for the prevention of the aviary H5N1 virus to the prevention of the aviary H5N1 virus." "" "" ""</seg>
<seg id="1894">Aflunov should be used in adults and elderly people for the protection against flu caused by the strain (type) H5N1 from the Influenza-A virus.</seg>
<seg id="1895">"" "" "" "this is a special kind of vaccines that could cause a future pandemic, which may cause a future pandemic." "" "" ""</seg>
<seg id="1896">"" "" "" "an influenza pandemic breaks out when a new strain of the Grippevirus appears to spread easily from man, because people still have no immunity (no protection)." "" "" ""</seg>
<seg id="1897">"" "" "" "after administration of the vaccine, the immune system recognizes the parts of the flu contained in the vaccine as" physical alien "and forming antibodies against it." "" "" ""</seg>
<seg id="1898">"" "" "" "thereby, the immune system later is able to form a contact with a grippevirus of this pedigree." "" "" ""</seg>
<seg id="1899">"" "" "" "subsequently, the membrane shell of the virus has been separated from the" surface antigens "(proteins on the membrane surface) separated, cleaned and used as a component of the vaccine." "" "" ""</seg>
<seg id="1900">An inspection of some of the study sites showed that the study was not performed according to the "good clinical practice" (GCP).</seg>
<seg id="1901">"" "" "" "thus the scope of the clinical data basis for evaluating the safety of the vaccine is not sufficient to meet the requirements of the guidelines of the EMEA for prepandemic vaccines." "" "" ""</seg>
<seg id="1902">"" "" "" "should you participate in a clinical trial and need further information about your treatment, please contact your doctor." "" "" ""</seg>
<seg id="1903">"" "" "" "if you wish more information regarding the recommendations of CHMP, please read the scientific discussion (also part of the EPAR)." "" "" ""</seg>
<seg id="1904">It is used in combination with other antiviral drugs for the treatment of adults and children over four years used with the human immunodeficiency syndrome (HIV-1) which caused the acquired immunodeficiency syndrome (AIDS).</seg>
<seg id="1905">"" "" "" "for patients who can not swallow the capsules, Agenerase is available as a solution to disposable, but this cannot be taken together with Ritonavir, because the safety of this combination has not been investigated." "" "" ""</seg>
<seg id="1906">"" "" "" "asgenerase should only be prescribed if the doctor has tested, which has taken an antiviral drug in the patient before, and the likelihood will discuss the virus." "" "" ""</seg>
<seg id="1907">"" "" "" "the recommended dose for patients over twelve years is 600 mg twice a day, which are taken with twice daily 100 mg of Ritonavir and with other antiviral drugs." "" "" ""</seg>
<seg id="1908">"" "" "" "in children between four and twelve years and in patients with a body weight of less than 50 kg, the recommended dose of asgenerase depends on the body weight." "" "" ""</seg>
<seg id="1909">"" "" "" "in combination with other antiviral drugs, Agenerase reduces the HIV-quantity in the blood and keeps it at a low level." "" "" ""</seg>
<seg id="1910">"" "" "" "AIDS is not to heal, but can delay the damage of the immune system and thus delay the development of AIDS associated infections and diseases." "" "" ""</seg>
<seg id="1911">"" "" "" "Afraase was examined in combination with other antiviral drugs, but without malonavir, in two main studies with 736 HIV-infected adults who had previously not been treated with Proteasehemiah." "" "" ""</seg>
<seg id="1912">"" "" "" "it was compared with low dosing Ritonavir reinforced pharmaceuticals Agenerase was compared with 206 adults who had taken earlier proteasehemmer, with other proteasehemiah." "" "" ""</seg>
<seg id="1913">"" "" "" "main indian indicator for efficacy was the portion of patients with non-demonstraable concentrations of HIV in the blood (viral load), or the change of viral load after treatment." "" "" ""</seg>
<seg id="1914">"" "" "" "in the studies of patients who had previously not taken Proteastia, after 48 weeks under Agenerase more patients had a viral load of 400 copies / ml under placebo, but Agenerase was less effective than Indinavir." "" "" ""</seg>
<seg id="1915">"" "" "" "in children, Agenerase had also treated the viral load, but were treated with the children who used to treat the treat earlier with proteastia." "" "" ""</seg>
<seg id="1916">"" "" "" "in the study with adults who had been treated with proteasehemiah, the viral load increased the viral load after 16-week treatment as well as other Proteasehemmer:" "" "" ""</seg>
<seg id="1917">"" "" "" "in patients with HIV, which was resistant to four other proteastia, it came under Agenerase together with Ritonavir to a stronger decrease of the viral load after four weeks than in those patients who continued their previous protests:" "" "" ""</seg>
<seg id="1918">The most common side effects of Agenerase (observed in more than 1 of 10 patients) are headaches, diarrhoea (diarrhea) and Nausea (nausea); vomiting, rash and Fatigue (fatigue).</seg>
<seg id="1919">"" "" "" "2 / 3 Agenerase may not be used in patients, which may be oversensitive (allergic) against ambleavir or any of the other components." "" "" ""</seg>
<seg id="1920">"" "" "" "Agenerase may also not be used in patients who are degraded in patients (an herbal supplement to treat depression) or drug, which are harmful as Agenerase and are harmful in high concentrations in the blood." "" "" ""</seg>
<seg id="1921">"" "" "" "as with other medicines, HIV is treated against HIV, an osteondrose (changes in the distribution of body fat) or an immunoystrophone (symptoms of infection) or an immunoactivation syndroid symptoms (symptoms of an infection caused by the restful immune system)." "" "" ""</seg>
<seg id="1922">"" "" "" "the Committee for Human Use (CHMP) reached the conclusion that the benefits of Agenerase in combination with other antiretroviral drugs treat HIV-1 infected adults and children over four years, compared to the risks." "" "" ""</seg>
<seg id="1923">"" "" "" "Agenerase is usually taken together with the pharmacokinetic amplifiers Ritonavir, but the use of Agenerase in combination with rite level of patients who had previously not been proven." "" "" ""</seg>
<seg id="1924">"" "" "" "Agenerase was originally approved under" "" "" "" "extraordinary circumstances" "" "" "" "at the time of approval from scientific reasons only limited information." "" "" ""</seg>
<seg id="1925">"" "" "" "in October 2000, the European Commission granted the Glaxo Group Limited authorization for the establishment of asgenerals throughout the European Union." "" "" ""</seg>
<seg id="1926">"" "" "" "in combination with other antiretroviral drugs for the treatment of HIV-1- infected, Proteassigmer (PI), pre-treated adults and children from 4 years now appear." "" "" ""</seg>
<seg id="1927">"" "" "" "usually, Afraase capsules are supposed to be administered to the pharmacokinetic bookless of amicavir along with low doses ranging from Ritonavir (see sections 4.2 and 4.5)." "" "" ""</seg>
<seg id="1928">"" "" "" "the use of Amburst avir should take place in consideration of individual viral resistance patterns and the treatment of patients (see Section 5.1)." "" "" ""</seg>
<seg id="1929">The bioavailability of Ammiavir as a solution to the intake is 14% lower than the capsule; therefore Afraase capsules and solution for insertion on a milligrams per milligram basis is not interchangeable (see Section 5.2).</seg>
<seg id="1930">The recommended dose for generic capsules is 600 mg of amplitudes twice daily with 100 mg of Ritonavir twice a day in combination with other antiretroviral drugs.</seg>
<seg id="1931">"" "" "" "2 If generic capsules are applied without the amplification of rite level (booklace), higher doses have to be applied to Agenerase (1200 mg twice daily)." "" "" ""</seg>
<seg id="1932">The recommended dose for generic capsules is 20 mg of amplitudes / kg body weight twice a day in combination with other antiretroviral drugs daily in combination with other antiretroviral drugs up to one day of the day of 2400 mg amicavir which should not be exceeded (see Section 5.1).</seg>
<seg id="1933">The pharmacokinetics, efficacy and safety of aging in combination with low doses of Ritonavir or other proteastia were not examined in children.</seg>
<seg id="1934">"" "" "" "Agenerase is not recommended for use in children under 4 years, due to the lack of data for impemability and efficacy (see Section 5.2)." "" "" ""</seg>
<seg id="1935">"" "" "" "based on the pharmacokinetic data, the dose to adult patients should be reduced to 450 mg twice daily and in patients with severe liver disorders on 300 mg twice daily." "" "" ""</seg>
<seg id="1936">"" "" "" "the simultaneous application should be done in patients with a slight or moderate liver function, in patients with severe liver interference it is contraindicated (see Section 4.3)." "" "" ""</seg>
<seg id="1937">"" "" "" "Agenerase may not be given simultaneously with pharmaceuticals, which have a low therapeutic width and also represent substrates of the Cytochrome P450-Isoenzyme 3A4 (CYP3A4)." "" "" ""</seg>
<seg id="1938">Herbal supplements that contain Johanniswort (Hypericum perforatum) may not be used due to the risk of reduced plasma concentration and a diminished therapeutic effect of ambleavir (see section 4.5).</seg>
<seg id="1939">"" "" "" "patients should be advised that Agenerase or any other antiretroviral therapy do not lead to a cure of HIV infection, and that they may continue to develop opportunistic infections or other complications of HIV infection." "" "" ""</seg>
<seg id="1940">"" "" "" "the current antiretroviral therapy including treatment with asgenerase does not prevent the risk of transmission from HIV to others by sexual contact or contamination with blood." "" "" ""</seg>
<seg id="1941">"" "" "" "usually, Agenerase capsules should be used together with low doses ranging from Ritonavir and in combination with other antiretroviral drugs (see Section 4.2)." "" "" ""</seg>
<seg id="1942">Patients who suffer from chronic hepatitis B or C and treated with a antiretroviral combination therapy, have an increased risk of severe liver effects with potentially fatal course.</seg>
<seg id="1943">"" "" "" "for the case of simultaneously viral treatment of Hepatitis B or C, please read the relevant information about this medicine." "" "" ""</seg>
<seg id="1944">Patients with pre-existing liver function including a chronic-active hepatitis show increased incidence of liver dysfunctions under a antiretroviral combination therapy and should be monitored according to clinical practice.</seg>
<seg id="1945">The simultaneous application of Agenerase and Ritonavir with Fluticason or other Glukokorticoids that are not recommended that the potential benefit of treatment according to Morbus Cushing and suppression of the epoxerenoid function (see section 4.5).</seg>
<seg id="1946">"" "" "" "because the metabolism of the HMG-CoA-reductase inhibitor is strongly recommended by CYP3A4 because of the increased risk of myopies including Rhabdomyolysis." "" "" ""</seg>
<seg id="1947">"" "" "" "4 For some medicines that may cause severe or threatening side effects, phenobarbital, phenobarbital, phenobarbital, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International standardization ratio), are available methods for determining active substances." "" "" ""</seg>
<seg id="1948">"" "" "" "in patients who take this medicine at the same time, Afraase may be less effective because of reduced plasma mask (see Section 4.5)." "" "" ""</seg>
<seg id="1949">"" "" "" "due to the possibility of metabolic interactions with amplitudes, the effectiveness of hormonal contraceptives may be altered, but the information is not sufficient to estimate the kind of interactions." "" "" ""</seg>
<seg id="1950">"" "" "" "if methadone is given at the same time with amplitudes, the patients should therefore be watched at Opiatentment symptoms, especially if also low doses of Ritonavir are given." "" "" ""</seg>
<seg id="1951">"" "" "" "due to the possible risk of toxicity by the high risk of toxicity, this formulation is contraindicated by children under an age of four years and should be used with caution in certain other patient groups." "" "" ""</seg>
<seg id="1952">"" "" "" "Agenerase should be set at duration 5, when a rash of systemic or allergic symptoms is accompanied or the mucous membranes are involved (see section 4.8)." "" "" ""</seg>
<seg id="1953">"" "" "" "in patients who received antiretroviral therapy including Proteasehemmer, was reported on the occurrence of diabetes mellitus, hyperglycemia or an expedition of an existing diabetes mellitus." "" "" ""</seg>
<seg id="1954">"" "" "" "many patients had other diseases, whose therapy drugs were required to be associated with the development of diabetes mellitus or hyperglycemia." "" "" ""</seg>
<seg id="1955">"" "" "" "B. a higher age, and with medication-dependent factors such as a longer lasting antiretroviral treatment and associated metabolic disorders associated with drugs." "" "" ""</seg>
<seg id="1956">"" "" "" "with hemophiles patients (type A and B), reports were treated with proteasehemiah, reports about an increase of bleeding including spontaneous mcutaneous hematoma and hematthroes." "" "" ""</seg>
<seg id="1957">"" "" "" "at the time of the introduction of an antiretroviral combination therapy (ART), HIV-infected patients may develop an inflamed reaction to asymptomatic or residual opportunistic infections that leads to severe clinical conditions or deterioration of symptoms." "" "" ""</seg>
<seg id="1958">"" "" "" "although a multi-factorial etiology is adopted (including use of corticosteroid, alcohol consumption, heavy Body Mass Index), cases of Osteonekrosis in particular in patients with advanced HIV disease and / or long-term application of antiretroviral combination therapy (ART)." "" "" ""</seg>
<seg id="1959">CYP3A4 substrates with low therapeutic width omisase may not be used simultaneously with medicines that have a low therapeutic width and also represent substrates of the Cytochrome P450-Isoenzyme 3A4 (CYP3A4).</seg>
<seg id="1960">CYP2D6 substrates with a low therapeutic breadth of Ageneral with malonavir cannot be used together with medicines that are active predominantly via CYP2D6 and are associated with increased purity and / or life-threatening side effects.</seg>
<seg id="1961">"" "" "" "it was shown that Rifampicin causes a 82% reduction in AUC by Amfliavir, which can lead to a virological failure and lead to a resistance development." "" "" ""</seg>
<seg id="1962">"" "" "" "attempting to increase the resulting plasma level by a dose of other protease inhibitors in combination with Ritonavir, very frequently unwanted effects were observed at the liver." "" "" ""</seg>
<seg id="1963">"" "" "" "currants (Hypericum perforatum) The serum mirrors of Amburst avir can be reduced by the simultaneous application of vegetable sugars with currants (Hypericum perforatum)." "" "" ""</seg>
<seg id="1964">"" "" "" "if a patient already takes cursor's wort, the amplitude and if possible, check the virus-load and remove the currant." "" "" ""</seg>
<seg id="1965">A dose adjustment for one of the medicine is not required if nelfinavir is given together with Ambert avir (see also the efavirenz below).</seg>
<seg id="1966">508% increase for Cmax by 30% if rite (100 mg twice daily) is administered in combination with Ammiavir capsules (600 mg twice daily).</seg>
<seg id="1967">"" "" "" "in clinical trials, doses of 600 mg of amplitudes twice daily and Ritonavir 100 mg were used twice daily, which determine the effectiveness and inconsistency of this treatment schemas." "" "" ""</seg>
<seg id="1968">52% decreases when the amplavir (750 mg twice daily) is administered in combination with caletra (400 mg Lopinavir + 100 mg of Ritonavir twice daily).</seg>
<seg id="1969">"" "" "" "the Cmin values of Amfliavir in the plasma, which were administered twice daily with Kaletra (400 mg daily) with Kaletra (600 mg twice daily) in combination with 100 mg of Ritonavir twice a day." "" "" ""</seg>
<seg id="1970">"" "" "" "recommended dosage for the simultaneous administration of Ammiavir and Kaletra can not be given, but it is recommended to provide a close monitoring because the effectiveness and lack of this combination is not known." "" "" ""</seg>
<seg id="1971">"" "" "" "there was no pharmacokinetic study carried out in combination with didano in combination with didano in combination, however, that the revenues of didano in and asgenerase are at least one hour apart." "" "" ""</seg>
<seg id="1972">Therefore in combination with the gift of Eavirenz in combination with amplitudes (600 mg twice daily) and Ritonavir (100 mg twice daily) no dosisadaption required.</seg>
<seg id="1973">The treatment with efavirenz in combination with Amburst avir and Saquinavir is not recommended since the exposure of both proteastia would be reduced.</seg>
<seg id="1974">The effect of Nevirapin to other proteastia and existing limited data suggest that Nevirapin had probably sunk into the serum concentration of ambleavir.</seg>
<seg id="1975">"" "" "" "if this medicine should be used simultaneously, caution is advisable because Delavirdin might be less effective because of the reduced and possibly subtherapeutic plasma level." "" "" ""</seg>
<seg id="1976">"" "" "" "when this medicine can be applied together, caution is advisable; a thorough clinical and virological monitoring should be made, as an accurate forecast of the effect of the combination of amplitudes and Ritonavir on Delavirdin is difficult." "" "" ""</seg>
<seg id="1977">The simultaneous gift of amplitudes and rifabutin resulted in a rise in plasma concentration of 193% and thus resulting in a rise in rifabutin-related side effects.</seg>
<seg id="1978">"" "" "" "if it is necessary for clinical reasons, Rifabutin is to be administered together with asgenerase, at least half of the recommended dose, although there is no clinical data." "" "" ""</seg>
<seg id="1979">"" "" "" "Pharmacokinetic studies with asgenerase in combination with erythromycin were not performed, however the plasma level of both medicines could be increased by the simultaneous administration." "" "" ""</seg>
<seg id="1980">The simultaneous application of twice daily 700 mg of Fosampon avir and 100 mg of ketoconazole once a day led to an increase in the Cmax of Ketoconazole once a day to increase the Cmax of Ketoconazole once a day without simultaneous use of Fosampelavir with a simultaneous usage of ketoconazole once a day.</seg>
<seg id="1981">"" "" "" "other medicines that are listed below, including substrates, inhibitor or induction of CYP3A4 can, if they can be used together with asgenerase, may cause interactions." "" "" ""</seg>
<seg id="1982">"" "" "" "patients should therefore be attached to toxic reactions which are associated with these medicines, if they are used in combination with Agenerase." "" "" ""</seg>
<seg id="1983">"" "" "" "based on the data of other proteastia, it is advisable that Antazida cannot be taken at the same time as Agenerase, as it can come to resorption disorders." "" "" ""</seg>
<seg id="1984">"" "" "" "the simultaneous application of anticonvulva that are known as enzymes are known (phenytoin, phenobarbital, carbamazepine), with amplitudes, lead to a decrease of the plasma level of amplitudes." "" "" ""</seg>
<seg id="1985">"" "" "" "the serum concentrations of calcium-cantiblockers such as amlodipine, dipine pin, pin pine, nimdipine, nimdipine, nanodipine and diapamil can be increased by amatevia up to the activity and toxicity of this drug." "" "" ""</seg>
<seg id="1986">"" "" "" "simultaneous taking with asgenerase, their plasma concentration may increase considerably and strengthen with PDE5 inhibitors, including hypotension, tendon disorders, and priapism (see Section 4.4)." "" "" ""</seg>
<seg id="1987">In a clinical study conducted in the Ritonavir 100 mg capsules twice a day together with 50 µg fluctuation propionate intranasal (4 times daily) over 7 days decreased (90% reduction interval between 82 and 89%).</seg>
<seg id="1988">"" "" "" "as a result, the simultaneous gift of Agenerase with Ritonavir is not recommended that the potential benefit of treatment will exceed the risk of systemic corticosterling effects (see Section 4.4)." "" "" ""</seg>
<seg id="1989">"" "" "" "for HMG-CoA-reductase inhibitors like Lovastatin and Simvastatin, whose nutrient change is strongly influenced by CYP3A4, increases the enhancements of the plasma level while anticipated by asgenerase." "" "" ""</seg>
<seg id="1990">"" "" "" "since plasma light increases in this HMG-CoA-reductase inhibiting to myopathy, including a Rhabdomyolysis, the combined application of these drugs with amplavir is not recommended." "" "" ""</seg>
<seg id="1991">"" "" "" "there is a more frequent monitoring of the therapeutic levels until stabilization of the mirror, because the plasma concentration of Cyclosporine, Rapamycin and tacrolimus can be further increased (see Section 4.4)." "" "" ""</seg>
<seg id="1992">"" "" "" "therefore, Agenerase may not be used together with oral intrudent Midazolam (see Section 4.3), while on the same application of generic Midazolam caution is advisable." "" "" ""</seg>
<seg id="1993">Data for simultaneous active midazolam with other proteaseinase inhibitors refer to a possible increase in the plasma level of Midazolam to 3 to 4 fader.</seg>
<seg id="1994">"" "" "" "when methadone is administered together with amplitudes, the patients should therefore be watched at Opiatentment symptoms, especially if also low doses of Ritonavir are given." "" "" ""</seg>
<seg id="1995">"" "" "" "due to the small reliability of historical comparisons, there is currently no recommendation to adapt, as the amplavir is administered simultaneously with methadone at the same time." "" "" ""</seg>
<seg id="1996">"" "" "" "while offering warfarin or other oral anticoagulants together with Agenerase, a reinforced control of the INR (International standardization ratio) is recommended because of the possibility of weakening or amplification of the antithrombotic effect (see Section 4.4)." "" "" ""</seg>
<seg id="1997">The effect of an additional appointment of Ritonavir on hormonal contraceptives is not predictable as well as alternative methods for contraception is recommended.</seg>
<seg id="1998">Careful monitoring of the therapeutic effects and side effects of tricyclic antidepressants (for example Desipramine and Nortryptilin) is recommended at the same gift of asgenerals (see Section 4.4).</seg>
<seg id="1999">"" "" "" "during pregnancy, this medicine may only be applied during pregnancy after careful consideration of possible use for the mother compared to the possible risks for the fetus." "" "" ""</seg>
<seg id="2000">"" "" "" "in the milk pudding rats were proven to amburst avir-related substances, however, it is not known whether ambleavir over humans into breast milk." "" "" ""</seg>
<seg id="2001">"" "" "" "a recurring study of pregnant rats, which was administered by the emptiness to the uterus up to the end of the downtime amidavir, showed a diminished increase of 12 body weight in postage." "" "" ""</seg>
<seg id="2002">"" "" "" "further development of income, including Fertility and Reproduction capacity was not affected by the administration of Ammiavir to the mothertier." "" "" ""</seg>
<seg id="2003">"" "" "" "in adults and for children from 4 years of controlled clinical trials in combination with various other antiretroviral drugs." "" "" ""</seg>
<seg id="2004">"" "" "" "most of the side-related side effects were slightly up to moderate, and rarely led to the treatment." "" "" ""</seg>
<seg id="2005">"" "" "" "with many of these events, it is not clear whether they are used in connection with the intake of Agenerase or another at the same time for HIV treatment, or whether they are a result of the disease." "" "" ""</seg>
<seg id="2006">"" "" "" "most of the above-mentioned side effects are from two clinical trials (PROAB3001, PROAB3006), in which patients were not treated 1200 mg Afraase two times daily." "" "" ""</seg>
<seg id="2007">Events (degree 2 to 4) which were evaluated by examining the investigator as in connection with the study medication and were listed in more than 1% of patients (Grade 3 to 4).</seg>
<seg id="2008">"" "" "" "the antiretroviral combination therapy was associated with a redistribution of the body fat (liftystrophy) in HIV patients, including a loss of peripheral and cervical fat tissue, hypertrophie of breasts and dorsovioral fat accumulation." "" "" ""</seg>
<seg id="2009">"" "" "" "under 113 antiretroviral not treated persons, which were treated with amplivudine in combination with Lamivudine / Zidovudine over a medium length of 36 weeks, was observed (&lt; 1%)." "" "" ""</seg>
<seg id="2010">In the study PROAB 3006 for 245 patients with amplaviavir 7 cases (3%) compared to 27 cases (11%) in 241 patients with Indinavir in combination with various NRTIs over a medium duration of 56 weeks (p &lt; 0.001).</seg>
<seg id="2011">"" "" "" "skin eruptions normally were mild to moderate, erythemed or makulopapulous nature, with or without itching and disappeared spontaneously during the second treatment week and disappeared spontaneously within two weeks without leaving the treatment with amplitudes." "" "" ""</seg>
<seg id="2012">Osteonsrose cases were reported in particular in patients with commonly known risk factors, advanced HIV disease or long-term application of antiretroviral combination therapy (ART).</seg>
<seg id="2013">"" "" "" "at the time of the introduction of an antiretroviral combination therapy (ART), HIV-infected patients may develop a inflammatory response to asymptomatic or residual opportunistic infections (see Section 4.4)." "" "" ""</seg>
<seg id="2014">"" "" "" "in combination with PI pre-treated patients, which were observed twice daily with low dosed rite levels (Grade 2 to 4) and laboratory changes (Grade 2 to 4) and Cpk values which were treated with low dosed rite levels, were used very frequently." "" "" ""</seg>
<seg id="2015">"" "" "" "in case of overdosing, the patient is to observe in signs of an intoxication (see section 4.8) when necessary, necessary supporting measures are necessary." "" "" ""</seg>
<seg id="2016">"" "" "" "Ammiavir binds to the active centre of HIV-1 protease and prevents the process of viral gag- and Gag-polarity detection with the result of a formation of inadequate, non-infectious viral particles." "" "" ""</seg>
<seg id="2017">The antiviral activity in vitro against HIV-1 IIIB was studied in acute and chronic lymphoblastic cell lines (MT-4, CEM-CCRF (H9) as well as peripheral blood cells.</seg>
<seg id="2018">The 50% Hemi concentration (IC50) from Amwiavir is found in the range from 0.012 to 0.08 µM in acute infected cells and is 0.41 µM in chronic infected cells.</seg>
<seg id="2019">"" "" "" "the connection between the activity of amlocomavir on HIV-1 in vitro and the inhibition of HIV-1 replication is not defined yet." "" "" ""</seg>
<seg id="2020">Treated with the treatment of antiretroviral treatment with the present Fosamprenavir / rite-dosages were observed - as with other rite-inhibitors - the mutations described only rarely.</seg>
<seg id="2021">"" "" "" "in sixteen cases of 434 antiretroviral treatment, the 700mg Fosamprenavir obtained twice daily in the ESS100732 study twice daily, whereby 14 isolates could be examined." "" "" ""</seg>
<seg id="2022">"" "" "" "a genotypic analysis of isolates from 13 out of 14 children, with which a virological failure occurred within 59 patients, showed resistance patterns that were similar to those in adults." "" "" ""</seg>
<seg id="2023">"" "" "" "L10F / I / V, V11I, V32I, V32I / M / V, I47V, M61V, I51V, V82A / I, I84V, I82A / I, I84V, I85V, L90M and I93L / M." "" "" ""</seg>
<seg id="2024">In the APV30003 study and the extension of APV30005 (700 mg Fosamprenavir / 100 mg of Ritonavir twice daily: n = 107) of patients with virological failures were present in patients with virological predictions for 96 weeks:</seg>
<seg id="2025">"" "" "" "based on genital resistance tests, Genotypic interpreting systems can be applied to the estimation of the activity of amplona / Ritonavir / Ritonavir / Ritonavir in patients with proteastia-resistant insulates." "" "" ""</seg>
<seg id="2026">The current (July 2006) ANRS-11-Algorithm for Fosamprenavir / Ritonavir defines resistance than the presence of mutations V32I + 147A / C / M / G / M / G / M / G / M / G / M / G / M / G / M / G / M / G / M / G / M / G / M / G / M / S / M / G / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M / S / M /</seg>
<seg id="2027">"" "" "" "the conclusions concerning the relevance of certain mutations or mutation samples can be subject to additional data, and it is recommended to draw the current interpretation systems to analyse resistance tests." "" "" ""</seg>
<seg id="2028">"" "" "" "based on photypical resistance tests clinically validated phenotypic interpreting systems can be used in conjunction with the genotypic data for the estimation of the activity of amplona / Ritonavir / Ritonavir / Ritonavir in patients with proteastia-resistant insulates." "" "" ""</seg>
<seg id="2029">Companies that drive diagnostic resistance tests have been clinically developed clinically phenotypic Cut-offs (separation points) for FPV / RTV which can be applied to interpretation of a resistance tests.</seg>
<seg id="2030">"" "" "" "each of these four with a reduced sensitivity to Amburst avir associated genetic patterns, however, produces a certain crossroads against the Indinavir, Nelfinavir and Saquinavir." "" "" ""</seg>
<seg id="2031">"" "" "" "there are currently data for the cruises between Amburst avir and other proteastia for all 4 Fosamprenavir Resistance, either alone or in combination with other mutations." "" "" ""</seg>
<seg id="2032">On the basis of twenty-five antiretroviral treatment patients with which a Fosampavir / Ritonavir (three out of 25 isolates), Inquinavir / Ritonavir (three out of 24 insulates) and the quinquavir / Ritonavir (three out of 24 insulates) and the Tipranavir / Ritonavir (four out of 24 insulates) and the Tipranavir / Ritonavir (four out of 24 insulates).</seg>
<seg id="2033">"" "" "" "" "" "" "" the reversal retains its activity against some other proteastia-resistant isolates; the receipt of this activity seems to be dependent on the number and type of resistance mutations in the isolates. "" "" "" "</seg>
<seg id="2034">"" "" "" "early waste of a failing therapy is recommended to keep the accumulation of a variety of mutations in boundaries, which can affect the following treatment." "" "" ""</seg>
<seg id="2035">The validity of the efficacy of Agenerase in combination with rite levels of 100 mg twice daily is based on the study PRO30017 (100 mg twice daily) and nucleontroaloga (100 mg twice daily) and nucleontroaloga (100 mg twice daily) and nucleoavialoga (100 mg twice daily) and the nucleoavir (standard of care).</seg>
<seg id="2036">"" "" "" "one hundred and sixty (n = 163) patients with impostulated virus sensitivity to Agenerase, at least another PI and at least one NRTI were included in the study A of PRO30017." "" "" ""</seg>
<seg id="2037">The primary analysis introduced the non-subsuperiority of APV / Ritonavir compared to the time-adjusted average change of the output value (HIV-1-RNA) in the plasma for 16 weeks with a non-shift shaft of 0,4-10 copies / ml.</seg>
<seg id="2038">"" "" "" "the validity of the efficacy of unleoosterated asgenerase is based on two uncontrolled trials involving a total of 288 HIV-infected children aged 2 to 18 years, of which 152 have been pretreated with PI." "" "" ""</seg>
<seg id="2039">"" "" "" "in studies, Afraase has been studied daily, 20 mg / kg daily, 20 mg / kg daily, 20 mg / kg daily and 22,5 mg / kg twice daily, whereby the majority of patients received 20 mg / kg twice daily." "" "" ""</seg>
<seg id="2040">There was no low dosed rite level given at the same time; the majority of the patients treated with PI had previously received at least one (78%) or two (42%) of the NRTIs.</seg>
<seg id="2041">"" "" "" "after 48 weeks, approximately 25% of patients enrolled in the study included a plasma-1 RNA concentration &lt; 10,000 copies / ml and 9% &lt; 400 copies / ml in a median increase in CD4 cell number from 26 cells / mm ³ (n = 74)." "" "" ""</seg>
<seg id="2042">"" "" "" "19 Based on these data should be considered at therapy optimisation, with PI pre-treated children who are expected to consider" unbooked "asgenerals." "" "" "" "</seg>
<seg id="2043">"" "" "" "after oral administration, the average duration (Tmax) up to the maximum serum concentration of amplitudes approximately 1 to 2 hours for the capsule and approx. 0,5 to 1 hour." "" "" ""</seg>
<seg id="2044">508% increase for Cmax by 30% if rite level (100 mg twice daily) is administered together with amplitudes (600 mg twice daily).</seg>
<seg id="2045">"" "" "" "the administration of Amburst avir with a meal lead to a 25% decrease in AUC, but has no effect on the concentration of amplitudes 12 hours after dosage (C12)." "" "" ""</seg>
<seg id="2046">"" "" "" "therefore, the minimal concentration in the Steady State (Cmin, ss) remained unaffected by the dietary intake, although the increase of the condition and the rate of resorption was affected." "" "" ""</seg>
<seg id="2047">The apparent field of distribution is approximately 430 l (6 l / kg with a body weight of 70 kg) and can be linked to a large distribution volume as well as a hindered penetration of the blood circulation in the tissue.</seg>
<seg id="2048">"" "" "" "this change leads to a decrease in the total concentration of active substance in plasma, with the amount of unbound amplitudes which constitutes the active part, probably remains unchanged." "" "" ""</seg>
<seg id="2049">"" "" "" "while the absolute concentration of unbound amidavir remains constant, the percentage of free active ingredients during the dosing concentration in the Steady State via the area of Cmax, ss to Cmin, ss." "" "" ""</seg>
<seg id="2050">"" "" "" "therefore, medicines that induce CYP3A4 or inhibit or inhibit the substrate of CYP3A4 if they are given simultaneously with asgenerase (see sections 4.3, 4.4 and 4.5)." "" "" ""</seg>
<seg id="2051">"" "" "" "the gift of Agenerase capsules, either 20 mg / kg twice per kg / kg daily, leads to a similar daily amplitudes exposure such as adults with a dose of 1200 mg twice daily." "" "" ""</seg>
<seg id="2052">"" "" "" "Ammiavir is made from the solution 14% less bioverfeed as out of the capsules, so Agenera solution and asgenerase capsules are not interchangeable on a Millions basis." "" "" ""</seg>
<seg id="2053">"" "" "" "the renal clearing of Ritonavir is also negligible, so the impact of a kidney disturbance on the elimination of Amwiavir and Ritonavir is likely to be minimal." "" "" ""</seg>
<seg id="2054">"" "" "" "these treatment schemata lead to amateavir plasma light equivalent to those that are achieved in healthy volunteers according to a dose of 1200 mg of amplitudes twice daily, without simultaneous administration of rite." "" "" ""</seg>
<seg id="2055">"" "" "" "in long-term studies on the carcinogenicity with amplitudes in mice and rats, the exposure involving human animals (mice) or 3,8- times (rat) of exposure involving individuals, after twice daily gift of 1200 mg of amplitudes, said." "" "" ""</seg>
<seg id="2056">"" "" "" "the 21 underlying mechanism for the emergence of hepatogenous cell-adenomes and carcinomas were not solved, and the relevance of the observed effects for human beings is unclear." "" "" ""</seg>
<seg id="2057">"" "" "" "out of the existing exposures data on humans, both clinical trials and therapeutic use, however, little evidence for the adoption of a clinical relevance of these findings." "" "" ""</seg>
<seg id="2058">"" "" "" "in a standard battery of In-vivo- and in-vitro-genotoxicity tests, microkernel testing on human peripheral lymphocytes, Ammiavir was neither mutagoxic nor genotoxic." "" "" ""</seg>
<seg id="2059">"" "" "" "these liver toxicity can be monitored and demonstrated in clinical daily life through the measurement of AST, ALT and the activity of alkaline phosphatase." "" "" ""</seg>
<seg id="2060">"" "" "" "previously, in clinical trials no significant liver toxicity was observed in patients, neither during the administration of agenerative ase after the end of the treatment." "" "" ""</seg>
<seg id="2061">"" "" "" "studies on the toxicity in young animals treated with a high level of 4 days, showed a high mortality rate during the inspection as well as with amplitudes with amplitudes." "" "" ""</seg>
<seg id="2062">"" "" "" "at systemic plasma exposure, significantly lower (rats) or not significantly higher (rats) as the expected exposure under therapeutic dosage, however, a number of minor changes including thymongation and minor skeleton changes were observed." "" "" ""</seg>
<seg id="2063">"" "" "" "24 If generic capsules are applied without the amplification of rite level (booklace), higher doses have to be applied to Agenerase (1200 mg twice daily)." "" "" ""</seg>
<seg id="2064">The recommended dose for generic capsules is 20 mg of amplitudes / kg body weight twice a day in combination with other antiretroviral drugs daily in combination with other antiretroviral drugs up to one day of the day of 2400 mg amicavir which should not be exceeded (see Section 5.1).</seg>
<seg id="2065">"" "" "" "the simultaneous application should be done in patients with low or easier liver interference with caution, in patients with severe liver interference it is contraindicated (see Section 4.3)." "" "" ""</seg>
<seg id="2066">"" "" "" "26 For some medicines that may cause serious or threatening side effects, phenobarbital, phenobarbital, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International standardization ratio), are available methods for determining active substances." "" "" ""</seg>
<seg id="2067">"" "" "" "Agenerase should be set at length 27 if a rash of systemic or allergic symptoms is accompanied or the mucous membranes are involved (see section 4.8)." "" "" ""</seg>
<seg id="2068">"" "" "" "an increased risk for a liystrophy was associated with individual factors, such as a higher age, and with medication-dependent factors such as a longer lasting antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="2069">"" "" "" "it was shown that Rifampicin causes a 82% reduction in AUC by Amfliavir, which can lead to a virological failure and lead to a resistance development." "" "" ""</seg>
<seg id="2070">508% increase for Cmax by 30% if rite (100 mg twice daily) is administered in combination with Ammiavir capsules (600 mg twice daily).</seg>
<seg id="2071">"" "" "" "the Cmin values of Amfliavir in the plasma, which were administered twice daily with Kaletra (400 mg daily) with Kaletra (600 mg twice daily) in combination with 100 mg of Ritonavir twice a day." "" "" ""</seg>
<seg id="2072">"" "" "" "recommended dosage for the simultaneous administration of Ammiavir and Kaletra can not be given, but it is recommended to provide a close monitoring because the effectiveness and lack of this combination is not known." "" "" ""</seg>
<seg id="2073">The treatment with efavirenz in combination with Amburst avir and Saquinavir is not recommended since the exposure of both proteastia would be reduced.</seg>
<seg id="2074">"" "" "" "when this medicine can be applied together, caution is advisable; a thorough clinical and virological monitoring should be made, as an accurate forecast of the effect of the combination of amplitudes and Ritonavir on Delavirdin is difficult." "" "" ""</seg>
<seg id="2075">"" "" "" "if it is necessary for clinical reasons, Rifabutin is advised along with asgenerase, to reduce the dose of rifabutin at least half of the recommended dose 31, although there is no clinical data." "" "" ""</seg>
<seg id="2076">"" "" "" "the serum concentrations of calcium-cantiblockers such as amlodipine, dipine pin, pin pine, nimdipine, nimdipine, Nisoldipine and Verapamil can increase the activity and toxicity of this drug." "" "" ""</seg>
<seg id="2077">In a clinical study conducted in the Ritonavir 100 mg capsules twice a day together with 50 µg fluctuation propionate intranasal (4 times daily) over 7 days decreased (90% reduction interval between 82 and 89%).</seg>
<seg id="2078">"" "" "" "while offering warfarin or other oral anticoagulants together with Agenerase, a reinforced control of the INR (International standardization ratio) is recommended because of the possibility of weakening or amplification of the antithrombotic effect (see Section 4.4)." "" "" ""</seg>
<seg id="2079">The simultaneous administration of Ortho-Novum 1 / 35 (0.035 mg ethinyletidiol plus 1,0 mg Norethindron) lead to a decrease in AUC and Cmin from Ammah avir 22% or about 22% respectively.</seg>
<seg id="2080">"" "" "" "during pregnancy, this medicine may only be applied during pregnancy after careful consideration of possible use for the mother compared to the possible risks for the fetus." "" "" ""</seg>
<seg id="2081">"" "" "" "a recurring study of pregnant rats, which was administered by the emptiness to the uterus up to the end of the breastfeeding in the uterus until the end of the downtime showed a diminished increase in body weight." "" "" ""</seg>
<seg id="2082">"" "" "" "in adults and for children from 4 years of controlled clinical trials in combination with various other antiretroviral drugs." "" "" ""</seg>
<seg id="2083">"" "" "" "in case of overdosing, the patient is to observe in signs of an intoxication (see section 4.8) when necessary, necessary supporting measures are necessary." "" "" ""</seg>
<seg id="2084">The antiviral activity in vitro against HIV-1 IIIB was studied in acute and chronic lymphoblastic cell lines (MT-4, CEM-CCRF (H9) as well as peripheral blood cells.</seg>
<seg id="2085">The 50% Hemi concentration (IC50) from Amwiavir is in the range from 0.012 to 0.08 µM for acute infected cells (1 µM = 0.50 µg / ml).</seg>
<seg id="2086">"" "" "" "" "" "" "" the reversal retains its activity against some other proteastia-resistant isolates; the receipt of this activity seems to be dependent on the number and type of resistance mutations in the isolates. "" "" "" "</seg>
<seg id="2087">"" "" "" "based on these data, pre-treated children should be considered an unexpected benefit from" unleoosterling "asgenerase." "" "" "" "</seg>
<seg id="2088">"" "" "" "while the absolute concentration of unbound ambush avir remains constant, the percentage of free active ingredients in the Steady State via the area of Cmax, ss to Cmin, ss.." "" "" ""</seg>
<seg id="2089">"" "" "" "therefore, medicines that induce CYP3A4 or inhibit or inhibit the substrate of CYP3A4 if they are given simultaneously with asgenerase (see sections 4.3, 4.4 and 4.5)." "" "" ""</seg>
<seg id="2090">The renal clearing of Ritonavir is also negligibly; therefore the impact of a kidney disturbance on the elimination of Amhavir and Ritonavir is likely to be minimal.</seg>
<seg id="2091">"" "" "" "in long-term studies on the carcinogenicity with amplitudes in mice and rats, the exposure involving human animals (mice) or 3,8- times (rat) of exposure involving individuals after twice daily gift of 1200 mg is ambleavir." "" "" ""</seg>
<seg id="2092">The underlying mechanism for the emergence of hepatoculary adenomes and carcinomas were not solved and the relevance of the observed effects for human beings is unclear.</seg>
<seg id="2093">"" "" "" "however, of the existing exposures data am human, both clinical trials and therapeutic use however, little evidence for the adoption of a clinical relevance of these findings." "" "" ""</seg>
<seg id="2094">"" "" "" "in a standard battery of in-vivo- and in-vitro plotoxicity tests, the bacterial reverse osynx test, microkernel test on human peripheral lymphocytes, was neither mutiny nor genotoxic." "" "" ""</seg>
<seg id="2095">"" "" "" "studies on the toxicity in young animals treated with a high level of 4 days, showed a high mortality rate during the inspection as well as with amplitudes with amplitudes." "" "" ""</seg>
<seg id="2096">"" "" "" "these results can be concluded that in young, the metabolism are not fully ransacked, so ambleavir or other critical components of the formulation (z)." "" "" ""</seg>
<seg id="2097">"" "" "" "Afraase solution is used in combination with other antiretroviral drugs for the treatment of HIV-1 infected, Proteassigmer (PI) pre-treated adults and children from 4 years." "" "" ""</seg>
<seg id="2098">"" "" "" "the use of Ritonavir" geboosterter "Agenerase" solution was not treated with PI pre-treated patients with PI pre-treated patients. "" "" "" "</seg>
<seg id="2099">The bioavailability of Ammiavir as a solution to the intake is 14% lower than the capsule; therefore Afraase capsules and solution for insertion on a milligrams per milligram basis is not interchangeable (see Section 5.2).</seg>
<seg id="2100">"" "" "" "patients should be able to swallow the capsules, as soon as they are able to swallow up the capsules with taking the solution (see Section 4.4)." "" "" ""</seg>
<seg id="2101">The recommended dose for Afraase solution is 17 mg (1.1 ml) Amfliavir / kg body weight three times a day in combination with other antiretroviral drugs up to a daily dose of 2800 mg of amplona which should not be exceeded (see Section 5.1).</seg>
<seg id="2102">"" "" "" "additionally, there is no dose recommended for the simultaneous application of Agenerase solution to disposing and low dosing Ritonavir can be avoided to avoid this combination with these patient groups." "" "" ""</seg>
<seg id="2103">"" "" "" "although a dosisadaption for Amburst avir is not considered to be necessary, an application of Agenerase solution is contraindicated in patients with kidney failure (see Section 4.3)." "" "" ""</seg>
<seg id="2104">"" "" "" "due to the potential risk of a toxic reaction as a result of high propyl glycol, Agenerase solution is contraindicated in patients with reduced liver function or liver failure and in patients with kidney failure." "" "" ""</seg>
<seg id="2105">"" "" "" "the simultaneous administration may lead to a competitive inhibiting of the metabolism, possibly causing serious and / or life-threatening side effects such as cardiac arrhythmia (z)." "" "" ""</seg>
<seg id="2106">"" "" "" "patients should be advised that Agenerase or any other antiretroviral therapy do not lead to a cure of HIV infection, and that they continue to develop opportunistic infections or other complications of HIV infection." "" "" ""</seg>
<seg id="2107">"" "" "" "the current antiretroviral therapy including treatment with asgenerase does not prevent the risk of 47 from HIV to others by sexual contact or contamination with blood." "" "" ""</seg>
<seg id="2108">"" "" "" "for some drugs such as carbamazepine, phenobarbital, phenobarbital, phenobarbital, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International standardization ratio), are available methods for determining active substances." "" "" ""</seg>
<seg id="2109">"" "" "" "Agenerase should be set on duration if a rash of systemic or allergic symptoms is accompanied or the mucous membranes are involved (see section 4.8)." "" "" ""</seg>
<seg id="2110">"" "" "" "an increased risk for a liystrophy was associated with individual factors, such as a higher age, and with drugs - 49 dependent factors such as a longer lasting antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="2111">"" "" "" "with hemophiles patients (type A and B), reports were treated with proteasehemiah, reports about an increase of bleeding including spontaneous mcutaneous hematoma and hematthroes." "" "" ""</seg>
<seg id="2112">"" "" "" "it was shown that Rifampicin causes a 82% reduction in AUC by Amfliavir, which can lead to a virological failure and lead to a resistance development." "" "" ""</seg>
<seg id="2113">508% increase for Cmax by 30% if rite (100 mg twice daily) is administered in combination with Ammiavir capsules (600 mg twice daily).</seg>
<seg id="2114">"" "" "" "simultaneous taking with asgenerase, their plasma concentration may increase considerably, and lead with PDE5 inhibitors including hypotension, tendon disorders, and priapism (see Section 4.4)." "" "" ""</seg>
<seg id="2115">"" "" "" "based on the data to 54 other CYP3A4 Inhibitors, Midazolam significantly increased significantly higher plasma concentration of Midazolam." "" "" ""</seg>
<seg id="2116">The potential risk for humans is not known. Agenera solution to get involved may not be applied during pregnancy due to possible toxic reactions of the fetus in the pregnancy (see section 4.3).</seg>
<seg id="2117">"" "" "" "in the milk pudding rats were proven to amburst avir-related substances, however, it is not known whether ambleavir over humans into breast milk." "" "" ""</seg>
<seg id="2118">"" "" "" "a recurring study of pregnant rats, which was administered by the emptiness to the uterus up to the end of the downtime Amhmetr, showed a diminished increase of 55 body weight in postage." "" "" ""</seg>
<seg id="2119">"" "" "" "in adults and for children from 4 years of controlled clinical trials in combination with various other antiretroviral drugs." "" "" ""</seg>
<seg id="2120">"" "" "" "with many of these events, it is not clear whether they are used in connection with the intake of Agenerase or another at the same time for HIV treatment, or whether they are a result of the disease." "" "" ""</seg>
<seg id="2121">Treated with the treatment of antiretroviral treatment with the present Fosamprenavir / rite-dosages were observed - as with other rite-inhibitors - the mutations described only rarely.</seg>
<seg id="2122">"" "" "" "early waste of a different 60 therapy is recommended to keep the accumulation of a variety of mutations in boundaries, which can affect the following treatment." "" "" ""</seg>
<seg id="2123">62 "" "" "" "62 Based on these data should be considered at therapy optimisation, with PI pre-treated children who are expected to consider" unbooked "asgenerals." "" "" "" "</seg>
<seg id="2124">The apparent field of distribution is approximately 430 l (6 l / kg with a body weight of 70 kg) and can be connected to a big couplings of ambush avir from the bloodstream into the tissue.</seg>
<seg id="2125">The underlying mechanism for the emergence of the Hepatocell-adenome and carcinomas were not solved and the relevance of the observed effects for human beings is unclear.</seg>
<seg id="2126">"" "" "" "at systemic plasma exposure, significantly lower (rats) or not significantly higher (rats) as the expected exposure under therapeutic dosage, however, a number of minor changes including thymongation and minor skeleton changes were observed." "" "" ""</seg>
<seg id="2127">"" "" "" "perhaps you would like to read this later again. − If you have further questions, please contact your doctor or pharmacist. − The medicine was given to you personally." "" "" ""</seg>
<seg id="2128">"" "" "" "it can harm other people even if these are the same discomforts as you are. − If any of the side effects are significantly impaired or you will notice any side effects that are not listed in this user information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2129">"" "" "" "your doctor will normally approach, askase capsules, together with low doses of Ritonavir to increase the effect of asgenerase." "" "" ""</seg>
<seg id="2130">The use of Agenerase is based on the individual viral resistance tests and your treatment history.</seg>
<seg id="2131">Inform your doctor if you suffer from one of the aforementioned diseases or take any of the aforementioned drugs.</seg>
<seg id="2132">"" "" "" "if your doctor has recommended that you are using Agenerase capsules with low doses ranging from Ritonavir to strengthen the effect (booklace), make sure you have carefully read the use information on Ritonavir." "" "" ""</seg>
<seg id="2133">"" "" "" "likewise, there are no sufficient information to use the application of Agenerase capsules along with rite level for children aged 4 to 12 years or generally recommended in patients under 50 kg of body weight." "" "" ""</seg>
<seg id="2134">"" "" "" "therefore, it is important that you start the section" At intake of asgenerase with other medicines, before starting with asgenerase. "" "" "" "</seg>
<seg id="2135">"" "" "" "you may need additional factor VIII to control the blood level. − With patients who have antiretroviral combination therapy, a redistribution, accumulation or loss of body fat can occur." "" "" ""</seg>
<seg id="2136">"" "" "" "if you are certain drugs that lead to severe side effects such as carbamazepine, phenylliin, cyclosporin, cyclosporine, cycyclic antidepressants, cycyclic antidepressants, cycyclic antidepressants, cycyclic antidepressants, cycyclic antidepressants, cyanolima, tricyclic antidepressants, consult your doctor may minimize additional safety problems." "" "" ""</seg>
<seg id="2137">"" "" "" "it is recommended that HIV positive women should feed their children under no circumstances in order to avoid a transfer of HIV." "" "" ""</seg>
<seg id="2138">"" "" "" "machines for the use of machinery, there were no studies on the influence of gearboxes or the ability to serve machines." "" "" ""</seg>
<seg id="2139">"" "" "" "please take this medicine only after consultation with your doctor, if you know that you suffer from a tolerability towards certain sugars." "" "" ""</seg>
<seg id="2140">"" "" "" "take Didano in), it is advisable to take this more than an hour before or after asgenerase, otherwise the effects of maple can be diminished." "" "" ""</seg>
<seg id="2141">"" "" "" "dose of generic capsules is 600 mg twice a day, with 100 mg of Ritonavir daily in combination with other antiretroviral drugs." "" "" ""</seg>
<seg id="2142">"" "" "" "if your doctor decides that the intake of rite is not suitable for you, you will have to take greater doses (1200 mg of amplitudes twice daily)." "" "" ""</seg>
<seg id="2143">"" "" "" "85 Damit Agenerating a wide range of benefits, it is very important that you have prescribed the whole daily dose that your doctor has prescribed." "" "" ""</seg>
<seg id="2144">"" "" "" "if you have taken a larger amount of asgenerase when you should have taken more than the prescribed dose of maple, you should immediately receive contact with your doctor or pharmacist." "" "" ""</seg>
<seg id="2145">"" "" "" "if you forget the consumption of asgenerase if you have forgotten the consumption of asgenerase, take it as soon as you think about it, and then continue the intake as before." "" "" ""</seg>
<seg id="2146">"" "" "" "in treating a HIV infection, it is not always possible to say whether there are any occurring side effects caused by asgenerase, to be taken at the same time or by the HIV illness." "" "" ""</seg>
<seg id="2147">Headache: anxiety diarrhea, disease-feeling, vomiting, bloating skin rash (redness, blister or itching) - occasionally the skin rash can be more serious and you may force this medication. "" "" "" "</seg>
<seg id="2148">"" "" "" "feelings, depression, sleep disorders, loss of appetite, loss of liver, discomfort or excessive stomach, soft chairs, increase of certain liver enzymes, the pancreas, called amylase" "" "" ""</seg>
<seg id="2149">Increased blood values for sugars or cholesterol (a certain blood fat) increases blood values of a substance called Bilirubin's swelling of the face, lips and tongue (angioedema).</seg>
<seg id="2150">"" "" "" "this can include fat loss of legs, arms and face, a fat inlay on the abdomen and in other inner organs, breast augmentation and fat curls in necks." "" "" ""</seg>
<seg id="2151">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will be significantly impaired or you will notice any side effects that are not listed in this manner." "" "" ""</seg>
<seg id="2152">"" "" "" "therefore, it is important that you start the section" At intake of asgenerase with other medicines, before starting with asgenerase. "" "" "" "</seg>
<seg id="2153">"" "" "" "in some patients who obtained a antiretroviral combination treatment, one can develop bones from bone tissue as a result of insufficient blood supply (bone)." "" "" ""</seg>
<seg id="2154">"" "" "" "take Didano in), it is advisable to take this more than an hour before or after asgenerase, otherwise the effects of maple can be diminished." "" "" ""</seg>
<seg id="2155">"" "" "" "94" "" "" "" 94 Damit Agenerating a wide range of benefits, it is very important that you have prescribed the whole daily dose that your doctor has prescribed. "" "" "" "</seg>
<seg id="2156">"" "" "" "if you forget the consumption of asgenerase if you have forgotten the consumption of asgenerase, take it as soon as you think about it, and then continue taking the intake as before." "" "" ""</seg>
<seg id="2157">Headache: anxiety diarrhea, disease-feeling, vomiting, bloating skin rash (redness, blister or itching) - occasionally the skin rash can be more serious and you may force this medication. "" "" "" "</seg>
<seg id="2158">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will be significantly impaired or you will notice any side effects that are not listed in this manner." "" "" ""</seg>
<seg id="2159">"" "" "" "dose of generic capsules is 600 mg twice a day, with 100 mg of Ritonavir daily in combination with other antiretroviral drugs." "" "" ""</seg>
<seg id="2160">"" "" "" "so that Agenerase brings a wide range of benefits, it is very important that you have prescribed the whole daily dose that your doctor has prescribed." "" "" ""</seg>
<seg id="2161">"" "" "" "if you have taken larger quantities of Agenerase when you should have taken more than the prescribed dose of maple, you should immediately receive contact with your doctor or pharmacist." "" "" ""</seg>
<seg id="2162">The use of Ritonavir "geboosterter" Agenerase "solution could not be used in patients with proteassists in pre-treated patients with proteastia.</seg>
<seg id="2163">"" "" "" "for the application of lower doses of Ritonavir (usually applied to gain amplification] from Agenerase capsules), along with asgenerase solution, cannot be used to allow dosing recommendations." "" "" ""</seg>
<seg id="2164">"" "" "" "Ritonavir solution for intake), or in addition propylglycol mix during the intake of asgenera solution (see also Agenerase must not be taken)." "" "" ""</seg>
<seg id="2165">"" "" "" "your doctor may be observed on side effects associated with the propylene glycol, in particular if you have kidney or liver disease." "" "" ""</seg>
<seg id="2166">111. if you are certain drugs that lead to severe adverse events such as carbamazepine, phenylliin, cyclosporine, cyclosporine, cyaplima, tricyclic antidepressants, cycyclic antidepressants, cycyclic antidepressants, cycyclic antidepressants and warfarin, to minimize risk of safety problems. "" "" "" "</seg>
<seg id="2167">"" "" "" "Ritonavir solution for intake) or additional propylene glycol, do not take (see Agenerase must not be taken)." "" "" ""</seg>
<seg id="2168">Important information about certain other components of Afraase solution for inserting the solution of propylene glycol mix which can cause side-effects in high doses.</seg>
<seg id="2169">"" "" "" "Propylglycol can cause a range of side effects including varicitation, dizziness, cardiac disease, and the reduction of red blood cells (see also Agenerase is necessary precautions)." "" "" ""</seg>
<seg id="2170">"" "" "" "if you forget the consumption of asgenerase if you have forgotten the consumption of asgenerase, take it as soon as you think about it, and then continue the intake as before." "" "" ""</seg>
<seg id="2171">Headache: anxiety diarrhea, disease-feeling, vomiting, bloating skin rash (redness, blister or itching) - occasionally the skin rash can be more serious and you may force this medication. "" "" "" "</seg>
<seg id="2172">"" "" "" "this can include fat loss of legs, arms and face, a fat inlay on the abdomen and in other inner organs, breast augmentation and fat curls in necks." "" "" ""</seg>
<seg id="2173">"" "" "" "the other components are propylene glycol, Macrogol 400 (polyethylene glycol 400), acetylenol, citric acid, citric acid, sodium citrate-dihydrat, purified water." "" "" ""</seg>
<seg id="2174">The applicability and duration of treatment with Aldara depend on the treatment of the treatment of Aldara up to a maximum of 16 weeks. • At little basal cell carcinoma during one or two four-week treatment cycles with four weeks break between the treatment cycles to be added three times per week.</seg>
<seg id="2175">"" "" "" "the cream is fertilized before bedtime to add the affected skin surfaces, so that they will remain sufficient for a long time (about eight hours) before being washed away." "" "" ""</seg>
<seg id="2176">"" "" "" "in all trials Aldara was compared with placebo (the same cream, but without the active substance). • Aldara was tested in four main studies at 923 patients with warts in the genital area for 16 weeks." "" "" ""</seg>
<seg id="2177">"" "" "" "the main indian indicator for efficacy was the number of patients treated with small basal cell carcinomas in two trials, during which patients were treated for six weeks or placebo either daily or five times per week." "" "" ""</seg>
<seg id="2178">"" "" "" "the main indicator for efficacy was the number of patients with complete separation of tumours after twelve weeks. • Aldara was also tested in two studies of 505 patients with actinical keratosis." "" "" ""</seg>
<seg id="2179">In all trials Aldara was more effective than the placebo. • A total healing rate of 66% to 52% were treated with Aldara patients in comparison to 0% to 3% in the placebo group.</seg>
<seg id="2180">The most common side effects of Aldara (observed in more than 1 of 10 patients) are reactions to the use of the cream (pain or itching).</seg>
<seg id="2181">"" "" "" "clinically typical, not hypertrophysiotic, non-hypertrophysical keratosis (AKS) in the face or on the scalp, limits the effectiveness and / or the acceptance of a cryotherapy and other topical treatment options are contraindicated or less suitable." "" "" ""</seg>
<seg id="2182">"" "" "" "Monday, Wednesday and Friday or Tuesday, Thursday and Saturday) before feeding and leave 6 to 10 hours on the skin." "" "" ""</seg>
<seg id="2183">"" "" "" "the treatment with imiquimodine cream is so long to continue, until all visible warnings of genital or periors are missing, or up to a maximum of 16 weeks per treatment period." "" "" ""</seg>
<seg id="2184">An interruption in the treatment process should be considered when intensive local inflammation occur (see Section 4.4) or when in the treatment area an infection is observed.</seg>
<seg id="2185">If the follow-up examination of 4 to 8 weeks after the second treatment period the treated lesions should only be incomplete and another therapy should be started (see section 4.4).</seg>
<seg id="2186">"" "" "" "if one dose was omitted, the patient should apply the cream as soon as he / she noticed this and then proceed with the usual therapy plan." "" "" ""</seg>
<seg id="2187">"" "" "" "imiquimodine cream is recycled into a thin layer and rub in the stoned, infected skin area until the cream is completely fenced." "" "" ""</seg>
<seg id="2188">"" "" "" "it should take a consideration between the benefits of treatment using Imiquimod, and the risk associated with a possible loss of autoimmune disease." "" "" ""</seg>
<seg id="2189">"" "" "" "in these patients, a consideration was done between the benefit of a treatment using Imiquimod and the risks associated with a possible organ and graft versus decei- reaction." "" "" ""</seg>
<seg id="2190">"" "" "" "in other studies, in which no daily prehauthygiene were performed, two cases of severe Phimosis and one case were observed with a leading Stricture." "" "" ""</seg>
<seg id="2191">"" "" "" "during an application of Imiquimodine cream in higher than the recommended doses there is a higher risk of severe local skin irritation (see Section 4.2.) In rare cases, severe local skin irritation were also observed, which made treatment necessary and / or to a temporary physical impairment." "" "" ""</seg>
<seg id="2192">"" "" "" "in cases where such reactions took place at the exit of the urethra, some women had trouble passing urine, which required an emergency catheter and treatment of the affected area." "" "" ""</seg>
<seg id="2193">"" "" "" "to apply Imiquimodine cream directly in connection to treatment with other cutaneous means applied to the treatment of external fever, no clinical experiences have been used." "" "" ""</seg>
<seg id="2194">"" "" "" "limited data suggest an increased rate of fine-interest reductions in HIV positive patients, Imiquimodine cream has shown in this patient group with regard to the removal of the pincers but a lower effectiveness." "" "" ""</seg>
<seg id="2195">"" "" "" "the treatment of Basal cell carcinoma with Imiquimod within 1 cm around the eyelids, the nose, the lips, or hair set has not been studied." "" "" ""</seg>
<seg id="2196">"" "" "" "local skin reactions are frequent, but the intensity of these reactions take in general during the therapy or the reactions form the treatment with imiquimodine cream." "" "" ""</seg>
<seg id="2197">"" "" "" "due to the complaints of the patient or due to the severity of the local skin reactions, a treatment period can be made of several days." "" "" ""</seg>
<seg id="2198">"" "" "" "after the regeneration of the treated skin, the clinical result of therapy can be evaluated approximately 12 weeks after the treatment." "" "" ""</seg>
<seg id="2199">"" "" "" "since there are currently no data on long-term healing rates of more than 36 months after treatment, other suitable treatment methods should be moved in consideration." "" "" ""</seg>
<seg id="2200">"" "" "" "in patients with recurrent and pre-treated BCCs, no clinical experiences are available, therefore the application is not recommended in pre-treated tumours." "" "" ""</seg>
<seg id="2201">Data from an open clinical study point out that at large tumours (&gt; 7.25 cm2) a lower likelihood of response to the imiquimod therapy.</seg>
<seg id="2202">"" "" "" "imiquimod has not been studied for the treatment of actinical keratosis on eyelids, inside the nose or ears or in the lipstick zone within the lipstick." "" "" ""</seg>
<seg id="2203">"" "" "" "there are only very limited data on the use of imiquimodine for the treatment of actinical keratosis, anatomical places outside the face and the scalp." "" "" ""</seg>
<seg id="2204">"" "" "" "the available data on the actinical keratosis on the forearms and hands do not support the efficacy in this application, therefore such an application is not recommended." "" "" ""</seg>
<seg id="2205">"" "" "" "local skin reactions occur frequently, but these reactions normally occur after the therapy in intensity or go back after placing the therapy with imiquimodine cream." "" "" ""</seg>
<seg id="2206">"" "" "" "if local skin reactions may cause large discomfort to the patient, the treatment can be exposed for a few days." "" "" ""</seg>
<seg id="2207">"" "" "" "out of the data from an open clinical study, patients with more than 8 files showed a lower complete healing rate compared to patients with less than 8 lesions." "" "" ""</seg>
<seg id="2208">"" "" "" "due to immunity stimulating properties, Imiquimod cream should be used with caution when patients receiving a immune suppressive treatment (see 4.4)." "" "" ""</seg>
<seg id="2209">"" "" "" "animal studies do not leave any direct or indirect effects on pregnancy, embryonic / reddish development, the binding or postnatal development (see 5.3)." "" "" ""</seg>
<seg id="2210">"" "" "" "although it is not yet possible after unique topical use (&gt; 5ng / ml), no recommendation can be given during breastfeeding." "" "" ""</seg>
<seg id="2211">"" "" "" "most commonly assigned and probably with the application of Imiquimodine cream, related side effects in the studies with three weekly treatment were local reactions in the treatment of the fever (33.7% of patients treated with Imiquimod patients)." "" "" ""</seg>
<seg id="2212">"" "" "" "most frequently reported and probably, possibly, possibly with the application of the Imiquimodine cream in the related side effects include complaints at the application location with an incidence of 28,1%." "" "" ""</seg>
<seg id="2213">"" "" "" "in 185 with Imiquimodine cream, Basalioma patients treated from a placebo-controlled clinical study reported side effects are shown below." "" "" ""</seg>
<seg id="2214">"" "" "" "the most common, probably or possibly with the application of the imiquimodine cream in the related side effects were a reaction on the application location (22% of patients treated with Imiquimod patients)." "" "" ""</seg>
<seg id="2215">"" "" "" "the side effects produced by 252 in placebo-controlled clinical trials with Imiquimodine cream treated patients with actinical keratosis, are listed below." "" "" ""</seg>
<seg id="2216">These according to test plan presented by clinical signs shows that in these placebo-controlled clinical trials including imiquimodine cream are frequently added to local skin reactions including Erythem (61%), exfoliation / evenings (23%) and odes (see section 4.4).</seg>
<seg id="2217">"" "" "" "these according to test plan presented by clinical evidence shows that in these studies with a five times of weekly treatment with Imiquimodine cream, severe erosions (13%), severe erosion and shrestation (19%) came." "" "" ""</seg>
<seg id="2218">"" "" "" "in clinical trials for examining the application of Imiquimod for the treatment of actinical keratosis, alopecia was diagnosed with an incidence of 0.4% (5 / 1214) in the area of treatment or in the surrounding area." "" "" ""</seg>
<seg id="2219">"" "" "" "the extraordinary unique recording of 200 mg of Imiquimod, which corresponds to the contents of approximately 16 bags, might cause nausea, vomiting, myalgia and fever." "" "" ""</seg>
<seg id="2220">"" "" "" "the clinically serious side effect, which occurred after several oral doses of &gt; 200 mg was normalized in hypotonia, which normalized after oral or intravenous liquid." "" "" ""</seg>
<seg id="2221">"" "" "" "after the topical application of Imiquimod, increasing systemic concentrations of alpha interferons and other cytokines were demonstrated." "" "" ""</seg>
<seg id="2222">"" "" "" "in 3 perceptive phase 3 efficacy studies, it could be shown that the effectiveness in relation to a complete wound healing of the fever therapy is superior to over 16 weeks of placebo treatment." "" "" ""</seg>
<seg id="2223">"" "" "" "at 60% of the total 119 with Imiquimod therapies, the cowards healed them completely; this was 20% of the 105 with placebo patients (95% CI):" "" "" ""</seg>
<seg id="2224">A complete allocation could be achieved in 23% of 157 with Imiquimod male patients treated against 5% of 161 with placebo-treated male patients (95% CI):</seg>
<seg id="2225">"" "" "" "the effectiveness of Imiquimod during five time application per week over 6 weeks was examined in two double-blind, placebo-controlled clinical trials." "" "" ""</seg>
<seg id="2226">The target tumors were histologically confirmed individual primary superfizielle basal cell carcinomas with a minimum size of 0.5 cm2 and a maximum diameter of 2 cm.</seg>
<seg id="2227">The data from an open, uncontrolled and long-term study after four years of present data suggest that approximately 79.3% [95% CI (73.7%, 84.9%) were treated clinically and this remained for 48 months.</seg>
<seg id="2228">"" "" "" "the effectiveness of imiquimod during three weeks of weekly application in one or two treatment periods of 4 weeks, interrupted by a four-week-treated period, was examined in two double-blind, placebo-controlled clinical trials." "" "" ""</seg>
<seg id="2229">"" "" "" "patients had clinically typical, visible, discrete, non-hypertrophysical, non-hypertrophic acesions within a connexion 25 cm2 of large treatment areals on the hairless scalp or face." "" "" ""</seg>
<seg id="2230">"" "" "" "the income data from two combined observation studies indicate a Rezidivrate of 27% (35 / 128 patients), for patients with clinical separation studies." "" "" ""</seg>
<seg id="2231">"" "" "" "the approved indications, actinical keratosis, and superfizial basal cell carcinoma usually occur at paediatric patients and were therefore not examined." "" "" ""</seg>
<seg id="2232">Aldara cream was examined in four randomised, double-blind placebo-controlled trials in children aged 2 to 15 years with molluscum contagiosum (Imiquimod n = 576, placebo n = 313).</seg>
<seg id="2233">"" "" "" "in these studies, the efficacy of Imiquimod could not be shown in these studies (3x / week for a period of ≤ 16 weeks bzw." "" "" ""</seg>
<seg id="2234">Minimal systemic absorption of the 5% Imiquimod cream through the skin of 58 patients with actinical keratosis was observed during the three times of weekly application during 16 weeks.</seg>
<seg id="2235">The highest Drug concentrations in serum at the end of the week 16 were observed between 9 and 12 hours and betrugen 0.1, 0.2 and 1.6 ng / ml during the use in the face (25mg, 2 bags) and on the head / arms (75 mg, 6 bags).</seg>
<seg id="2236">The calculated half-value time was about 10times higher than the 2hour half-time after the subcutaneous application in a previous study; this indicates an extended Retention of Drug with the skin.</seg>
<seg id="2237">"" "" "" "the data of systemic exposure showed that the absorption of Imiquimod following topical application was low in the age of 6 to 12 years and comparable to the healthy adult and adult patients with actinical keratosis or superfizil basal cell carcinoma." "" "" ""</seg>
<seg id="2238">"" "" "" "in a four month study on the paint toxicity in a rat of 0.5 and 2.5 mg / kg kg significantly reduced body weight and increased milz weight; one also four months long-run study for the paint application showed no similar effects in the mouse." "" "" ""</seg>
<seg id="2239">A two-year study of carcinogenicity in mice in two days per week does not induced any tumors at the application.</seg>
<seg id="2240">"" "" "" "the corresponding mechanism is not known, but since Imiquimod has only one low systemic absorption from human skin and not mutagen is a risk to look at the systemic exposure due to systemic exposure." "" "" ""</seg>
<seg id="2241">"" "" "" "the tumors were treated in the group of mice, which was treated with the nutrient-free cream, previously used in larger numbers than in the control group with low UVR." "" "" ""</seg>
<seg id="2242">"" "" "" "it can harm other people even if they have the same symptoms as you. − If any of the listed side effects are significant, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2243">● footpples (Condylomata acuminata) created on the skin in the area of genitalia (genitals) and Anus (After) created a superficial basal cell carcinoma with very low probability of spreading on other parts of the body.</seg>
<seg id="2244">"" "" "" "if it remains untreated, it may lead to resolutions, in particular in the face - therefore a screening test is important." "" "" ""</seg>
<seg id="2245">"" "" "" "actinical keratosis are harsh areas of the skin which occur with people, who were exposed to sunlight during their previous life." "" "" ""</seg>
<seg id="2246">Aldara should only be applied with a healthy immune system in the face and on the scalp in patients with a healthy immune system where your doctor has decided that Aldara is the best suitable treatment.</seg>
<seg id="2247">Aldara cream supports your body's own immune system in the production of natural substances that help your body to fight the superficial basal cell carcinoma, the actinical keratosis or the virus infection.</seg>
<seg id="2248">"" "" "" "O If you have already used Aldara cream or other, similar preparations, please inform Aldara cream until you have problems with your immune system. o Avoid having problems with your eyes, lips and nasal mucosa." "" "" ""</seg>
<seg id="2249">"" "" "" "if you accidentally contact the cream by rinsing with water. don't use cream instead of using Aldara cream without any inconvenience caused by Aldara cream, you do not wash the cream with a mild soap and water." "" "" ""</seg>
<seg id="2250">"" "" "" "once the reactions are disclosed, you can take care of your doctor if they don't have a normal blood picture." "" "" ""</seg>
<seg id="2251">"" "" "" "if this daily cleansing is not performed under the foreskin, the skin or difficulties can be calculated if the skin or difficulty passing the foreskin." "" "" ""</seg>
<seg id="2252">Do not apply Aldara cream in the urethra (urethra) in the vagina (vagina) and cervical (uterine cervix) or within the anus (anus).</seg>
<seg id="2253">"" "" "" "taking other drugs serious problems with your immune system, you should use this medication for no more than a treatment course." "" "" ""</seg>
<seg id="2254">"" "" "" "if you have intercourse during the infection with cowards in the genital area, the treatment with Aldara cream is performed after intercourse (not previously)." "" "" ""</seg>
<seg id="2255">"" "" "" "please inform your doctor or pharmacist if you apply other medicines or recently used, even if it is not prescription drugs." "" "" ""</seg>
<seg id="2256">Breastfeeding your infant during treatment with Aldara cream not known as if Imiquimodine is over into the breast milk.</seg>
<seg id="2257">"" "" "" "the frequency and duration of treatment are different with fever, basal cell carcinoma and actinical keratosis (see specific instructions for each application area)." "" "" ""</seg>
<seg id="2258">"" "" "" "wear a thin layer Aldara cream on the clean, dry skin with the tilt and rub the cream gently on your skin until the cream is completely fenced." "" "" ""</seg>
<seg id="2259">Men with cowries under the foreskin must remove the skin every day and wash the skin area underneath (see Section 2 "What must you consider before using Aldara cream?).</seg>
<seg id="2260">"" "" "" "please contact your doctor or pharmacist if you have the impression that the effect of aldara is too strong or weak." "" "" ""</seg>
<seg id="2261">"" "" "" "for 6 weeks each week, apply a sufficient amount of Aldara cream to cover the affected area and 1 cm around this area." "" "" ""</seg>
<seg id="2262">Very frequent side effects (in more than 1 of 10 patients expected) Frequent side effects (in less than 1 of 10 patients to be expected) Very rare side effects (in less than 1 of 10 patients) Very rare side effects (in less than 1 of 10,000 patients)</seg>
<seg id="2263">Inform your doctor / your doctor / pharmacist / pharmacist instantly when you feel at ease during the use of Aldara cream.</seg>
<seg id="2264">"" "" "" "if your skin reacts strongly to the treatment with Aldara cream, you should not continue the cream to wash the affected area with water and a mild soap and communicate your doctor or pharmacist." "" "" ""</seg>
<seg id="2265">"" "" "" "a humbled number of blood cells may make you vulnerable to infections; it can cause you to create a blue stain, or she can cause distraction." "" "" ""</seg>
<seg id="2266">Inform your doctor or pharmacist if one of the listed side effects will be significantly impaired or you will notice any side effects that are not listed in this use.</seg>
<seg id="2267">"" "" "" "in addition, you can find itching (32% of patients) or pain in the areas where you applied to Aldara cream (8% of patients)." "" "" ""</seg>
<seg id="2268">"" "" "" "this is usually about easier skin reactions, which resumes the treatment within about 2 weeks after placing the treatment." "" "" ""</seg>
<seg id="2269">"" "" "" "occasionally some patients notice changes in the application location (wound secretion, inflammation, swelling, shame, dermatitis) or irritability, nausea, dry mouth, flu-like symptoms and fatigue." "" "" ""</seg>
<seg id="2270">"" "" "" "occasionally, some patients suffer from change in the application location (Blued, inflammations, wound secretion, swelling or flu), depression, eye irritation, swelling, mimic pain, fever, weakness, or chills." "" "" ""</seg>
<seg id="2271">Aldurazyme is used for the enzyme therapy in patients with secured diagnosis of a Mucysaccharide deficiency (symptoms that are not related to the brain or nerves in connection).</seg>
<seg id="2272">"" "" "" "this means that certain substances (glycoherogllykane, gags) are not dismantled and thus accumulate in most organs in the body, and these are damage." "" "" ""</seg>
<seg id="2273">"" "" "" "the following non-neurological symptoms of the MPS I may occur: enlarged liver, stiff joints, complicate movements, reduced lung volume, heart and eye disease." "" "" ""</seg>
<seg id="2274">Treatment with Aldurazyme should be supervised by a doctor that has experience in the treatment of patients with MPS I or other hereditary metabolic diseases.</seg>
<seg id="2275">"" "" "" "the administration of Aldurazyme should be performed in a hospital or hospital with revitalization equipment, and patients need appropriate medicines to prevent an allergic reaction." "" "" ""</seg>
<seg id="2276">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europe.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.europa.europa.eu http: / / www.emea.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europa.europ</seg>
<seg id="2277">"" "" "" "in the study, mainly the safety of drugs was investigated, but it was also measured by its effectiveness (by investigating the concentration of Gag-concentrations in the urine and in relation to the size of the liver)." "" "" ""</seg>
<seg id="2278">"" "" "" "in children under five years old Aldurazyme the Gag-concentrations in the urine rose by about 60%, and half of the treated children showed a normal great liver at the end of the study." "" "" ""</seg>
<seg id="2279">"" "" "" "the most common side effects of Aldurazyme at the age of over five years (observed in more than 1 of 10 patients) are headaches, nausea, abdominal pain, skin rash, pain and reactions on the infusion agency." "" "" ""</seg>
<seg id="2280">Very frequent side effects in patients under five years are increased blood pressure, reduced oxygen saturation (a measurement size of lung function) and speedometer (accelerated blood pressure), fever and chills.</seg>
<seg id="2281">"" "" "" "Aldurazyme may react to patients who may be highly sensitive to laronidase or any of the other components (anaphylaktic reaction), not applied." "" "" ""</seg>
<seg id="2282">"" "" "" "each year, the European Medicines Agency (EMEA) will evaluate all new information that may be known to, and update this abstract." "" "" ""</seg>
<seg id="2283">"" "" "" "Aldurazyme, the manufacturer of Aldurazyme, will observe the reactions to infusion and the development of antibodies." "" "" ""</seg>
<seg id="2284">"" "" "" "in June 2003, the European Commission approved Genzyme Europe B.V. to provide permission for the transport of Aldurazyme throughout the European Union." "" "" ""</seg>
<seg id="2285">Laronidase is a recombinant form of human -L-Iduronidase and is produced by recombinant DNA technology using Cho-mammal cell cultures (Chinese Hamster Ovary, ovstock of the Chinese hamsters).</seg>
<seg id="2286">Aldurazyme is indicated for the long-term enzyme therapy in patients with secured diagnosis of a Mucysaccharide deficiency in patients to treat the non-neurological manifestations of the disease (see Section 5.1).</seg>
<seg id="2287">Treatment with Aldurazyme should be performed by a doctor that has experience in the treatment of patients with MPS I or other hereditary metabolic diseases.</seg>
<seg id="2288">The initial infusion rate of 2 E / kg / h can be increased if the patient carries this to a maximum dose of 43 E / kg / h every 15 minutes in single steps.</seg>
<seg id="2289">Safety and effectiveness of Aldurazyme in adults over 65 years was not determined and for these patients no dosing scheme can be recommended.</seg>
<seg id="2290">"" "" "" "the safety and effectiveness of Aldurazyme in patients with kidney or liver failure was not determined, and for these patients no dosing scheme can be recommended." "" "" ""</seg>
<seg id="2291">"" "" "" "with Aldurazyme patients, patients may develop infusion reactions which are defined as any related side effect, which occurs during infusion or until the end of the infusion (see section 4.8)." "" "" ""</seg>
<seg id="2292">"" "" "" "for this reason, these patients should also be supervised close meshed and the infusion of Aldurazyme should only be provided in appropriate clinical conditions, in the revitational equipment for medical emergencies." "" "" ""</seg>
<seg id="2293">"" "" "" "due to the clinical Phase 3 study, almost all patients IgG antibody to be found against Laronidase, usually within 3 months from the treatment begins." "" "" ""</seg>
<seg id="2294">"" "" "" "patients who develop antibodies or symptoms of an infusion reaction, must be handled using Aldurazyme with caution (see sections 4.3 and 4.8)." "" "" ""</seg>
<seg id="2295">"" "" "" "as little experience in the recovery of treatment after a longer interruption, due to the theoretically increased risk action has to be cautious after an interruption of treatment." "" "" ""</seg>
<seg id="2296">60 minutes before the start of infusion with drugs (antihistamines and / or anti pypyretics) to minimize the potential occurrence of unauthorized reactions.</seg>
<seg id="2297">"" "" "" "in case of light or medium-heavy infusion reaction, treatment with antihistamines and paracetamol / ibuprofen should be considered and / or a reduction of the infusion rate, in which the reaction has occurred." "" "" ""</seg>
<seg id="2298">"" "" "" "in case of a single, heavy infusion reaction the infusion must be stopped until the symptoms are brought to decline, a treatment with antihistamines and paracetamol / ibuprofen is too weakened." "" "" ""</seg>
<seg id="2299">"" "" "" "infusion can be resumed with a reduction of the infusion rate on 1 / 2 - 1 / 4 of the infusion rate, when the reaction has occurred again." "" "" ""</seg>
<seg id="2300">3 are used (antihistamines and paracetamol / ibuprofen and / or corticosteroids) as well as a reduction of infusion rates on 1 / 2 - 1 / 4 of the infusion rate.</seg>
<seg id="2301">Aldurazyme should not be used simultaneously with chloroquin or procaine because a potential risk of interference with the intracellular intake of Laronidase.</seg>
<seg id="2302">"" "" "" "experimental studies do not apply to direct or indirect effects on pregnancy, the embryonic / fetal development, birth and postnatal development (see Section 5.3)." "" "" ""</seg>
<seg id="2303">"" "" "" "since no data on newborns, which were exponated towards the mother's milk, is recommended to not breastfeed during treatment with Aldurazyme." "" "" ""</seg>
<seg id="2304">The side effects in clinical trials were mainly classified as infusion-related reactions which were observed in 53% of patients in the Phase 3 study (treatment duration of up to 4 years) and 35% of patients were observed in patients under 5 years (duration of treatment up to 1 year).</seg>
<seg id="2305">Unwanted medication reactions in connection with Aldurazyme which were observed during the period of 5 years or older in a duration of 45 patients (≥ 1 / 10); frequently (≥ 1 / 100 to &lt; 1 / 10).</seg>
<seg id="2306">"" "" "" "in some patients with severe MPS-I-related involvement of the upper respiratory system and lungs in the prehistory there were severe reactions, including bronchospasmus, breathing and facial oils (see Section 4.4)." "" "" ""</seg>
<seg id="2307">"" "" "" "children Unwanted medication related to Aldurazyme, reported in a phase of 20 patients with a total of 20 patients aged under 5, reported in the table." "" "" ""</seg>
<seg id="2308">"" "" "" "100 E / kg intravenously once a week (recommended dose), 200 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks." "" "" ""</seg>
<seg id="2309">"" "" "" "most patients received it within 3 months after the treatment of a Seroconversion, with a severe disintegration form usually within 5 years (average after 26 days against 45 days of patients at the age of 5 and older)." "" "" ""</seg>
<seg id="2310">"" "" "" "until the end of the Phase 3 study (or until a premature ejecting of the study), 13 / 45 patients were not detectable by Radioimmunopcipation (RIP) Assay, which had never been to Seroconversion." "" "" ""</seg>
<seg id="2311">"" "" "" "patients with lacked up to low antiviral levels showed a robust reduction of Gag-Spiegels in Harn, while in patients with high antibodies to determine a variable reduction of Gag in the harn." "" "" ""</seg>
<seg id="2312">Four patients (three in the Phase 3 study and one in the Phase 2 study showed a marginal to low neutralising effect on the enzymatic laronidase- activity in vitro which does not affect clinical efficacy and / or reduction of Gag in the hardn.</seg>
<seg id="2313">"" "" "" "the presence of antibodies seemed to stand not in connection with the incidence of adverse drug reactions, even if the occurrence of adverse drug reactions typically coincided with the formation of IgG antibodies." "" "" ""</seg>
<seg id="2314">"" "" "" "the justification for the enzyme therapy is in one for the hydrolysis of accumulated substrats, preventing further accumulation of adequate restoration of the activity." "" "" ""</seg>
<seg id="2315">"" "" "" "after intravenous infusion Laronidase is quickly removed from the circulation and cells into lysosomes, most likely about Mannose-6 phosphate receptors." "" "" ""</seg>
<seg id="2316">"" "" "" "the safety and efficacy of Aldurazyme were examined in a randomised, double-blind, placebo-3 study enrolled 45 to 43 years." "" "" ""</seg>
<seg id="2317">"" "" "" "although patients were recruited for the study, the majority of patients were recruited from the mean phenotype and only one patient showed the severe phenotype." "" "" ""</seg>
<seg id="2318">Patients were recruited if they had a forced expiratory volume (FEV) of less than 80% of the expected value and they had to be able to stand for 6 minutes and 5 metres.</seg>
<seg id="2319">The primary endpoints for the effectiveness were the percentage change of the expected FEV and the absolute walking distance in the 6-minute walk test.</seg>
<seg id="2320">"" "" "" "all patients were recruited for an open-label extension study, where they received more 3.5 years (182 weeks) every week 100 E / kg Aldurazyme." "" "" ""</seg>
<seg id="2321">"" "" "" "after 26 weeks of therapy, the patients were treated with Aldurazyme to improve lung function and enviability, which is shown in the following table." "" "" ""</seg>
<seg id="2322">The open extension study showed an improvement and / or maintain this effect of up to 208 weeks in the Aldurazyme group and from 182 weeks in the placebo / Aldurazyme group as shown from the following table.</seg>
<seg id="2323">The decrease in the expected percentage of FEV is clinically significant over this period and the absolute lung volume increased further in proportion to the height of the children.</seg>
<seg id="2324">"" "" "" "of the 26 patients with a heptic hesive treatment reached 22 (85%) until the end of the study, a normal liver size." "" "" ""</seg>
<seg id="2325">"" "" "" "within the first 4 weeks a clear waste of the Gag mirror in Harn (µg / mg of Kreatarginine) was noted, which remained constant until the end of the study." "" "" ""</seg>
<seg id="2326">"" "" "" "regarding the heterogeneous disease event between the patients, which was taken into account by using a combined end point, observed clinically significant changes across 10 patients (58%), no change in 10 patients (22%) and worsening in 9 patients (20%)." "" "" ""</seg>
<seg id="2327">"" "" "" "it was conducted a one year-old Phase 2 study, which was mainly investigating the safety and pharmacokinetics of Aldurazyme at 20 patients (16 patients with a heavy abandonment form and 4 with the middle abandonment form)." "" "" ""</seg>
<seg id="2328">"" "" "" "in four patients, the dosage due to increased casting mirrors in the harn increased to 200 E / kg in the last 26 weeks." "" "" ""</seg>
<seg id="2329">In several patients a magnitude (n = 7) and a weight gain (n = 3) was found according to the mean age group (n = 3) and all 4 patients with the mean age form only limited or no progress in cognitive development.</seg>
<seg id="2330">"" "" "" "in a Phase 4 study, investigations of pharmacodynamic effects of various Aldurazyme metering schemas were performed on the gag mirror in the harn, the liver volume and the 6-minute walk test." "" "" ""</seg>
<seg id="2331">"" "" "" "100 E / kg intravenously once a week (recommended dose), 200 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks." "" "" ""</seg>
<seg id="2332">The dosage scheme with 200 E / kg intravenously every 2 weeks can be represented in patients who have difficulties with weekly infusions; however it is not proven that the long-term clinical effectiveness of these two dosing schemas is equivalent.</seg>
<seg id="2333">"" "" "" "the European Medicines Agency (EMEA) will evaluate any new information, which will evaluate each year, and if necessary, the summary of the characteristics of the medication will be updated." "" "" ""</seg>
<seg id="2334">The pharmacokinetic profile in patients under 5 years of age was similar to the patients affected by older and less affected patients.</seg>
<seg id="2335">"" "" "" "based on conventional studies on security macology, toxicity in unique gift and reproduction, the preventive data do not recognize any particular dangers for humans." "" "" ""</seg>
<seg id="2336">"" "" "" "since no intolerance studies were performed, this medicine may not be mixed with other medicines, except those listed below 6.6." "" "" ""</seg>
<seg id="2337">"" "" "" "if the ready to use preparation is not used immediately, it is no longer used for 24 hours at 2 ° C - 8º C, where the dilution is controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2338">5 ml concentrate on producing a solution in perforation bottle (type I-glass) with stoppers (silicone chlorobite rubber) and sealing (aluminum) with cutters (polypropylene).</seg>
<seg id="2339">10 Preparation of Aldurazyme infusion (with aseptic Techniques) • Je to determine the number of patients to be diluted.</seg>
<seg id="2340">"" "" "" "within the given time, the holder of permission to conclude the programme will form the basis for the annual evaluation report of the benefit-risk ratio." "" "" ""</seg>
<seg id="2341">This register is treated longer-term safety and effectiveness of patients who were treated with Aldurazymets as well as data for the natural propagation of the disease in patients without treatment.</seg>
<seg id="2342">"" "" "" "in patients who suffer from MPS I, there is an enzyme called" -L-Iduronidase that certain substances in the body (glycosamogllykane), either entirely missing, or this enzyme is missing completely. "" "" "" "</seg>
<seg id="2343">If you are allergic to any of the ingredients of Aldurazyme or if you have occurred a serious allergic reaction to laronidase.</seg>
<seg id="2344">An infusion-conditional reaction is any side effect that occurs during infusion or until the end of the infusion (see section 4 "What side effects are possible).</seg>
<seg id="2345">When using Aldurazyme with other medicines please inform your doctor if you are using drugs that contain chlorine oquin or procain because a possible risk of reduced effect from Aldurazyme exists.</seg>
<seg id="2346">"" "" "" "please inform your doctor or pharmacist if you have taken other medicines or have recently taken, including non-prescription medication." "" "" ""</seg>
<seg id="2347">Indications for handling - dilution and application The concentrate on production of an infusion solution must be diluted in prior to application and is intended for intravenous application (see information for doctors or medical staff).</seg>
<seg id="2348">"" "" "" "the initial infusion rate of 2 E / kg / h can be increased if the patient carries this, every 15 minutes gradually increases to a maximum dose of 43 E / kg / h." "" "" ""</seg>
<seg id="2349">"" "" "" "in some patients with severe MPS-I- conditional participation of the upper respiratory system and lungs in the pre-history nevertheless heavy reactions came up, including bronchospasmus, breathing and facial oils." "" "" ""</seg>
<seg id="2350">Very frequently (occurrence at more than 1 of 10 patients): • headaches • nausea • abdominal pain • skin pain, joint pain, pain in the arms and legs • vomiting or less oxygen in the blood • Reaction at the infusion office</seg>
<seg id="2351">"" "" "" "the European Medicines Agency (EMEA) will evaluate any new information, which will evaluate each year, and if necessary, the package will be updated." "" "" ""</seg>
<seg id="2352">"" "" "" "if the ready to use preparation is not used immediately, it is no longer used for 24 hours at 2 ° C - 8º C, where the dilution is controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2353">Preparation of the Alduracyme infusion (with aseptic Techniques) • Je to determine the number of patients to be diluted.</seg>
<seg id="2354">Alimta is used together with cisplatin (a different drug against cancer) in patients which can not be removed from cancer compared to other parts of the body (cancer or cancer) or are probably spreading on other parts of the body.</seg>
<seg id="2355">"" "" "" "Alimta is treated with patients who have previously not been treated, in combination with Cisplatin and in patients who previously had already applied other chemotherapy regimens." "" "" ""</seg>
<seg id="2356">"" "" "" "to reduce side effects, patients during treatment with Alimta should take corticosteroid as well as folic acid (a vitamin) and get injections of vitamin B12." "" "" ""</seg>
<seg id="2357">"" "" "" "if Alimta is administered together with cisplatin, a" anti-therapeutic agent "(drug against vomiting) and liquids (to prevent dehydration to prevent dehydration)." "" "" ""</seg>
<seg id="2358">"" "" "" "in patients whose blood is changed or with which certain other side effects occur, treatment should be pushed up, canceled or decreases the dose." "" "" ""</seg>
<seg id="2359">"" "" "" "the active form of pemetrack slows down the formation of the DNA and RNA, thereby preventing the cells." "" "" ""</seg>
<seg id="2360">"" "" "" "the transformation of pemetremixed in its active form is easier than in healthy cells, which leads to higher concentrations of the active form of drug and a longer active time in cancer cells." "" "" ""</seg>
<seg id="2361">"" "" "" "for the treatment of malignant Pleuramesothelioms, Alimta was studied in a study study of 456 patients who had previously received chemotherapy against their disease." "" "" ""</seg>
<seg id="2362">"" "" "" "the effects of alimta in a study were compared with chemotherapy in a study of 571 patients with local advanced or metastasis, compared with chemotherapy with the effects of docetaxel (another drug against cancer)." "" "" ""</seg>
<seg id="2363">"" "" "" "Alimta was compared with gemcitabine (another drug against cancer), and in combination with cisplatin in a study of 1 725 patients who previously had no chemotherapy for lung cancer." "" "" ""</seg>
<seg id="2364">"" "" "" "patients who were treated with Alimta and Cisplatin had an average of 12.1 months compared to 9.3 months during the sole administration of Cisplatin." "" "" ""</seg>
<seg id="2365">"" "" "" "in patients who previously received chemotherapy was the average survival time with Alimta 8.3 months, compared with 7.9 months at docetaxel." "" "" ""</seg>
<seg id="2366">"" "" "" "however in both studies, patients who were not diagnosed with the epithelium cells when cancer was diagnosed by alimta during the administration of Alimta." "" "" ""</seg>
<seg id="2367">"" "" "" "in September 2004, the European Commission granted Eli Lilly Nederland B.V. for the establishment of Alimta in the entire European Union." "" "" ""</seg>
<seg id="2368">Each water bottle must be dissolved with 4,2 ml 0.9% sodium chloride injection solution (9 mg / ml) which gives a solution of 25 mg / ml.</seg>
<seg id="2369">The corresponding volume of the necessary Do- SIS is taken in the flow bottle and diluted with a 0.9% sodium chloride injector solution (9 mg / ml) to 100 ml (see section 6.6).</seg>
<seg id="2370">ALIMTA is indicated in combination with cisplatin indicated for the first-line therapy of patients with locally advanced or metastatic colocarcinoma (see Section 5.1).</seg>
<seg id="2371">ALIMTA in mono is indicated for treatment in second-line treatment of patients with Lo- Kal advanced or metastatic non-single bronchial carcinoma (see Section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² body surface (KOF) is administered as intravenous infusion about a period of 10 minutes on the first day of every 21-day treatment course.</seg>
<seg id="2373">The recommended dose of cisplatin is 75 mg / m ² KOF as infusion about a period of 2 hours approximately 30 minutes after finishing the Pemetrexed- infusion the first day of every 21-day treatment course.</seg>
<seg id="2374">In patients with non-small bronchial carcinoma after previous chemotherapy is the recommended dose of ALIMTA 500 mg / m ² KOF. the recommended dose of ALIMTA 500 mg / m ² KOF is administered as a intravenous infusion over a period of 10 minutes on the first day of every 21-day treatment course.</seg>
<seg id="2375">"" "" "" "for reducing the frequency and severity of skin reactions, the day before and on the day of the emetrexed gift as well as the day after treatment a cortikosteroid had to be given." "" "" ""</seg>
<seg id="2376">"" "" "" "during the seven days before the first dose of Pemetrack, at least 5 doses of folate must be taken and the intake must be continued during the entire therapy period as well as for another 21 days after the last Pemetrexed- dose." "" "" ""</seg>
<seg id="2377">Patients must also receive an intramuscular injection of vitamin B12 (1000 micrograms) in the week before the first Pemetrack dose and after each third movement cycle.</seg>
<seg id="2378">"" "" "" "in patients who received the emetrack, a complete blood image should be created prior to each gift, including a differentiation of the leukocytes and a thrombocyte story." "" "" ""</seg>
<seg id="2379">Alkaline phosphatase (AP), aspartat transaminase (AST or SGOT) and Alanin transaminase (ALT or SGPT) should amount to ≤ 3 times the upper limit value.</seg>
<seg id="2380">"" "" "" "at the start of a new therapy cycle, a dose-examination is taking place under the recuperation of Nadirs of the blood image or maximum non-hematological toxicity of the premating therapy cycles." "" "" ""</seg>
<seg id="2381">"" "" "" "after the recovery, the patients need to be treated accordingly to the tables in tables 1, 2 and 3, to apply for ALIMTA as a monthly or in combination with Cisplatin." "" "" ""</seg>
<seg id="2382">These criteria meet the definition of the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) ≥ CTC degree 2 bleeding.</seg>
<seg id="2383">"" "" "" "should patients be non-hematological toxicity 3 (except neurotoxicity), the therapy must be interrupted with ALIMTA." "" "" ""</seg>
<seg id="2384">Treatment with ALIMTA must be canceled if in patients after 2 dosissions a hematological toxicity or non-hematological toxicity level 3 or 4 occurs or soonically when the occurrence of degrees 3 or 4 neurotoxicity.</seg>
<seg id="2385">Clinical studies did not notice that in patients at age 65 years or in comparison to patients in the age 65 years an increased by-effectively idios- ko exists.</seg>
<seg id="2386">ALIMTA is not recommended for use in children under 18 years due to non-sufficient data for impemability and effectiveness.</seg>
<seg id="2387">"" "" "" "in clinical trials, patients with a creatinine Clearance of ≥ 45 ml / min does not need to go to dose adaptations required for all patients recommended dose adaptations." "" "" ""</seg>
<seg id="2388">The data situation in patients with a creatinine Clearance of less than 45 ml / min was not sufficient; therefore the application is not recommended (see section 4.4).</seg>
<seg id="2389">However patients with a liver function of &gt; the 1.5-fold of the upper Bilirubin- limit value and / or transaminases of the upper limit value (at the presence of liver metastases) or &gt; 5.0-times of the upper limit value (in the presence of liver metastases) were not specially examined in studies.</seg>
<seg id="2390">Patients must be monitored with regard to the bone marrow and pemetrexed should not be given to patients once again a value of ≥ 1500 cells / mm ³ and the thromhole figure has a value of ≥ 100.000 cells / mm ³.</seg>
<seg id="2391">A dose-reduction for further cycles is based on the Nadir of the absolute neutrophilensic count and maximum-hematological toxicity as they were observed in the preceding treatment cycles - (see Section 4.2).</seg>
<seg id="2392">A lower toxicity and a reduction of degrees 3 / 4 hematological and nichthmatology toxicity such as neutrropenie and infection with degrees 3 / 4 neutropenie has taken place when a pre-treatment with folic acid and vitamin B12 had occurred.</seg>
<seg id="2393">"" "" "" "therefore, all patients with Pemetrexed patients need to be used in folic acid and vitamin B12 as well as prophy- lactic measure (see paragraph 4.2)." "" "" ""</seg>
<seg id="2394">Patients with mild to moderate renal insufficiency (creatinine-Clearance 45 to 79 ml / min) must avoid the simultaneous insteroid anti-inflammatory drugs (&gt; 1.3 g daily) for at least 2 days before the therapy and at least 2 days after the therapy (see section 4.5).</seg>
<seg id="2395">"" "" "" "all patients, intended for treatment with pemetrack, must avoid taking NSAIDs for at least 5 days before the therapy, on the day of therapy and at least 2 days after the therapy (see section 4.5)." "" "" ""</seg>
<seg id="2396">"" "" "" "many patients with which these events occurred, had appropriate risk factors for the occurrence of renal events, including dehydration, existing high blood pressure or diabetes." "" "" ""</seg>
<seg id="2397">Therefore in patients with clinically significant fluid buildup collection in the transculary space a drainage of the result will be considered before the pemetrack treatment.</seg>
<seg id="2398">"" "" "" "5 Serious cardiovascular events, including myocardial infarction, and cerebrovascular events contained in clinical trials in combination with a different cytotoxic substance." "" "" ""</seg>
<seg id="2399">"" "" "" "for this reason, the same use attenuate vital substances (except yellow fever, this vaccination is contraceptive) is not recommended (see Section 4.3 and 4.5)." "" "" ""</seg>
<seg id="2400">"" "" "" "since the possibility of irreversible cranial condition is to be pointed out by Pemetraxed, men should be advised before the treatment of Ginn." "" "" ""</seg>
<seg id="2401">"" "" "" "in patients with normal kidney function (NSAIDs, such as Ibuprofen &gt; 1600 mg / day) and acetylsalicylic acid in high dosage (≥ 1.3 g daily) to a reduced breakdown reduction of side effects." "" "" ""</seg>
<seg id="2402">Therefore caution is advisable to be used when in patients with normal kidney function (creatinine Clearance ≥ 80 ml / min) high doses of NSAIDs or Ace- tylsalicylic acid in high dosage.</seg>
<seg id="2403">(ibuprofen) or acetylsalicylic acid in high doses for at least 2 days before the therapy to be avoided on the day of therapy and at least 2 days after the therapy (see Section 4.4).</seg>
<seg id="2404">"" "" "" "since no data has been submitted to the interaction potentials with NSAIDs, such as Piro- xicam or Rofecoxib, must be avoided for at least 5 days before the therapy, on the day of therapy and at least 2 days after the therapy." "" "" ""</seg>
<seg id="2405">The large intra-individual variability of the tinness status during the disease and the possibility of interactions between oral anticoagulants and antineoplastic chemotherapy requires a increased surveillance frequency of the INR (International standardization ratio) when the decision was made to treat the patient ducks with oral anticoagulants.</seg>
<seg id="2406">"" "" "" "there are no data for the use of Pemetremixed during pregnant women, but as at ande- and antimetabolites are expected severe birth defects in pregnancy." "" "" ""</seg>
<seg id="2407">Pemetrebate may not be used during pregnancy except when essential and after careful consideration of the use for the mother and risk for the fetus (see section 4.4).</seg>
<seg id="2408">"" "" "" "since the possibility of irreversible cranial of reproductive capacity is to be pointed out, men should be advised before the treatment of treatment, advice regarding sperm contours." "" "" ""</seg>
<seg id="2409">"" "" "" "it is not known whether Pemetremixed into the milk, and unwanted effects during the embroidered infant can't be excluded." "" "" ""</seg>
<seg id="2410">"" "" "" "the following table shows the frequency and severity unwanted effects that were reported in &gt; 5% of 168 patients with mesotheliom, and in 163 patients with mesotheliom, which were randomly received cisplatin as monotherapy." "" "" ""</seg>
<seg id="2411">"" "" "" "adverse events multiplies: very common (≥ 1 / 100 and &lt; 1 / 100), occasionally (≥ 1 / 1000 and &lt; 1 / 100), rarely (≥ 1 / 1000 and &lt; 1 / 1000), very rare (&lt; 1 / 1000 and &lt; 1 / 1000), rarely (≥ 1 / 1000 and &lt; 1 / 1000)." "" "" ""</seg>
<seg id="2412">* Over to National Cancer Institute CTC Version 2 for any toxicity except the event "kidneys / genital tract" other. "* * * Been on National Cancer Institute CTC (v2.0; NCI 1998) should be reported to detect flavours and hair loss only as degrees 1 or 2.</seg>
<seg id="2413">"" "" "" "for this table, a threshold of 5% was determined for the intake of all events where the report doctor has a connection with Pemetremixed and Cisplatin for possible." "" "" ""</seg>
<seg id="2414">"" "" "" "clinically relevant CTC toxicity, reported in patients with &lt; 1% (occasionally) of patients, randomised arrhythmia and motoric neuropathy." "" "" ""</seg>
<seg id="2415">"" "" "" "the following table shows the frequency and severity unwanted effects that received in &gt; 5% of 265 patients received with gifts of follic- re and vitamin B12 as well as 276 patients, randomised docetaxel as monotherapies." "" "" ""</seg>
<seg id="2416">* Over to National Cancer Institute CTC Version 2 for each toxicity. * * Been on National Cancer Institute CTC (v2.0; NCI 1998) is supposed to be reported only as degrees 1 or 2.</seg>
<seg id="2417">"" "" "" "for this table, a threshold of 5% was determined for the inclusion of all events where the report doctor has a connection with Pemetreshuffle." "" "" ""</seg>
<seg id="2418">"" "" "" "clinically relevant CTC toxicity, reported in patients with &lt; 1% (occasionally) of patients, included supreventricular arrhythmixes included." "" "" ""</seg>
<seg id="2419">The clinically relevant laboratory toxicity 3 and 4 was in the combined results of three different Pemetrexed monotherapists (n = 164) of Phase 2 (12.3% compared with 5.3%) and an increase of Alanine-saminase (15.2% compared to 1.9%).</seg>
<seg id="2420">"" "" "" "these differences are likely to lead to differences in the patient population, as the Pha- se 2 studies of both chemonaive and well-treated breast cancer patients were included in the liver function tests." "" "" ""</seg>
<seg id="2421">"" "" "" "the following table shows the frequency and severity unwanted effects; they were received at &gt; 5% of 839 patients with NSCLC, which received randomised Cisplatin and gemcitabin." "" "" ""</seg>
<seg id="2422">11 * P-values &lt; 0,05 comparison of Pemetremixed / Cisplatin and gemcitabine / Cisplatin. * * * related to National Cancer Institute CTC (v2.0; NCI 1998) should be reported on the National Cancer Institute of CTC (v2.0; NCI 1998).</seg>
<seg id="2423">"" "" "" "for this table, for the inclusion of all events where the report doctor has fixed a connection with Pemetrexed and Cisplatin for possible, a threshold of 5%." "" "" ""</seg>
<seg id="2424">"" "" "" "clinically relevant toxicity that were reported in ≥ 1% and ≤ 5% (often) of patients, randomised Cisplatin and Pemetrexed, were recorded:" "" "" ""</seg>
<seg id="2425">Clinically relevant toxicity that were reported at &lt; 1% (occasionally) of the patients who received Cisplatin and Pemetrexed was included:</seg>
<seg id="2426">Serious kardiovasculine and cerebrovascular events including myocardial infarction and cerebrovascular attacks were usually given in combination with another cytotoxic drug that is usually reported occasionally.</seg>
<seg id="2427">"" "" "" "clinical trials were reported in patients with pemetremixed treatment for occasionally cases of coli- tis (including intestinal and rectal bleeding, sometimes fatal accidents, intestinal necrosis and typhlitis)." "" "" ""</seg>
<seg id="2428">"" "" "" "clinical trials have been reported in patients with pemetremixed treatment, occasionally interstically interstitial Pneumonitis with respiratory failure." "" "" ""</seg>
<seg id="2429">It was reported about cases of acute kidney failure at Pemetreshuffle or in combination with other chemicals (see section 4.4).</seg>
<seg id="2430">"" "" "" "there were cases of radiation pneumonitis in patients who were irradiated before, during or after their sequential therapy (see Section 4.4)." "" "" ""</seg>
<seg id="2431">ALIMTA (Pemetraxed) is a antinetic antifolate that uses its effect by shifting the acid-dependent metabolic processes that are necessary for cell replication.</seg>
<seg id="2432">"" "" "" "in vitro studies, Pemetretainuclease (TS), Dihydrotoruclease (TS), Dihydrotoruclease (GARFT) blocked the folatly-dependent key enzymes of de Novo Biosynthesis by Thymidine and Purinnucleotides." "" "" ""</seg>
<seg id="2433">"" "" "" "EMPHACIS, a multi-centric, randomised, randomised Phase 3 study of patients with malignaitin patients treated with malignaitin patients with malignaitin patients treated with malignaitin patients suffering from cisplatin compared to patients with cisplatin." "" "" ""</seg>
<seg id="2434">"" "" "" "the primary analysis of this study was undertaken in the population of all patients who received the treatment poor in therapy, randomised and treated." "" "" ""</seg>
<seg id="2435">A statistically significant improvement of clinically relevant symptoms (pain and dyspnoe) in connection with the malignant Pleuramesotheliom acid was shown in the ALIMTA / Cisplatin arm (212 patients) compared to the sole Cisplatin arm (218 patients).</seg>
<seg id="2436">The differences between the two arms accumulates in the ALIMTA / Cisplatin arm and a shift of lung function in the course of time in control.</seg>
<seg id="2437">A multi-centric, randomised, open Phase III study with advanced or metastatic NSCLC in patients with locally advanced or metastatic NSCLC in patients (Intent Population n = 283) and 7.9 months were treated with docetaxel (ITT n = 288). "" "" "" "</seg>
<seg id="2438">An analysis of the influence of histology on the treatment effect in favour of the overall survival compared to the overall survival of ALIMTA (n = 399; 95% CI = 0.56; 95% CI = 1.08-2.26; p = 0.08-2.26).</seg>
<seg id="2439">Limited data of a separate randomised controlled phase 3 study shows that efficacy data (survival and progression-free survival) for pemetremixed between patients with (n = 41) and without (n = 540) treatment is similar in docetaxel.</seg>
<seg id="2440">The efficacy analysis of the PQ population are consistent with the analysis of ITT population and support the non-subsuperiority of ALIMTA Cisplatin combination with gemcitabine Cisplatin combination.</seg>
<seg id="2441">The mean value was 4.8 months for the combination of gemcitabine Cisplatin (adjusted HR = 1.04; 95% CI = 0.94 - 33.9) for the combination of gemcitabine Cisplatin (95% CI = 25.0 - 31,4) for the combination of gemcitabine Cisplatin.</seg>
<seg id="2442">"" "" "" "the analysis of the influence of NSCLC's influence on survival showed clinically relevant differences according to histology, see table below." "" "" ""</seg>
<seg id="2443">CI = Confidential interval; ITT = Intent-to-Treat; N = size of the total population a statistical significance for HR (= Hazard ratio) clearly under the non-lower portion of 1.17645 (p &lt; 0.001).</seg>
<seg id="2444">Patients who were treated with ALIMTA and Cisplatin (16.1% versus 27.3% versus 27.3%, p &lt; 0.001) and Thromboxycyclessions (1.8% versus 4.5%, p = 0.002).</seg>
<seg id="2445">"" "" "" "furthermore the patients need selen- tener the gift of erythropoetin / Darbopoetin (3.1% versus 18.1%, p = 0.004), and iron preparations (4.3% versus 7.0%, p = 0,021)." "" "" ""</seg>
<seg id="2446">"" "" "" "the pharmacokinetic characteristics of Pemetremixed after gift as Monotherapist was investigated in doses of 426 cancer patients with various solid tumors ranging from 0.2 to 838 mg / m ² in infusicannons during a period of 10 minutes." "" "" ""</seg>
<seg id="2447">Pemetremixed is mainly left in urine and 70% to 90% of the given dose will be found unchanged within 24 hours after the application remains unchanged in the urine.</seg>
<seg id="2448">Pemetremixed has a total of 91.8 ml / min and the half-time in plasma is 3.5 hours in patients with normal kidney funtion (creatinine Clearance 90 ml / min).</seg>
<seg id="2449">"" "" "" "in a study of Beagle-dogs who had received intravenous injections for 9 months, testicular changes were observed (Degenetic) / Necrosis of the seminiferous epithelium." "" "" ""</seg>
<seg id="2450">"" "" "" "unless uncontaminated, the storage periods and conditions are not taken after the preparation in the responsibility of the user and should normally not overwrite 24 hours at 2 to 8 ° C, unless the preparation / thinning has taken place under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2451">Loosen the contents of 100 mg-throughput bottles with 4,2 ml 0.9% sodium chloride injector solution (9 mg / ml) without preservatives; resulting in a solution with a concentration of approximately 25 mg / ml Pemetremixed.</seg>
<seg id="2452">"" "" "" "the resulting solution is clear and the coloring is ranging from colorless to yellow or greenish yellow, without the product quality impaired." "" "" ""</seg>
<seg id="2453">Each water bottle must be dissolved with 20 ml 0.9% sodium chloride injections (9 mg / ml) which gives a solution of 25 mg / ml.</seg>
<seg id="2454">"" "" "" "23 The severe cardiac events, including myocardial infarction, and cerebrovascular events contained in clinical trials in combination with a different cytotoxic substance." "" "" ""</seg>
<seg id="2455">"" "" "" "* Over to National Cancer Institute CTC Version 2 for any toxicity, except the event" kidneys / genital tract "* *" "" "" "" * * * "" "" "" "* * *" "" "" "" "* *" "" "" "" "* *" "" "" "". "* * *" "" "" ""</seg>
<seg id="2456">"" "" "" "for this table, a threshold of 5% is stipulated regarding the intake of all events where the reporting doctor prescribed an connection with Pemetrexed and Cisplatin for possible." "" "" ""</seg>
<seg id="2457">* Over to National Cancer Institute CTC Version 2 for each toxicity. * * Been on National Cancer Institute CTC (v2.0; NCI 1998) is supposed to be reported only as degrees 1 or 2.</seg>
<seg id="2458">29 * P-values &lt; 0,05 comparison of Pemetremixed / Cisplatin and gemcitabine / Cisplatin. * * * Been on National Cancer Institute CTC (v2.0; NCI 1998) should be reported on the National Cancer Institute of CTC (v2.0; NCI 1998).</seg>
<seg id="2459">Clinically relevant toxicity that were reported at &lt; 1% (occasionally) of the patients who received Cisplatin and Pemetrexed was included:</seg>
<seg id="2460">An analysis of the influence of histology on the treatment effect in favour of the overall survival compared to the overall survival of ALIMTA (n = 399; 95% CI = 0.56; 95% CI = 1.08-2.26; p = 0.08-2.26).</seg>
<seg id="2461">Solve the content of the 500 mg of water bottles with 20 ml 0.9% sodium chloride injector solution (9 mg / ml) without preservatives; resulting in a solution with a concentration of approximately 25 mg / ml Pemetremixed.</seg>
<seg id="2462">"" "" "" "the resulting solution is clear and the colouring - from colorless to yellow or greenish, without the product quality impaired." "" "" ""</seg>
<seg id="2463">"" "" "" "the owner of the vehicle permission to ensure that the pharmaceutical covigilance System, as described in version 2.0, is ready and is ready for delivery, as soon as the product is placed in the traffic and while the product is on the market." "" "" ""</seg>
<seg id="2464">Risk Management Plan The holder of the approval of the Intended Transport Plan commits the studies and supplementation activities according to the Risk Management Plan (RMP) in Module 1.8.2. the approval of the entry system and all the subsequent updates of the RMP that were decided by CHMP.</seg>
<seg id="2465">"" "" "" "according to CHMP Guideline on Risk Management Systems for the Products for Human use, a updated RMP must be submitted simultaneously with the next" periodic safety update Report "(PSUR)." "" "" ""</seg>
<seg id="2466">"" "" "" "in addition, a updated RMP has to be submitted as new information, which could have an effect on the current safety specifications, the pharmaceutical covigilance plan or risk of risk (pharmaceutical grade) milestones" "" "" ""</seg>
<seg id="2467">ALIMTA 100 mg of powder to manufacture a concentrates for the production of an infusion drainage ALIMTA 500 mg of powder to manufacture a concentrates for production of an infusion drainage.</seg>
<seg id="2468">ALIMTA is used in patients who have received no previous chemotherapy; used in combination with cisplatin (malignant disease of the Rippfells) in combination with cisplatin and other medicines for cancer diseases.</seg>
<seg id="2469">"" "" "" "if you have a kidney disease or earlier, please discuss this with your doctor or hospital library since you may not get ALIMTA." "" "" ""</seg>
<seg id="2470">"" "" "" "in case of any infusion of blood tests, you will be checked whether your kidney and liver function is sufficient, and if you have enough blood cells to get ALIMTA to 49." "" "" ""</seg>
<seg id="2471">"" "" "" "your doctor may change the dose, or canceling the treatment, if it requires your general state and if your blood values are too low." "" "" ""</seg>
<seg id="2472">"" "" "" "if you receive Cisplatin, your doctor will ensure that your body contains sufficient water and you need to avoid the prescribed medicines in order to prevent vomiting before and after Cisplatin's gift." "" "" ""</seg>
<seg id="2473">"" "" "" "if you are a fluid collection around the lungs, your doctor may choose to eliminate those liquid before you get ALIMTA." "" "" ""</seg>
<seg id="2474">"" "" "" "if you would like to use a child during treatment or in the first 6 months after treatment, please contact your doctor or pharmacist." "" "" ""</seg>
<seg id="2475">"" "" "" "any interactions with other medicines Please tell your doctor if you are drugs against pain or inflammation, including drugs, which are non-prescription (like ibuprofen)." "" "" ""</seg>
<seg id="2476">"" "" "" "depending on the planned promotion of your ALIMTA Infusion and / or the extent of your renal function, your doctor will tell you what other drugs you can take, and when." "" "" ""</seg>
<seg id="2477">"" "" "" "please inform your doctor or pharmacist if you have taken other medicines or recently taken, even if it is not prescription drugs - Delt." "" "" ""</seg>
<seg id="2478">A hospital holder, the nursing staff or a doctor will mix the ALIMTA powder with sterile 0,9% sodium chloride injections (9 mg / ml) before it is applied to you.</seg>
<seg id="2479">Your doctor will spade you cortison tablets (according to 4 mg of Dexametha- son two times daily) which you need to take the day before and on the day after the use of ALIMTA.</seg>
<seg id="2480">Your doctor will promote your folic acid (a vitamin) for inhalation or multivitamins which contain the folic acid (350 to 1000 micrograms) which you need to use during the use of ALIMTA one time daily.</seg>
<seg id="2481">A week before the application of ALIMTA and about every 9 weeks (according to 3 cycles of treatment with ALIMTA) you will also receive an injection of vi- tamin B12 (1000 micrograms).</seg>
<seg id="2482">"" "" "" "in this manual information a side effect is described as" very common, "means that it was reported by at least 1 of 10 patients." "" "" ""</seg>
<seg id="2483">"" "" "" "if a side effect is described as" frequently ", this means that it was reported by at least 1 of 100 patients, but reported less than 1 out of 10 patients." "" "" ""</seg>
<seg id="2484">"" "" "" "if a side effect is described as" occasional, "this indicates that it was reported by at least 1 of 1,000 but less than 1 of 100 patients is reported that it was reported by at least 1 of 10,000 patients less than 1 of 1,000 patients." "" "" ""</seg>
<seg id="2485">"" "" "" "fever or infection (often): if you have a body temperature of 38 ° C or above, sweating or other signs of infection (because you may have less white blood cells than normal, which is very common)." "" "" ""</seg>
<seg id="2486">"" "" "" "if you feel tired or weak, get rapidly into respiratory or pale (because you may have less hemoglobin than normal, which is very common)." "" "" ""</seg>
<seg id="2487">"" "" "" "if you find the blood of the gum, the nose or mouth or another blood, which does not come to a halt, or a reddish or pink urine (cause you possibly have less blood platelets as normal, which is very common)." "" "" ""</seg>
<seg id="2488">Occasionally (occurs at least 1 of 1000 patients) (less than 1 of 100 patients) increased pulsation Colitis (inflammation of the inner liner); Interstitila Pneumonitis (narration of lung blower) oil (leaving water into the body tissues that leads to swelling).</seg>
<seg id="2489">"" "" "" "rarely (occurs during more than 1 of 10,000 patients, but less than 1 out of 1,000 patients)" Radiation Recall "(a rash similar to a heavy sunburn), appearance on the skin which was exposed to radiation before (a couple of days to years)." "" "" ""</seg>
<seg id="2490">"" "" "" "occasionally, patients, ALIMTA, usually joined in combination with other cancers, got a stroke or stroke with a minor damage." "" "" ""</seg>
<seg id="2491">"" "" "" "in patients who receive treatment during or after ALIMTA treatment, a radiation treatment can occur through radiation (narration of lung disease that is related to radiation treatment)." "" "" ""</seg>
<seg id="2492">52 Informing your doctor or pharmacist if one of the listed side effects will be substantial - or if you notice side effects that are not stored in this package.</seg>
<seg id="2493">"" "" "" "as prescribed as prescribed, the chemical and physical stability of the diluted and the infusion solution for storing in the fridge or at 25 ° C for a period of 24 hours." "" "" ""</seg>
<seg id="2494">Tél / Tel: + 32 - + 32- (0) 2 548 84 84 Persecures Recession Persecures Recession Persecutive Advantage. - Performative Drives Award. - Percentereská Republika ELI LILLY-R, s.r.o.</seg>
<seg id="2495">"" "" "" "Tel: + 420 234 664 111 Danmark Eli Lilly Danmark A / S Tlf. Tel: + 49 45 26 6100 Germany Lilly Deutschland GmbH." "" "" ""</seg>
<seg id="2496">Tel: + 34-91-623-1732-1732 France Lilly France SAS Tél: + 33- (0) Limited Tel: + 353- (0) 1 661 4377 Ísland Icepharma hf.</seg>
<seg id="2497">Tel: + 357 22 715000 Latvija M. Latviev Ltd. Tel: + 357 22 715000 Latvija Eli Lilly Holvija Eli Lilly Holvija Eli Lilly Holvija Eli Lilly Holvija Eli Lileistovybtel. + 370 (5) 2649600</seg>
<seg id="2498">Tel.: + 48 (0) 22 440 33 00 Portugal Lilly Portugal - Produtos Farmacêuticos, LDA Tel: + 351-21-4126600 România Eli Lilly România S.R.L..</seg>
<seg id="2499">Tel: + 421 220 663 111 Suomi / Finland Oy Eli Lilly United Kingdom Eli Lilly and Company Limited Tel: + 44- (0) 8 7378800 United Kingdom Eli Lilly and Company Limited Tel: + 44- (0) 1256 315999</seg>
<seg id="2500">Solve the content of 100 mg capsules with 4.2 ml 0.9% sodium chloride injector solution (9 mg / ml) without preservative what a solution with a concentration of approximately 25 mg / ml Pemetremixed results.</seg>
<seg id="2501">Solve the content of the 500 mg of water bottles with 20 ml 0.9% sodium chloride injector solution (9 mg / ml) without preservative what a solution with a concentration of approximately 25 mg / ml Pemetremixed results.</seg>
<seg id="2502">"" "" "" "the resulting solution is clear and the coloring is ranging from colorless to yellow or greenish yellow, without the probing quality is impaired." "" "" ""</seg>
<seg id="2503">It is used for overweight adults with a body mass index (Body Mass Index - BMI) of ≥ 28 kg per square meter in combination with a calorie-calorie diet.</seg>
<seg id="2504">"" "" "" "patients who take in alli gains no weight loss after 12 weeks, should contact their doctor or pharmacist." "" "" ""</seg>
<seg id="2505">"" "" "" "if these enzymes are inhibited, they can not diminish some fat in the food, which yields about a quarter of food associated with food." "" "" ""</seg>
<seg id="2506">"" "" "" "in a third study, alli was compared with a BMI between 25 and 28 kg / m2 with placebo." "" "" ""</seg>
<seg id="2507">"" "" "" "in the two trials of patients with a BMI of ≥ 28 kg / m2, patients had a total weight loss of 4.8 kg, compared with 2.3 kg when taking placebo." "" "" ""</seg>
<seg id="2508">"" "" "" "in the study with alli in patients with a BMI between 25 and 28 kg / m2, there could be no more relevant weight loss for patients." "" "" ""</seg>
<seg id="2509">The most common side effects of alli (observed in more than 1 of 10 patients) are oily stains at the anus; Flatus (winds) with stools, stools / oily chair; oily shelf (threads) and soft chairs (winch) and soft chairs.</seg>
<seg id="2510">It must not be applied in patients who are treated with Ciclosporin (to prevent organ of transplanting) or with medicines such as warfarin for preventing blood clots.</seg>
<seg id="2511">It may also not be applied in patients who suffer from a long-term malabsorption syndrome (with which non-insufficient nutrients from the digestive tract) or to cholestase (a liver disease) or with pregnant mothers.</seg>
<seg id="2512">"" "" "" "in July 2007, the European Commission granted Glaxo Group Limited authorization of the agency of Orlistat GSK throughout the European Union." "" "" ""</seg>
<seg id="2513">Alli is indicated for weight reduction of adults with overweight (Body Mass Index BMI ≥ 28 kg / m2) and should be used in conjunction with a slightly hypokalo-fat-fat diet.</seg>
<seg id="2514">Alli is not allowed to be used by children and youngsters under 18 since there are insufficient data on efficacy and safety.</seg>
<seg id="2515">"" "" "" "however, orlistat is only minimal resortive, is necessary in elderly and in patients with reduced liver and / or kidney function." "" "" ""</seg>
<seg id="2516">• Pregnation against the active substance or any of the other components • Premature Malabsorption syndrome • cholecase • pregnancy (see section 4.6) • Still time (see section 4.6) • nursing treatment with warfarin or other oral anticoagulants (see sections 4.5 and 4.8)</seg>
<seg id="2517">The likelihood of gastrointestinal symptoms (see section 4.8) can take up if alli is taken along with a low-fat meal or low-fat diet.</seg>
<seg id="2518">"" "" "" "since the weight reduction in diabetes can be reached with an improved metabolic check, patients suffering from diabetes should consult a doctor or pharmacist prior to treatment with alli gains a doctor or pharmacist." "" "" ""</seg>
<seg id="2519">"" "" "" "patients, the alli, and drug against hypertension or an increased Cholesterinspiegel, should ask if the dose of this drug should be adjusted." "" "" ""</seg>
<seg id="2520">It is recommended to meet additional fluctuating measures in order to prevent the oral contraceps in case of severe diarrhoea (see section 4.5).</seg>
<seg id="2521">"" "" "" "in a study on the effects of pharmaceuticals as well as in several cases of simultaneous application of orlistat and Ciclosporin, a reduction of Ciclosporin plasma plates was observed." "" "" ""</seg>
<seg id="2522">"" "" "" "in combination with warfarin or other oral anticoagulants in combination with orlistat, the Quick values (internationally standardised ratio, INR) might be affected (see section 4.8)." "" "" ""</seg>
<seg id="2523">"" "" "" "in most patients receiving clinical trials up to 4 full years with orlistat were treated, the concentration of vitamins A, D, E and K and beta-carotenes remained in the norm range." "" "" ""</seg>
<seg id="2524">"" "" "" "however, patients should be recommended to take a supplement of supplements to ensure adequate vitamin intake (see Section 4.4)." "" "" ""</seg>
<seg id="2525">"" "" "" "after the gift of a single dose Amiodarone, a limited number of healthy volunteers, which at the same time received orlistat once received a slight decrease in the Amiodaron plasma concentration." "" "" ""</seg>
<seg id="2526">"" "" "" "experimental studies did not show direct or indirect effects on pregnancy, embryonic / fetal development, birth or postnatal development (see Section 5.3)." "" "" ""</seg>
<seg id="2527">"" "" "" "the side effects of orlistat are mainly gastrointestinal nature and are associated with the pharmacological effect of the medication, as the absorption of frozen fat is prevented." "" "" ""</seg>
<seg id="2528">Gastrointestinal effects were determined from clinical trials involving orlistat 60 mg over a period of 18 months to 2 years and were generally easy and temporary.</seg>
<seg id="2529">"" "" "" "the skins are defined as follows: very frequently (≥ 1 / 100, &lt; 1 / 100, &lt; 1 / 100), occasionally (≥ 1 / 1000, &lt; 1 / 1000), but not known (frequency on the basis of available data not invaluable)." "" "" ""</seg>
<seg id="2530">"" "" "" "the frequency of those side effects that were noted after the launch of Orlistat is not known, as these events were voluntarily reported by a population of uncertainties." "" "" ""</seg>
<seg id="2531">† It is plausible that the treatment with alli gains effect on potential or actual gastrointestinal effects.</seg>
<seg id="2532">Individual doses of 800 mg of Orlistat and multiple columns of up to 400 mg three times daily have been administered by normal important and overweight people without significant clinical findings.</seg>
<seg id="2533">"" "" "" "with the majority of Orlistat-overdosing reported, no side effects or similar effects were reported as at the recommended dose of orlistat." "" "" ""</seg>
<seg id="2534">"" "" "" "based on human and animal studies, from a fast retroformation of any systemic effects that are attributable to the lipastive properties of orlistat, can be assumed." "" "" ""</seg>
<seg id="2535">"" "" "" "the therapeutic effect uses the lumens of the stomach and the upper thin film by covalent bonds of the active serene and pankreatic lipasen." "" "" ""</seg>
<seg id="2536">"" "" "" "clinical trials was derived from clinical trials that 60 mg of Orlistat is taken three times daily, the absorption of approximately 25% of the food-fat are blocked." "" "" ""</seg>
<seg id="2537">"" "" "" "two double-blind, randomised controlled trials in adults with a BMI ≥ 28 kg / m2 occupy the efficacy of 60 mg of Orlistat that was taken three times daily in combination with hypokalorical, fatty nutrition." "" "" ""</seg>
<seg id="2538">"" "" "" "the primary parameter, the change of body weight compared to the initial value (at the time of Randomization), has been rated as the percentage of the body weight in the course of study (table 1) and more than 10% of their output weight (table 2)." "" "" ""</seg>
<seg id="2539">"" "" "" "even though in both studies the weight reduction was observed over 12 months, the biggest weight loss occurred in the first 6 months." "" "" ""</seg>
<seg id="2540">The average change in the overall cholesterin amounted to 60 mg-2.4% (output value 5.20 mmol / l) and with placebo + 2.8% (output level 5.26 mmol / l).</seg>
<seg id="2541">The average change in the LDL cholesterol was 60 mg-3.5% (output level 3.30 mmol / l) and with placebo + 3.8% (output level 3.41 mmol / l).</seg>
<seg id="2542">The waist circumference was the average change -4.5 cm with orlistat 60 mg (output value 103.7 cm) and placebo -3.6 cm (output value 103.5 cm).</seg>
<seg id="2543">Plasma concentrations of non-metabolic orlistat were not measurable 8 hours after the oral gift of 360 mg orlistat (&lt; 5 ng / ml).</seg>
<seg id="2544">"" "" "" "7 In general, the therapeutic dosages was not only sporadically sporadically in plasma and very low concentrations (&lt; 10 ng / ml or 0.02 µmol) and without signs of cumulation." "" "" ""</seg>
<seg id="2545">"" "" "" "in a study involving obese patients, the minimal systemic resorised dose could be identified (M1, in position 4 hydrolysed Lactonring) and M3 (M1 into position 4 hydrolytic leucine-group)." "" "" ""</seg>
<seg id="2546">"" "" "" "based on conventional studies on Safety Pharmacology, Toxicity in repeating gift, Genotoxicity, kanzerogenic potential and Reproductive reactions leave the preventive data to recognize any particular danger for human beings." "" "" ""</seg>
<seg id="2547">"" "" "" "" "" "" "" "the holder of the approval of the pharmaceutical company must ensure that the pharmaceutical covigilance system must be applied, applied in accordance with the 1.8.1. of the approval application, before and while the product is available on the market." "" "" ""</seg>
<seg id="2548">Risk-management plan The holder of approval for the transport company is committed to comply with the studies and additional pharmaceutical-vigilance plan such as the pharmaceutical company plan (RMP) in October 2008 as well as all other updates of the Rx which will be agreed with the Committee for Human Use (CHMP).</seg>
<seg id="2549">"" "" "" "according to the CHMP guidelines on risk-management systems for human medicines, the updated RMP must be submitted with the next PSUR (periodic safety update Report)." "" "" ""</seg>
<seg id="2550">"" "" "" "furthermore, a updated RMP should be filed: • When new information is available, current security policies or risk assessment may affect the acquisition of pharmaceutical-vigilance or risk exposure to the European Medicines Agency (EMEA) within 60 days of experiencing an important system." "" "" ""</seg>
<seg id="2551">"" "" "" "12 PSURs The holder of approval for transportation will be submitted for the first year after order picking over the alli 60 mg of hard capsules, for two years and then every three years." "" "" ""</seg>
<seg id="2552">Do not use when you are under 18 when you are pregnant or breastfeed if you suffer from sensitive to orlistat or other blood thinner ingredients • If you have sensitive to orlistat or other blood thinner matter if you have problems with food intake (chronic malabsorption syndrome).</seg>
<seg id="2553">"" "" "" "• Take three times a day with each main meal, the fat contains, one capsule containing water. • You should not take one day before bedtime, a multivitamintine (with vitamins A, D, E and K). • You should no longer apply for 6 months." "" "" ""</seg>
<seg id="2554">"" "" "" "application: • Take three times a day with each main meal the fat contains, one capsule containing water. • You should not take one capsule daily, before bedtime a multivitamintine (with vitamins A, D, E and K)." "" "" ""</seg>
<seg id="2555">"" "" "" "perhaps you would like to read this later again. • If you have reached your doctor or pharmacist if you have further information or advice, ask a doctor or pharmacist for advice after 12 weeks." "" "" ""</seg>
<seg id="2556">"" "" "" "possibly you need to stop the intake of alli. • If one of the listed side effects will be significantly impaired or you will notice any side effects that are not listed in this user information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2557">What do you need to consider before taking alli? • alli is not allowed to be used • Specific caution when taking alli is required • For the intake of alli in combination with food and beverages • pregnancy & lactation and the use of machines 3.</seg>
<seg id="2558">How do I take to take stock? • How can you take your weight withdrawal? O Average your starting point? O adults from 18 years o How long should I take alli in too large quantities o If you have forgotten the intake of alli 4.</seg>
<seg id="2559">Which side effects are possible? • severe side effects • Very frequent side effects • Frequent side effects • Effect on blood tests • How can you control nutritional supplements?</seg>
<seg id="2560">Further information • What alli contains • How alli looks and content of the package • Pharmaceutical entrepreneur and manufacturer • Further helpful information</seg>
<seg id="2561">Alli gains the weight reduction and is used for overweight adults from 18 years with a Body Mass Index (BMI) of 28 or above. alli in combination with a low and calorie diet should be used.</seg>
<seg id="2562">"" "" "" "the BMI helps you to determine whether you have a normal weight in relation to your body size, or overweight." "" "" ""</seg>
<seg id="2563">"" "" "" "even if these diseases first do not lead to feel uncomfortable, you should still ask your doctor for inspection." "" "" ""</seg>
<seg id="2564">"" "" "" "for each 2 kg body weight that you take on a diet, you can lose an additional kilogram with the help of alli." "" "" ""</seg>
<seg id="2565">"" "" "" "please inform your doctor or pharmacist if you have taken other medicines or recently taken, even if it is not prescription drugs." "" "" ""</seg>
<seg id="2566">Ciclosporin is used for organ transplants to have severe rheumatoid arthritis and certain serious skin diseases. • Warfarin or other medicines that have a blood thinner effect.</seg>
<seg id="2567">Oral contraceptives and alli • The effect of oral increasing means of pregnancy prevention (pill) will be weakened or lifted under circumstances if you have strong diarrhoea (diarrhea).</seg>
<seg id="2568">"" "" "" "before taking alli in your doctor or pharmacist, please contact your doctor or pharmacist if you use: • to apply Amiodaron to treat heart rhythm disorders." "" "" ""</seg>
<seg id="2569">"" "" "" "if you take care of your doctor or pharmacist if you take drugs to high blood pressure, since you may take drugs to high cholesterol, because it needs to be adjusted." "" "" ""</seg>
<seg id="2570">How to define your calorials and Fettoberlimits you can find out more helpful information on the blue pages in section 6.</seg>
<seg id="2571">"" "" "" "if you don't have a meal or contains a meal, take no capsule. alli can only work if the food contains fat." "" "" ""</seg>
<seg id="2572">"" "" "" "if you take the capsule in conjunction with a meal, which contains too much fat, risk food-related accompanying symptoms (see section 4)." "" "" ""</seg>
<seg id="2573">"" "" "" "to get used to your body to the new eating habits, start first capsulation with a kaloride and fetal-fat diet." "" "" ""</seg>
<seg id="2574">"" "" "" "dietary surveys are effective since you can understand what you eat, how much you eat and it will probably become easier to alter your nutritional habits." "" "" ""</seg>
<seg id="2575">"" "" "" "to secure your goal, you should set two daily goals in advance: one for the calories and one for fat." "" "" ""</seg>
<seg id="2576">"" "" "" "• feed-fat, to reduce the probability of dietary supplements (see Section 4). • Try to move more, before taking the capsules." "" "" ""</seg>
<seg id="2577">"" "" "" "remember to ask your doctor if you are not used physical activity. • Stay in ingestion, and also after the termination of the intake of alli is physically active." "" "" ""</seg>
<seg id="2578">"" "" "" "• alli gains no longer be taken for 6 months. • If you can find no reduction of weight during twelve weeks of application, please ask your doctor or pharmacist for advice." "" "" ""</seg>
<seg id="2579">"" "" "" "under circumstances you need to stop taking alli. • With a successful weight loss, it is not about to return the diet and return to the old habits." "" "" ""</seg>
<seg id="2580">"" "" "" "• When less than one hour has passed since the last meal, take the intake of the capsule. • If more than one hour has passed since the last meal, take no capsule." "" "" ""</seg>
<seg id="2581">Flatulence with and without leaking exit, sudden or increased bowel urge and soft chair) are attributable to the mode of action (see section 1).</seg>
<seg id="2582">"" "" "" "severe allergic reactions • severe allergic reactions proceed to the following changes: severe respiratory emergency, welding outbreaks, skin rash, itching, swelling in the face, heart rashes, circulatory collapse." "" "" ""</seg>
<seg id="2583">29 Very frequent side effects These can occur in more than 1 out of 10 persons, to occur. • Bläger (flatulence) with and without hilious exit • Weider chair Informing your doctor or pharmacist if any of these side effects will be amplified or significantly impaired.</seg>
<seg id="2584">"" "" "" "common side effects These can occur at 1 of 10 people, to take in, • Inkontinenz (abdominal pain) • Inkontinenz (stomach) • Ensulation / liquid chair • Will your doctor or pharmacist if any of these side effects will be amplified or significantly impaired." "" "" ""</seg>
<seg id="2585">Effects on blood tests It is not known as often these effects occur. • Increase of certain liver enzymes • effects on the blood clotting in patients who treat warfarin or other blood thcoagulation (anticoagulated) medicine.</seg>
<seg id="2586">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will be significantly impaired or you will notice any side effects that are not listed in this manner." "" "" ""</seg>
<seg id="2587">"" "" "" "the most common side effects are associated with the mode of action of capsules, and thereby causing fat from the body." "" "" ""</seg>
<seg id="2588">"" "" "" "these side effects occur usually within the first weeks of treatment, as you may not have reduced the fat percentage of fat in the diet." "" "" ""</seg>
<seg id="2589">"" "" "" "using the following basic rules, you can learn to minimize the nutrition-related accompanying diet. • Learn more about the usual fat content of your favorite food and about the size of portions you usually take." "" "" ""</seg>
<seg id="2590">"" "" "" "if you know exactly how much you eat, the likelihood is that you will exceed your fat limit. • Do you share your recommended fat-quantity equally on daily meals." "" "" ""</seg>
<seg id="2591">"" "" "" "save the amount of calories and fat that you may have done per meal, not to use it in the form of a bold main court or an extensive post. • Most people in which these accompanying symptoms can be used to control them by adjusting their diet." "" "" ""</seg>
<seg id="2592">"" "" "" "• Store medicines for children unaccessible. • They are not allowed to store any more than 25 ° C. The container is sealed to protect the contents from moisture. • The bottle contains two white-sealed containers with silicone gel that serve to keep the capsules dry." "" "" ""</seg>
<seg id="2593">"" "" "" "do not swallow it in any case. • You can lead your daily dose to alli in the blue transport box (shuttle), which is included in this pack." "" "" ""</seg>
<seg id="2594">"" "" "" "FAMAR, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge Close, Headway, Great Oakley, Corby, Northamptonshire NN18 8HS, United Kingdom" "" "" ""</seg>
<seg id="2595">Overweight has an effect on your health and increases the risk for the formation of various serious diseases such as: • hypertension • diabetes • determination of cancers • osteoarthritis Please consult your doctor about your risk for these disorders.</seg>
<seg id="2596">"" "" "" "a permanent weight loss, for example by improving the diet and more movement, can prevent serious diseases and has a positive impact on your health." "" "" ""</seg>
<seg id="2597">"" "" "" "choose meals, which contain a wide range of nutrients, and learn to feed themselves permanently." "" "" ""</seg>
<seg id="2598">"" "" "" "energy is also measured in Kilojoule, which you can also find the recommended calorie intake, how many calories you should take maximum per day." "" "" ""</seg>
<seg id="2599">"" "" "" "note the tables below in this section below. • The recommended fat supply in grams is the maximum amount of fat, which you should take with each meal." "" "" ""</seg>
<seg id="2600">"" "" "" "what quantity is appropriate for you, refer to the below information that gives the number of calories available which is appropriate for you. • To ensure the recommended intake of the capsule is crucial." "" "" ""</seg>
<seg id="2601">"" "" "" "if you take the same amount of fat as before, it can mean that your body can't process the amount of fat." "" "" ""</seg>
<seg id="2602">"" "" "" "by adherence to the recommended fat supply, you can maximize weight loss and reduce the probability of nutrition-related accompanying symptoms. • You should try to gradually increase gradually." "" "" ""</seg>
<seg id="2603">"" "" "" "34 These low calorie intake should allow you to gradually lose weight and continuously lose weight about 0.5 kg per week without frustrations and disappointments." "" "" ""</seg>
<seg id="2604">"" "" "" "the more active you are, the higher your recommended calorie intake. •" low physical activity "means that you work daily 150 kcal per day, e.g. due to 3 km walking, 30- to 45-minute garden work or 2 km running in 15 minutes." "" "" ""</seg>
<seg id="2605">"" "" "" "• For permanent weight loss, it is necessary to set out realistic calori- and fatty targets. • Do you want to move a dietary supplement with information about the caloride and fat content of your meals. • Try to move more before you start to taking alli." "" "" ""</seg>
<seg id="2606">"" "" "" "the alli program to support weight loss combines the capsules with a food plan and a large number of other information materials that can help you feed and feed themselves, physically active." "" "" ""</seg>
<seg id="2607">"" "" "" "in conjunction with a cut-cut program to support weight loss, you can help you develop a healthier lifestyle and achieve your goal." "" "" ""</seg>
<seg id="2608">Aloxi is used in chemotherapy; the severe trigger for nausea and vomiting are (such as cisplatin) and in chemotherapy; the regular trigger for nausea and vomiting are (such as cyclophosphamide, doxorubicin or carboplatin).</seg>
<seg id="2609">The effectiveness of alxi can be increased by the extra gift of a corticosteroids (a drug which can be used as an anti-therapeutic agent).</seg>
<seg id="2610">The application of patients under the age of 18 is not recommended since there is no enough information to the effects in this age group.</seg>
<seg id="2611">"" "" "" "this means that the substance prevents the bond of a chemical substance in the body, 5 hydroxytryptamine (5HT, also known as serotonin) to the receptors in the intestines." "" "" ""</seg>
<seg id="2612">Aloxi has been studied in three main studies at 1 842 adults who received the chemotherapy for nausea and vomiting in three main studies.</seg>
<seg id="2613">"" "" "" "with chemotherapy, a strong catalyst for nausea and vomiting, 59% of patients who were treated with alxi (132 of 223), compared with 57% of patients treated with ondansetron (126 of 221)." "" "" ""</seg>
<seg id="2614">"" "" "" "with chemotherapy, the regular trigger for nausea and vomiting, 81% of patients who were treated with alxi (153 from 189), compared to 69% of patients treated with ondansetron patients (127 of 185)." "" "" ""</seg>
<seg id="2615">"" "" "" "when compared with Dolasetron, these values are 63% for alxi (119 of 189 patients) and 53% for Dolasetron (101 of 191 patients)." "" "" ""</seg>
<seg id="2616">"" "" "" "in March 2005, the European Commission granted Helsinn Birex Pharmaceuticals Ltd. a approval of the transport of alxi in the entire European Union." "" "" ""</seg>
<seg id="2617">Aloxi is indexed: to prevention of acute nausea and vomiting with strongly emetogenic chemotherapy due to a cancer disease and for nausea and vomiting in moderately-etogenic chemotherapy because of a cancer disease.</seg>
<seg id="2618">"" "" "" "the efficacy of alxi to prevention of nausea and vomiting, which is induced by a severely emetogenic chemotherapy, can be enhanced by adding one of the corticosteroids." "" "" ""</seg>
<seg id="2619">"" "" "" "since Palonosetron can prolong the colon assay, patients with anamnesty obtaination or signs of a sub-acute Ileus after injection can be monitored." "" "" ""</seg>
<seg id="2620">"" "" "" "however, as with other 5HT3 antagonists, caution is advisable while offering palonosetron with medicines that extend the QT interval or in patients with which the QT- interval is extended or that inclination to such an extension." "" "" ""</seg>
<seg id="2621">"" "" "" "except in connection with a further chemotherapy first, Aloxi should neither be used for nausea and vomiting in days after chemotherapy." "" "" ""</seg>
<seg id="2622">"" "" "" "in pre-clinical studies, Palonosetron does not undergo tumor-related activity of the five examined chemotherapy, cyclophosphamide, cyanoabine, doxorubicin and Mitomycin C)." "" "" ""</seg>
<seg id="2623">In a clinical study no significant pharmacokinetic interaction between a unique intravenous dose of palonosetron and one steady state- Metoclopramids, a CYP2D6 inhibitors.</seg>
<seg id="2624">"" "" "" "in a population based pharmacokinetic analysis a significant effect of CYP2D6-Inhibitors, Cimetiine, chlorprooine, Cimetiine, Cimetiine, Cimetidin, kinidin, kgoaline and terbinafine) had no significant impact on the Clearance of Palonosetron." "" "" ""</seg>
<seg id="2625">"" "" "" "experience on applying Palonosetron on human gestures are not found, therefore Palonosetron should not be used by pregnant women, unless it is considered to be considered necessary." "" "" ""</seg>
<seg id="2626">"" "" "" "in clinical trials the most frequent in a dose of 250 microgram has been observed (altogether 633 patients), which at least possibly by Aloxi (9%) and obstipation (5%)." "" "" ""</seg>
<seg id="2627">Very rare cases (&lt; 1 / 10.000) of hypersensitivity reactions and reactions by appointment (burning, hardening, complaints and pain) were reported in post-marketing experiences.</seg>
<seg id="2628">"" "" "" "in the group with the highest dosage, similar things showed themselves of adverse events such as in other dozing groups, there were no dose of active relationships." "" "" ""</seg>
<seg id="2629">"" "" "" "no dialysis studies were performed, due to the large distribution volume, however, a dialysis is probably not an effective therapy for alopia overdosing." "" "" ""</seg>
<seg id="2630">"" "" "" "in two randomised double-blind studies, 1,132 mg / m2 faxorubicin and 250 mg / m2 doxorubicin and 250 mg / m2 dosasetron received, with patients compared to 32 mg of ondansetron (half-time 7.3 hours), which was given on day 1 without examinethason intravenously." "" "" ""</seg>
<seg id="2631">"" "" "" "in a randomised double-blind study, 667 patients with ≥ 60 mg / m2cisplatin were obtained, with patients compared to 32 mg of Ondansetron, which were given at day 1 intravenously." "" "" ""</seg>
<seg id="2632">Results of studies with moderately-etogenic chemotherapy and the study with strongly emetogenic chemotherapy are summarized in the following tables.</seg>
<seg id="2633">"" "" "" "in clinical trials for indicator-induced nausea and vomiting (CINV) were comparable to the effects of palonosetron on blood pressure, heart rate and EKG parameters including the corresponding effects of ondansetron and dolasetron." "" "" ""</seg>
<seg id="2634">"" "" "" "according to clinical studies, Palonosetron possesses the ability to block the ion channels in ventricular De- and repolarization to extend the duration of the action potential." "" "" ""</seg>
<seg id="2635">"" "" "" "the study of the study conducted at 221 healthy volunteers conducted the evaluation of the EKG effects of I.V. ionosetron in individual doses of 0,25, 0.75 and 2.25 mg." "" "" ""</seg>
<seg id="2636">"" "" "" "after intravenous gift, resignation follows a slow elimination of the body with an average terminological half-time of about 40 hours." "" "" ""</seg>
<seg id="2637">The average maximum plasma concentration (Cmax) and the surface under the concentration time curve (AUC0- ∞) are generally proportional to the total dose range of 0.3- 90 μ g / kg in case of bids and cancer patients.</seg>
<seg id="2638">After intravenous gift of palonosetron 0.25 mg every second day for a total of 3 doses occurred with 11 ± 34% increase in palonosetron plasma concentration at 42 ± 34%.</seg>
<seg id="2639">"" "" "" "out of pharmacokinetic simulations, that occurred at once daily intravenous administration of 0.25 mg of Palonosetron at 3 consecutive days, the Cmax was above 0.75 mg higher." "" "" ""</seg>
<seg id="2640">"" "" "" "about 40% are eliminated by the kidneys, and roughly 50% are being transformed into two primary metabolites in comparison to Palonosetron on less than 1% of the antagonistic effect on the 5HT3 receptor." "" "" ""</seg>
<seg id="2641">"" "" "" "in-vitro studies on the metabolism have shown that CYP2D6 and, in any lower extent, the Isoonis CYP3A4 and CYP1A2 are involved in the metabolism of Palonosetron." "" "" ""</seg>
<seg id="2642">Elimination After a intravenous single dose of 10 micrograms / kg [14C] -Palonosetron were found approximately 80% of the dose within 144 hours in urine was found as unaltered active substance made about 40% of the given dose.</seg>
<seg id="2643">"" "" "" "after a unique intravenous injections, the total body-type 173 ± 73 ml / min and the renal clearing was 53 ± 29 ml / min." "" "" ""</seg>
<seg id="2644">"" "" "" "although patients with severe liver function increases the terminale elimination-time and the average systemic exposure with palonosetron, but reducing the dose is not justified." "" "" ""</seg>
<seg id="2645">"" "" "" "in pre-clinical studies, effects were observed only after expositions which are considered sufficiently above the maximum human therapeutic exposure, which indicates a low relevance for clinical use." "" "" ""</seg>
<seg id="2646">"" "" "" "10 out of clinical studies, Palonosetron can only block Palonosetron, who are involved in ventricular De- and repolarisation, which can extend the duration of action." "" "" ""</seg>
<seg id="2647">"" "" "" "high doses of palonosetron (each dose spoke in about 30times of therapeutic exposure to humans) that led to a increased frequency of liver tumors, endocrine Neoplasms (in thyroid, pituermark) and skin tumors on rats, but not in mice." "" "" ""</seg>
<seg id="2648">"" "" "" "the underlying mechanisms are not completely known, but due to the high dosages and because Aloxi is intended for the unique application, the relevance of these results will be very low." "" "" ""</seg>
<seg id="2649">The owner of this authorization must inform the European Commission on the plans for the transport of the regulatory framework in the framework of this decision approved.</seg>
<seg id="2650">"" "" "" "• If one of the listed side effects are significantly impaired or you may notice any side effects that are not listed in this user information, please inform your doctor." "" "" ""</seg>
<seg id="2651">• Aloxi is a clear and coloured injection solution for injection in a Vene. • The active substance (Palonosetron) is a group of drugs that may cause nausea and vomiting. • Aloxi is used for prevention against nausea and vomiting which occur in connection with chemotherapy because of cancer.</seg>
<seg id="2652">"" "" "" "21 At use of alxi with other medicines please inform your doctor if you have taken other medicines / apply or used recently, even if it is not prescription drugs." "" "" ""</seg>
<seg id="2653">"" "" "" "pregnancy If you are pregnant or believe, get pregnant, your doctor will not give you alxi, unless it is definitely required." "" "" ""</seg>
<seg id="2654">"" "" "" "before taking all drugs, ask your doctor or pharmacist for advice if you are pregnant or believe or become pregnant." "" "" ""</seg>
<seg id="2655">"" "" "" "in some very rare cases, allergic reactions to alxi or to burn or pain at the entry level." "" "" ""</seg>
<seg id="2656">How Aloxi looks and content of the pack Aloxi injection solution is a clear and colorful solution and is available in a package with 1 throughs bottle made of glass that contains 5 ml of the solution.</seg>
<seg id="2657">"" "" "" "Reductors, Performative Performationist, Performative Perspectives in Performations.com." "" "" "" "Aсон." "" "" "" ": + 359 2 975 13 95 (6)" "" "" ""</seg>
<seg id="2658">Latvija Pharmacy of the Street Riga and LV-1011 Tel: + 37167502185 Lietuva Ulysuva Ulysmyniš kist.</seg>
<seg id="2659">United Kingdom IS Pharmaceuticals Ltd Office Village Chester Business Park Chester CH4 9QZ - UK Tel: + 44 1244 625 152</seg>
<seg id="2660">"" "" "" "in June 2006, the Committee for Human Use (CHMP) adopted a negative report for the treatment of hepatitis C prescribed medicines intended for the treatment of hepatitis C 6 million IE / ml injection solution." "" "" ""</seg>
<seg id="2661">This means that Alpheon should resemble a biological medicine called Roferon-A with the same chemically effective ingredient that is already approved in the EU (also called "reference drug").</seg>
<seg id="2662">Alpheon should be used for the treatment of adult patients with chronic (long-lasting) hepatitis C (a fatal liver disease).</seg>
<seg id="2663">"" "" "" "in a microscopic examination the liver damage indicates, the values of the liver enzyme Alanine Aminotransferase (ALT) are increased in the blood." "" "" ""</seg>
<seg id="2664">"" "" "" "it is produced by a yeast which has been introduced into a gene (DNA), which contributes to the formation of active substance." "" "" ""</seg>
<seg id="2665">"" "" "" "the manufacturer of Alpheon presented data, which prove the comparison of Alpheon with Roferon-A, composition, purity of the drug, mode of mode, safety and efficacy of hepatitis C)." "" "" ""</seg>
<seg id="2666">"" "" "" "in the study of patients with hepatitis C, the Alpheon effectiveness was compared with the efficacy of reference to 455 patients." "" "" ""</seg>
<seg id="2667">"" "" "" "in the study, as many patients were treated after 12 of 48 treatment weeks as well as 6 months after setting of treatment to the medication (i.e. no sign of the virus in the blood)." "" "" ""</seg>
<seg id="2668">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.eu.int © EMEA 2006 Reproduction and / or Distribution of this document is Authorised for non business-only in the EMEA 2006. what were the greatest concerns to say the CHMP recommendation?</seg>
<seg id="2669">"" "" "" "in addition, concerns were worned, that the data is not sufficient for the stability of active substance and marketing." "" "" ""</seg>
<seg id="2670">"" "" "" "the number of patients with hepatitis C, which spoke on the treatment with Alpheon and Roferon-A, was similar in clinical study." "" "" ""</seg>
<seg id="2671">"" "" "" "after setting the treatment with Alpheon, the disease in more patients retardant at more than with the reference department; Alpheon had more side effects." "" "" ""</seg>
<seg id="2672">"" "" "" "apart from that, the study included an immune response in the study (i.e. the body forms antibodies - special proteins - against the drug), not adequately validated." "" "" ""</seg>
<seg id="2673">It can be used for the treatment of Immergo (one with crustentions of hereditary skin infection) and small infected by-infected wounds (crack or liquor) wounds.</seg>
<seg id="2674">Altargo should not be used to treat infections which have been verified or probably caused by methicileresisted Staphylococcus aureus (MRSA) because Alargo against this kind of infections may not be effected.</seg>
<seg id="2675">"" "" "" "Altargo can be used for patients from the age of nine months, but patients under the age of 18 may not be more than 2% of the body surface." "" "" ""</seg>
<seg id="2676">"" "" "" "if the patient does not apply to treatment two or three days, the doctor should examine the patient again and consider alternative treatments in consideration." "" "" ""</seg>
<seg id="2677">It works by blocking the bacterial giant (the parts of the bacterial cell where proteins are produced) and inhibits the growth of bacteria.</seg>
<seg id="2678">"" "" "" "the main indicator of the effectiveness was in all five studies the proportion of patients whose infection was decreased after the end of the treatment." "" "" ""</seg>
<seg id="2679">119 (85.6%) of 139 patients under Altargo and 37 (52.1%) of 71 patients under placebo spoke to the treatment.</seg>
<seg id="2680">"" "" "" "in the treatment of infected dogs, Altargo and Cefalexin demonstrated similar rates: if the results of both studies were joined together at Hautwunden, some 90% of the patients were treated to treatment." "" "" ""</seg>
<seg id="2681">"" "" "" "in these two studies, however, that Altargo has been caused by the treatment of abscesses (eiterfilled cavities in the body tissue) or of infections which were demonstrably or probably caused by MRSA." "" "" ""</seg>
<seg id="2682">"" "" "" "the most common side effect with Altargo (which was observed in 1 to 10 of 100 patients) is a irritation of the Principal." "" "" ""</seg>
<seg id="2683">"" "" "" "the Committee for Human Use (CHMP) reached the conclusion that the benefits of Altargo abounds in the following surface treatment against the risks: • Impetigo, infected small infirs, depreciations or sewn wounds." "" "" ""</seg>
<seg id="2684">"" "" "" "in May 2007, the European Commission approved the Glaxo Group Ltd. a permit for the transport of Altargo throughout the European Union." "" "" ""</seg>
<seg id="2685">"" "" "" "patients with which have no improvement within two to three days, should be investigated again and considered an alternative therapy (see Section 4.4)." "" "" ""</seg>
<seg id="2686">"" "" "" "in case of a sensitizing or severe local irritation by the use of retapamulin Salbe the treatment is aborted, the ointment must be carefully removed and an appropriate alternative treatment of infection." "" "" ""</seg>
<seg id="2687">"" "" "" "Retapamulin should not be used to treat infections, to which MRSA is known as a pathogen or suspects (see Section 5.1)." "" "" ""</seg>
<seg id="2688">"" "" "" "in clinical studies of secondary wounds the effectiveness of retapamulin at patients with infections, caused by a methicillin-resistant Staphylococcus aureus (MRSA)." "" "" ""</seg>
<seg id="2689">"" "" "" "alternative therapy is to be considered when after a 2- or 3-day treatment, no improvement or deterioration of infected place occurs." "" "" ""</seg>
<seg id="2690">"" "" "" "the impact of the simultaneous application of retapamulin and other topical means of the same skin area is not investigated, and the simultaneous application of other topical drugs is not recommended." "" "" ""</seg>
<seg id="2691">"" "" "" "due to low plasma concentrations, which have been achieved in humans after topical applied skin or infected superficial wounds, a clinically relevant inhibition in vivo can not be expected (see Section 5.2)." "" "" ""</seg>
<seg id="2692">"" "" "" "3 As for simultaneous treatment of 2 times daily 200 mg Ketoconazole, the medium retapamulin AUC (0-24) and Cmax after topical application of 1% Retapamulin Salbe increased to reduced skin of healthy adult men by 81%." "" "" ""</seg>
<seg id="2693">"" "" "" "due to the low systemic exposure after topical application, dosisadaptations are not required if topical retapamulin are applied during a systemic treatment with CYP3A4 Inhibitors." "" "" ""</seg>
<seg id="2694">"" "" "" "animal studies have shown a reproduction of reproduction after oral surgery, inadequate regarding a statement regarding the birth and the fetal / postnatal development (see Section 5.3)." "" "" ""</seg>
<seg id="2695">Retapamulin Salbe should be applied during pregnancy when a topical antibacterial therapy is clear and the use of retapamulin to present the gift of an systemic antibiotic.</seg>
<seg id="2696">"" "" "" "if the breastfeeding continued, the breastfeeding continued, or the therapy with Altargo continues to stop, is between the benefit of lactation for the infant and the benefit of the Altargo therapy for the woman." "" "" ""</seg>
<seg id="2697">"" "" "" "in clinical studies of 2150 patients with superficial skin infections that Altargo were the most frequently reported side effects, which was about 1% of the patients." "" "" ""</seg>
<seg id="2698">Mode of action Retapamulin is a semi-synthetic derivatives of Pleuromutilin, a substance that is used by fermentation from clitopilus passeckanus (formerly Pleurotus passeckanus).</seg>
<seg id="2699">"" "" "" "the effect mechanism of retapamulin is based on the selective inhibiting of bacterial protein synthesis by interaction in a certain ties of the 50s of the bacterial giant, which differs from the binding of other ribosomal interaggerating antibacterial substances." "" "" ""</seg>
<seg id="2700">Data point out that the bonds of ribosomal protein L3 is involved and located in the region of the ribosomal P bonds and Peptidyltransferral centre.</seg>
<seg id="2701">"" "" "" "through bonding to this engagement level, Pleuromutiline inhibit P-binding interactions and prevent normal formation of active 50s mosbosom subunits." "" "" ""</seg>
<seg id="2702">"" "" "" "due to the local prevalence of resistance, the use of retapamulin at least some infectious forms should be conceivable, should be targeted by experts." "" "" ""</seg>
<seg id="2703">"" "" "" "there were no differences in in-vitro activity from retapamulin to S.aureus, regardless of whether the insulates were sensitive or resistant to methicillin." "" "" ""</seg>
<seg id="2704">"" "" "" "in case of failure to treat S.aureus, the presence of tribes with additional virulence factors (such as PVL = Panton-Valentine Leucocidin) should be considered." "" "" ""</seg>
<seg id="2705">"" "" "" "resorption In a study with healthy adults, 1% Retapamulin Saline was brought daily under occlusion on intact and reduced skin for up to 7 days." "" "" ""</seg>
<seg id="2706">"" "" "" "from 516 patients (adults and children), which received 1% Retapamulin Saline twice daily for 5 days for topical treatment of secondary traumatic wounds, individual plasmaproben have been won." "" "" ""</seg>
<seg id="2707">The sampling occurred on days 3 or 4 in adult patients each before the medication and the children between 0-12 hours after the last application.</seg>
<seg id="2708">However the maximum individual systemic intake of humans after topical application of 1% of ointment is reduced to 200 cm2 (Cmax = 22 ng / ml; AUC (0-24) = 238 ng (h / ml) = 238 ng (h / ml).</seg>
<seg id="2709">Metabolic metabolism in vitro oxidant metabolism in human liver microsomen was primarily mediated by CYP C8 and CYP2D6 (see section 4.5).</seg>
<seg id="2710">"" "" "" "in studies of oral toxicity on rats (50, 150 or 450 mg / kg) which were performed over 14 days, there were signs of adaptive liver and thyroid changes." "" "" ""</seg>
<seg id="2711">In-vitro examination on gene mutation and / or chromosomal effects in the mouse lymphaoma test or in cultures of human peripheral blood lymphocytes and in rats microkernel test for in-vivo examination chromosomal effects.</seg>
<seg id="2712">"" "" "" "there was neither male nor female rats with oral dosages of 50, 150 or 450 mg / kg / day, which has been achieved by up to 5 times higher exposure than the highest estimated exposure to people (topical application on 200 cm2)." "" "" ""</seg>
<seg id="2713">In an embryotoxicity study at oral dosages of ≥ 150 mg / kg / day (according to the ≥ 3 times of the estimated human exposure (see above)), development stoicity and delayed toxicity) and maternal toxicity.</seg>
<seg id="2714">"" "" "" "the approval of the approval process is to ensure that a pharmaceutical covigilance system is present, as in the 1.8.1 system of the application form, and will work before the product is marketed as long as the marketed product will be marketed." "" "" ""</seg>
<seg id="2715">"" "" "" "the approval of approval for the supervisory board is required to implement detailed studies and additional pharmaceutical-vigilance plan, as well as all additional updates of the RMP, as well as all additional updates of the RMP, which will be agreed with CHMP." "" "" ""</seg>
<seg id="2716">"" "" "" "as described in the CHMP" Guideline on Risk Management Systems for Human Use, "the updated RMP will be submitted to the next periodic safety update Report." "" "" ""</seg>
<seg id="2717">"" "" "" "irritation or other signs and symptoms show in the treated place, you should finish the use of altargo and talk to your doctor." "" "" ""</seg>
<seg id="2718">"" "" "" "do not apply other salads, creams or lotions on the surface which is treated with Altargo if it has not been prescribed by your doctor." "" "" ""</seg>
<seg id="2719">"" "" "" "it may not be applied in the eyes, mouth or on the lips, in the nose or female genital area." "" "" ""</seg>
<seg id="2720">"" "" "" "if the ointment is visible on one of these surfaces, wash the spot with water and ask your doctor to help advice if complaints occur." "" "" ""</seg>
<seg id="2721">"" "" "" "after carrying the ointment you can cover the affected area with a sterile association or a Gazeverband, unless your doctor has advised you to cover the surface." "" "" ""</seg>
<seg id="2722">"" "" "" "it is offered in aluminium tube with plastic closure, containing 5, 10 or 15 grams of ointment, or in an aluminum bag that contains 0,5 g of ointment." "" "" ""</seg>
<seg id="2723">"" "" "" "Ambirix is used to protect hepatitis C and hepatitis B (diseases which concern the liver) in children aged between one and 15, which are not immune to these two diseases." "" "" ""</seg>
<seg id="2724">"" "" "" "Ambirix is applied to an existing vaccination within two doses, whereby an protection against hepatitis B may be achieved only after administration of the second dose." "" "" ""</seg>
<seg id="2725">"" "" "" "for this reason, Ambirix is only allowed to be used while immunisation is a low risk of hepatitis B infection and ensured that the two doses can be led to an end." "" "" ""</seg>
<seg id="2726">"" "" "" "if a searchable dose against hepatitis A or B is desired, Ambirix can be used or another Hepatitis B or B vaccine." "" "" ""</seg>
<seg id="2727">Vaccines influence the immune defence (the natural defense of the body) and bring it against a disease.</seg>
<seg id="2728">"" "" "" "after a child has received the vaccine, the immune system recognises viruses and surface antigens as" alien "and creates antibodies against it." "" "" ""</seg>
<seg id="2729">"" "" "" "Ambirix contains the same components as the vaccine approved since 1996, and the Twinrix children have been approved since 1997." "" "" ""</seg>
<seg id="2730">"" "" "" "the three vaccines are used to protect the same diseases, however, Twinrix adults and Twinrix children are administered at the existing vaccination." "" "" ""</seg>
<seg id="2731">"" "" "" "because Ambirix and Twinrix adults contain identical ingredients, some of the data which are used by Twinrix Adults are also used as receipt for the application of Ambirix." "" "" ""</seg>
<seg id="2732">"" "" "" "the main indicator for efficacy was the proportion of vaccinated children, which had developed a month after the last injection a protective antiviral concentrations." "" "" ""</seg>
<seg id="2733">"" "" "" "in an additional study with 208 children, the efficacy of the vaccine was compared with six months and a 12-month distance between the two injections." "" "" ""</seg>
<seg id="2734">Ambient conditions resulted in between 98 and 100% of vaccinated children a month after the last injection of the antibody concentration of hepatitis A and B.</seg>
<seg id="2735">"" "" "" "the additional study showed that the degree of protection from Ambirix was similar in a six-month period between the injections." "" "" ""</seg>
<seg id="2736">"" "" "" "the most common side effects of Ambirix (seen at more than 1 of 10 vaccine doses) are headache, loss of appetite, pain, redness, matureness, etc." "" "" ""</seg>
<seg id="2737">"" "" "" "Ambirix is allowed to react in patients suffering from any other components or Neomycin (an antibiotic), which may not be applied." "" "" ""</seg>
<seg id="2738">"" "" "" "August 2002, the European Commission granted the GlaxoSmithKline Biologicals. a permit for the creation of Ambirix in the entire region." "" "" ""</seg>
<seg id="2739">"" "" "" "the standardization plan for the pridimmization with Ambirix consists of two vaccines, whereby the first dose is given on the date of choice and the second dose administered after the first dose." "" "" ""</seg>
<seg id="2740">"" "" "" "if a searchable vaccination is desired for hepatitis B and hepatitis B, it can be vaccinated with the respective monovalents vaccines or with a combination." "" "" ""</seg>
<seg id="2741">"" "" "" "the anti-hepatitis C virus (anti-HBV) antibody, anti-hepatitis C virus (anti-HAV) antibody, anti-hepatitis C virus (anti-HAV) are in the same size as after vaccination with the respective monovalents vaccines." "" "" ""</seg>
<seg id="2742">"" "" "" "it is not yet fully secured, whether immuno-A- vaccine is addressed to a risk of hepatitis as protection, since they may also be protected by immunological memory." "" "" ""</seg>
<seg id="2743">"" "" "" "3 As for all injection of injections, the rare case of an anaphylaktic reaction after the gift of the vaccine should always be available for medical treatment and monitoring." "" "" ""</seg>
<seg id="2744">"" "" "" "if an faster protection against hepatitis B is required, the standardization scheme is recommended to contain 360 ELISA units of inactivated hepatitis C virus and 10 µg recombinable hepatitis B surface." "" "" ""</seg>
<seg id="2745">"" "" "" "in case of hemostalysis patients and persons with disorders of the immune system, inadequate anti-HAV- and anti-HBS antibodies is not achieved so that in these cases the gift of other vaccines may be required." "" "" ""</seg>
<seg id="2746">"" "" "" "as an intradermal injection or intramuscular administration in the body muscle could lead to an optimal impacted, these injections should be avoided." "" "" ""</seg>
<seg id="2747">"" "" "" "however, at Thrombocytopenia or blood clotting disorders, ambitions can be injected insubcutaneous subcutaneous, since it can occur in these cases after intramuscular administration to bleeding." "" "" ""</seg>
<seg id="2748">When Ambirix was administered in the second year of a separate injection at the same time with a combined diphtheritis, tetra and hair-cellulae type b vaccine (DTPa-IPV / HIB) or with a combined masthe- mumps-Röttle vaccine is enough (see Section 5.1).</seg>
<seg id="2749">"" "" "" "patients under immune pressure therapy or patients with immune defects must be assumed, that possibly no adequate immune response is achieved." "" "" ""</seg>
<seg id="2750">"" "" "" "in a clinical study conducted with 3 vaccines of this formulation in adults, the frequency of pain, redness, swelling, gastroenteritis, headaches and fever comparable to the frequency that has been observed in previous Thiomerically and preservative-containing vaccines." "" "" ""</seg>
<seg id="2751">"" "" "" "in clinical trials, 2029 vaccines were administered at a total of 1027 vaccines at the age of 1 and including 15 years." "" "" ""</seg>
<seg id="2752">"" "" "" "in a study with 300 participants from 12 to 15 years, the tolerability of Ambirix was compared with the 3-doses of combination." "" "" ""</seg>
<seg id="2753">"" "" "" "only exceptions were the higher frequencies of pain and mat at a calculation base per vaccine dose of Ambirix, but not at a calculation base per person." "" "" ""</seg>
<seg id="2754">Pain was observed after the gift of Ambirix at 50,7% of the subjects compared with 39.1% in the subjects according to the gift of a 3-doses.</seg>
<seg id="2755">"" "" "" "after the complete vaccincycle, 66.4% of subjects which were administered by the ambitions were reported over pain, versus 63,8% among the subjects which were vaccinated with the 3-dose combination." "" "" ""</seg>
<seg id="2756">"" "" "" "however, the frequency of maturing was comparable per proband (i.e. through the entire vaccincycle at 39.6% of the subjects that were obtained with 36.2% compared with 36.2% in combination with the 3 doses." "" "" ""</seg>
<seg id="2757">"" "" "" "the prevalence of pain and mat was low and comparable, which was observed by the 3-doses vaccines after administration of the combination." "" "" ""</seg>
<seg id="2758">"" "" "" "in a comparative study of 1-11-year-old vaccines, the appearance of localreinteractions and general interactions were comparable with the 3-doses-unactivated hepatitis C virus and 10 µg recombinant hepatitis B surface." "" "" ""</seg>
<seg id="2759">"" "" "" "however, with the 6- to 11- year old, however, after vaccination with Ambirix a little occurrence of pain (at the injection center) per dose, was not reported per proband." "" "" ""</seg>
<seg id="2760">"" "" "" "the share of vaccines, which reported over severe side effects during the 2 doses of vaccine doses with 360 ELISA- units, ininactivated hepatitis C virus and 10 µg recombinant hepatitis B- surface coating, was statistically different." "" "" ""</seg>
<seg id="2761">"" "" "" "in clinical trials which were carried out at vaccines during the age of 1 and including 15 years after the first dose and 100% a month after the second, the month 6 (i.e. in month 7)." "" "" ""</seg>
<seg id="2762">"" "" "" "the seroconvergence for anti-HBS were 74.2% a month after the first dose and 100% a month after the second, to the month 6 (i.e. in month 7)." "" "" ""</seg>
<seg id="2763">"" "" "" "7 In a comparative study, which was performed in 12- and including 15-year-old, 142 two doses of Ambirix and 147 were obtained with three doses." "" "" ""</seg>
<seg id="2764">"" "" "" "among the 289 persons whose immunogenicity was proved, the seroprotection rates (SP in the table below) against hepatitis B was significantly higher in the month 2 and 6 after the gift of the 3-dose result." "" "" ""</seg>
<seg id="2765">"" "" "" "the immunoanswers that were reached in a clinical trial study at 1-11-year-old one month after the completion of the full vaccines (i.e. in month 7), are listed in the following table." "" "" ""</seg>
<seg id="2766">"" "" "" "in both studies, the vaccinations received either a 2-doses-vaccine with a combination of 360 ELISA units, ininactivated hepatitis C virus and 10µg recombinant Hepatitis B surface." "" "" ""</seg>
<seg id="2767">For individuals who were aged between 12 and 15 years old the persistence of anti-HAV- and anti-HBS antibodies were detected within 24 months after immunisation with Ambirix in the 0-6 months vaccination scheme.</seg>
<seg id="2768">The immune response against both antigens was comparable to the vaccination of 3 doses with a combination of 360 ELISA units and ininactivated heptis- A virus and 10 µg recombinant hepatitis B surface coating in a dose of 0.5 ml.</seg>
<seg id="2769">"" "" "" "in a clinical study at 12- to including 15-year olds, the persistence of anti-HAV- and anti-HBS antibodies were comparable to immunisation in the 0-12 months vaccination scheme." "" "" ""</seg>
<seg id="2770">When the first dose of ambient is administered at the beginning of the second year with a combined diphtheritis of a combined diphtheritis, inactivated poliomyelitis and 8 Haemophilus influenza vaccines (DTPa-IPV / HIB) or with the first dose of a combined measles type b-mumps for vaccination was sufficient.</seg>
<seg id="2771">"" "" "" "a clinical study conducted with 3 doses of the current formulation in adults, showed similar seroprotective and seroconversions as for the former formulation." "" "" ""</seg>
<seg id="2772">"" "" "" "the vaccine is applied both before and after the resignation by eye on any foreign particles and / or physically visible changes." "" "" ""</seg>
<seg id="2773">"" "" "" "pursuant to Article 114 of the directive 2001 / 83 / EG, the State Charm release will be authorized by a government laboratory or the authorized laboratory." "" "" ""</seg>
<seg id="2774">14 information AUF DER for external wrapping 1 FERTIGSPRITZE WITHOUT WITHOUT CARBOARD WITHOUT WITHOULY 10 FERTIGSPRITZE 10 FERTIGSPRITZEN WITHOUT CARBOARD WITH 10 FERTIGSPRITZEN WITHOUT CARBOARD WITHOUT...</seg>
<seg id="2775">Suspension for injection 1 finished injections without needle spliners with needle 10 finished injecting without needles 10 finished injecting with needles 50 finished injections without needles 1 dose (1 ml)</seg>
<seg id="2776">EU / 1 / 02 / 001 / 002 1 finished injection without needle / 1 / 02 / 2.10 finished injection with needle / 1 / 02 / 004 / 004 10 finished spindles with Nadel EU / 1 / 02 / 004 / 004 10 finished moulds without needles EU / 1 / 02 / 224 50 finished injection without needles</seg>
<seg id="2777">"" "" "" "hepatitis C virus is usually transmitted by viruselous food and beverages, but can also be transmitted by other ways, such as swimming in water-contaminated waters." "" "" ""</seg>
<seg id="2778">"" "" "" "you can feel very tired, have a dark urine, an inflatable face, yellow skin and / or eyes (jaundice) and other symptoms that possibly make a stationary treatment necessary." "" "" ""</seg>
<seg id="2779">"" "" "" "as with all vaccines, ambitions can not fully protect against hepatitis C or hepatitis B virus infection, even if the complete vaccines have been completed with 2 doses." "" "" ""</seg>
<seg id="2780">If you are infected with hepatitis C or hepatitis B virus before administration of both vaccination or hepatitis B virus (although you feel / your child does not feel uncomfortable or ill) it may not prevent a vaccination.</seg>
<seg id="2781">"" "" "" "a protection against other infections that may harm the liver or symptoms that are similar to hepatitis C or hepatitis B infection, can not be communicated." "" "" ""</seg>
<seg id="2782">"" "" "" "• if you have an allergic reaction to Ambirix, or any component of this vaccine including Neomycin (an antibiotic)." "" "" ""</seg>
<seg id="2783">An allergic reaction may appear due to itulating skin eruptions, respiratory or swelling of the face or the tongue. • If you have an allergic reaction to an earlier vaccination against hepatitis A or hepatitis B. • If you have a serious infection with fever.</seg>
<seg id="2784">"" "" "" "• If you want to have a protection against hepatitis B (i.e., within 6 months and prior to the second vaccine dose)." "" "" ""</seg>
<seg id="2785">"" "" "" "in a possible risk of infection with hepatitis B infection between the first and second vaccination, the doctor will advise you / your child from vaccination by ambitions." "" "" ""</seg>
<seg id="2786">Instead he will recommend to you / your child 3 injections of a combined hepatitis C / Hepatitis B vaccine with a reduced content of active hepatitis C virus and 10 micrograms of a recombinant Hepatitis B surface coating.</seg>
<seg id="2787">"" "" "" "the second vaccines of this vaccination with reduced content of effective components is usually administered one month after the first dose, and should give you a vaccination before completion of the vaccines." "" "" ""</seg>
<seg id="2788">"" "" "" "sometimes ambitions will suffer with people suffering from severe bleeding disorders, when you are weakened to the skin and not into the muscle." "" "" ""</seg>
<seg id="2789">"" "" "" "Ambirix can be given in these cases, but the immune response of these persons on vaccination can not be sufficient, so as a blood test can be necessary to see how strongly the reaction to vaccination is." "" "" ""</seg>
<seg id="2790">"" "" "" "21 Say you to your doctor if you have taken further drugs, or if you have been vaccinated in your child or if you have been insoftened / has been given to your child or have planned it in the near future." "" "" ""</seg>
<seg id="2791">"" "" "" "but it may be that in this case the immune response is not sufficient, therefore the person is not protected against either one or both hepatitis A and B virus." "" "" ""</seg>
<seg id="2792">"" "" "" "if another vaccines have to be given at the same time with Ambirix, separate spots and limbs should be vaccinated as possible." "" "" ""</seg>
<seg id="2793">"" "" "" "if ambitions should be administered at the same time or shortly before or after an injection of Immunglobulinen, it is likely that the reaction to the vaccine will be sufficient." "" "" ""</seg>
<seg id="2794">"" "" "" "usually ambitions will not be administered pregnant or lactating women, unless it is urgent need to be vaccinated both against hepatitis A and hepatitis B." "" "" ""</seg>
<seg id="2795">Important information about certain other components of Ambirix Please inform your doctor if you have already shown an allergic reaction to Neomycin (antibiotic).</seg>
<seg id="2796">"" "" "" "if you miss the agreed appointment for the second vaccination, talk to your doctor and make an appointment as soon as possible." "" "" ""</seg>
<seg id="2797">♦ is very common (more than 1 case per 10 extracted doses): • pain or discomfort in the sticking or redness • Stimulation • headache • appetite of appetite</seg>
<seg id="2798">♦ often (up to 1 case per 10 injured doses): • swelling of the injection centre • fever (over 38 ° C) • Rezziness • Gastro-intestine problems</seg>
<seg id="2799">"" "" "" "other side effects, the days or weeks after the vaccination with comparable combination or individual vaccines against hepatitis B and hepatitis B were very rare (less than 1 case per 10,000 injured cans) are:" "" "" ""</seg>
<seg id="2800">"" "" "" "these include locally-limited or extensive envelopes that can be or are puzzling, swelling of the eyes and face, awful breathing or swallowing, sudden blood pressure and lack of consciousness." "" "" ""</seg>
<seg id="2801">"" "" "" "influenza-like discomforts, including chills, muscle and joint pain cramping cases, multiple sclerosis, diseases of the optic nerve, loss of sensation or exercise ability of manoeuvens, disruption of normal brain functions" "" "" ""</seg>
<seg id="2802">"" "" "" "impotence of inflammations, blood vessels, diarrhea, diarrhea, and abdominal pain changed liver function testing lymph and hemorrhages (bruises), caused by trash of blood plateliness." "" "" ""</seg>
<seg id="2803">"" "" "" "23 Including your doctor or pharmacist if one of the listed side-effects you / your child will notice, or you will notice any side effects that are not listed in this package." "" "" ""</seg>
<seg id="2804">Ambirix is available in packs of 1 and 10 with or without needles and in packs of 50 without needles.</seg>
<seg id="2805">"" "" "" "on the basis of data, which have been known since issuance of the first permission for the transport system, the CHMP noted that the benefit-risk ratio for ambitions remains positive." "" "" ""</seg>
<seg id="2806">"" "" "" "however, since ambitions were only brought into a member state (in the Netherlands since May 2003), the available safety data for this medicine was limited due to the low patient exposure." "" "" ""</seg>
<seg id="2807">Ammoneseed may also be used in patients at the age of over a month with incomplete enzyme or with hyperammonium cephalopathy (brain-compensation due to high ammoniperceptions) in history.</seg>
<seg id="2808">Ammoneseed is divided - split by several individual doses to the meals - at the same time a gastrostomieschg (through the abdominal wall in the stomach-leading tube) or a nasal probe (due to the nose in the stomach-leading tube).</seg>
<seg id="2809">"" "" "" "it was not a comparative study, since ammonaps could not be compared with another treatment or placebo (e.g. no active substance)." "" "" ""</seg>
<seg id="2810">"" "" "" ammoniliquor may also result of loss of appetite, a abnormal acid content in the blood, depression, irritability, nausea, constipation, nausea, constipation, skin rash, uncomfortable body odor, or weight gain. "" "" "" "</seg>
<seg id="2811">"" "" "" "at the end, the Committee for Human Use (CHMP) reached the conclusion that ammoneseed is effectively prevented in patients with malfunctions of the urinary cycle." "" "" ""</seg>
<seg id="2812">"" "" "" "ammonaps has been approved under" "" "" "" "by the selenity of the condition at the time of admission only limited information on this medicine." "" "" ""</seg>
<seg id="2813">"" "" "" "the use is indian in all patients, with which a complete enlack of enzyme already manifests in the newborn term (within the first 28 days of life)." "" "" ""</seg>
<seg id="2814">"" "" "" "in patients with a late enzyme (incomplete enzyme is manifested after the first time of life), an indication of hyperammonium encephalopathy is made possible." "" "" ""</seg>
<seg id="2815">"" "" "" "for babies, for children who are not able to swallow tablets or for patients with gorgestion, AMMONAPS is also available in granule form." "" "" ""</seg>
<seg id="2816">"" "" "" "the daily dose is individually taken into consideration of protein tolerances, growth and development of daily protein intake." "" "" ""</seg>
<seg id="2817">According to previous clinical experiences the normal daily dose of sodium phenylbutyh: • 450 - 600 mg / kg / day with children with a body weight of less than 20 kg • 9.9 g / m ² / day with children with a body weight over 20 kg and for adults and adults.</seg>
<seg id="2818">"" "" "" "in patients who suffer from an early manifest deficiency of Carbamylphosphatsynthetase or ornithintranates, substitution of Citrullin or arginine is required in a dose of 0,17 g / kg / day or 3.8 g / m ² / day." "" "" ""</seg>
<seg id="2819">Patients with an Argininosuccinatsynthetase lack need arginine in a dose of 0,4 g / kg / day or 8,8 - 15.4 g / m ² / day.</seg>
<seg id="2820">"" "" "" "AMMONAPS tablets may not be taken with ingestion, as there is a risk for the emergence of esophagus if the tablets are unable to enter into the stomach." "" "" ""</seg>
<seg id="2821">Each tablet AMMONAPS contains 62 mg (2,7 mmol) sodium, corresponding to 2.5 g (108 mmol) sodium per 20 g sodium polyphenylbutyrat, which corresponds to the maximum daily dose.</seg>
<seg id="2822">"" "" "" "therefore, AMMONAPS should therefore be used with congestive heart failure or severe kidney failure, as well as with sodium retention and odembopting incoming clinical conditions only with caution." "" "" ""</seg>
<seg id="2823">"" "" "" "since metabolism and excretion of sodium phenylbutyrat is carried out over the liver and kidneys, AMMONAPS should be used with liver or kidney failure only with extreme caution." "" "" ""</seg>
<seg id="2824">The significance of these results in relation to pregnant women is not known; the use of AMMONAPS during pregnancy is contraindicated (see 4.3).</seg>
<seg id="2825">"" "" "" "at subcutaneous preparation of phenylacetat to young rats in high dosage (190 - 474 mg / kg), it came to a slowdown of neurons and increased loss of neurons." "" "" ""</seg>
<seg id="2826">"" "" "" "a delayed appeal of cerebral synapses and a reduced number of functional nerve damage in the brain, and therefore a disability of brain growth." "" "" ""</seg>
<seg id="2827">"" "" "" "it could not be noticed if phenylacetat is excreted into breast milk, and for this reason the use of AMMONAPS during the breastfeeding is contraindicated (see 4.3)." "" "" ""</seg>
<seg id="2828">In clinical trials with AMMONAPS in 56% of patients at least an unwanted event (AE) and 78% of those unwanted events was assumed that they were not connected with AMMONAPS.</seg>
<seg id="2829">"" "" "" "the frequency is defined as follows: very frequently (≥ 1 / 100, &lt; 1 / 10, &lt; 1 / 10) and occasionally (≥ 1 / 1.000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="2830">"" "" "" "a likely toxic reaction to AMMONAPS (450 mg / kg / day) was reported by a metabolic ducephalopathy associated with lactic acid, pancytopenia, peripheral Neuropathy, and pancreatitis." "" "" ""</seg>
<seg id="2831">"" "" "" "a case of overdosing occurred in a 5 months old toddler with an accidental single dose of 10 g (1370 mg / kg)." "" "" ""</seg>
<seg id="2832">"" "" "" "these symptoms occur with accumulation of phenylacetat, which showed a dosislimiting neurotoxicity with an intravenous administration of doses of up to 400 mg / kg / day." "" "" ""</seg>
<seg id="2833">Phenylacetat is a metabolic active compound associated with acetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacet</seg>
<seg id="2834">"" "" "" "phenylacetylacetylglutamine is comparable to urea (both compounds contain 2 nitrogen atoms); phenylacetylglutamine is therefore ideally suited as an alternative carrier for excretion of surplus nitrogen." "" "" ""</seg>
<seg id="2835">5 patients with malfunctions of the urea-cycle may be assumed that for each gram eives sodium polyphenylbutyrat between 0.12 and 0.15 g phenylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacet</seg>
<seg id="2836">"" "" "" "it is of significance that the diagnosis is made early on and the treatment is immediate, in order to improve the chances of survival and the clinical outcome." "" "" ""</seg>
<seg id="2837">"" "" "" "the prognosis of the early manifest form of the disease with the appearance of the first symptoms in the newborn child was earlier almost always infringing, and the disease carried out in treatment with peritonealdialysis and essential amino acids or with their sticking-free analyser within the first half of life." "" "" ""</seg>
<seg id="2838">"" "" "" "by hemostalysis, the use of alternative ways of nitrogen excretion (sodium polyphenylacetate), proteins and possibly substitution of essential amino acids it was possible to increase the survival rate of the patient at postpartal (however within the first lifetime)." "" "" ""</seg>
<seg id="2839">"" "" "" "in patients whose illness was diagnosed during pregnancy and the survival of hyperammonium encephalopathy was diagnosed already before the first appearance of a hyperammonium Encephalopathy, but the survival compared with many too intellectual disabilities or other neurological deficits was diagnosed." "" "" ""</seg>
<seg id="2840">In patients with a late patients suffering from the heterozygous form of the disease (including female patients with the heterozygist bamylase-deficiency) which were treated with sodium polyphenylbutyrat and a proteinated diet that was treated 98%.</seg>
<seg id="2841">"" "" "" "already existing neurological deficits are hardly reversible and in some patients a further deterioration of the neurological status can occur." "" "" ""</seg>
<seg id="2842">"" "" "" "it is known that phenylbutyal is oxidized to phenylacetate, which is conjugated in the liver and kidneys with glutamine." "" "" ""</seg>
<seg id="2843">"" "" "" "concentrations of phenylbutyrat and its metabolites in plasma and urine were obtained after gift of a single dose of 5 g sodium polyphenylsalyrat, and with liver cirrhosis after individual entry and repeated gifts of oral doses of up to 20 g / day (not controlled trials)." "" "" ""</seg>
<seg id="2844">"" "" "" "also in cancer patients, the behavior of phenylbutyrat and its metabolism was also studied after intravenous injection of sodium phenylbutyrat (up to 2 g / m ²) or phenylacetate." "" "" ""</seg>
<seg id="2845">"" "" "" "after an oral component of 5 g sodium polyphenylbutyrat in tablet form, 15 minutes after taking measurable plasma concentration of phenylbutyrat have been noted." "" "" ""</seg>
<seg id="2846">"" "" "" "in the majority of patients with urea-cyclic disorders, or hemoglobinies were demonstrable after different doses of phenylbutyal (300-650 mg / kg / day up to 20 g / day) in the next morning after nightly fasting and no phenylacetate in the plasma." "" "" ""</seg>
<seg id="2847">"" "" "" "in three of six patients with liver cirrhosis, which were repeatedly treated with sodium phenylbutyrat (20 g / day oral in three single doses), the medium-level phenylacetate concentrations in the plasma level were five times higher than after the first gifts." "" "" ""</seg>
<seg id="2848">Excretion The drug is discharged within 24 hours to approximately 80 - 100% in the form of conjugated product Phenylacetylglutamine over the kidneys.</seg>
<seg id="2849">"" "" "" "after the results of Micronucleus tests, sodium polyphenylbutyrat have been treated with toxic and non-toxic doses (examination 24 and 48 h after oral administration of an individual dose of 878 to 2800 mg / kg)." "" "" ""</seg>
<seg id="2850">AMMONAPS Granules is either orally taken (babies and children who have not swallowed any tablets or patients with swallowing disorders) or a gastrostomieschi or a nasal probe.</seg>
<seg id="2851">According to previous clinical experiences the normal daily dose of sodium phenylbutyrat: • 450 - 600 mg / kg / day with a body weight of less than 20 kg • 9.9 g / m ² / day with children with a body weight over 20 kg and for adults and adults.</seg>
<seg id="2852">"" "" "" "the concentration of ammonia, arginine, essential amino acids (especially branched-chain amino acids), carnitine and serum proteins should be kept within the normal area." "" "" ""</seg>
<seg id="2853">"" "" "" "in patients who suffer from an early manifest deficiency of Carbamylphosphatsynthetase or ornithintranates, substitution of Citrullin or arginine is required in a dose of 0,17 g / kg / day or 3.8 g / m ² / day." "" "" ""</seg>
<seg id="2854">AMMONAPS Granules contains 124 mg (5.4 mmol) sodium per gram sodium polyphenylbutyrat, corresponding to 2.5 g (108 mmol) sodium per 20 g sodium polyphenylbutyrat, which corresponds to the maximum daily dose.</seg>
<seg id="2855">"" "" "" "when rats were exposed to phenylacetat (active Metaboite of phenylbutyrat), it came to lesions in the pyramids of the cortex." "" "" ""</seg>
<seg id="2856">"" "" "" "a likely toxic reaction to AMMONAPS (450 mg / kg / day) was reported by a metabolic ducephalopathy associated with lactic acid, pancytopenia, peripheral Neuropathy, and pancreatitis." "" "" ""</seg>
<seg id="2857">"" "" "" "phenylacetylacetylglutamine is comparable to urea (both compounds contain 2 nitrogen atoms); Phenylacetylglutamine is therefore suitable as an alternative carrier for excretion of surplus value." "" "" ""</seg>
<seg id="2858">On the basis of investigations about the excretion of phenylacetylglutamine in patients with disorders of the urea-cycle can be assumed that for each gram eives sodium polyphenylbutyrat between 0.12 and 0.15 g phenylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacetylacet</seg>
<seg id="2859">"" "" "" "already existing neurological deficits are hardly reversible, and in some patients a further deterioration of the neurological status can occur." "" "" ""</seg>
<seg id="2860">"" "" "" "after an oral component of 5 g sodium polyphenylbutyrat in granulatform, 15 minutes after taking measurable plasma concentration of phenylbutyrat have been noted." "" "" ""</seg>
<seg id="2861">"" "" "" "during the duration of durability, the patient may store the finished product once a period of 3 months at a temperature of no more than 25 ° C." "" "" ""</seg>
<seg id="2862">In this case the small measuring spoon is 0.95 g for the medium measuring spoon 2.9 g and the large measuring spoon 8.6 g sodium polyphenylbutyrat.</seg>
<seg id="2863">If a patient must obtain the medicine above a probe, AMMONAPS can also be dissolved in water (the solubility of sodium phenylbutyrat is up to 5 g in 10 ml of water).</seg>
<seg id="2864">"" "" "" "in patients with these rare illnesses, certain liver enzymes are missing, so that they accumulate in the body from protein in the body, not excrete." "" "" ""</seg>
<seg id="2865">"" "" "" "if lab examinations are made, you must notify the doctor that you can take AMMONAPS, since sodium phenylbutyrat may affect the results of certain laboratory investigations." "" "" ""</seg>
<seg id="2866">"" "" "" "when taking AMMONAPS with other medicines please inform your doctor or pharmacist if you have taken other medicines or recently taken, even if it is not prescription drugs." "" "" ""</seg>
<seg id="2867">"" "" "" "during the breastfeeding time, you may not take AMMONAPS, because the drug may damage the breast milk and damage your baby." "" "" ""</seg>
<seg id="2868">"" "" "" "in rare cases, congestion, headaches, flavours, impediment, impediency and deterioration of existing neurological states have been observed." "" "" ""</seg>
<seg id="2869">"" "" "" "if you find one of these symptoms, get in immediately with your doctor or with the emergency of your hospital in writing an appropriate treatment." "" "" ""</seg>
<seg id="2870">"" "" "" "if you forget the intake of AMMONAPS, take the corresponding dose as soon as possible with the next meal." "" "" ""</seg>
<seg id="2871">"" "" "" "changes of blood (red blood cells, white blood cells, thrombocytes), diminished appetite, depression, irritability, nausea, constipation, nausea, constipation, skin rash, kidney failure, weight gain, and anomal laboratory values." "" "" ""</seg>
<seg id="2872">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will be significantly impaired or you will notice any side effects that are not listed in this manner." "" "" ""</seg>
<seg id="2873">You may not use AMMONAPS following the box and the container. usable until the expiry date does not use any more.</seg>
<seg id="2874">"" "" "" "like AMMONAPS, the contents of the package AMMONAPS tablets are of whitish colour and oval shape, and they are provided with the embossing" UCY 500. "" "" "" ""</seg>
<seg id="2875">"" "" "" "30 If laboratory investigations be made, you must notify the doctor that you may take AMMONAPS, since sodium phenylbutyrat may affect the results of certain laboratory investigations." "" "" ""</seg>
<seg id="2876">"" "" "" "when taking AMMONAPS with other medicines please inform your doctor or pharmacist if you have taken other medicines or recently taken, even if it is not prescription drugs." "" "" ""</seg>
<seg id="2877">You should take AMMONAPS to be carried out on the same solos orally or via a stomach torch (hose that runs through the abdominal wall directly into the stomach) or a nasal probe (Hose which is guided through the nose into the stomach).</seg>
<seg id="2878">"" "" "" "31 • Take off a measuring spoon of granulate, for example, remove a straight edge, e.g. a measuring spoon with a measuring spoon. • Use the recommended number of measuring spoon granulate from the container." "" "" ""</seg>
<seg id="2879">Angiox is used for the treatment of adult patients with acute coronarsyndrome (ACS, reduced blood supply to the heart) or for instance with unstable anxiety (a form of pain in breast cancer with different starch) or myocardial infarction (heart attack) or myocardial infarction (cardiography) or electrocardiac infarction (electrocardiogram or EKG).</seg>
<seg id="2880">"" "" "" "if Angiox is applied to preventing blood clots in patients, which is administered to a PCI and the infusion can be continued up to four hours after the procedure." "" "" ""</seg>
<seg id="2881">"" "" "" "in case of patients suffering from angina or heart attack, this can contribute to the maintenance of blood flow to heart and increase effectiveness of a PCI." "" "" ""</seg>
<seg id="2882">"" "" "" "approximately 14 000 patients attended the main study on the treatment of ACS, where the effect of angiox or IIIA inhibitor (GPI, another medicines for preventing blood clots) with common combination treatment with Heparin (another anticoagulans) and a GPI was compared." "" "" ""</seg>
<seg id="2883">"" "" "" "during the PCI the patient was frequently used a stent (a short tube, which remains in the lottery to prevent a lock) and they received additional medicines for preventing blood clots, such as Abciximab and aspirin." "" "" ""</seg>
<seg id="2884">"" "" "" "in the treatment of ACS was Angiox - with or without a gift of GPI - in preventing new events (deaths, heart attacks or reascularisation) after 30 days or a year as effective as conventional treatment." "" "" ""</seg>
<seg id="2885">"" "" "" "in patients who undergo a PCI was Angiox, with regards to all indicators just as effective as Heparin, except for heavy blood vessels, with which it was much more effective than heparin." "" "" ""</seg>
<seg id="2886">Angiox is not allowed to be used in patients who may be sensitive to bivalent (allergic) against bivalirudine, other miludine or other components.</seg>
<seg id="2887">"" "" "" "furthermore, it must not be applied in patients who recently had a hemorrhage, as well as in people with heavy hypertension or severe kidney problems." "" "" ""</seg>
<seg id="2888">The Committee for Human Use (CHMP) reached the conclusion that Angiox is in the treatment of ACS and during a PCI an acceptable replacement for Heparin.</seg>
<seg id="2889">"" "" "" "in September 2004, the European Commission granted approval of the Medicines Company UK Ltd, an approval of the establishment of Angiox in the entire European Union." "" "" ""</seg>
<seg id="2890">For the treatment of adult patients with acute coronardromes (instabile angina / failure - ST / NSTEMI)) in an emergency attack or if an early intervention is provided.</seg>
<seg id="2891">The recommended initial dose of angiox in patients with ACS is an intravenous bolt of 0.1 mg / kg followed by an infusion of 0.25 mg / kg / h.</seg>
<seg id="2892">"" "" "" "if a PCI is performed in another sequence, an additional Bolus of 0.5 mg / kg should be increased and infusion should be increased to 1.75 mg / kg / h for the duration of the intervention." "" "" ""</seg>
<seg id="2893">"" "" "" "according to the PCI, according to clinical requirements the reduced infusion dose of 0.25 mg / kg / h can be recorded for 4 to 12 hours." "" "" ""</seg>
<seg id="2894">"" "" "" "immediately prior to the procedure, a resolution of 0.5 mg / kg should be given, followed by an infusion of 1.75 mg / kg / h for the duration of the intervention." "" "" ""</seg>
<seg id="2895">The recommended dose of angiox in patients with a PCI consists of an initials intravenous bolt of 0.75 mg / kg of body weight and an immediate subsequent intravenous infusion with a dose of 1.75 mg / kg of body weight / h at least for the duration of the intervention.</seg>
<seg id="2896">"" "" "" "the safety and effectiveness of a sole Bolus gift of angiox was not examined and is not recommended, even if a short PCI procedure is planned." "" "" ""</seg>
<seg id="2897">"" "" "" "if this value is shortened (ACT after 5 minutes) to 225 seconds, a second bolt of 0.3 mg / kg / bodyweight should be reduced." "" "" ""</seg>
<seg id="2898">"" "" "" "to reduce the occurrence of lower ACT values, the reconvened and diluted medicine should be carefully mixed before application and given to the bolus dose intravenously." "" "" ""</seg>
<seg id="2899">"" "" "" "once the ACT value is more than 225 seconds, another monitoring is no longer required, provided that the 1.75 mg / kg infusion dose is given correctly." "" "" ""</seg>
<seg id="2900">In case of patients with moderate renal reduction of kidney disease (GFR 30-59 ml / min) which is subjected to a PCI (whether suffering from Bivalirudin against ACS or not) should be used as a lower infusion rate of 1.4 mg / kg / h.</seg>
<seg id="2901">"" "" "" "if the ACT-value is under 225 seconds, a second bolus dose of 0.3 mg / kg is to be fed and the ACT 5 minutes after the second bolus dose." "" "" ""</seg>
<seg id="2902">In case of patients with moderate kidney damage caused in the Phase III- PCI study (replace 2-2) which was included in the phase III- PCI trial without dosisadaption at an average 366 ± 89 seconds.</seg>
<seg id="2903">"" "" "" "3 In patients with severe kidney damage (GFR &lt; 30 ml / min) and also in dialysis, Angiox is contraindicated (see section 4.3)." "" "" ""</seg>
<seg id="2904">Treatment with angiox can be initiated 30 minutes after the completion of the administered intravenous heparin or 8 hours after the completion of the subcutaneous administration of low-molecular heparin.</seg>
<seg id="2905">"" "" "" "• known hypersensitivity to the active substance or other components or against braudine bleeding due to a disturbance of hemostatic disorders and / or irreversible cerebral disorders, • heavier kidney damage (GFR &lt; 30 ml / min) and dialysis probable patients" "" "" ""</seg>
<seg id="2906">"" "" "" "patients are meticulous in treating symptoms and signs of blood, especially if bivalent in combination with another anticoagulans is given (see section 4.5)." "" "" ""</seg>
<seg id="2907">"" "" "" "even if in case of PCI-patients suffering from Bivalirudine, most bleeding in arterial points can occur in patients suffering from percutaneous coronarintervention (PCI), during treatment in principle haemorrhages." "" "" ""</seg>
<seg id="2908">"" "" "" "in patients who are receiving alfarin and treated with bivalirudine, a monitoring of INR Werts (International standardization ratio) should ensure that the value after placing the treatment with bivalirudine is once again achieved before the treatment." "" "" ""</seg>
<seg id="2909">"" "" "" "starting from knowledge about the mechanism of anticoagulants (Heparin, Warfarin, Thrombolytics or Thrombogaggainemmer), these substances can increase the risk of blood." "" "" ""</seg>
<seg id="2910">"" "" "" "in combination of bivalirudin with Thrombozytenaggregational mines or anticoagulants, clinical and biological hemostaseparameters are regularly monitored in any case." "" "" ""</seg>
<seg id="2911">"" "" "" "the experimental studies are inadequate for the effects on pregnancy, embryonic / fetal development, the binding or postnatal development (see Section 5.3)." "" "" ""</seg>
<seg id="2912">4612 were randomized to Bivalirudine alone, 4604 were randomized to either GPIIb / IIIA inhibitor and 4603 were randomised to either infractionated Heparin or Enoxaparin plus GPIIb / IIIA inhibitor.</seg>
<seg id="2913">"" "" "" "both in the Bivalirudine Group as well as in patients with Heparin treated cases, women and patients over 65 years were more common to adverse events than in male or younger patients." "" "" ""</seg>
<seg id="2914">Heavy bleeding were defined after ACUITY and Timi scale bars for heavy bleeding as in table 2 in the footnotes.</seg>
<seg id="2915">"" "" "" "both light and severe bleeding were significantly lower than in the groups with Heparin plus GPIIb / IIIA inhibitor, plus GPIIb / IIIa- Inhibitor (see table 2)." "" "" ""</seg>
<seg id="2916">An ACUITY severe bleeding was defined as one of the following events: intraperitoneal, intraperitoneal, intraocular bleeding or bleeding in the point of point that implantation of hemoglobin mirror with a diameter of ≥ 5 g / dl with a well-known hemorrhaystation of ≥ 5 g / dl with a known hemorrhavent or effect of blood products to transfusion.</seg>
<seg id="2917">"" "" "" "further, less frequently observed hemorrhages that came up with more than 0.1% (occasionally) were" Other "points, Gastrointestinal, ear, nose or neck." "" "" ""</seg>
<seg id="2918">"" "" "" "the following data of side effects are based on data from a clinical study using Bivalirudine in 6,000 patients who undergo a PCI." "" "" ""</seg>
<seg id="2919">"" "" "" "both in the Bivalirudine Group as well as in patients with Heparin treated cases, women and patients over 65 years were more common to adverse events than in male or younger patients." "" "" ""</seg>
<seg id="2920">Both light and severe bleeding were significantly less frequent compared to Bivalirudin compared to Heparin plus GPIIb / IIIA inhibitor.</seg>
<seg id="2921">"" "" "" "the following side effects, which are not listed above, were reported following comprehensive application in practice, and are classified according to system organclasses in Table 6." "" "" ""</seg>
<seg id="2922">"" "" "" "in case of overdosing, treatment with bivalirudine is downright to break and the patient with regard to sign of bleeding." "" "" ""</seg>
<seg id="2923">"" "" "" "Angiox contains Bivalirudine, a direct and specific Thrombinforor, which binds both on the catalytic centre as well as at the animal maternity region of Thrombin, regardless of whether Thrombin is bound in the liquid phase or at the clause." "" "" ""</seg>
<seg id="2924">"" "" "" "the bond of Bivalirudine at Thrombin, and with it its effect, is reversible because Thrombin regenerates the bond of Bivalirudine-Arg3-Pro4, thereby reducing the function of the active centre of thrombin regenerates." "" "" ""</seg>
<seg id="2925">"" "" "" "in addition, Bivalirudine induced thrombosis / heparinsurgia / heparininducing thrombosis syndrome (HIT / HITTS) had come to induce thrombosis syndrome (HIT / HITTS)." "" "" ""</seg>
<seg id="2926">"" "" "" "in healthy volunteers and in patients, Bivalirudine shows anticoagulatory effect, which is occupied by the extension of ACT, aPTT, PT, INR and TT." "" "" ""</seg>
<seg id="2927">"" "" "" "if in the patient a PCI was performed below, an additional Bolus of 0.5mg / kg Bivalirudine should be increased and the infusion should be increased to 1.75 mg / kg / h." "" "" ""</seg>
<seg id="2928">In the arms A of the ACUITY study was administered infractionated Heparin or Enoxaparin according to the relevant guidelines for the treatment of acute Koronarsyndrome (ACS) in patients with unstable anxiety (IA / NSTEMI).</seg>
<seg id="2929">Patients in arm A and B were also randomized to either obtain a GPIIb / IIIA inhibitor either before the angiography (at the time of maromization) or in the PCI.</seg>
<seg id="2930">"" "" "" "the ACUITY study showed the characteristics of high-risk experiments, which required angiography within 72 hours, evenly distributed over the 3 treatment arms." "" "" ""</seg>
<seg id="2931">About 77% of patients had a recurring ischemia of 70% had dynamic EKG- Changes or enhanced cardials biomarker, 28% were subjected to diabetes and about 99% of patients undergone a angiography within 72 hours.</seg>
<seg id="2932">The primary analysis and results of the ACUITY study for the 30-day and the 1 year deadline for the overall population (ITT) and for the patients that received aspirin and Clopidogrel on protocol (before angiography or PCI) were presented in tables 7 and 8.</seg>
<seg id="2933">"" "" "" "ACUITY study; 30-day and 1-year risk difference for the combined end point and its components for patients, aspirin and Clopidogrel against protocol *" "" "" ""</seg>
<seg id="2934">Patients who were aspirin and Clopidogrel against minutes received arm A arm B Arm C UIOx Bival B- A C- A Bival + GPIIb / IIIA risk diff.</seg>
<seg id="2935">The frequency of bleeding in the ACUITY- as well as in the Timi scale up to Day 30 for the total population (ITT) and for patients who received aspirin and Clopidogrel on protocol has been shown in Table 9.</seg>
<seg id="2936">Patients who inhibitor aspirin and Clopidogrel IOP (N = 2911) inhibitor (N = 2924) inhibitor (N = 2924)% inhibitor (N = 4604) (N = 4604) (N = 2842)%%%</seg>
<seg id="2937">* Clopidogrel against angiography or front of PCI 1 A ACUITY severe bleeding was defined as one of the following events: intraperito-Neale, intraocular bleeding or bleeding in the point of point, reduction by hemosto-bell mirror with a blood pressure or surgery due to a bleeding, use of blood products to transfusion.</seg>
<seg id="2938">"" "" "" "the 30-day results, based on four-triple and triple-score points of a randomised double-blind study with more than 6,000 patients undergone a PCI (replace-2), are shown in Table 10." "" "" ""</seg>
<seg id="2939">Clinical trials with a small number of patients provided limited information on the use of angiox in patients with HIT / HITTS.</seg>
<seg id="2940">The pharmacokinetic properties of bivalent in patients were evaluated using a percutaneous coronary intervention (PCI) as well as in patients with ACS.</seg>
<seg id="2941">"" "" "" "it is expected that Bivalirudin as Peptide is a catabolic components, followed by subsequent recovery of amino acids in the body pool." "" "" ""</seg>
<seg id="2942">The primary metaboite that results from the division of the Arg3-Pro4-To-terminal sequence by thrombin is not effective because of the loss of its affinity to the catalytic centre of thrombin.</seg>
<seg id="2943">"" "" "" "elimination occurs in patients with normal kidney function, after a process first order with a terminal half-time of 25 ± 12 minutes." "" "" ""</seg>
<seg id="2944">"" "" "" "based on conventional studies on Safety Pharmacology, Toxicity at repeating gift, Genotoxicity or Reproductive data, the preventive data do not recognize any particular dangers." "" "" ""</seg>
<seg id="2945">Toxicity in animals with repeated or continuous exposure (1 day to 4 weeks in a exposure to the 10-faxes of the clinical Steady state plasma concentration) limited pharmacological effects.</seg>
<seg id="2946">"" "" "" "side effects due to long-term physiological burden as a reaction to a non-homeostatic coagulation were similar to those in clinical application, even at a very much higher dosage." "" "" ""</seg>
<seg id="2947">"" "" "" "if the production of the ready-to-use solution is not performed under controlled and validated aseptic conditions, it is no longer available 24 hours at 2 ° C up to 8 ° C." "" "" ""</seg>
<seg id="2948">Angiox is a weighted powder in single dose of water in single dose of 10 ml; sealed with a butyl rubber blades and sealed to a cap made of pressed aluminium.</seg>
<seg id="2949">"" "" "" "5 ml of the water for injections are given in a cylindrical bottle Angiox, which everything is fully dissolved and the solution is clear." "" "" ""</seg>
<seg id="2950">5 ml will be taken from the water bottle and diluted with 5% glucose solutions for injection or with 9 mg / ml (0.9%) sodium chloride solution for injection in a total volume of 50 ml to obtain a concentration of 5mg / ml bivalirudine.</seg>
<seg id="2951">"" "" "" "the approval of approval for the vehicle legislation is to be specified, as in version 4 of the risk management plan (RMP) and in Module 1.8.2 of approval of the RMP, as well as any subsequent changes of the RMP, of which the CHMP has been approved." "" "" ""</seg>
<seg id="2952">"" "" "" "according to CHMP Guideline at risk management systems for human medicines, the revised RMP should be submitted simultaneously with the next periodic safety update Report (PSUR)." "" "" ""</seg>
<seg id="2953">• Patients with breast cancer due to a cardiac disease (acute Koronarmes - ACS) • Patients which are operated on the treatment of closures in the blood vessels (angioplasty and / or percutaneous Koronarangioplasty - PCI).</seg>
<seg id="2954">"" "" "" "• You are pregnant or discouraged that you could be pregnant, trying to get pregnant, she is pregnant." "" "" ""</seg>
<seg id="2955">"" "" "" "there were no investigations on the effects on the transport and the ability to serve machines, but you know that the effects of this medication is short in short term." "" "" ""</seg>
<seg id="2956">"" "" "" "should bleeding occur, treatment with angiox is broken. • Before the beginning of injection or infusion you will inform your doctor about possible signs of an allergic reaction." "" "" ""</seg>
<seg id="2957">Such reactions are rare (they occur at less than 1 of 1000 treated patients). • A particularly careful monitoring is performed when you maintain a radiation therapy for the vessels that you receive from your body weight and type of therapy that you get.</seg>
<seg id="2958">• 0.1 mg / kg body weight as an injection followed by an infusion (0.25 mg / kg body weight) for each kilogram of body weight; 0.25 mg / kg body weight per hour means a quarter of a millimeter of medication for each kilogram of body weight per hour).</seg>
<seg id="2959">More likely if Angiox is administered in combination with other cointernal or antithrombotic medicines (see Section 2 "For applying angiox with other medicines).</seg>
<seg id="2960">These are occasional side effects (in less than 1 out of 100 patients treated). • Thrombosis (blood clots) that could lead to serious complications such as heart attack.</seg>
<seg id="2961">This is an occasional side effect (in less than 1 out of 100 patients treated). • pain, bleeding and blood-cast at the point level (after a PCI treatment).</seg>
<seg id="2962">"" "" "" "please inform your doctor if one of the listed side effects will significantly affect you or you will notice any side effects that are not listed in this manual information." "" "" ""</seg>
<seg id="2963">"" "" "" "angiox should not be applied on the label and the box after" useable up until the expiry date of the expiry date. "" "" "" "</seg>
<seg id="2964">Polska The Medicines Company UK Ltd.: + 800 843 633 26 Lub + 41 61 564 1320-59 λ: + 30 210 5281700 E-mail:</seg>
<seg id="2965">"" "" "" "Apidra is used for the treatment of adults, adolescents and children over six years with diabetes, which require treatment with insulin." "" "" ""</seg>
<seg id="2966">Apidra is injected subcutaneous (under the skin) into the abdominal wall, the thighs or upper arm injected or infusion with a insulin pump.</seg>
<seg id="2967">Diabetes is a disease in which the body does not produce enough insulin to regulate the glucose level (sugar) or the insulin is not effective.</seg>
<seg id="2968">"" "" "" "insulin lulisin differs very slightly for humankind, and the change means that it has an faster effect and a shorter active life has a short-effective humankind." "" "" ""</seg>
<seg id="2969">Apidra was used in the application in combination with type 1 diabetes in patients with type 1 diabetes in which the body does not produce insulin in two studies with a total of 1 549 adults and a study of 572 children aged between four and 17.</seg>
<seg id="2970">"" "" "" "in type 2 diabetes, with the body insulin, Apidra was examined in a study involving 878 adults." "" "" ""</seg>
<seg id="2971">"" "" "" "the main indicator for efficacy was the change of concentration of the substance glycoagulated hemoglobin (HbA1c) in the blood, which shows how good blood sugar is adjusted." "" "" ""</seg>
<seg id="2972">"" "" "" "in the first study of adults with type 1 diabetes, a reduction of 0.14% (7,60% to 7.46%) in comparison to a reduction of 0.14% was found in insulin." "" "" ""</seg>
<seg id="2973">"" "" "" "in adults with type 2 diabetes, the reduction in HbA1c concentration was 0,46% after six months with Apidra, compared to 0.30% in human normal insulin." "" "" ""</seg>
<seg id="2974">"" "" "" "Apidra is not allowed to be used in patients who are perhaps oversensitive (allergic) against insulin lulisin or any of the other ingredients, or in patients who already suffer from a hypoglycemia." "" "" ""</seg>
<seg id="2975">"" "" "" "the doses of Apidra must be adjusted if it is administered together with a number of other drugs, which can impact on blood glucose levels." "" "" ""</seg>
<seg id="2976">"" "" "" "in September 2004, the European Commission granted Sanofi-Aventis Germany GmbH granted approval for the transport of Apidra in the entire European Union." "" "" ""</seg>
<seg id="2977">Apidra is either used as a subcutaneous injection either in the field of abdominal wall which can apply or subcutaneous through continuous infusion in the area of abdominal wall CKE.</seg>
<seg id="2978">"" "" "" "due to the reduced glucose level capacity and the diminished insulin metabolism, the insulin requirement can be reduced in patients with a reduction of liver function." "" "" ""</seg>
<seg id="2979">"" "" "" "any changes to the action strength, the brand (Her- Steller), the type of insulin (normal, NPH, zinc delasible, etc.), the type of insulin (animal insulin) and / or the production method can draw a change of the insulin demand." "" "" ""</seg>
<seg id="2980">"" "" "" "3. an inadequate dose or treatment of treatment, especially in patients with insulated diabetes, can lead to hyperglycemia and a diabetic converter; these conditions are potentially life threatening." "" "" ""</seg>
<seg id="2981">"" "" "" "the conversion of a patient to another insulin type or a insulin from another manufacturer should take place under strict medical supervision, and can make a change in dosage." "" "" ""</seg>
<seg id="2982">"" "" "" "the timing of a hypoglycemia depends on the drug profile of the used insulin, and can therefore change the treatment schemas." "" "" ""</seg>
<seg id="2983">"" "" "" "to strengthen the substances that can increase blood sugar levels and inclination to hypoglyphs, angiotensin-Converting-enzyme, Monoamine, fluoxetine, propoxycycline, propoxycycline and sulfonamide antibiotics." "" "" ""</seg>
<seg id="2984">"" "" "" "in addition, among the effects of sympathies such as beta blockers, Clonidin, Guanethidin, Guanethidin, and reserves the symptoms of adrenergen counterregulation could be weakened or absent." "" "" ""</seg>
<seg id="2985">"" "" "" "there were no differences between Insu- linglulisin and Humanity regarding the pregnancy, the embryonic / fetal development, birth or postnatal development (see Section 5.3)." "" "" ""</seg>
<seg id="2986">"" "" "" "it is not known whether insulin overcomes into human breast milk, but in general insulin is not absorbed into the breast milk, nor is it absorbed to oral application." "" "" ""</seg>
<seg id="2987">"" "" "" "below, the results of clinical trials are listed below: ≥ 1 / 100, &lt; 1 / 100; frequently: ≥ 1 / 100, &lt; 1 / 100; very rare: ≥ 1 / 100; very rare (Frequency on the basis of their baak- data not invaluable)." "" "" ""</seg>
<seg id="2988">"" "" "" "cold cold welding, bold and soft skin, fatigue, nervousness or treach, anxiety, unusual fatigue, lack of concentration, lack of concentration, nausea, and heartbeat." "" "" ""</seg>
<seg id="2989">"" "" "" "Lipodystrophy is failed to continuously change the injection of injection within the injection area, and can occur in a result of a liystrophy at the injection station." "" "" ""</seg>
<seg id="2990">Severe hypoglycemic bodies with difficulty-lessness can be given by an intramuscular or subcutaneous injection of glukagon (0.5 to 1 mg) which is given by an intramuscular relief of glucose by a doctor.</seg>
<seg id="2991">"" "" "" "after a gluten development, the patient should be supervised in a hospital to identify the urine cause of severe hypoglycemia and to avoid similar episodes." "" "" ""</seg>
<seg id="2992">Insulin lowers blood sugar levels by stimulating the peripheral glucose levels (especially through skeleton muscles and fat) and inhibition of glucose levels in the liver.</seg>
<seg id="2993">Studies with healthy volunteers and patients with diabetes showed that in subcutaneous Ga- be of insulin lulisin efficiency occurs faster and the duration of action is shorter than at hu- manem normal insulin.</seg>
<seg id="2994">In a study of 18 male persons aged 21 to 50 years with type 1 diabetes mulli- TUS showed insulin-type damped dosing range from 0,075 to 0.15 E / kg and a proportional increase in the draught effect as well as humaninsulin.</seg>
<seg id="2995">"" "" "" "insulin lulisin has twice as fast action occurs as normal human insulin, and achieve full draught effect approximately 2 hours earlier than humankind." "" "" ""</seg>
<seg id="2996">"" "" "" "using an application of insulin lulisin 2 minutes before the meal, a similar postpranal glycemic control is achieved as with human normal insulin, which is 30 minutes before the meal." "" "" ""</seg>
<seg id="2997">"" "" "" "was canceled insulin lulisin 2 minutes before the meal, a better postpranal control was given in 2 minutes before the meal was reached." "" "" ""</seg>
<seg id="2998">Is used to take insulin lulisin 15 minutes after the meal begins - a comparable glycemic control is given as in human normal insulin that is given 2 Mi- Nuts before the meal (see figure 1).</seg>
<seg id="2999">Insulin lulisin in gift 2 minutes (GLULISIN - previously) before the meal was given to human normal insulin the 30 minutes (NORMAL - 30 min.) before the beginning of the meal was given (figure 1A) and compared to human normal insulin (NORMAL - before) before a meal (figure 1B).</seg>
<seg id="3000">Insulin lulisin in gift for 15 minutes (GLULISIN - after beginning of the meal compared to human Nor- malinsulin after 2 minutes (NORMAL - before) before the meal was given (Figure 1C).</seg>
</doc>
</tstset>
